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INTRODUCTION 
 
Content 
 
The purpose of this report is to provide an estimate of cancer incidence for each of the 351 cities and 
towns of Massachusetts for the five-year time period 2008 through 2012.  For each city and town, 
Standardized Incidence Ratios (SIRs) are presented for twenty-three types of invasive cancer and for 
all invasive cancer types combined.  These ratios compare the cancer incidence experience of each city 
or town with the cancer experience of the state as a whole.  The method involves comparing the 
number of cases that were observed for a city or town to the number of cases that would be expected if 
the city or town had the same cancer rates as the state as whole.  The report is organized into the 
following sections: 
 
METHODS PROVIDES a detailed explanation of the data collection, data processing, and 
statistical techniques employed in this report. 
 
TABLES present data for selected types of cancer by city/town and sex. 
 
APPENDIX I provides a listing of International Classification of Diseases for Oncology codes 
used in the preparation of this report. 
 
APPENDIX II provides selected resources for information on cancer. 
 
APPENDIX III describes the Massachusetts Department of Public Health’s current cancer 
control initiatives, and provides links to bureaus within the department that address some aspect 
of cancer.  Links to resources for publications are also provided. 
 
Comparison with Previous Reports 
 
This report updates previous annual reports published by the Massachusetts Cancer Registry (MCR).   
It is available on line at http://www.mass.gov/dph/mcr.  For questions about the report, contact the 
MCR at: 
  
 Massachusetts Cancer Registry 
 Office of Data Management and Outcomes Assessment 
 Massachusetts Department of Public Health 
 250 Washington Street, 6th floor 
 Boston, MA 02108-4619 
telephone 617-624-5642; fax 617-624-5695  
 
The preceding report, Cancer Incidence in Massachusetts 2007-2011:  City and Town Supplement, 
included data for diagnosis years 2007 through 2011.  This report contains data for the diagnosis years 
2008 through 2012.  There have been no changes in this report’s format from the previous report.   
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METHODS 
 
Data Sources 
 
Cancer Incidence 
 
The MCR collects reports of newly diagnosed cancer cases from health care facilities and practitioners 
throughout Massachusetts. Facilities that  reported the 2008-2012 diagnoses that comprise this report  
include 69 Massachusetts  acute care hospitals, 5  radiation/oncology centers, 2 endoscopy centers, 2 
surgical centers, 10 independent laboratories, 3 medical practice associations, and approximately 500 
private practice physicians. The MCR signed the modified National Data Exchange Agreement on 
March 28, 2013. This is a single agreement that allows participating states to exchange data on cases 
diagnosed or treated in other areas.  Together with states participating in the agreement, and states 
with individual agreements, the MCR now has reciprocal reporting agreements with 37 states and with 
Puerto Rico and Guam to obtain data on Massachusetts residents diagnosed out of state. Currently the 
MCR collects information on in situ and invasive cancers and benign tumors of the brain and 
associated tissues. The MCR does not collect information on basal and squamous cell carcinomas of 
the skin. 
 
The MCR also collects information from reporting hospitals on cases diagnosed and treated in staff 
physician offices when this information is available. Not all hospitals report this type of case, 
however, some hospitals report such cases as if the patients had been diagnosed and treated by the 
hospital directly. Collecting these types of data makes the MCR’s overall case ascertainment more 
complete. Some cancer types that may be reported to the MCR in this manner are melanoma, prostate, 
colon/rectum, and oral cancers. 
 
In addition, the MCR identifies previously unreported cancer cases through review of death certificate 
data to further improve case completeness. This process is referred to as death clearance and identifies 
cancers mentioned on death certificates that were not previously reported to the MCR. In some 
instances, the MCR obtains additional information on these cases through follow-up activities with 
hospitals, nursing homes, hospice residences, and physicians’ offices. In other instances, a cancer-
related cause of death recorded on a Massachusetts death certificate is the only source of information 
for a cancer case. Thus these “death certificate only” cancer diagnoses are poorly documented and 
have not been confirmed by review of clinical and pathological information. Such cases are included 
in this report, but they comprise less than 3% of all cancer cases. 
 
All case reports that provided the basis for this report were coded following the International 
Classification of Diseases for Oncology, Third Edition (ICD-O-3), which was implemented in North 
America with cases diagnosed as of January 1, 2001. (1)  Please see Appendix A for the classification 
of cancers by ICD-O3 codes. 
 
Each year, the North American Association of Central Cancer Registries (NAACCR) reviews cancer 
registry data for quality, completeness, and timeliness. For 2008-2012, the MCR’s annual case count 
was estimated by NAACCR to be more than 95% complete for each year. The MCR has achieved the 
gold standard for this certification element as well as for six other certification elements for each case 
year since 1997.  
 
The Massachusetts cancer cases presented in this report are primary cases of cancer diagnosed among 
Massachusetts residents during 2008-2012 and reported to the MCR as of December 18, 2015.  These 
data include some additional cases diagnosed in 2008-2011 that were not counted in the previous 
report,   Cancer Incidence in Massachusetts 2007-2011:  City and Town Supplement.   The lag time 
between this report and the annual statewide report of 2008-2012 cancer cases is due to the fact that 
data for this city and town report needed to be cleaned for accuracy of residence within Massachusetts.  
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The statewide report presented data at the state level and did not require such accuracy of city and 
town of residence.  The numbers presented in this report may change slightly in future reports, 
reflecting late reported cases or corrections based on subsequent details from the reporting facilities.  
Such changes might result in slight differences in numbers and rates in future reports of MCR data, 
reflecting the nature of population-based cancer registries that receive case reports on an ongoing 
basis. 
Massachusetts cancer cases presented in this report are primary cases of cancer diagnosed among 
Massachusetts residents during 2008-2012.  The Massachusetts data presented include invasive 
cancers only (except cancer of the urinary bladder, where in situ cancers are also included).  Invasive 
cancers have spread beyond the layer of cells where they started and have the potential to spread to 
other parts of the body.  In situ cancers are neoplasms diagnosed at the earliest stage, before they have 
spread, when they are limited to a small number of cells and have not invaded the organ itself.  
Typically, published incidence rates do not combine invasive and in situ cancers due to differences in 
the biologic significance, survival prognosis and types of treatment of the tumors.  Cancer of the 
urinary bladder is the only exception, due to the specific nature of the diagnostic techniques and 
treatment patterns. 
  
Presentation of Data 
 
Each city and town in Massachusetts is listed alphabetically in the TABLES section.  The observed 
number of cases, the expected number of cases, the standardized incidence ratios, and 95% confidence 
intervals are presented for twenty-three main types of cancer and for all cancer types combined.  The 
“all cancers combined” category includes the twenty-three main types presented in this report and 
other malignant neoplasms.  This category is meant to provide a summary of the total cancer 
experience in a community.  As different cancers have different causes, this category does not reflect 
any specific risk factor that may be important for this community. 
 
Observed and Expected Case Counts 
 
The observed case count (Obs) for a particular type of cancer in a city/town is the actual number of 
newly diagnosed cases among residents of that city/town for a given time period.  
 
A city/town’s expected case count (Exp) for a certain type of cancer for this time period is a calculated 
number based on that city/town’s population distribution2 (by sex and among eighteen age groups) for 
the time period 2008-2012, and the corresponding statewide average annual age-specific incidence 
rates.  The city/town level population data for the 2008 to 2012 period in this report was calculated by 
multiplying 2010 city and town data by five (2).   
 
Standardized Incidence Ratios 
 
A Standardized Incidence Ratio (SIR) is an indirect method of adjustment for age and sex that 
describes in numerical terms how a city/town’s cancer experience in a given time period compares 
with that of the state as a whole. 
 An SIR of exactly 100 indicates that a city/town’s incidence of a certain type of cancer is equal 
to that expected based on statewide average age-specific incidence rates. 
 An SIR of more than 100 indicates that a city/town’s incidence of a certain type of cancer is 
higher than expected for that type of cancer based on statewide average annual age-specific 
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incidence rates.  For example, an SIR of 105 indicates that a city/town’s cancer incidence is 5% 
higher than expected based on statewide average annual age-specific incidence rates. 
 An SIR of less than 100 indicates that a city/town’s incidence of a certain type of cancer is 
lower than expected based on statewide average age-specific incidence rates.  For example, an 
SIR of 85 indicates that a city/town’s cancer incidence is 15% lower than expected based on 
statewide average annual age-specific incidence rates.  
 
Statistical Significance and Interpretation of SIRs 
 
The interpretation of the SIR depends on both how large it is and how stable it is.  Stability in this 
context refers to how much the SIR changes when there are small increases or decreases in the 
observed or expected number of cases.  Two SIRs may have the same size but not the same stability.  
For example, an SIR of 150 may represent 6 observed cases and 4 expected cases, or 600 observed 
cases and 400 expected cases.  Both represent a 50 percent excess of observed cases.  However, in the 
first instance, one or two fewer cases would change the SIR a great deal, whereas in the second 
instance, even if there were several fewer cases, the SIR would only change minimally.  When the 
observed and expected numbers of cases are relatively small, their ratio is easily affected by one or 
two cases.  Conversely, when the observed and expected numbers of cases are relatively large, the 
value of the SIR is stable. 
 
A 95 percent confidence interval (CI) has been presented for each SIR in this report (when the 
observed number of cases is at least 5), to indicate if the observed number of cases is significantly 
different from the expected number, or if the difference is most likely due to chance.  A confidence 
interval is a range of values around a measurement that indicates the precision of the measurement.  In 
this report, the 95% confidence interval is the range of estimated SIR values that has a 95% probability 
of including the true SIR for a specific city or town.  If the 95% confidence interval range does not 
include the value 100.0, then the number of observed cases is significantly different from the expected 
number of cases.  “Significantly different” means there is at most a 5% chance that the difference 
between the number of observed and expected cancer cases is due solely to chance alone.  If the 
confidence interval does contain the value 100, there is no significant difference between the observed 
and expected numbers.  Statistically, the width of the interval reflects the size of the population and 
the number of events; smaller populations and smaller observed numbers of cases yield less precise 
estimates that have wider confidence intervals.  Wide confidence intervals indicate instability, 
meaning that small changes in the observed or expected number of cases would change the SIR a great 
deal. 
 
Examples: 
 SIR = 137.0; 95% CI (101.6 - 180.6) – the confidence interval does not include 100.0 and the 
interval is above 100.0, indicating that the number of observed cases is statistically significantly 
higher than the expected number. 
 
 SIR = 71.0; 95% CI (56.2 – 88.4) – the confidence interval does not include 100.0 and the interval 
is below 100.0, indicating that the number of observed cases is statistically significantly lower 
than the expected number. 
 
 SIR = 108.8 95% CI (71.0-159.4) – the confidence interval DOES include 100.0 indicating that 
the number of observed cases is NOT statistically significantly different from what is expected, 
and the difference is likely due to chance.  When the interval includes 100.0, then the true SIR 
may be 100.0. 
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Example of Calculation of an SIR and Its Significance 
 
 
SIR = 
OBSERVED CASES 
X 100 
 EXPECTED CASES 
 
The following example illustrates the method of calculation for a hypothetical town for one type of 
cancer and one sex for the years 2008-2012: 
 
 
 Town X State Town X Town X 
 Age  Age-Specific Expected Observed 
 Group Population Incidence Rate Cases Cases 
 (A) (B) (C) = (A) x (B) (D) 
 00-04 74,657 0.0001 7.47 11 
 05-09 134,957 0.0002 26.99 25 
 10-14 54,463 0.0005 27.23 30 
 15-19 25,136 0.0015 37.70 40 
 20-24 17,012 0.0018 30.62 30 
    UP TO 
 85+ 6,337 0.0010 6.34 8 
  Total:     136.35 144 
 
 
SIR = 
Observed Cases 
X 100 = 
(column D total) 
X 100 = 
144 
X 100 ≈ 106 
Expected Cases (column C total) 136.35 
 
Thus the SIR for this type of cancer in Town X is 106, indicating that the incidence of this cancer in 
Town X is 6% higher than the corresponding statewide average incidence for this cancer.  However, 
the range for the 95% confidence interval (89.1-124.3) (calculation not shown) indicates that the true 
value may be as low as 89.1 or as high as 124.3  Also, since the range includes the value 100, it means 
that the observed number of cases is not statistically significantly higher or lower than what is 
expected. 
 
Whenever the number of observed cases is less than five, the corresponding SIR is neither calculated 
nor tested for statistical significance. This is indicated with an (nc) (“not calculated”).  However, the 
number of observed and expected cases is shown in these circumstances. 
 
Notes about Data Interpretation 
 
The SIR is a useful indication of the disease categories that have relatively high or low rates for a 
given community.  These statistics, however, should be used with care.  Such statistics provide a 
starting point for further research and investigation into a possible health problem, but they do not by 
themselves confirm or deny the existence of a particular health problem.  Many factors unrelated to 
disease causation may contribute to an elevated SIR, including demographic factors, changes in 
diagnostic techniques, and changes in data collection or recording methods over time, as well as the 
natural variation in disease occurrence.   
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When reviewing the data tables, it is important to keep in mind that an SIR compares the observed 
cancer incidence in a particular community with the expected incidence based on statewide average 
annual age-specific incidence rates.  This means that valid comparisons can only be made between a 
community and the state as a whole.  SIRs for different cities and towns CANNOT and SHOULD NOT be 
compared to each other.  (Comparisons between two communities would be valid only if there were 
no differences in the age and sex distributions of the two communities’ populations.) 
 
Another point to keep in mind when reviewing these data is the large number of statistical tests being 
performed in this report.  For each of the 351 cities and towns, we evaluate 18 types of cancer that can 
occur in both males and females, 3 types that occur only in females and 2 types that occur only in 
males, resulting in 41 gender/cancer categories.  This results in 14,391 possible calculations (351 cities 
and towns x 41 gender cancer categories).  Note that gender/cancer categories with less than 5 
observed cases are not evaluated for statistical significance, so the actual numbers of tests is slightly 
lower than 14,391. This is important for the reader because when multiple significance tests are 
performed, some will result in a significant finding due to chance alone. Based on the number of 
calculations in this report, we expect 720 significant findings to be due to chance alone.  Half of these 
would be significant excesses (360) and half would be significant deficits (360).  There are statistical 
techniques that can be used to reduce this number, however use of these techniques leads to the 
opposite problem – true significant differences that may be missed.  We choose to err on the side of 
caution and identify more significant results, knowing that some will be due to chance alone.   
 
Data Limitations 
 
It should be emphasized that apparent increases or decreases in cancer incidence over time might 
reflect changes in diagnostic methods or case reporting rather than true changes in cancer incidence.  
Four other limitations must be considered when interpreting cancer incidence data for Massachusetts 
cities and towns:  under-reporting in areas close to neighboring states; under-reporting for cancers that 
may not be diagnosed in hospitals; cases being assigned to incorrect cities/towns; and standardized 
incidence ratios based on small numbers of cases. 
 
Border Areas and Neighboring States 
 
Some areas of Massachusetts appear to have low cancer incidence, but this may be due to loss of 
Massachusetts resident cases who are diagnosed in neighboring or other states and not reported to the 
MCR. The MCR has reciprocal reporting agreements with 37 states and with Puerto Rico and Guam. 
 
Cases Diagnosed in Non-Hospital Settings 
 
During the time period covered by this report, the MCR’s primary information source for most newly 
diagnosed cases of cancer was hospitals. In addition the MCR collected information from reporting 
hospitals on cases diagnosed and treated in staff physician offices, when this information was 
available. Other reporting sources include dermatologists and dermatopathology laboratories, 
urologists’ offices and a general laboratory. Some types of cancer in this report may be under-reported 
because they are diagnosed primarily by private physicians, private laboratories, health maintenance 
organizations, radiotherapy centers that escape identification systems used by hospitals.  The most 
common types of cancer diagnosed or treated outside of the hospital include melanoma and prostate 
cancer.   The exact extent of this under-reporting has not been determined, but cases included in this 
report represent the great majority of cases statewide and provide an essential basis for evaluating 
statewide cancer incidence patterns. 
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City/Town Misassignment 
 
In accordance with standard central cancer registry procedures, each case reported to the MCR ideally 
should be assigned to the city/town in which the patient lived at the time of diagnosis, based on the 
address provided by the reporting hospital.  In practice, however, a patient may provide the hospital 
with his/her mailing address (e.g., a post office box located outside the patient’s city/town of 
residence); a business address; a temporary address (e.g., the patient is staying with a relative while 
receiving treatment and reports the relative’s address as his/her own); or a locality or post office name 
(e.g., “Chestnut Hill” rather than “Boston,” “Brookline,” or “Newton”).  In addition, if a patient has 
moved since being diagnosed, the hospital may report the patient’s current address.  Because of the 
large number of cases reported to the MCR, and because data are reported to the MCR via electronic 
media, most city/town case assignments are performed by an automated computer process.  This 
simplified matching process may misassign some cases based on the reported locality name.  When 
MCR staff become aware of such misassignments, they manually correct the errors.  Furthermore, in 
order to minimize such errors, cases from fifty geographic localities prone to city/town misassignment 
are reviewed manually. 
 
Small Numbers of Cases 
 
Standardized incidence ratios based on small numbers of cases result in estimates that are very 
unstable.  This situation is common when the population of a city or town is small or if the particular 
cancer type is rare.  SIRs and statistical significance are not calculated when the number of observed 
cases for a specific category is less than five.  In these instances, the observed and expected cases are 
presented in the tables for qualitative comparison only. 
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APPENDIX I:  INTERNATIONAL CLASSIFICATION OF DISEASES FOR ONCOLOGY (THIRD 
EDITION) 
CODES USED FOR THIS REPORT 1 
 
Cancer Site / Type Primary Site Codes Histologic Type Codes 2 
 
Bladder, Urinary C67.0 - C67.9 all except 9590 - 9989 
 
Brain and Other  C70.0 - C72.9 all except 9590 - 9989 
Nervous System   
 
Breast C50.0 - C50.9 all except 9590 - 9989 
 
Cervix Uteri C53.0 - C53.9 all except 9590 - 9989 
 
Colon / Rectum C18.0 - C18.9, C19.9, all except 9590 - 9989 
 C20.9, C26.0  
 
Esophagus C15.0 - C15.9 all except 9590 - 9989 
 
Hodgkin Lymphoma  C00.0 - C80.9 9650 - 9667 
 
Kidney and Renal Pelvis 3 C64.9, C65.9 all except 9590 - 9989 
 
Larynx C32.0 - C32.9 all except 9590 - 9989 
 
Leukemia  C00.0 - C80.9 9733, 9742, 9800 - 9820, 9826, 
 9831 - 9948, 9963, 9964 
 C42.0, C42.1, C42.4 9823, 9827 
 
Liver and Intrahepatic Bile Ducts C22.0, C22.1 all except 9590 - 9989 
 
Lung and Bronchus C34.0 - C34.9 all except 9590 - 9989 
 
Melanoma of Skin C44.0 - C44.9 8720 - 8790 
 
Multiple Myeloma C00.0 - C80.9 9731, 9732, 9734 
 
Non-Hodgkin Lymphoma C00.0 - C80.9 9590 - 9595, 9670 - 9729 
 all except C42.0, C42.1, C42.4 9823, 9827 
 
Oral Cavity and Pharynx C00.0 - C14.8 all except 9590 - 9989 
 
Ovary C56.9 all except 9590 - 9989 
 
Pancreas C25.0 - C25.9 all except 9590 - 9989 
 
Prostate C61.9 all except 9590 - 9989 
 
Stomach C16.0 - C16.9 all except 9590 - 9989 
 
Testis C62.0 - C62.9 all except 9590 - 9989 
 
Thyroid C73.9 all except 9590 - 9989 
 
Uteri, Corpus and Uterus, NOS C54.0 - C54.9, C55.9 all except 9590 - 9989 
 
All Sites / Types C00.0 - C80.9 8000 - 9989 
 
1 includes codes added to the International Classification of Diseases for Oncology, Third Edition since its publication. 
2 Only invasive cancers (those with invasive behaviors) are included in this publication except Bladder, Urinary, which 
includes invasive and in situ behaviors.  Non-invasive (in situ) cancers are not included. 
3 Massachusetts hospital coding conventions may have assigned some cases to a “not otherwise specified” site category 
that is not included in this cancer type. 
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APPENDIX II:  SELECTED RESOURCES FOR 
INFORMATION ON CANCER 
 
This Appendix contains a listing of selected resources for additional information on cancer. 
Cancers are complex diseases, many of which have multiple factors that may contribute to their 
development.   
 
For information on cancer risk factors or prevention, you may wish to contact the following: 
Cancer Information Service (National Cancer Institute): 1-800-4-CANCER (1-800-422-6237) 
Cancer Response Line (American Cancer Society): 1-800-ACS-2345 (1-800-227-2345) 
 
In addition, the following selected Internet websites provide information on cancer.  Many of 
these also provide links to other sites (not listed) which may be of interest. 
Massachusetts Department of Public Health:  http://www.mass.gov/dph 
 
American Cancer Society:  http://www.cancer.org 
 
Centers for Disease Control and Prevention 
 Home Page:  http://www.cdc.gov 
 Cancer Prevention and Control Program:  http://www.cdc.gov/cancer 
Fruits and Veggies More Matters™ Campaign (nutrition – formerly 5-A-Day Program):  
http://www.FruitsandVeggiesMatter.gov 
 
National Cancer Institute 
 Information:  http://www.cancer.gov 
 Cancer Literature in PubMed:  http://www.cancer.gov/search/cancer_literature 
 Surveillance, Epidemiology, and End Results (SEER) Program data:  http://seer.cancer.gov 
 
Your Cancer Risk (Siteman Cancer Center at Barnes-Jewish Hospital and Washington 
University School of Medicine; formerly at Harvard Center for Cancer Prevention):  
http://www.yourdiseaserisk.wustl.edu 
 
OncoLink (Abramson Cancer Center of the University of Pennsylvania): 
http://www.oncolink.upenn.edu 
 
Cancerquest (Emory University – Winship Cancer Institute):  www.cancerquest.org 
 
Cancer News on the Net® (information on diagnosis and treatment for cancer patients and 
their families):  http://www.cancernews.com 
 
National Coalition for Cancer Survivorship:  http://www.canceradvocacy.org 
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APPENDIX III:  MDPH CANCER PREVENTION AND CONTROL INITIATIVES  
 
The Massachusetts Department of Public Health is working to reduce the incidence and mortality 
of cancer in the Commonwealth.  Partnerships between MDPH programs, researchers, healthcare 
providers and nonprofit organizations collect information about cancer, lead quality improvement 
projects, coordinate evidenced-based workshops for managing living with chronic disease 
(including cancer), provide education for health professionals and bring shared messages to the 
public. Our collaborated efforts focus on reducing cancer risk, incidence and mortality through 
healthy lifestyles, early diagnosis, increased access to care, and improved quality of life for 
cancer survivors. The Department’s programs address the impact of tobacco, alcohol, nutrition, 
and physical activity on cancer prevention, along with environmental and occupational hazards 
for cancer. Throughout all of our efforts there is an emphasis on reducing disparate health 
outcomes and unequal access to cancer care. 
 
MDPH Bureaus and Programs:  
Bureau of Environmental Health, www.mass.gov/dph/environmental_health  
Bureau of Substance Abuse Services, www.mass.gov/dph/bsas 
Comprehensive Cancer Prevention and Control Network, www.mass.gov/compcancer 
Cancer Care Coordination Program, www.mass.gov/dph/cccp 
Tobacco Cessation and Prevention Program, www.mass.gov/dph/mtcp  
Occupational Health Surveillance Program, www.mass.gov/dph/ohsp 
Office of Healthy Aging, www.mass.gov/dph/healthyaging  
Oral Health Program, www.mass.gov/dph/oralhealth  
Division of Prevention and Wellness www.mass.gov/dph/healthpromotion 
 
MDPH publications on cancer prevention and screening are available at the Massachusetts Health 
Promotion Clearinghouse, www.maclearinghouse.com.  
 
Massachusetts Cancer Registry Publications are available through the Massachusetts Cancer 
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Abington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 18 14.7 122.5 (72.6-193.7)   Male 14 10.1 138.3 (75.5-232.0) 
Female 7 5.5 128.3 (51.4-264.4)   Female 13 8.6 151.6 (80.6-259.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 3.1 nc (nc-nc)   Male 4 2.9 nc (nc-nc) 
Female 4 2.6 nc (nc-nc)   Female 2 2.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.5 nc (nc-nc)   Male 9 8.9 100.7 (45.9-191.1) 
Female 63 65.3 96.5 (74.2-123.5)   Female 5 7.6 65.5 (21.1-152.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 7.5 80.1 (29.2-174.3) 
Female 3 2.4 nc (nc-nc)   Female 3 3.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 21 17.0 123.7 (76.5-189.1)             
Female 21 16.9 124.3 (76.9-190.0)   Female 8 5.9 135.9 (58.5-267.7) 
Esophagus            Pancreas     
Male 4 4.2 nc (nc-nc)   Male 4 5.2 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 3 5.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 1.4 nc (nc-nc)   Male 61 57.2 106.6 (81.5-136.9) 
Female 2 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 20 8.8 228.6 (139.5-353.0)   Male 4 3.6 nc (nc-nc) 
Female 8 5.0 158.8 (68.4-312.9)   Female 4 2.1 nc (nc-nc) 
Larynx            Testis     
Male 2 2.3 nc (nc-nc)   Male 2 2.4 nc (nc-nc) 
Female 6 0.8 767.0 (280.1-1669.4)             
Leukemia            Thyroid     
Male 3 6.1 nc (nc-nc)   Male 3 4.3 nc (nc-nc) 
Female 8 4.6 175.2 (75.4-345.3)   Female 21 13.1 160.4 (99.2-245.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 5.4 111.4 (40.7-242.5)             
Female 1 1.7 nc (nc-nc)   Female 18 14.8 121.3 (71.9-191.8) 
Lung and Bronchus            All Sites / Types     
Male 46 27.1 169.7 (124.3-226.4)   Male 250 208.0 120.2 (105.8-136.1) 
Female 43 29.0 148.1 (107.2-199.5)   Female 258 215.4 119.8 (105.6-135.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
10 
Acton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 21 20.3 103.5 (64.0-158.2)   Male 13 14.2 91.8 (48.8-157.0) 
Female 7 7.0 99.6 (39.9-205.2)   Female 17 11.3 150.1 (87.4-240.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 8 4.4 183.3 (78.9-361.1)   Male 3 4.1 nc (nc-nc) 
Female 1 3.5 nc (nc-nc)   Female 5 3.1 161.3 (52.0-376.5) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.7 nc (nc-nc)   Male 14 12.5 111.9 (61.1-187.8) 
Female 102 90.3 112.9 (92.1-137.1)   Female 14 10.1 139.3 (76.1-233.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 10.8 92.9 (44.5-170.8) 
Female 3 3.3 nc (nc-nc)   Female 5 4.3 115.5 (37.2-269.4) 
Colon / Rectum            Ovary     
Male 20 24.0 83.4 (50.9-128.8)             
Female 22 22.1 99.4 (62.3-150.5)   Female 14 8.0 176.0 (96.1-295.3) 
Esophagus            Pancreas     
Male 5 5.8 85.5 (27.6-199.6)   Male 10 7.2 139.3 (66.7-256.1) 
Female 3 1.4 nc (nc-nc)   Female 4 6.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 1.8 nc (nc-nc)   Male 81 79.7 101.6 (80.7-126.3) 
Female 1 1.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 11 12.4 88.7 (44.2-158.8)   Male 1 5.0 nc (nc-nc) 
Female 5 6.8 73.9 (23.8-172.5)   Female 4 2.7 nc (nc-nc) 
Larynx            Testis     
Male 2 3.3 nc (nc-nc)   Male 2 2.9 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 8.6 105.2 (48.0-199.7)   Male 5 6.0 83.8 (27.0-195.6) 
Female 11 6.0 183.6 (91.5-328.5)   Female 14 17.7 78.9 (43.1-132.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 7.7 nc (nc-nc)             
Female 2 2.2 nc (nc-nc)   Female 19 20.2 93.8 (56.5-146.5) 
Lung and Bronchus            All Sites / Types     
Male 19 37.8 50.3 (30.3-78.6)   Male 250 290.2 86.1 (75.8-97.5) 
Female 26 37.9 68.5 (44.8-100.4)   Female 299 288.7 103.6 (92.1-116.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
11 
Acushnet 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 20 12.5 160.5 (98.0-247.9)   Male 8 8.0 99.6 (42.9-196.3) 
Female 5 4.4 112.7 (36.3-263.1)   Female 5 6.2 80.9 (26.1-188.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 2.3 310.4 (124.4-639.6)   Male 3 2.4 nc (nc-nc) 
Female 0 1.9 nc (nc-nc)   Female 4 1.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 11 7.1 155.0 (77.3-277.3) 
Female 44 48.0 91.6 (66.6-123.0)   Female 6 5.9 101.6 (37.1-221.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 5.7 nc (nc-nc) 
Female 1 1.6 nc (nc-nc)   Female 2 2.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 15 13.7 109.5 (61.2-180.6)             
Female 10 13.5 74.0 (35.4-136.1)   Female 4 4.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 3.4 nc (nc-nc)   Male 8 4.2 189.2 (81.5-372.8) 
Female 0 0.9 nc (nc-nc)   Female 4 4.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 4 0.9 nc (nc-nc)   Male 55 45.2 121.8 (91.7-158.5) 
Female 1 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 9 6.8 133.3 (60.8-253.0)   Male 1 2.9 nc (nc-nc) 
Female 4 3.8 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Larynx            Testis     
Male 2 1.9 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 4.8 nc (nc-nc)   Male 1 3.0 nc (nc-nc) 
Female 6 3.5 173.1 (63.2-376.8)   Female 11 8.6 127.7 (63.7-228.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 4.2 nc (nc-nc)             
Female 0 1.3 nc (nc-nc)   Female 11 10.9 100.5 (50.1-179.8) 
Lung and Bronchus            All Sites / Types     
Male 34 22.6 150.2 (104.0-209.9)   Male 197 166.0 118.7 (102.7-136.4) 
Female 22 23.0 95.5 (59.8-144.5)   Female 152 162.7 93.5 (79.2-109.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
12 
Adams 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 10 11.6 86.1 (41.2-158.3)   Male 5 7.1 70.5 (22.7-164.4) 
Female 6 4.4 137.2 (50.1-298.6)   Female 4 5.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.9 nc (nc-nc)   Male 6 2.1 282.3 (103.1-614.4) 
Female 2 1.7 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 7 6.3 111.4 (44.6-229.6) 
Female 34 42.3 80.4 (55.7-112.3)   Female 9 5.6 162.0 (73.9-307.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 4.8 nc (nc-nc) 
Female 2 1.4 nc (nc-nc)   Female 0 2.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 11 12.3 89.4 (44.6-159.9)             
Female 12 13.2 91.1 (47.0-159.1)   Female 3 3.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 3.0 nc (nc-nc)   Male 3 3.9 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 5 4.3 116.2 (37.4-271.1) 
Hodgkin Lymphoma            Prostate     
Male 1 0.7 nc (nc-nc)   Male 45 38.5 116.8 (85.2-156.3) 
Female 1 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 5.7 nc (nc-nc)   Male 0 2.6 nc (nc-nc) 
Female 3 3.5 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Larynx            Testis     
Male 1 1.6 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 4.4 nc (nc-nc)   Male 3 2.5 nc (nc-nc) 
Female 2 3.3 nc (nc-nc)   Female 5 7.1 70.5 (22.7-164.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 3.6 nc (nc-nc)             
Female 0 1.3 nc (nc-nc)   Female 7 9.7 72.5 (29.0-149.3) 
Lung and Bronchus            All Sites / Types     
Male 18 20.6 87.6 (51.9-138.4)   Male 134 146.3 91.6 (76.7-108.5) 
Female 36 21.9 164.6 (115.3-227.9)   Female 144 149.2 96.5 (81.4-113.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
13 
Agawam 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 36 36.6 98.5 (68.9-136.3)   Male 20 22.7 88.0 (53.8-136.0) 
Female 13 14.7 88.5 (47.1-151.3)   Female 14 18.6 75.2 (41.1-126.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 6.2 80.3 (25.9-187.5)   Male 5 6.7 74.3 (23.9-173.3) 
Female 3 5.7 nc (nc-nc)   Female 4 6.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.1 nc (nc-nc)   Male 24 20.1 119.2 (76.4-177.4) 
Female 156 142.4 109.5 (93.0-128.1)   Female 17 18.7 91.0 (53.0-145.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 24 15.7 152.8 (97.9-227.4) 
Female 7 4.6 151.6 (60.7-312.4)   Female 9 7.6 118.0 (53.8-224.0) 
Colon / Rectum            Ovary     
Male 42 39.6 106.1 (76.5-143.5)             
Female 45 44.6 100.8 (73.5-134.9)   Female 11 13.3 83.0 (41.4-148.5) 
Esophagus            Pancreas     
Male 6 9.4 63.8 (23.3-138.9)   Male 12 12.3 97.9 (50.5-171.1) 
Female 3 2.8 nc (nc-nc)   Female 12 14.5 82.5 (42.6-144.2) 
Hodgkin Lymphoma            Prostate     
Male 0 2.5 nc (nc-nc)   Male 110 123.5 89.1 (73.2-107.4) 
Female 4 2.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 22 18.5 118.9 (74.5-180.1)   Male 12 8.4 143.1 (73.8-249.9) 
Female 8 11.7 68.6 (29.5-135.2)   Female 5 5.7 87.6 (28.2-204.4) 
Larynx            Testis     
Male 6 5.1 116.6 (42.6-253.9)   Male 2 3.9 nc (nc-nc) 
Female 1 1.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 14.0 64.4 (29.4-122.2)   Male 7 8.1 86.1 (34.5-177.5) 
Female 9 11.2 80.6 (36.8-153.1)   Female 19 23.9 79.6 (47.9-124.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 11.7 59.7 (23.9-123.0)             
Female 2 4.2 nc (nc-nc)   Female 25 32.4 77.2 (50.0-114.0) 
Lung and Bronchus            All Sites / Types     
Male 81 64.6 125.4 (99.6-155.9)   Male 461 467.6 98.6 (89.8-108.0) 
Female 77 72.1 106.8 (84.2-133.4)   Female 479 501.2 95.6 (87.2-104.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
14 
Alford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.0 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.1 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 4 3.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 1.1 nc (nc-nc)             
Female 0 0.9 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 2 3.9 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.5 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 2 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.3 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 1.9 nc (nc-nc)   Male 3 13.3 nc (nc-nc) 
Female 0 1.6 nc (nc-nc)   Female 8 10.7 74.9 (32.2-147.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
15 
Amesbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 23 15.4 149.1 (94.5-223.8)   Male 14 10.6 132.1 (72.2-221.7) 
Female 10 6.2 161.9 (77.5-297.8)   Female 9 9.3 96.9 (44.2-184.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 3.2 nc (nc-nc)   Male 5 3.1 163.5 (52.7-381.5) 
Female 6 2.8 212.6 (77.6-462.7)   Female 2 2.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 10 9.3 107.0 (51.2-196.8) 
Female 81 71.2 113.8 (90.4-141.5)   Female 11 8.4 130.3 (64.9-233.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 14 7.8 178.8 (97.7-300.0) 
Female 2 2.6 nc (nc-nc)   Female 5 3.6 140.1 (45.2-327.0) 
Colon / Rectum            Ovary     
Male 22 17.8 123.5 (77.4-187.0)             
Female 29 19.3 150.2 (100.6-215.7)   Female 8 6.4 124.4 (53.6-245.1) 
Esophagus            Pancreas     
Male 10 4.3 230.9 (110.5-424.6)   Male 10 5.4 186.0 (89.1-342.1) 
Female 1 1.2 nc (nc-nc)   Female 7 6.0 116.2 (46.6-239.4) 
Hodgkin Lymphoma            Prostate     
Male 2 1.4 nc (nc-nc)   Male 58 58.7 98.8 (75.1-127.8) 
Female 1 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 9.1 nc (nc-nc)   Male 2 3.7 nc (nc-nc) 
Female 3 5.5 nc (nc-nc)   Female 1 2.4 nc (nc-nc) 
Larynx            Testis     
Male 1 2.4 nc (nc-nc)   Male 1 2.4 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 6.4 140.5 (64.1-266.7)   Male 1 4.4 nc (nc-nc) 
Female 5 5.1 98.6 (31.8-230.1)   Female 13 13.8 94.1 (50.0-160.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 5.7 87.9 (28.3-205.1)             
Female 3 1.9 nc (nc-nc)   Female 13 16.0 81.1 (43.2-138.8) 
Lung and Bronchus            All Sites / Types     
Male 30 28.4 105.7 (71.3-151.0)   Male 243 216.1 112.4 (98.7-127.5) 
Female 44 31.9 137.9 (100.2-185.1)   Female 273 236.8 115.3 (102.0-129.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
16 
Amherst 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 14 20.6 68.0 (37.1-114.1)   Male 8 13.7 58.5 (25.2-115.2) 
Female 2 8.0 nc (nc-nc)   Female 14 13.4 104.5 (57.1-175.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 4.8 nc (nc-nc)   Male 4 3.8 nc (nc-nc) 
Female 2 4.5 nc (nc-nc)   Female 0 3.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.6 nc (nc-nc)   Male 8 12.8 62.3 (26.8-122.7) 
Female 75 83.0 90.4 (71.1-113.3)   Female 14 11.2 125.5 (68.5-210.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 9.3 107.7 (51.5-198.0) 
Female 3 3.0 nc (nc-nc)   Female 2 4.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 17 22.2 76.7 (44.7-122.9)             
Female 19 24.5 77.4 (46.6-120.9)   Female 12 8.5 141.1 (72.8-246.6) 
Esophagus            Pancreas     
Male 3 5.4 nc (nc-nc)   Male 5 6.9 72.5 (23.4-169.2) 
Female 0 1.5 nc (nc-nc)   Female 5 7.9 63.3 (20.4-147.8) 
Hodgkin Lymphoma            Prostate     
Male 0 3.8 nc (nc-nc)   Male 66 71.7 92.0 (71.1-117.0) 
Female 1 3.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 10.7 55.9 (20.4-121.7)   Male 1 4.7 nc (nc-nc) 
Female 5 6.8 73.5 (23.7-171.5)   Female 1 3.2 nc (nc-nc) 
Larynx            Testis     
Male 1 3.0 nc (nc-nc)   Male 2 6.6 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 9.6 93.9 (42.8-178.2)   Male 5 6.2 81.3 (26.2-189.7) 
Female 5 7.3 68.5 (22.1-160.0)   Female 5 20.6 24.2 (7.8-56.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 6.9 nc (nc-nc)             
Female 2 2.4 nc (nc-nc)   Female 14 19.3 72.6 (39.6-121.8) 
Lung and Bronchus            All Sites / Types     
Male 15 36.8 40.7 (22.8-67.2)   Male 199 283.0 70.3 (60.9-80.8) 
Female 20 40.9 48.9 (29.9-75.5)   Female 221 303.7 72.8 (63.5-83.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
17 
Andover 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 26 34.1 76.1 (49.7-111.6)   Male 21 22.8 92.2 (57.1-141.0) 
Female 13 12.9 100.8 (53.6-172.4)   Female 24 18.6 128.9 (82.6-191.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 6.7 88.9 (32.5-193.6)   Male 8 6.7 119.6 (51.5-235.7) 
Female 5 5.8 86.2 (27.8-201.2)   Female 6 5.5 108.6 (39.7-236.4) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.1 nc (nc-nc)   Male 25 20.1 124.4 (80.5-183.7) 
Female 144 145.7 98.8 (83.4-116.4)   Female 17 17.4 97.6 (56.8-156.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 24 16.8 142.8 (91.5-212.5) 
Female 2 5.1 nc (nc-nc)   Female 5 7.3 68.3 (22.0-159.4) 
Colon / Rectum            Ovary     
Male 28 38.8 72.1 (47.9-104.2)             
Female 33 40.1 82.4 (56.7-115.7)   Female 17 13.2 129.2 (75.2-206.9) 
Esophagus            Pancreas     
Male 7 9.5 73.6 (29.5-151.7)   Male 12 11.9 101.2 (52.3-176.9) 
Female 3 2.5 nc (nc-nc)   Female 11 12.6 87.3 (43.5-156.2) 
Hodgkin Lymphoma            Prostate     
Male 3 2.7 nc (nc-nc)   Male 127 128.8 98.6 (82.2-117.3) 
Female 3 2.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 12 19.5 61.5 (31.7-107.4)   Male 10 8.1 122.7 (58.7-225.7) 
Female 10 11.4 88.0 (42.1-161.8)   Female 4 5.0 nc (nc-nc) 
Larynx            Testis     
Male 2 5.3 nc (nc-nc)   Male 6 4.2 141.7 (51.7-308.4) 
Female 2 1.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 20 13.8 144.5 (88.2-223.2)   Male 15 9.0 166.5 (93.1-274.7) 
Female 13 10.5 124.2 (66.1-212.5)   Female 34 26.9 126.5 (87.6-176.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 10 12.3 81.2 (38.9-149.3)             
Female 2 3.9 nc (nc-nc)   Female 28 32.7 85.6 (56.9-123.7) 
Lung and Bronchus            All Sites / Types     
Male 37 62.9 58.8 (41.4-81.1)   Male 432 470.4 91.8 (83.4-100.9) 
Female 41 66.6 61.6 (44.2-83.6)   Female 451 485.9 92.8 (84.5-101.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
18 
Aquinnah 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 0.4 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 3 1.3 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.0 nc (nc-nc) 
Larynx            Testis     
Male 0 0.1 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.1 nc (nc-nc)             
Female 0 0.0 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 0.6 nc (nc-nc)   Male 4 4.6 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 3 4.6 nc (nc-nc) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
19 
Arlington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 44 47.8 92.1 (66.9-123.6)   Male 32 30.7 104.3 (71.4-147.3) 
Female 20 19.7 101.4 (61.9-156.7)   Female 28 27.1 103.4 (68.7-149.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 8.7 nc (nc-nc)   Male 12 9.0 134.1 (69.2-234.2) 
Female 8 8.3 96.9 (41.7-191.0)   Female 8 8.3 96.6 (41.6-190.4) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.5 nc (nc-nc)   Male 21 27.0 77.7 (48.1-118.7) 
Female 234 204.2 114.6 (100.4-130.2)   Female 29 25.8 112.3 (75.2-161.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 14 21.0 66.8 (36.5-112.1) 
Female 1 7.3 nc (nc-nc)   Female 17 10.6 160.2 (93.3-256.5) 
Colon / Rectum            Ovary     
Male 44 52.2 84.3 (61.2-113.2)             
Female 54 60.3 89.6 (67.3-116.9)   Female 20 18.7 107.0 (65.3-165.3) 
Esophagus            Pancreas     
Male 15 12.3 121.6 (68.0-200.5)   Male 12 16.0 75.0 (38.7-131.0) 
Female 1 3.8 nc (nc-nc)   Female 19 19.3 98.2 (59.1-153.4) 
Hodgkin Lymphoma            Prostate     
Male 2 3.6 nc (nc-nc)   Male 154 160.3 96.1 (81.5-112.5) 
Female 5 3.2 156.9 (50.6-366.3)             
Kidney & Renal Pelvis            Stomach     
Male 24 25.1 95.7 (61.3-142.4)   Male 10 11.1 90.5 (43.3-166.4) 
Female 14 16.5 84.8 (46.3-142.3)   Female 5 7.6 65.7 (21.2-153.3) 
Larynx            Testis     
Male 3 6.8 nc (nc-nc)   Male 7 6.2 112.5 (45.1-231.8) 
Female 2 2.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 16 18.8 85.2 (48.7-138.4)   Male 12 11.5 104.1 (53.7-181.8) 
Female 13 15.6 83.4 (44.4-142.6)   Female 36 37.8 95.2 (66.6-131.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 18 15.5 115.8 (68.6-183.1)             
Female 3 5.8 nc (nc-nc)   Female 41 45.8 89.6 (64.3-121.5) 
Lung and Bronchus            All Sites / Types     
Male 71 85.0 83.5 (65.2-105.3)   Male 557 618.8 90.0 (82.7-97.8) 
Female 77 99.6 77.3 (61.0-96.6)   Female 695 705.5 98.5 (91.3-106.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
20 
Ashburnham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 9 5.7 157.1 (71.7-298.3)   Male 2 4.1 nc (nc-nc) 
Female 2 1.7 nc (nc-nc)   Female 4 2.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.2 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 3 3.6 nc (nc-nc) 
Female 20 23.0 86.8 (53.0-134.0)   Female 3 2.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 3.2 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 6.8 nc (nc-nc)             
Female 4 5.4 nc (nc-nc)   Female 1 2.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.7 nc (nc-nc)   Male 2 2.1 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.5 nc (nc-nc)   Male 22 23.6 93.2 (58.4-141.1) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 3.6 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 2 1.7 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Larynx            Testis     
Male 0 1.0 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 2.4 205.4 (66.2-479.4)   Male 3 1.7 nc (nc-nc) 
Female 3 1.5 nc (nc-nc)   Female 4 4.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.3 nc (nc-nc)             
Female 0 0.6 nc (nc-nc)   Female 5 5.2 95.4 (30.7-222.5) 
Lung and Bronchus            All Sites / Types     
Male 6 10.8 55.7 (20.3-121.2)   Male 67 83.9 79.8 (61.9-101.4) 
Female 8 9.3 85.9 (37.0-169.3)   Female 66 72.9 90.5 (70.0-115.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
21 
Ashby 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 3.0 nc (nc-nc)   Male 5 2.2 231.8 (74.7-541.0) 
Female 2 0.9 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.6 nc (nc-nc)   Male 3 0.6 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 3 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.9 nc (nc-nc) 
Female 13 12.2 106.3 (56.5-181.7)   Female 2 1.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.7 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 3.6 nc (nc-nc)             
Female 2 3.0 nc (nc-nc)   Female 4 1.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.9 nc (nc-nc)   Male 2 1.1 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 2 0.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.3 nc (nc-nc)   Male 9 12.5 71.9 (32.8-136.4) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.9 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Larynx            Testis     
Male 2 0.5 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.3 nc (nc-nc)   Male 2 0.9 nc (nc-nc) 
Female 2 0.8 nc (nc-nc)   Female 1 2.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.2 nc (nc-nc)             
Female 2 0.3 nc (nc-nc)   Female 5 2.8 180.2 (58.1-420.6) 
Lung and Bronchus            All Sites / Types     
Male 3 5.7 nc (nc-nc)   Male 40 44.5 89.9 (64.2-122.4) 
Female 5 5.1 98.4 (31.7-229.7)   Female 50 39.0 128.1 (95.1-168.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
22 
Ashfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 2.3 nc (nc-nc)   Male 0 1.5 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.4 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 4 1.3 nc (nc-nc) 
Female 13 9.1 143.5 (76.4-245.5)   Female 1 1.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.1 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 2.6 nc (nc-nc)             
Female 2 2.3 nc (nc-nc)   Female 2 0.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.7 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 7 9.3 75.3 (30.2-155.1) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.3 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.4 nc (nc-nc)   Male 2 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.9 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 1.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.9 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 4 2.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 4.3 nc (nc-nc)   Male 22 32.1 68.6 (43.0-103.9) 
Female 1 4.1 nc (nc-nc)   Female 26 29.6 87.7 (57.3-128.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
23 
Ashland 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 15 14.9 100.7 (56.3-166.1)   Male 6 10.4 57.5 (21.0-125.2) 
Female 4 5.4 nc (nc-nc)   Female 5 8.8 57.1 (18.4-133.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 3.2 nc (nc-nc)   Male 6 3.0 200.5 (73.2-436.4) 
Female 3 2.7 nc (nc-nc)   Female 3 2.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 10 9.2 108.9 (52.1-200.3) 
Female 66 67.6 97.7 (75.6-124.3)   Female 4 7.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 7.8 nc (nc-nc) 
Female 2 2.6 nc (nc-nc)   Female 3 3.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 10 17.5 57.2 (27.4-105.3)             
Female 20 16.8 119.3 (72.8-184.2)   Female 10 6.0 166.0 (79.5-305.3) 
Esophagus            Pancreas     
Male 8 4.2 188.5 (81.2-371.5)   Male 6 5.2 114.4 (41.8-249.1) 
Female 2 1.0 nc (nc-nc)   Female 6 5.2 116.3 (42.5-253.1) 
Hodgkin Lymphoma            Prostate     
Male 2 1.4 nc (nc-nc)   Male 48 57.7 83.1 (61.3-110.2) 
Female 1 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 9 9.0 99.5 (45.4-189.0)   Male 4 3.6 nc (nc-nc) 
Female 3 5.1 nc (nc-nc)   Female 4 2.1 nc (nc-nc) 
Larynx            Testis     
Male 1 2.4 nc (nc-nc)   Male 4 2.4 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 6.3 nc (nc-nc)   Male 5 4.4 112.6 (36.3-262.7) 
Female 8 4.6 173.5 (74.7-341.9)   Female 23 13.8 166.7 (105.6-250.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 5.6 nc (nc-nc)             
Female 4 1.7 nc (nc-nc)   Female 16 15.3 104.2 (59.5-169.3) 
Lung and Bronchus            All Sites / Types     
Male 27 27.5 98.1 (64.6-142.7)   Male 179 212.2 84.4 (72.5-97.7) 
Female 39 29.0 134.6 (95.7-183.9)   Female 237 219.1 108.1 (94.8-122.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
24 
Athol 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 17 13.2 128.8 (75.0-206.3)   Male 6 8.4 71.1 (26.0-154.8) 
Female 4 4.9 nc (nc-nc)   Female 4 6.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 2.4 nc (nc-nc)   Male 1 2.5 nc (nc-nc) 
Female 0 2.1 nc (nc-nc)   Female 0 2.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 4 7.5 nc (nc-nc) 
Female 35 50.2 69.7 (48.5-96.9)   Female 4 6.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 5.9 170.0 (81.4-312.7) 
Female 0 1.7 nc (nc-nc)   Female 4 2.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 19 14.5 131.4 (79.1-205.2)             
Female 12 15.1 79.5 (41.0-138.8)   Female 7 4.7 150.4 (60.3-309.9) 
Esophagus            Pancreas     
Male 6 3.5 173.3 (63.3-377.3)   Male 5 4.5 112.2 (36.2-261.9) 
Female 0 0.9 nc (nc-nc)   Female 5 4.8 103.3 (33.3-241.0) 
Hodgkin Lymphoma            Prostate     
Male 4 1.0 nc (nc-nc)   Male 32 45.9 69.8 (47.7-98.5) 
Female 2 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 9 7.0 129.4 (59.0-245.7)   Male 1 3.1 nc (nc-nc) 
Female 5 4.1 123.1 (39.7-287.2)   Female 0 1.9 nc (nc-nc) 
Larynx            Testis     
Male 2 1.9 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 5.2 nc (nc-nc)   Male 0 3.2 nc (nc-nc) 
Female 5 3.9 128.6 (41.4-300.1)   Female 12 9.1 131.3 (67.8-229.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 4.4 114.2 (36.8-266.6)             
Female 1 1.4 nc (nc-nc)   Female 23 11.3 203.2 (128.8-304.9) 
Lung and Bronchus            All Sites / Types     
Male 38 23.6 160.7 (113.7-220.6)   Male 178 173.0 102.9 (88.3-119.2) 
Female 28 24.5 114.4 (76.0-165.3)   Female 166 174.4 95.2 (81.3-110.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
25 
Attleboro 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 43 42.5 101.2 (73.2-136.3)   Male 28 28.6 98.0 (65.1-141.7) 
Female 15 16.0 93.7 (52.4-154.5)   Female 17 23.7 71.8 (41.8-114.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 11 8.6 128.6 (64.1-230.1)   Male 5 8.2 60.7 (19.6-141.7) 
Female 7 7.3 95.6 (38.3-197.0)   Female 6 6.8 87.8 (32.1-191.2) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.4 nc (nc-nc)   Male 16 25.3 63.3 (36.2-102.9) 
Female 175 177.8 98.4 (84.4-114.1)   Female 19 21.7 87.6 (52.7-136.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 24 20.4 117.9 (75.5-175.5) 
Female 7 6.5 107.6 (43.1-221.7)   Female 10 9.0 110.7 (53.0-203.6) 
Colon / Rectum            Ovary     
Male 50 48.2 103.8 (77.0-136.8)             
Female 40 49.6 80.7 (57.6-109.9)   Female 31 16.2 191.6 (130.1-271.9) 
Esophagus            Pancreas     
Male 10 11.5 87.0 (41.7-160.1)   Male 17 14.5 116.9 (68.1-187.2) 
Female 5 3.1 163.3 (52.6-381.2)   Female 16 15.6 102.3 (58.5-166.2) 
Hodgkin Lymphoma            Prostate     
Male 9 3.8 236.6 (108.0-449.2)   Male 143 152.6 93.7 (79.0-110.4) 
Female 1 3.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 18 24.0 74.9 (44.4-118.5)   Male 7 10.1 69.3 (27.8-142.9) 
Female 12 14.1 85.4 (44.1-149.2)   Female 7 6.2 112.4 (45.0-231.6) 
Larynx            Testis     
Male 5 6.4 78.3 (25.2-182.6)   Male 6 6.7 89.5 (32.7-194.8) 
Female 3 2.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 17.5 45.8 (19.7-90.3)   Male 11 11.6 94.8 (47.2-169.6) 
Female 10 13.2 75.7 (36.2-139.2)   Female 24 35.0 68.6 (44.0-102.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 12 14.8 81.0 (41.8-141.5)             
Female 10 4.8 207.0 (99.1-380.8)   Female 43 39.8 108.2 (78.3-145.7) 
Lung and Bronchus            All Sites / Types     
Male 101 76.9 131.3 (106.9-159.5)   Male 563 577.7 97.5 (89.6-105.8) 
Female 90 82.5 109.1 (87.7-134.1)   Female 593 602.0 98.5 (90.7-106.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
26 
Auburn 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 22 22.3 98.5 (61.7-149.1)   Male 10 13.6 73.7 (35.3-135.5) 
Female 9 7.9 114.1 (52.0-216.5)   Female 6 10.3 58.4 (21.3-127.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 3.7 nc (nc-nc)   Male 2 4.0 nc (nc-nc) 
Female 4 3.2 nc (nc-nc)   Female 8 3.3 242.8 (104.5-478.4) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.7 nc (nc-nc)   Male 10 12.0 83.1 (39.8-152.8) 
Female 77 78.7 97.9 (77.2-122.3)   Female 13 10.1 128.1 (68.1-219.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 13 9.1 143.6 (76.4-245.6) 
Female 1 2.6 nc (nc-nc)   Female 2 4.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 19 23.6 80.4 (48.4-125.5)             
Female 24 23.9 100.6 (64.5-149.7)   Female 8 7.3 110.2 (47.5-217.2) 
Esophagus            Pancreas     
Male 5 5.6 89.7 (28.9-209.3)   Male 6 7.4 81.6 (29.8-177.6) 
Female 2 1.5 nc (nc-nc)   Female 7 7.7 90.3 (36.2-186.1) 
Hodgkin Lymphoma            Prostate     
Male 2 1.4 nc (nc-nc)   Male 55 71.8 76.6 (57.7-99.7) 
Female 2 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 13 10.8 119.8 (63.7-204.9)   Male 4 5.0 nc (nc-nc) 
Female 6 6.4 93.4 (34.1-203.3)   Female 1 3.0 nc (nc-nc) 
Larynx            Testis     
Male 6 3.0 197.4 (72.1-429.6)   Male 4 2.2 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 8.4 119.0 (57.0-218.9)   Male 3 4.7 nc (nc-nc) 
Female 5 6.0 82.7 (26.7-193.1)   Female 15 13.6 110.6 (61.9-182.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 6.8 102.4 (41.0-211.0)             
Female 0 2.3 nc (nc-nc)   Female 18 17.8 101.0 (59.8-159.6) 
Lung and Bronchus            All Sites / Types     
Male 28 39.2 71.5 (47.5-103.3)   Male 239 277.8 86.0 (75.5-97.7) 
Female 45 39.7 113.3 (82.6-151.6)   Female 277 274.4 100.9 (89.4-113.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
27 
Avon 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 5.4 130.0 (52.1-267.8)   Male 4 3.4 nc (nc-nc) 
Female 0 2.1 nc (nc-nc)   Female 3 2.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.0 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 2 0.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 4 3.0 nc (nc-nc) 
Female 25 21.3 117.3 (75.9-173.2)   Female 2 2.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 2.4 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 5.9 nc (nc-nc)             
Female 3 6.2 nc (nc-nc)   Female 4 1.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.4 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 2 0.4 nc (nc-nc)   Female 2 2.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.4 nc (nc-nc)   Male 8 18.4 43.4 (18.7-85.6) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 2.8 213.6 (78.0-465.0)   Male 1 1.2 nc (nc-nc) 
Female 2 1.7 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Larynx            Testis     
Male 1 0.8 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 2.1 nc (nc-nc)   Male 2 1.3 nc (nc-nc) 
Female 2 1.6 nc (nc-nc)   Female 5 3.7 136.4 (43.9-318.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 1.8 nc (nc-nc)             
Female 0 0.6 nc (nc-nc)   Female 1 4.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 16 9.7 165.7 (94.7-269.1)   Male 77 69.8 110.3 (87.0-137.8) 
Female 14 10.8 129.7 (70.8-217.6)   Female 72 73.4 98.1 (76.7-123.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
28 
Ayer 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 6.4 108.8 (43.6-224.3)   Male 3 4.5 nc (nc-nc) 
Female 3 2.5 nc (nc-nc)   Female 4 3.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.4 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 2 1.2 nc (nc-nc)   Female 3 1.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 0 4.0 nc (nc-nc) 
Female 35 28.6 122.6 (85.4-170.5)   Female 3 3.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 3.3 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 2 1.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 7.5 92.8 (37.2-191.3)             
Female 6 7.7 77.4 (28.3-168.5)   Female 3 2.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 6 1.8 335.0 (122.3-729.1)   Male 3 2.2 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 3 2.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.7 nc (nc-nc)   Male 21 24.0 87.5 (54.2-133.8) 
Female 2 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 3.9 nc (nc-nc)   Male 2 1.6 nc (nc-nc) 
Female 1 2.2 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Larynx            Testis     
Male 2 1.0 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 2.8 nc (nc-nc)   Male 3 1.9 nc (nc-nc) 
Female 0 2.1 nc (nc-nc)   Female 4 5.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 2.4 nc (nc-nc)             
Female 1 0.8 nc (nc-nc)   Female 9 6.3 142.8 (65.2-271.2) 
Lung and Bronchus            All Sites / Types     
Male 14 11.8 118.4 (64.7-198.7)   Male 83 90.7 91.5 (72.9-113.4) 
Female 15 12.9 116.0 (64.9-191.4)   Female 104 95.6 108.8 (88.9-131.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
29 
Barnstable 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 87 70.8 122.9 (98.5-151.6)   Male 65 42.5 152.8 (117.9-194.8) 
Female 26 24.3 107.0 (69.9-156.8)   Female 50 30.8 162.4 (120.5-214.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 11 11.1 99.3 (49.5-177.6)   Male 11 12.9 85.6 (42.7-153.1) 
Female 9 9.5 95.2 (43.5-180.8)   Female 13 10.2 127.2 (67.7-217.6) 
Breast            Non-Hodgkin Lymphoma     
Male 4 2.1 nc (nc-nc)   Male 39 37.4 104.2 (74.1-142.5) 
Female 298 242.4 122.9 (109.4-137.7)   Female 40 31.2 128.3 (91.7-174.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 25 28.5 87.6 (56.7-129.3) 
Female 9 7.5 119.5 (54.5-226.9)   Female 14 12.8 109.2 (59.6-183.2) 
Colon / Rectum            Ovary     
Male 63 73.9 85.2 (65.5-109.0)             
Female 68 71.9 94.6 (73.5-119.9)   Female 22 22.4 98.3 (61.6-148.8) 
Esophagus            Pancreas     
Male 19 17.9 105.9 (63.7-165.4)   Male 27 23.4 115.5 (76.1-168.0) 
Female 3 4.7 nc (nc-nc)   Female 26 23.6 110.0 (71.8-161.2) 
Hodgkin Lymphoma            Prostate     
Male 4 4.1 nc (nc-nc)   Male 295 235.3 125.4 (111.5-140.5) 
Female 2 3.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 30 34.2 87.6 (59.1-125.1)   Male 17 15.9 106.9 (62.3-171.2) 
Female 19 19.9 95.3 (57.4-148.8)   Female 8 9.1 88.3 (38.0-174.0) 
Larynx            Testis     
Male 10 9.8 101.9 (48.8-187.4)   Male 9 5.9 151.7 (69.2-288.0) 
Female 2 3.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 34 25.9 131.3 (90.9-183.5)   Male 12 14.1 85.2 (44.0-148.8) 
Female 26 18.1 143.6 (93.8-210.4)   Female 25 39.1 64.0 (41.4-94.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 22 21.9 100.6 (63.0-152.4)             
Female 8 7.2 111.7 (48.1-220.0)   Female 52 56.5 92.0 (68.7-120.7) 
Lung and Bronchus            All Sites / Types     
Male 91 126.3 72.1 (58.0-88.5)   Male 959 883.2 108.6 (101.8-115.7) 
Female 126 125.9 100.1 (83.3-119.1)   Female 918 842.3 109.0 (102.1-116.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
30 
Barre 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 5.6 106.7 (39.0-232.2)   Male 3 3.8 nc (nc-nc) 
Female 2 1.9 nc (nc-nc)   Female 2 2.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.1 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 2 0.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 1 3.3 nc (nc-nc) 
Female 14 21.5 65.3 (35.6-109.5)   Female 0 2.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 2.8 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 8 6.4 124.9 (53.8-246.0)             
Female 5 5.9 84.5 (27.2-197.2)   Female 1 2.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.6 nc (nc-nc)   Male 0 2.0 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.5 nc (nc-nc)   Male 24 21.6 111.3 (71.3-165.6) 
Female 1 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 3.2 155.1 (50.0-361.8)   Male 0 1.3 nc (nc-nc) 
Female 1 1.7 nc (nc-nc)   Female 2 0.7 nc (nc-nc) 
Larynx            Testis     
Male 1 0.9 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 2.3 nc (nc-nc)   Male 0 1.5 nc (nc-nc) 
Female 3 1.6 nc (nc-nc)   Female 1 4.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.0 nc (nc-nc)             
Female 0 0.6 nc (nc-nc)   Female 7 4.8 145.1 (58.1-299.0) 
Lung and Bronchus            All Sites / Types     
Male 12 10.3 116.4 (60.1-203.4)   Male 77 78.1 98.6 (77.8-123.2) 
Female 7 9.6 73.0 (29.3-150.5)   Female 58 71.7 80.9 (61.4-104.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
31 
Becket 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 2.5 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.4 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 3 1.4 nc (nc-nc) 
Female 9 8.6 104.4 (47.6-198.2)   Female 2 1.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 1.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 2.7 nc (nc-nc)             
Female 0 2.2 nc (nc-nc)   Female 3 0.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.7 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 6 10.0 59.7 (21.8-130.0) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.4 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.9 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 1.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.9 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 5 2.1 242.9 (78.3-566.7) 
Lung and Bronchus            All Sites / Types     
Male 5 4.7 106.2 (34.2-247.9)   Male 25 34.5 72.4 (46.8-106.9) 
Female 2 4.0 nc (nc-nc)   Female 24 28.2 85.1 (54.5-126.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
32 
Bedford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 22 21.3 103.5 (64.8-156.7)   Male 18 12.5 143.6 (85.1-226.9) 
Female 5 6.0 82.9 (26.7-193.4)   Female 3 8.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 3.3 nc (nc-nc)   Male 2 3.8 nc (nc-nc) 
Female 0 2.5 nc (nc-nc)   Female 2 2.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.6 nc (nc-nc)   Male 11 11.2 98.6 (49.2-176.5) 
Female 58 62.2 93.2 (70.8-120.5)   Female 7 7.8 89.4 (35.8-184.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 8.2 85.0 (34.0-175.1) 
Female 0 2.1 nc (nc-nc)   Female 4 3.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 25 22.3 112.0 (72.5-165.4)             
Female 20 18.3 109.3 (66.8-168.9)   Female 1 5.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 5.2 nc (nc-nc)   Male 10 6.9 144.5 (69.2-265.7) 
Female 2 1.2 nc (nc-nc)   Female 7 5.9 118.5 (47.5-244.2) 
Hodgkin Lymphoma            Prostate     
Male 1 1.2 nc (nc-nc)   Male 60 64.9 92.4 (70.5-118.9) 
Female 1 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 9.8 81.3 (35.0-160.2)   Male 4 4.7 nc (nc-nc) 
Female 3 5.0 nc (nc-nc)   Female 4 2.3 nc (nc-nc) 
Larynx            Testis     
Male 1 2.8 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 7.9 89.0 (35.6-183.3)   Male 4 4.1 nc (nc-nc) 
Female 5 4.7 107.1 (34.5-250.0)   Female 11 10.7 102.8 (51.2-183.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 6.3 nc (nc-nc)             
Female 0 1.8 nc (nc-nc)   Female 11 14.0 78.7 (39.2-140.8) 
Lung and Bronchus            All Sites / Types     
Male 24 36.7 65.4 (41.9-97.4)   Male 233 256.5 90.8 (79.5-103.3) 
Female 30 30.8 97.5 (65.8-139.2)   Female 187 213.7 87.5 (75.4-101.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
33 
Belchertown 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 9 12.9 69.8 (31.9-132.5)   Male 9 9.2 98.2 (44.8-186.4) 
Female 5 4.6 107.6 (34.7-251.2)   Female 6 7.7 77.8 (28.4-169.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 2.8 210.9 (77.0-459.1)   Male 2 2.6 nc (nc-nc) 
Female 3 2.4 nc (nc-nc)   Female 2 2.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 13 8.1 161.0 (85.6-275.3) 
Female 54 60.3 89.5 (67.2-116.8)   Female 7 6.7 104.3 (41.8-214.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 7.1 nc (nc-nc) 
Female 1 2.2 nc (nc-nc)   Female 7 2.9 240.2 (96.2-494.9) 
Colon / Rectum            Ovary     
Male 14 15.4 90.9 (49.6-152.5)             
Female 16 14.6 109.4 (62.5-177.7)   Female 4 5.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 3.8 nc (nc-nc)   Male 2 4.6 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 3 4.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 1.2 nc (nc-nc)   Male 51 52.6 96.9 (72.1-127.4) 
Female 0 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 8.1 62.0 (20.0-144.6)   Male 6 3.2 187.9 (68.6-409.0) 
Female 3 4.5 nc (nc-nc)   Female 4 1.8 nc (nc-nc) 
Larynx            Testis     
Male 2 2.1 nc (nc-nc)   Male 4 2.0 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 5.5 108.9 (39.8-237.0)   Male 1 4.0 nc (nc-nc) 
Female 2 4.0 nc (nc-nc)   Female 8 12.2 65.7 (28.3-129.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 5.1 nc (nc-nc)             
Female 2 1.5 nc (nc-nc)   Female 16 13.8 116.0 (66.2-188.3) 
Lung and Bronchus            All Sites / Types     
Male 17 24.1 70.6 (41.1-113.1)   Male 167 188.6 88.6 (75.6-103.1) 
Female 18 25.3 71.3 (42.2-112.7)   Female 173 193.3 89.5 (76.7-103.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
34 
Bellingham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 15.1 72.9 (36.4-130.5)   Male 5 10.5 47.7 (15.4-111.4) 
Female 7 5.5 128.0 (51.3-263.8)   Female 11 8.7 126.9 (63.3-227.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 3.2 187.7 (68.5-408.5)   Male 1 3.0 nc (nc-nc) 
Female 4 2.7 nc (nc-nc)   Female 1 2.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 15 9.2 162.4 (90.8-267.8) 
Female 76 66.8 113.8 (89.6-142.4)   Female 15 7.7 194.9 (109.0-321.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 7.7 90.6 (36.3-186.7) 
Female 2 2.5 nc (nc-nc)   Female 3 3.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 12 17.5 68.7 (35.5-120.0)             
Female 17 16.9 100.4 (58.5-160.8)   Female 2 5.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 6 4.3 140.6 (51.4-306.1)   Male 6 5.3 114.0 (41.6-248.1) 
Female 0 1.1 nc (nc-nc)   Female 5 5.3 94.8 (30.6-221.3) 
Hodgkin Lymphoma            Prostate     
Male 1 1.4 nc (nc-nc)   Male 65 57.7 112.7 (87.0-143.7) 
Female 2 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 9.0 88.5 (38.1-174.3)   Male 5 3.7 136.8 (44.1-319.2) 
Female 5 5.1 97.2 (31.3-226.9)   Female 2 2.1 nc (nc-nc) 
Larynx            Testis     
Male 2 2.4 nc (nc-nc)   Male 2 2.4 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 6.3 110.9 (44.4-228.6)   Male 4 4.4 nc (nc-nc) 
Female 3 4.6 nc (nc-nc)   Female 13 13.4 97.0 (51.6-165.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 5.6 107.4 (39.2-233.8)             
Female 0 1.7 nc (nc-nc)   Female 16 15.0 106.7 (61.0-173.3) 
Lung and Bronchus            All Sites / Types     
Male 34 27.9 121.8 (84.3-170.2)   Male 222 212.8 104.3 (91.0-119.0) 
Female 21 29.6 71.0 (43.9-108.5)   Female 220 218.6 100.6 (87.8-114.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
35 
Belmont 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 26 28.9 89.9 (58.7-131.8)   Male 15 18.2 82.6 (46.2-136.2) 
Female 5 10.6 47.4 (15.3-110.5)   Female 9 14.8 61.0 (27.8-115.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 5.1 97.3 (31.4-227.1)   Male 6 5.4 112.0 (40.9-243.8) 
Female 6 4.6 130.7 (47.7-284.5)   Female 5 4.5 111.6 (36.0-260.5) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.9 nc (nc-nc)   Male 17 16.0 106.0 (61.7-169.7) 
Female 135 113.1 119.4 (100.1-141.3)   Female 9 14.0 64.1 (29.2-121.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 12.4 nc (nc-nc) 
Female 1 4.0 nc (nc-nc)   Female 4 5.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 22 31.3 70.3 (44.0-106.4)             
Female 27 32.3 83.6 (55.1-121.6)   Female 11 10.3 106.7 (53.2-190.9) 
Esophagus            Pancreas     
Male 5 7.5 67.1 (21.6-156.6)   Male 9 9.7 92.9 (42.4-176.4) 
Female 3 2.0 nc (nc-nc)   Female 9 10.3 87.1 (39.8-165.4) 
Hodgkin Lymphoma            Prostate     
Male 3 2.0 nc (nc-nc)   Male 88 97.8 90.0 (72.2-110.9) 
Female 2 1.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 9 14.9 60.5 (27.6-114.8)   Male 4 6.6 nc (nc-nc) 
Female 4 9.0 nc (nc-nc)   Female 5 4.1 123.0 (39.6-287.0) 
Larynx            Testis     
Male 0 4.1 nc (nc-nc)   Male 3 3.3 nc (nc-nc) 
Female 0 1.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 11.2 nc (nc-nc)   Male 9 6.6 136.5 (62.3-259.1) 
Female 4 8.4 nc (nc-nc)   Female 20 20.8 96.1 (58.7-148.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 9.2 nc (nc-nc)             
Female 3 3.2 nc (nc-nc)   Female 24 25.6 93.9 (60.1-139.7) 
Lung and Bronchus            All Sites / Types     
Male 31 51.6 60.1 (40.8-85.3)   Male 288 371.8 77.5 (68.8-86.9) 
Female 41 54.1 75.7 (54.3-102.7)   Female 350 385.7 90.8 (81.5-100.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
36 
Berkley 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 5.1 nc (nc-nc)   Male 5 3.8 131.5 (42.4-306.9) 
Female 1 1.6 nc (nc-nc)   Female 4 3.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.2 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 4 3.4 nc (nc-nc) 
Female 29 23.6 123.1 (82.4-176.8)   Female 4 2.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 3.0 nc (nc-nc) 
Female 2 0.9 nc (nc-nc)   Female 2 1.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 6.3 95.7 (34.9-208.3)             
Female 7 5.3 131.1 (52.5-270.1)   Female 0 2.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.5 nc (nc-nc)   Male 1 1.9 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 2 1.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.5 nc (nc-nc)   Male 19 21.5 88.5 (53.2-138.2) 
Female 1 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 3.4 146.4 (47.2-341.7)   Male 2 1.3 nc (nc-nc) 
Female 2 1.7 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Larynx            Testis     
Male 2 0.9 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 2.3 nc (nc-nc)   Male 4 1.7 nc (nc-nc) 
Female 4 1.5 nc (nc-nc)   Female 6 5.1 116.9 (42.7-254.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 2.1 nc (nc-nc)             
Female 0 0.6 nc (nc-nc)   Female 5 5.2 96.4 (31.1-224.9) 
Lung and Bronchus            All Sites / Types     
Male 9 9.7 92.4 (42.2-175.4)   Male 75 77.3 97.0 (76.3-121.6) 
Female 7 9.2 76.5 (30.6-157.6)   Female 86 73.5 117.0 (93.6-144.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
37 
Berlin 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 3.9 nc (nc-nc)   Male 5 2.5 201.8 (65.0-471.0) 
Female 2 1.3 nc (nc-nc)   Female 0 1.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.7 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.1 nc (nc-nc)   Male 0 2.2 nc (nc-nc) 
Female 16 14.4 110.8 (63.3-180.0)   Female 2 1.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 1.8 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 4.2 nc (nc-nc)             
Female 2 3.9 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.1 nc (nc-nc)   Male 4 1.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.3 nc (nc-nc)   Male 12 14.3 83.9 (43.3-146.5) 
Female 1 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 2.1 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Larynx            Testis     
Male 0 0.6 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.5 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 3 2.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.3 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 5 3.3 150.7 (48.6-351.7) 
Lung and Bronchus            All Sites / Types     
Male 11 7.2 153.3 (76.4-274.3)   Male 59 51.7 114.1 (86.9-147.2) 
Female 5 7.0 71.0 (22.9-165.7)   Female 44 48.3 91.0 (66.1-122.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
38 
Bernardston 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 3.2 nc (nc-nc)   Male 2 2.0 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 6 1.3 447.5 (163.4-974.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.5 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 4 1.8 nc (nc-nc) 
Female 10 10.7 93.4 (44.7-171.7)   Female 3 1.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 1.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 3.5 nc (nc-nc)             
Female 5 3.0 169.2 (54.5-394.9)   Female 3 1.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 0.9 nc (nc-nc)   Male 2 1.1 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.2 nc (nc-nc)   Male 16 11.4 140.4 (80.2-228.0) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.7 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Larynx            Testis     
Male 0 0.5 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.2 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.1 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 2 2.5 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 5 5.8 86.2 (27.8-201.2)   Male 42 41.9 100.4 (72.3-135.7) 
Female 4 5.3 nc (nc-nc)   Female 38 36.1 105.2 (74.4-144.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
39 
Beverly 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 54 43.4 124.3 (93.4-162.2)   Male 39 27.8 140.2 (99.7-191.7) 
Female 23 16.5 139.2 (88.2-208.9)   Female 34 23.1 147.0 (101.8-205.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 12 7.9 150.9 (77.9-263.7)   Male 9 8.2 110.3 (50.3-209.3) 
Female 7 7.1 98.3 (39.4-202.6)   Female 5 7.0 71.6 (23.1-167.1) 
Breast            Non-Hodgkin Lymphoma     
Male 3 1.4 nc (nc-nc)   Male 29 24.6 117.7 (78.8-169.0) 
Female 177 172.9 102.3 (87.8-118.6)   Female 22 21.8 100.8 (63.1-152.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 27 19.5 138.4 (91.2-201.4) 
Female 3 6.0 nc (nc-nc)   Female 13 9.0 143.8 (76.5-246.0) 
Colon / Rectum            Ovary     
Male 32 47.6 67.2 (46.0-94.9)             
Female 53 50.6 104.8 (78.5-137.1)   Female 17 16.0 106.2 (61.8-170.0) 
Esophagus            Pancreas     
Male 12 11.4 104.9 (54.1-183.2)   Male 14 14.7 95.4 (52.1-160.0) 
Female 3 3.1 nc (nc-nc)   Female 13 16.2 80.3 (42.7-137.3) 
Hodgkin Lymphoma            Prostate     
Male 3 3.4 nc (nc-nc)   Male 170 151.6 112.1 (95.9-130.3) 
Female 1 3.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 23 22.9 100.4 (63.6-150.7)   Male 5 10.1 49.6 (16.0-115.7) 
Female 15 13.9 107.9 (60.4-178.0)   Female 4 6.4 nc (nc-nc) 
Larynx            Testis     
Male 6 6.3 95.0 (34.7-206.9)   Male 10 5.7 175.3 (83.9-322.5) 
Female 3 2.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 22 17.1 128.3 (80.4-194.3)   Male 11 10.5 104.8 (52.3-187.6) 
Female 13 13.1 98.9 (52.6-169.1)   Female 35 32.3 108.2 (75.4-150.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 13 14.5 89.5 (47.6-153.0)             
Female 13 4.9 264.9 (140.9-452.9)   Female 39 39.3 99.2 (70.5-135.6) 
Lung and Bronchus            All Sites / Types     
Male 87 77.8 111.8 (89.6-138.0)   Male 633 571.0 110.9 (102.4-119.8) 
Female 97 83.7 115.8 (93.9-141.3)   Female 662 597.0 110.9 (102.6-119.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
40 
Billerica 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 53 38.2 138.9 (104.0-181.6)   Male 35 26.6 131.7 (91.7-183.1) 
Female 18 13.2 136.2 (80.7-215.2)   Female 22 20.9 105.2 (65.9-159.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 8.1 86.4 (34.6-178.1)   Male 12 7.7 156.8 (80.9-273.9) 
Female 6 6.4 93.1 (34.0-202.7)   Female 5 5.8 86.3 (27.8-201.3) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.3 nc (nc-nc)   Male 20 23.4 85.6 (52.2-132.1) 
Female 151 161.4 93.6 (79.2-109.7)   Female 20 18.7 107.2 (65.4-165.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 18 19.7 91.1 (54.0-144.1) 
Female 3 5.9 nc (nc-nc)   Female 9 7.9 113.8 (51.9-216.1) 
Colon / Rectum            Ovary     
Male 28 44.3 63.3 (42.0-91.4)             
Female 55 40.7 135.2 (101.8-175.9)   Female 18 14.5 124.5 (73.8-196.8) 
Esophagus            Pancreas     
Male 11 11.0 100.2 (50.0-179.4)   Male 17 13.5 126.4 (73.6-202.3) 
Female 3 2.6 nc (nc-nc)   Female 10 12.8 78.3 (37.5-144.0) 
Hodgkin Lymphoma            Prostate     
Male 4 3.6 nc (nc-nc)   Male 140 151.3 92.5 (77.8-109.2) 
Female 1 2.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 27 23.1 116.7 (76.9-169.8)   Male 9 9.3 97.0 (44.3-184.1) 
Female 11 12.5 88.3 (44.0-158.1)   Female 6 5.0 119.7 (43.7-260.5) 
Larynx            Testis     
Male 4 6.1 nc (nc-nc)   Male 7 6.3 111.0 (44.5-228.6) 
Female 0 2.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 23 15.9 144.6 (91.6-216.9)   Male 15 11.3 132.9 (74.3-219.2) 
Female 20 11.1 180.8 (110.4-279.2)   Female 31 32.0 96.8 (65.7-137.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 11 14.2 77.6 (38.7-138.9)             
Female 2 4.2 nc (nc-nc)   Female 29 36.8 78.9 (52.8-113.3) 
Lung and Bronchus            All Sites / Types     
Male 86 71.5 120.4 (96.3-148.6)   Male 573 545.8 105.0 (96.6-113.9) 
Female 98 72.2 135.8 (110.2-165.5)   Female 556 528.7 105.2 (96.6-114.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Blackstone 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 8.0 99.6 (42.9-196.2)   Male 4 5.6 nc (nc-nc) 
Female 4 3.1 nc (nc-nc)   Female 5 4.8 104.7 (33.8-244.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 1.7 nc (nc-nc)   Male 0 1.6 nc (nc-nc) 
Female 0 1.5 nc (nc-nc)   Female 3 1.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.3 nc (nc-nc)   Male 5 5.0 100.5 (32.4-234.6) 
Female 29 36.2 80.1 (53.7-115.1)   Female 5 4.3 117.3 (37.8-273.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 4.2 nc (nc-nc) 
Female 0 1.3 nc (nc-nc)   Female 4 1.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 9.5 63.3 (23.1-137.7)             
Female 6 9.6 62.3 (22.7-135.6)   Female 5 3.3 153.1 (49.3-357.2) 
Esophagus            Pancreas     
Male 8 2.3 352.2 (151.6-694.0)   Male 0 2.8 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 2 3.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.8 nc (nc-nc)   Male 25 30.7 81.5 (52.7-120.3) 
Female 0 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 4.8 nc (nc-nc)   Male 1 2.0 nc (nc-nc) 
Female 5 2.8 178.5 (57.5-416.5)   Female 0 1.2 nc (nc-nc) 
Larynx            Testis     
Male 3 1.3 nc (nc-nc)   Male 2 1.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 3.4 nc (nc-nc)   Male 2 2.4 nc (nc-nc) 
Female 5 2.6 193.2 (62.3-450.8)   Female 3 7.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 3.0 nc (nc-nc)             
Female 0 0.9 nc (nc-nc)   Female 11 8.1 136.0 (67.8-243.4) 
Lung and Bronchus            All Sites / Types     
Male 25 14.7 169.7 (109.8-250.6)   Male 119 113.9 104.5 (86.5-125.0) 
Female 16 16.1 99.6 (56.9-161.7)   Female 123 120.0 102.5 (85.2-122.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Blandford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 1.7 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 3 5.5 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.8 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 1.9 nc (nc-nc)             
Female 1 1.3 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.5 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 7 6.7 104.6 (41.9-215.5) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.9 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 1 0.2 nc (nc-nc) 
Larynx            Testis     
Male 1 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 1 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.7 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.6 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 2 1.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 3.1 nc (nc-nc)   Male 18 23.2 77.5 (45.9-122.5) 
Female 3 2.3 nc (nc-nc)   Female 17 17.5 97.0 (56.5-155.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
43 
Bolton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 4.2 nc (nc-nc)   Male 2 3.1 nc (nc-nc) 
Female 0 1.4 nc (nc-nc)   Female 2 2.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.0 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 2 2.7 nc (nc-nc) 
Female 23 19.6 117.1 (74.2-175.7)   Female 2 2.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 2.5 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 5.2 96.0 (30.9-224.0)             
Female 2 4.5 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.3 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.4 nc (nc-nc)   Male 24 19.0 126.5 (81.0-188.2) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 2.9 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 2 1.4 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Larynx            Testis     
Male 1 0.8 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 1.8 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 3 3.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.8 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 11 4.4 248.4 (123.8-444.6) 
Lung and Bronchus            All Sites / Types     
Male 5 8.1 61.6 (19.8-143.7)   Male 61 65.0 93.8 (71.7-120.5) 
Female 5 7.6 66.1 (21.3-154.2)   Female 57 60.8 93.8 (71.0-121.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Boston 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 350 452.6 77.3 (69.4-85.9)   Male 252 313.5 80.4 (70.8-91.0) 
Female 155 178.6 86.8 (73.7-101.6)   Female 202 296.3 68.2 (59.1-78.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 76 100.7 75.5 (59.5-94.5)   Male 102 87.2 117.0 (95.4-142.0) 
Female 84 90.8 92.5 (73.8-114.5)   Female 115 76.3 150.7 (124.4-180.8) 
Breast            Non-Hodgkin Lymphoma     
Male 10 14.3 69.8 (33.4-128.3)   Male 297 279.5 106.3 (94.5-119.1) 
Female 1823 1991.0 91.6 (87.4-95.9)   Female 238 248.9 95.6 (83.8-108.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 251 217.8 115.3 (101.4-130.4) 
Female 91 80.5 113.0 (91.0-138.8)   Female 113 102.6 110.1 (90.8-132.4) 
Colon / Rectum            Ovary     
Male 573 511.1 112.1 (103.1-121.7)             
Female 587 550.9 106.6 (98.1-115.5)   Female 185 187.4 98.7 (85.0-114.0) 
Esophagus            Pancreas     
Male 116 122.2 94.9 (78.4-113.8)   Male 145 155.2 93.5 (78.9-110.0) 
Female 37 34.4 107.7 (75.8-148.5)   Female 185 174.2 106.2 (91.5-122.7) 
Hodgkin Lymphoma            Prostate     
Male 55 57.7 95.3 (71.8-124.0)   Male 1953 1633.1 119.6 (114.3-125.0) 
Female 59 53.2 110.8 (84.4-143.0)             
Kidney & Renal Pelvis            Stomach     
Male 232 258.3 89.8 (78.6-102.2)   Male 148 107.5 137.6 (116.4-161.7) 
Female 181 159.3 113.6 (97.7-131.5)   Female 104 69.5 149.7 (122.3-181.4) 
Larynx            Testis     
Male 88 67.8 129.7 (104.0-159.8)   Male 93 112.7 82.5 (66.6-101.1) 
Female 23 24.0 95.7 (60.7-143.6)             
Leukemia            Thyroid     
Male 146 196.8 74.2 (62.7-87.3)   Male 152 138.1 110.0 (93.2-129.0) 
Female 117 155.5 75.3 (62.2-90.2)   Female 506 464.2 109.0 (99.7-118.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 272 157.0 173.3 (153.3-195.1)             
Female 96 54.5 176.1 (142.6-215.1)   Female 446 448.7 99.4 (90.4-109.1) 
Lung and Bronchus            All Sites / Types     
Male 903 818.4 110.3 (103.3-117.8)   Male 6719 6287.1 106.9 (104.3-109.5) 
Female 843 928.6 90.8 (84.8-97.1)   Female 6722 6913.6 97.2 (94.9-99.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
45 
Bourne 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 34 27.1 125.4 (86.8-175.3)   Male 22 16.8 131.2 (82.2-198.7) 
Female 11 9.8 112.0 (55.8-200.4)   Female 16 12.4 128.8 (73.6-209.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 4.6 131.3 (47.9-285.7)   Male 7 5.0 139.9 (56.0-288.2) 
Female 6 3.8 156.4 (57.1-340.3)   Female 3 4.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.8 nc (nc-nc)   Male 15 14.7 101.7 (56.9-167.8) 
Female 89 96.9 91.8 (73.7-113.0)   Female 9 12.6 71.7 (32.7-136.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 14 11.5 122.2 (66.7-205.0) 
Female 3 3.0 nc (nc-nc)   Female 5 5.1 97.1 (31.3-226.6) 
Colon / Rectum            Ovary     
Male 23 28.7 80.2 (50.8-120.4)             
Female 20 29.1 68.8 (42.0-106.2)   Female 14 9.0 156.0 (85.2-261.7) 
Esophagus            Pancreas     
Male 8 7.1 113.3 (48.8-223.3)   Male 7 9.1 77.2 (30.9-159.0) 
Female 6 1.9 317.9 (116.1-691.9)   Female 11 9.6 114.6 (57.1-205.1) 
Hodgkin Lymphoma            Prostate     
Male 0 1.9 nc (nc-nc)   Male 102 93.8 108.7 (88.6-131.9) 
Female 1 1.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 13 13.7 95.0 (50.6-162.5)   Male 5 6.2 81.2 (26.2-189.5) 
Female 7 8.0 87.4 (35.0-180.2)   Female 5 3.7 136.1 (43.9-317.6) 
Larynx            Testis     
Male 7 3.9 180.6 (72.4-372.1)   Male 2 2.9 nc (nc-nc) 
Female 4 1.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 10.3 87.7 (40.0-166.5)   Male 1 5.9 nc (nc-nc) 
Female 7 7.4 95.2 (38.1-196.1)   Female 17 15.7 108.1 (62.9-173.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 8.7 57.6 (18.6-134.3)             
Female 1 2.9 nc (nc-nc)   Female 22 22.6 97.4 (61.0-147.4) 
Lung and Bronchus            All Sites / Types     
Male 56 49.1 114.1 (86.2-148.1)   Male 365 348.4 104.8 (94.3-116.1) 
Female 63 50.5 124.9 (95.9-159.8)   Female 341 338.6 100.7 (90.3-112.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Boxborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 4.2 nc (nc-nc)   Male 5 3.2 157.7 (50.8-368.0) 
Female 1 1.3 nc (nc-nc)   Female 5 2.4 204.7 (66.0-477.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.0 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 2 0.7 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 2.8 nc (nc-nc) 
Female 22 19.8 111.1 (69.6-168.3)   Female 4 2.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 2.6 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 5.3 nc (nc-nc)             
Female 7 4.4 159.6 (63.9-328.9)   Female 1 1.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 1.3 nc (nc-nc)   Male 3 1.6 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 2 1.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.4 nc (nc-nc)   Male 22 18.4 119.4 (74.8-180.8) 
Female 1 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 2.9 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 0 1.4 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Larynx            Testis     
Male 0 0.7 nc (nc-nc)   Male 3 0.7 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 1.9 nc (nc-nc)   Male 3 1.4 nc (nc-nc) 
Female 2 1.2 nc (nc-nc)   Female 2 4.0 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.8 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 6 4.5 134.0 (48.9-291.7) 
Lung and Bronchus            All Sites / Types     
Male 5 8.1 61.7 (19.9-144.1)   Male 58 65.2 88.9 (67.5-115.0) 
Female 9 7.5 119.3 (54.4-226.4)   Female 74 60.6 122.0 (95.8-153.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Boxford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 9.2 76.3 (30.6-157.2)   Male 18 6.1 295.1 (174.8-466.5) 
Female 1 2.8 nc (nc-nc)   Female 12 4.3 276.4 (142.6-482.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.8 nc (nc-nc)   Male 1 1.8 nc (nc-nc) 
Female 4 1.4 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.3 nc (nc-nc)   Male 1 5.4 nc (nc-nc) 
Female 45 35.6 126.5 (92.3-169.3)   Female 2 4.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 4.6 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 10.5 47.7 (15.4-111.3)             
Female 6 8.7 68.7 (25.1-149.5)   Female 3 3.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 2.6 nc (nc-nc)   Male 1 3.2 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 2 2.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.7 nc (nc-nc)   Male 50 36.0 138.9 (103.1-183.1) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 5.3 nc (nc-nc)   Male 2 2.2 nc (nc-nc) 
Female 1 2.7 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Larynx            Testis     
Male 0 1.5 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 3.6 192.6 (77.2-396.8)   Male 3 2.4 nc (nc-nc) 
Female 3 2.3 nc (nc-nc)   Female 7 6.5 107.0 (42.9-220.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 3.4 nc (nc-nc)             
Female 0 0.9 nc (nc-nc)   Female 6 8.2 73.5 (26.8-160.0) 
Lung and Bronchus            All Sites / Types     
Male 6 17.1 35.0 (12.8-76.3)   Male 124 127.8 97.0 (80.7-115.7) 
Female 7 15.3 45.8 (18.4-94.4)   Female 114 113.6 100.4 (82.8-120.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
48 
Boylston 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 4.8 124.6 (45.5-271.2)   Male 4 3.2 nc (nc-nc) 
Female 0 1.7 nc (nc-nc)   Female 8 2.5 316.6 (136.3-623.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.9 nc (nc-nc)   Male 3 1.0 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 2 2.8 nc (nc-nc) 
Female 27 20.0 135.2 (89.1-196.7)   Female 0 2.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 2.4 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 5.5 nc (nc-nc)             
Female 8 5.2 153.6 (66.1-302.7)   Female 4 1.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.4 nc (nc-nc)   Male 1 1.7 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 2 1.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 13 18.6 69.8 (37.1-119.3) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 2.8 nc (nc-nc)   Male 4 1.2 nc (nc-nc) 
Female 0 1.5 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Larynx            Testis     
Male 0 0.8 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.9 nc (nc-nc)   Male 2 1.3 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 3 3.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.8 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 3 4.6 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 4 8.9 nc (nc-nc)   Male 58 67.1 86.5 (65.6-111.8) 
Female 6 9.1 66.3 (24.2-144.2)   Female 69 65.8 104.9 (81.6-132.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
49 
Braintree 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 50 42.6 117.4 (87.2-154.8)   Male 29 26.5 109.3 (73.2-157.0) 
Female 23 16.8 136.7 (86.6-205.1)   Female 31 22.2 139.8 (95.0-198.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 8 7.4 107.5 (46.3-211.8)   Male 4 7.8 nc (nc-nc) 
Female 7 6.9 102.0 (40.9-210.1)   Female 8 7.0 114.0 (49.1-224.7) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.3 nc (nc-nc)   Male 26 23.5 110.7 (72.3-162.3) 
Female 187 168.2 111.2 (95.8-128.3)   Female 21 21.7 96.8 (59.9-148.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 18 17.9 100.5 (59.5-158.8) 
Female 8 5.7 140.5 (60.5-276.9)   Female 8 8.8 90.5 (39.0-178.3) 
Colon / Rectum            Ovary     
Male 56 45.8 122.3 (92.4-158.8)             
Female 74 50.9 145.5 (114.2-182.6)   Female 13 15.5 84.1 (44.7-143.7) 
Esophagus            Pancreas     
Male 13 10.8 120.3 (64.0-205.7)   Male 13 14.1 92.0 (48.9-157.3) 
Female 5 3.2 156.1 (50.3-364.3)   Female 18 16.5 109.2 (64.7-172.6) 
Hodgkin Lymphoma            Prostate     
Male 5 3.0 167.1 (53.9-390.0)   Male 132 140.1 94.2 (78.8-111.7) 
Female 5 2.7 188.1 (60.6-439.0)             
Kidney & Renal Pelvis            Stomach     
Male 18 21.5 83.9 (49.7-132.5)   Male 10 9.7 102.9 (49.3-189.3) 
Female 12 13.8 87.1 (45.0-152.1)   Female 8 6.5 124.0 (53.4-244.3) 
Larynx            Testis     
Male 4 5.9 nc (nc-nc)   Male 3 4.9 nc (nc-nc) 
Female 6 2.1 287.4 (105.0-625.6)             
Leukemia            Thyroid     
Male 11 16.4 66.9 (33.4-119.7)   Male 9 9.5 94.6 (43.1-179.5) 
Female 19 13.1 145.1 (87.3-226.6)   Female 35 29.8 117.4 (81.7-163.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 16 13.4 119.3 (68.1-193.7)             
Female 5 4.9 102.5 (33.0-239.3)   Female 37 37.6 98.3 (69.2-135.5) 
Lung and Bronchus            All Sites / Types     
Male 68 75.4 90.2 (70.0-114.3)   Male 536 540.7 99.1 (90.9-107.9) 
Female 88 85.0 103.5 (83.0-127.5)   Female 671 587.6 114.2 (105.7-123.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
50 
Brewster 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 17 19.9 85.3 (49.7-136.6)   Male 17 11.2 151.2 (88.0-242.2) 
Female 8 7.2 110.4 (47.5-217.5)   Female 16 8.1 196.7 (112.4-319.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 2.7 nc (nc-nc)   Male 3 3.5 nc (nc-nc) 
Female 2 2.5 nc (nc-nc)   Female 1 3.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.6 nc (nc-nc)   Male 14 9.9 140.7 (76.9-236.1) 
Female 80 64.2 124.6 (98.8-155.1)   Female 12 8.8 135.6 (70.0-236.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 7.3 109.7 (47.2-216.1) 
Female 1 1.8 nc (nc-nc)   Female 2 3.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 17 20.1 84.6 (49.3-135.5)             
Female 16 21.4 74.8 (42.8-121.6)   Female 4 6.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 4.8 nc (nc-nc)   Male 6 6.5 92.9 (33.9-202.3) 
Female 3 1.4 nc (nc-nc)   Female 4 7.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.9 nc (nc-nc)   Male 75 62.4 120.1 (94.5-150.6) 
Female 0 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 8.8 79.8 (32.0-164.4)   Male 3 4.4 nc (nc-nc) 
Female 5 5.5 91.6 (29.5-213.7)   Female 0 2.7 nc (nc-nc) 
Larynx            Testis     
Male 2 2.6 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 7.0 86.1 (31.5-187.5)   Male 0 3.3 nc (nc-nc) 
Female 3 5.2 nc (nc-nc)   Female 8 8.9 89.9 (38.7-177.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 5.7 nc (nc-nc)             
Female 0 2.0 nc (nc-nc)   Female 15 15.2 98.9 (55.3-163.2) 
Lung and Bronchus            All Sites / Types     
Male 29 34.6 83.7 (56.1-120.3)   Male 237 236.3 100.3 (87.9-113.9) 
Female 17 35.5 47.8 (27.8-76.6)   Female 216 232.1 93.1 (81.1-106.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
51 
Bridgewater 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 27 23.2 116.2 (76.6-169.1)   Male 19 16.5 115.0 (69.2-179.5) 
Female 12 7.5 160.4 (82.8-280.3)   Female 17 12.0 141.7 (82.5-226.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 5.1 117.2 (42.8-255.2)   Male 2 4.7 nc (nc-nc) 
Female 7 3.8 185.0 (74.1-381.2)   Female 3 3.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.8 nc (nc-nc)   Male 10 14.6 68.4 (32.7-125.7) 
Female 88 89.5 98.4 (78.9-121.2)   Female 8 10.6 75.8 (32.7-149.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 12.4 56.5 (22.6-116.4) 
Female 4 3.3 nc (nc-nc)   Female 6 4.5 134.5 (49.1-292.8) 
Colon / Rectum            Ovary     
Male 24 27.4 87.5 (56.1-130.2)             
Female 25 23.3 107.5 (69.5-158.6)   Female 10 8.2 122.6 (58.7-225.5) 
Esophagus            Pancreas     
Male 8 6.7 119.7 (51.6-235.9)   Male 8 8.3 96.9 (41.7-191.0) 
Female 1 1.4 nc (nc-nc)   Female 12 7.2 166.0 (85.7-289.9) 
Hodgkin Lymphoma            Prostate     
Male 2 2.5 nc (nc-nc)   Male 88 91.6 96.1 (77.1-118.4) 
Female 1 2.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 11 14.3 76.9 (38.3-137.5)   Male 4 5.7 nc (nc-nc) 
Female 4 6.9 nc (nc-nc)   Female 5 2.9 172.3 (55.5-402.0) 
Larynx            Testis     
Male 3 3.7 nc (nc-nc)   Male 1 4.5 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 10.0 50.2 (16.2-117.2)   Male 13 7.3 178.1 (94.7-304.6) 
Female 3 6.4 nc (nc-nc)   Female 27 18.6 145.2 (95.6-211.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 14 8.8 159.5 (87.1-267.6)             
Female 3 2.3 nc (nc-nc)   Female 15 20.2 74.4 (41.6-122.7) 
Lung and Bronchus            All Sites / Types     
Male 55 43.1 127.6 (96.1-166.1)   Male 332 336.0 98.8 (88.5-110.0) 
Female 31 39.9 77.6 (52.7-110.2)   Female 299 297.3 100.6 (89.5-112.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
52 
Brimfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 4.1 nc (nc-nc)   Male 0 2.8 nc (nc-nc) 
Female 0 1.4 nc (nc-nc)   Female 1 2.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.8 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 5 2.4 205.6 (66.3-479.9) 
Female 16 16.6 96.6 (55.2-156.9)   Female 4 1.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 2.1 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 2 0.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 4.7 nc (nc-nc)             
Female 1 4.2 nc (nc-nc)   Female 0 1.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.2 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.3 nc (nc-nc)   Male 11 16.4 67.1 (33.4-120.0) 
Female 2 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 2.4 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 0 1.3 nc (nc-nc)   Female 2 0.5 nc (nc-nc) 
Larynx            Testis     
Male 1 0.7 nc (nc-nc)   Male 3 0.5 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 1.6 nc (nc-nc)   Male 2 1.1 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 4 3.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.5 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 4 3.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 6 7.7 78.0 (28.5-169.7)   Male 49 57.9 84.6 (62.6-111.9) 
Female 11 7.4 148.5 (74.0-265.8)   Female 51 54.1 94.3 (70.2-124.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
53 
Brockton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 77 82.9 92.9 (73.3-116.1)   Male 32 55.7 57.5 (39.3-81.2) 
Female 28 31.8 88.0 (58.5-127.3)   Female 28 48.5 57.7 (38.3-83.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 12 17.3 69.3 (35.8-121.1)   Male 14 16.0 87.4 (47.7-146.6) 
Female 15 15.3 98.0 (54.8-161.6)   Female 14 13.6 102.6 (56.0-172.1) 
Breast            Non-Hodgkin Lymphoma     
Male 2 2.7 nc (nc-nc)   Male 43 49.4 87.1 (63.0-117.3) 
Female 327 359.3 91.0 (81.4-101.4)   Female 43 43.7 98.4 (71.2-132.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 39 39.7 98.1 (69.8-134.2) 
Female 25 13.4 187.2 (121.1-276.4)   Female 17 18.2 93.3 (54.3-149.4) 
Colon / Rectum            Ovary     
Male 114 93.5 121.9 (100.5-146.4)             
Female 109 97.7 111.5 (91.6-134.5)   Female 40 32.9 121.6 (86.9-165.6) 
Esophagus            Pancreas     
Male 22 22.6 97.5 (61.1-147.6)   Male 32 28.5 112.1 (76.7-158.3) 
Female 8 6.1 130.8 (56.3-257.7)   Female 37 31.0 119.5 (84.1-164.7) 
Hodgkin Lymphoma            Prostate     
Male 3 7.8 nc (nc-nc)   Male 320 303.4 105.5 (94.2-117.7) 
Female 8 6.8 117.1 (50.4-230.7)             
Kidney & Renal Pelvis            Stomach     
Male 57 47.0 121.4 (91.9-157.3)   Male 24 19.7 122.0 (78.2-181.6) 
Female 26 28.5 91.3 (59.7-133.9)   Female 15 12.3 122.4 (68.4-201.9) 
Larynx            Testis     
Male 17 12.5 135.7 (79.0-217.2)   Male 12 13.6 88.1 (45.5-153.8) 
Female 6 4.4 137.5 (50.2-299.3)             
Leukemia            Thyroid     
Male 26 34.9 74.6 (48.7-109.3)   Male 31 22.7 136.8 (92.9-194.2) 
Female 22 26.9 81.8 (51.2-123.8)   Female 101 72.7 138.8 (113.1-168.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 36 29.0 124.0 (86.9-171.7)             
Female 16 9.8 164.0 (93.7-266.4)   Female 78 81.4 95.9 (75.8-119.6) 
Lung and Bronchus            All Sites / Types     
Male 184 150.9 122.0 (105.0-140.9)   Male 1187 1136.5 104.4 (98.6-110.6) 
Female 202 166.3 121.4 (105.3-139.4)   Female 1271 1216.1 104.5 (98.9-110.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
54 
Brookfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 4.0 150.4 (54.9-327.4)   Male 4 2.7 nc (nc-nc) 
Female 2 1.4 nc (nc-nc)   Female 1 2.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.8 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 2.3 nc (nc-nc) 
Female 16 15.7 101.6 (58.1-165.1)   Female 3 1.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 2.0 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 3 0.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 4.5 nc (nc-nc)             
Female 7 4.2 166.1 (66.5-342.2)   Female 1 1.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.1 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.3 nc (nc-nc)   Male 14 15.8 88.7 (48.5-148.9) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 2.3 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Larynx            Testis     
Male 0 0.6 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.6 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 0 2.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.4 nc (nc-nc)             
Female 3 0.4 nc (nc-nc)   Female 5 3.7 136.9 (44.1-319.6) 
Lung and Bronchus            All Sites / Types     
Male 10 7.5 133.7 (64.0-245.8)   Male 46 55.5 82.8 (60.6-110.5) 
Female 8 7.7 104.5 (45.0-205.8)   Female 57 52.8 107.9 (81.7-139.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
55 
Brookline 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 54 55.2 97.9 (73.5-127.7)   Male 42 35.5 118.4 (85.3-160.0) 
Female 14 20.9 66.9 (36.5-112.2)   Female 43 32.6 131.9 (95.4-177.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 14 10.5 133.9 (73.1-224.7)   Male 10 10.2 97.8 (46.8-179.8) 
Female 10 9.9 100.6 (48.2-185.1)   Female 8 8.9 89.8 (38.7-176.9) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.7 nc (nc-nc)   Male 40 31.4 127.4 (91.0-173.4) 
Female 253 223.9 113.0 (99.5-127.8)   Female 35 28.5 122.9 (85.6-170.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 21 24.0 87.6 (54.2-133.9) 
Female 1 8.7 nc (nc-nc)   Female 8 11.7 68.2 (29.4-134.4) 
Colon / Rectum            Ovary     
Male 38 59.4 63.9 (45.2-87.8)             
Female 44 63.9 68.8 (50.0-92.4)   Female 32 21.1 151.3 (103.5-213.7) 
Esophagus            Pancreas     
Male 6 14.3 41.9 (15.3-91.2)   Male 22 18.5 118.7 (74.4-179.8) 
Female 2 4.0 nc (nc-nc)   Female 26 20.6 126.3 (82.5-185.1) 
Hodgkin Lymphoma            Prostate     
Male 4 5.0 nc (nc-nc)   Male 192 189.4 101.4 (87.5-116.8) 
Female 6 5.2 114.4 (41.8-249.0)             
Kidney & Renal Pelvis            Stomach     
Male 33 28.8 114.7 (79.0-161.2)   Male 10 12.7 78.8 (37.7-144.9) 
Female 18 18.1 99.5 (58.9-157.2)   Female 9 8.1 111.2 (50.7-211.1) 
Larynx            Testis     
Male 1 7.8 nc (nc-nc)   Male 13 9.4 138.6 (73.7-236.9) 
Female 0 2.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 33 22.1 149.1 (102.6-209.4)   Male 17 13.8 123.5 (71.9-197.7) 
Female 26 17.5 148.6 (97.0-217.7)   Female 53 48.7 108.8 (81.5-142.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 17.7 39.5 (15.8-81.3)             
Female 6 6.3 94.9 (34.7-206.6)   Female 47 51.7 90.9 (66.8-120.9) 
Lung and Bronchus            All Sites / Types     
Male 66 98.2 67.2 (52.0-85.5)   Male 674 722.3 93.3 (86.4-100.6) 
Female 79 106.8 74.0 (58.5-92.2)   Female 779 782.9 99.5 (92.6-106.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
56 
Buckland 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 2.4 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 3 1.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.4 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 3 1.4 nc (nc-nc) 
Female 12 9.7 123.7 (63.9-216.1)   Female 0 1.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 1.2 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 2.7 nc (nc-nc)             
Female 3 2.6 nc (nc-nc)   Female 2 0.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.7 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 3 0.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 10 9.3 107.2 (51.3-197.1) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 1.3 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Larynx            Testis     
Male 1 0.4 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.9 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 0 1.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.9 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 0 2.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 4.5 nc (nc-nc)   Male 26 33.0 78.8 (51.4-115.4) 
Female 5 4.7 106.3 (34.3-248.1)   Female 38 32.6 116.5 (82.5-159.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
57 
Burlington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 30 30.0 100.1 (67.6-143.0)   Male 15 19.0 79.1 (44.2-130.5) 
Female 7 10.8 64.9 (26.0-133.8)   Female 16 14.7 108.9 (62.2-176.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 9 5.3 169.4 (77.3-321.7)   Male 6 5.6 107.3 (39.2-233.5) 
Female 2 4.5 nc (nc-nc)   Female 5 4.6 109.8 (35.4-256.3) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.9 nc (nc-nc)   Male 26 16.6 156.4 (102.2-229.2) 
Female 123 112.5 109.3 (90.9-130.5)   Female 15 14.2 105.9 (59.2-174.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 9 12.8 70.0 (32.0-133.0) 
Female 3 3.8 nc (nc-nc)   Female 4 5.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 32 32.1 99.7 (68.2-140.8)             
Female 30 32.1 93.6 (63.1-133.6)   Female 7 10.3 68.2 (27.3-140.4) 
Esophagus            Pancreas     
Male 4 7.8 nc (nc-nc)   Male 11 10.0 109.8 (54.8-196.5) 
Female 1 2.1 nc (nc-nc)   Female 13 10.4 124.6 (66.3-213.1) 
Hodgkin Lymphoma            Prostate     
Male 1 2.2 nc (nc-nc)   Male 99 102.1 97.0 (78.8-118.1) 
Female 1 1.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 18 15.5 116.0 (68.7-183.3)   Male 5 6.9 72.9 (23.5-170.0) 
Female 8 9.2 87.1 (37.5-171.7)   Female 5 4.0 124.4 (40.1-290.3) 
Larynx            Testis     
Male 3 4.3 nc (nc-nc)   Male 4 3.5 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 18 11.5 156.1 (92.4-246.6)   Male 11 6.9 159.4 (79.5-285.2) 
Female 7 8.4 83.2 (33.3-171.5)   Female 28 20.2 138.5 (92.0-200.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 8 9.6 83.1 (35.8-163.7)             
Female 3 3.2 nc (nc-nc)   Female 31 25.7 120.7 (82.0-171.4) 
Lung and Bronchus            All Sites / Types     
Male 47 54.4 86.5 (63.5-115.0)   Male 398 386.9 102.9 (93.0-113.5) 
Female 55 56.8 96.8 (72.9-126.0)   Female 399 387.5 103.0 (93.1-113.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
58 
Cambridge 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 43 73.3 58.7 (42.4-79.0)   Male 56 51.3 109.2 (82.5-141.8) 
Female 20 27.9 71.8 (43.8-110.9)   Female 41 49.6 82.7 (59.4-112.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 17 16.6 102.6 (59.7-164.3)   Male 16 13.9 115.1 (65.8-187.0) 
Female 14 14.8 94.8 (51.8-159.1)   Female 11 12.0 91.6 (45.7-163.9) 
Breast            Non-Hodgkin Lymphoma     
Male 3 2.3 nc (nc-nc)   Male 37 45.6 81.2 (57.1-111.9) 
Female 300 313.8 95.6 (85.1-107.0)   Female 32 39.7 80.6 (55.1-113.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 33 34.4 96.0 (66.0-134.8) 
Female 9 13.6 66.1 (30.2-125.5)   Female 13 16.3 79.7 (42.4-136.3) 
Colon / Rectum            Ovary     
Male 77 81.5 94.5 (74.6-118.2)             
Female 76 85.4 89.0 (70.1-111.4)   Female 18 30.1 59.9 (35.5-94.6) 
Esophagus            Pancreas     
Male 9 19.5 46.1 (21.1-87.6)   Male 29 25.0 116.0 (77.7-166.6) 
Female 6 5.4 111.4 (40.7-242.4)   Female 25 27.2 92.0 (59.6-135.9) 
Hodgkin Lymphoma            Prostate     
Male 7 10.7 65.4 (26.2-134.8)   Male 243 260.8 93.2 (81.8-105.6) 
Female 6 9.5 62.9 (23.0-136.8)             
Kidney & Renal Pelvis            Stomach     
Male 26 41.2 63.1 (41.2-92.5)   Male 12 17.3 69.4 (35.8-121.2) 
Female 11 25.2 43.7 (21.8-78.1)   Female 9 10.8 83.6 (38.1-158.6) 
Larynx            Testis     
Male 8 10.8 74.1 (31.9-146.0)   Male 24 22.4 107.1 (68.6-159.4) 
Female 2 3.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 20 32.0 62.4 (38.1-96.4)   Male 29 23.3 124.4 (83.3-178.6) 
Female 20 24.6 81.3 (49.6-125.6)   Female 79 79.8 99.0 (78.4-123.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 20 24.7 80.9 (49.4-124.9)             
Female 11 8.6 127.5 (63.5-228.1)   Female 70 72.3 96.9 (75.5-122.4) 
Lung and Bronchus            All Sites / Types     
Male 109 131.7 82.8 (68.0-99.8)   Male 876 1017.3 86.1 (80.5-92.0) 
Female 107 146.2 73.2 (60.0-88.5)   Female 952 1101.8 86.4 (81.0-92.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
59 
Canton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 21 26.5 79.1 (49.0-120.9)   Male 18 16.4 109.8 (65.0-173.5) 
Female 9 10.1 88.7 (40.5-168.4)   Female 14 13.4 104.8 (57.2-175.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 4.6 nc (nc-nc)   Male 6 4.9 123.1 (45.0-268.0) 
Female 5 4.1 120.9 (39.0-282.2)   Female 8 4.2 189.2 (81.5-372.9) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.8 nc (nc-nc)   Male 12 14.6 82.3 (42.5-143.8) 
Female 95 101.6 93.5 (75.7-114.4)   Female 16 13.1 122.4 (69.9-198.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 11.2 89.3 (42.7-164.2) 
Female 2 3.4 nc (nc-nc)   Female 10 5.4 186.9 (89.5-343.7) 
Colon / Rectum            Ovary     
Male 31 28.5 108.6 (73.8-154.2)             
Female 29 31.1 93.3 (62.5-134.0)   Female 7 9.4 74.8 (29.9-154.0) 
Esophagus            Pancreas     
Male 6 6.8 88.7 (32.4-193.1)   Male 10 8.8 113.2 (54.2-208.2) 
Female 1 1.9 nc (nc-nc)   Female 9 10.0 89.8 (41.0-170.5) 
Hodgkin Lymphoma            Prostate     
Male 1 1.8 nc (nc-nc)   Male 81 88.0 92.1 (73.1-114.4) 
Female 2 1.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 11 13.3 82.7 (41.2-148.0)   Male 2 6.1 nc (nc-nc) 
Female 4 8.2 nc (nc-nc)   Female 2 4.0 nc (nc-nc) 
Larynx            Testis     
Male 4 3.7 nc (nc-nc)   Male 2 2.8 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 15 10.2 146.8 (82.1-242.1)   Male 10 5.8 171.6 (82.2-315.7) 
Female 6 7.9 75.7 (27.6-164.7)   Female 28 17.9 156.0 (103.7-225.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 8.4 nc (nc-nc)             
Female 0 2.9 nc (nc-nc)   Female 26 22.7 114.4 (74.7-167.6) 
Lung and Bronchus            All Sites / Types     
Male 40 46.7 85.6 (61.1-116.6)   Male 322 336.7 95.6 (85.5-106.7) 
Female 61 50.1 121.9 (93.2-156.6)   Female 368 354.0 104.0 (93.6-115.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
60 
Carlisle 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 6.0 nc (nc-nc)   Male 7 4.0 174.8 (70.0-360.2) 
Female 1 1.6 nc (nc-nc)   Female 6 2.7 225.5 (82.4-490.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.1 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 2 3.5 nc (nc-nc) 
Female 23 22.3 103.0 (65.3-154.5)   Female 5 2.4 208.9 (67.3-487.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 3.1 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 8 6.8 117.5 (50.6-231.5)             
Female 2 5.0 nc (nc-nc)   Female 3 2.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 1.8 nc (nc-nc)   Male 3 2.1 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 27 24.8 109.1 (71.9-158.7) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 3.5 nc (nc-nc)   Male 2 1.4 nc (nc-nc) 
Female 1 1.7 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Larynx            Testis     
Male 0 1.0 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 2.4 nc (nc-nc)   Male 4 1.5 nc (nc-nc) 
Female 2 1.3 nc (nc-nc)   Female 7 4.0 173.5 (69.5-357.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 2.3 nc (nc-nc)             
Female 1 0.6 nc (nc-nc)   Female 6 5.3 112.8 (41.2-245.6) 
Lung and Bronchus            All Sites / Types     
Male 3 11.4 nc (nc-nc)   Male 71 85.1 83.5 (65.2-105.3) 
Female 3 9.4 nc (nc-nc)   Female 68 69.7 97.5 (75.7-123.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
61 
Carver 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 15 13.3 112.9 (63.1-186.2)   Male 8 8.7 92.4 (39.8-182.1) 
Female 11 4.8 230.8 (115.1-413.0)   Female 14 6.8 207.3 (113.2-347.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 2.5 nc (nc-nc)   Male 2 2.6 nc (nc-nc) 
Female 3 2.1 nc (nc-nc)   Female 2 2.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 7 7.6 92.2 (37.0-190.1) 
Female 42 52.7 79.7 (57.4-107.7)   Female 14 6.4 217.9 (119.0-365.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 6.2 97.5 (35.6-212.1) 
Female 1 1.8 nc (nc-nc)   Female 1 2.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 13 14.6 89.1 (47.4-152.4)             
Female 13 14.4 90.3 (48.1-154.5)   Female 6 4.8 125.1 (45.7-272.3) 
Esophagus            Pancreas     
Male 5 3.6 138.7 (44.7-323.7)   Male 5 4.5 110.2 (35.5-257.1) 
Female 0 0.9 nc (nc-nc)   Female 4 4.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 1.0 nc (nc-nc)   Male 51 48.5 105.1 (78.2-138.2) 
Female 1 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 7.3 82.5 (30.1-179.7)   Male 2 3.1 nc (nc-nc) 
Female 6 4.2 143.3 (52.3-311.9)   Female 0 1.8 nc (nc-nc) 
Larynx            Testis     
Male 2 2.0 nc (nc-nc)   Male 5 1.6 312.6 (100.7-729.5) 
Female 0 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 5.2 95.9 (30.9-223.8)   Male 2 3.3 nc (nc-nc) 
Female 3 3.8 nc (nc-nc)   Female 7 9.5 73.6 (29.5-151.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 4.6 nc (nc-nc)             
Female 2 1.5 nc (nc-nc)   Female 14 12.2 114.3 (62.4-191.8) 
Lung and Bronchus            All Sites / Types     
Male 33 24.4 135.2 (93.0-189.9)   Male 183 178.3 102.6 (88.3-118.6) 
Female 34 25.2 135.1 (93.5-188.7)   Female 197 177.5 111.0 (96.0-127.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
62 
Charlemont 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 1.8 nc (nc-nc)   Male 3 1.2 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 11 6.1 181.3 (90.4-324.5)   Female 0 0.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 0.8 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 2 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 2.0 nc (nc-nc)             
Female 2 1.6 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.5 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 4 6.8 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 1.0 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.7 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.6 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 3.4 nc (nc-nc)   Male 24 24.2 99.1 (63.5-147.4) 
Female 1 2.8 nc (nc-nc)   Female 21 20.1 104.5 (64.7-159.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
63 
Charlton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 14 12.8 109.3 (59.7-183.4)   Male 4 8.6 nc (nc-nc) 
Female 5 4.5 112.1 (36.1-261.7)   Female 4 6.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 2.6 nc (nc-nc)   Male 2 2.5 nc (nc-nc) 
Female 1 2.1 nc (nc-nc)   Female 5 1.9 260.9 (84.1-608.9) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 9 7.7 117.2 (53.5-222.4) 
Female 56 52.3 107.0 (80.8-139.0)   Female 3 6.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 6.3 nc (nc-nc) 
Female 2 1.9 nc (nc-nc)   Female 3 2.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 11 14.8 74.2 (37.0-132.8)             
Female 13 14.3 91.1 (48.4-155.7)   Female 3 4.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 3.5 nc (nc-nc)   Male 3 4.4 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 5 4.4 114.3 (36.8-266.7) 
Hodgkin Lymphoma            Prostate     
Male 0 1.1 nc (nc-nc)   Male 25 45.9 54.4 (35.2-80.3) 
Female 1 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 7.3 96.2 (38.5-198.2)   Male 2 3.1 nc (nc-nc) 
Female 3 4.0 nc (nc-nc)   Female 0 1.8 nc (nc-nc) 
Larynx            Testis     
Male 1 1.9 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 3 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 5.3 nc (nc-nc)   Male 2 3.5 nc (nc-nc) 
Female 3 3.7 nc (nc-nc)   Female 10 10.4 96.0 (46.0-176.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 4.5 nc (nc-nc)             
Female 1 1.4 nc (nc-nc)   Female 13 11.4 113.7 (60.5-194.5) 
Lung and Bronchus            All Sites / Types     
Male 22 22.9 96.1 (60.2-145.6)   Male 136 174.5 77.9 (65.4-92.2) 
Female 31 22.6 137.1 (93.1-194.6)   Female 186 173.0 107.5 (92.6-124.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
64 
Chatham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 15 16.1 93.3 (52.2-153.9)   Male 23 8.7 264.1 (167.4-396.4) 
Female 11 5.5 201.5 (100.4-360.5)   Female 11 5.7 193.3 (96.4-345.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 2.0 251.5 (81.0-586.8)   Male 2 2.7 nc (nc-nc) 
Female 2 1.7 nc (nc-nc)   Female 4 2.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 5 7.7 65.2 (21.0-152.1) 
Female 58 45.2 128.3 (97.4-165.9)   Female 7 6.5 107.6 (43.1-221.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 5.3 151.3 (65.2-298.2) 
Female 4 1.2 nc (nc-nc)   Female 1 2.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 17 15.6 109.2 (63.6-174.9)             
Female 14 15.6 89.6 (49.0-150.4)   Female 4 4.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 3.7 nc (nc-nc)   Male 7 5.1 137.5 (55.1-283.3) 
Female 0 1.0 nc (nc-nc)   Female 5 5.4 92.9 (29.9-216.9) 
Hodgkin Lymphoma            Prostate     
Male 0 0.6 nc (nc-nc)   Male 47 47.4 99.2 (72.9-132.0) 
Female 1 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 6.6 91.2 (33.3-198.5)   Male 2 3.4 nc (nc-nc) 
Female 5 4.0 125.3 (40.4-292.4)   Female 0 2.0 nc (nc-nc) 
Larynx            Testis     
Male 0 2.0 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 5.4 111.3 (40.6-242.2)   Male 4 2.3 nc (nc-nc) 
Female 2 3.7 nc (nc-nc)   Female 0 5.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 4.2 nc (nc-nc)             
Female 2 1.5 nc (nc-nc)   Female 9 10.7 84.3 (38.4-160.0) 
Lung and Bronchus            All Sites / Types     
Male 20 27.8 72.0 (43.9-111.1)   Male 184 182.7 100.7 (86.7-116.4) 
Female 28 27.3 102.7 (68.2-148.4)   Female 193 167.7 115.1 (99.4-132.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
65 
Chelmsford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 39 39.9 97.7 (69.5-133.5)   Male 25 25.6 97.5 (63.1-144.0) 
Female 16 14.9 107.7 (61.5-175.0)   Female 25 20.5 122.2 (79.1-180.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 8 7.3 109.8 (47.3-216.4)   Male 10 7.6 131.9 (63.1-242.6) 
Female 5 6.3 79.5 (25.6-185.5)   Female 7 6.3 110.9 (44.4-228.5) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.3 nc (nc-nc)   Male 24 22.6 106.4 (68.1-158.3) 
Female 180 159.5 112.8 (97.0-130.6)   Female 17 19.7 86.3 (50.3-138.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 21 18.0 116.7 (72.2-178.4) 
Female 5 5.4 92.6 (29.8-216.1)   Female 8 8.2 98.0 (42.2-193.2) 
Colon / Rectum            Ovary     
Male 39 43.7 89.2 (63.4-121.9)             
Female 47 45.0 104.5 (76.8-138.9)   Female 16 14.5 110.3 (63.0-179.2) 
Esophagus            Pancreas     
Male 9 10.6 84.7 (38.6-160.7)   Male 12 13.5 88.6 (45.7-154.8) 
Female 5 2.9 175.1 (56.4-408.7)   Female 19 14.5 131.1 (78.9-204.8) 
Hodgkin Lymphoma            Prostate     
Male 2 2.9 nc (nc-nc)   Male 110 141.3 77.9 (64.0-93.9) 
Female 5 2.4 210.2 (67.7-490.4)             
Kidney & Renal Pelvis            Stomach     
Male 22 21.4 103.0 (64.5-155.9)   Male 4 9.3 nc (nc-nc) 
Female 8 12.7 62.8 (27.0-123.7)   Female 6 5.6 106.3 (38.8-231.4) 
Larynx            Testis     
Male 6 5.9 102.3 (37.3-222.6)   Male 7 4.6 151.7 (60.8-312.6) 
Female 3 2.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 19 15.6 121.8 (73.3-190.3)   Male 14 9.6 146.0 (79.8-245.0) 
Female 25 11.6 215.1 (139.2-317.6)   Female 36 28.4 127.0 (88.9-175.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 11 13.4 82.4 (41.1-147.4)             
Female 3 4.4 nc (nc-nc)   Female 42 36.2 115.9 (83.5-156.6) 
Lung and Bronchus            All Sites / Types     
Male 71 72.4 98.0 (76.6-123.7)   Male 495 526.7 94.0 (85.9-102.6) 
Female 76 77.4 98.2 (77.4-123.0)   Female 596 541.5 110.1 (101.4-119.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
66 
Chelsea 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 22 24.2 90.9 (57.0-137.7)   Male 7 17.4 40.1 (16.1-82.7) 
Female 9 8.8 102.2 (46.6-194.0)   Female 7 14.9 47.0 (18.8-96.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 5.9 117.7 (47.1-242.4)   Male 4 4.8 nc (nc-nc) 
Female 3 4.8 nc (nc-nc)   Female 3 3.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.8 nc (nc-nc)   Male 17 15.6 109.3 (63.6-174.9) 
Female 85 101.7 83.6 (66.8-103.4)   Female 17 12.4 136.7 (79.6-219.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 12.2 49.3 (18.0-107.3) 
Female 9 4.3 208.0 (94.9-394.8)   Female 7 5.1 136.3 (54.6-280.8) 
Colon / Rectum            Ovary     
Male 31 28.3 109.7 (74.5-155.8)             
Female 25 27.8 89.8 (58.1-132.5)   Female 3 9.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 6 6.6 91.3 (33.3-198.7)   Male 9 8.4 107.6 (49.1-204.3) 
Female 1 1.7 nc (nc-nc)   Female 16 8.6 185.5 (105.9-301.2) 
Hodgkin Lymphoma            Prostate     
Male 1 3.2 nc (nc-nc)   Male 63 86.7 72.7 (55.8-93.0) 
Female 1 2.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 12 14.6 82.2 (42.4-143.6)   Male 10 5.9 170.5 (81.6-313.6) 
Female 14 8.0 174.1 (95.1-292.1)   Female 3 3.5 nc (nc-nc) 
Larynx            Testis     
Male 5 3.7 136.7 (44.1-319.1)   Male 2 6.5 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 15 11.2 134.3 (75.1-221.5)   Male 7 8.0 87.2 (34.9-179.7) 
Female 8 8.2 97.8 (42.1-192.7)   Female 40 24.2 165.6 (118.3-225.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 17 8.6 198.0 (115.3-317.1)             
Female 5 2.7 185.7 (59.9-433.4)   Female 14 22.1 63.2 (34.5-106.1) 
Lung and Bronchus            All Sites / Types     
Male 71 43.6 163.0 (127.3-205.6)   Male 344 342.7 100.4 (90.1-111.6) 
Female 55 44.8 122.6 (92.4-159.6)   Female 356 348.2 102.2 (91.9-113.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
67 
Cheshire 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 4.4 114.1 (36.8-266.3)   Male 8 2.8 281.1 (121.0-553.9) 
Female 3 1.4 nc (nc-nc)   Female 1 1.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.8 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 2 2.5 nc (nc-nc) 
Female 11 15.4 71.4 (35.6-127.7)   Female 0 1.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 2.1 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 4.8 124.0 (45.3-269.9)             
Female 2 4.2 nc (nc-nc)   Female 4 1.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.2 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.3 nc (nc-nc)   Male 22 17.1 129.0 (80.8-195.3) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 2.4 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 2 1.2 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Larynx            Testis     
Male 0 0.7 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.7 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 2 2.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.5 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 5 3.6 138.4 (44.6-323.0) 
Lung and Bronchus            All Sites / Types     
Male 15 8.1 184.1 (103.0-303.7)   Male 76 59.9 126.9 (100.0-158.8) 
Female 3 7.2 nc (nc-nc)   Female 38 51.3 74.0 (52.4-101.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Chester 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 1.7 nc (nc-nc)   Male 2 1.1 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 4 5.9 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 0.8 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 1.9 nc (nc-nc)             
Female 0 1.5 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.5 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 9 6.4 141.2 (64.4-268.1) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.9 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.7 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 0.6 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 4 3.1 nc (nc-nc)   Male 27 23.0 117.6 (77.5-171.1) 
Female 4 2.6 nc (nc-nc)   Female 13 19.2 67.9 (36.1-116.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
69 
Chesterfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.5 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 2 5.7 nc (nc-nc)   Female 2 0.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.8 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 1.7 nc (nc-nc)             
Female 1 1.4 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.4 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 4 6.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.9 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.6 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.6 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 2.8 nc (nc-nc)   Male 14 21.1 66.4 (36.3-111.4) 
Female 1 2.5 nc (nc-nc)   Female 9 18.3 49.1 (22.4-93.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Chicopee 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 67 62.8 106.7 (82.7-135.5)   Male 25 39.8 62.8 (40.6-92.7) 
Female 17 24.8 68.4 (39.8-109.5)   Female 20 33.3 60.1 (36.7-92.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 10 11.3 88.2 (42.2-162.3)   Male 11 11.7 93.9 (46.8-168.1) 
Female 11 10.3 106.7 (53.2-191.0)   Female 8 10.4 76.8 (33.1-151.4) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.9 nc (nc-nc)   Male 31 35.2 88.0 (59.8-125.0) 
Female 236 248.7 94.9 (83.2-107.8)   Female 34 32.2 105.5 (73.0-147.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 29 27.5 105.5 (70.7-151.5) 
Female 8 8.4 95.3 (41.0-187.8)   Female 25 13.2 189.3 (122.5-279.5) 
Colon / Rectum            Ovary     
Male 88 68.1 129.2 (103.6-159.2)             
Female 82 74.9 109.5 (87.1-136.0)   Female 30 23.2 129.4 (87.3-184.8) 
Esophagus            Pancreas     
Male 16 16.4 97.7 (55.8-158.6)   Male 20 21.1 94.7 (57.8-146.3) 
Female 4 4.7 nc (nc-nc)   Female 29 24.3 119.2 (79.8-171.2) 
Hodgkin Lymphoma            Prostate     
Male 5 4.8 103.8 (33.5-242.3)   Male 165 216.8 76.1 (64.9-88.6) 
Female 2 4.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 33 32.6 101.2 (69.6-142.1)   Male 15 14.5 103.7 (58.0-171.0) 
Female 23 20.4 112.6 (71.4-169.0)   Female 17 9.5 179.1 (104.3-286.8) 
Larynx            Testis     
Male 8 9.0 88.7 (38.2-174.7)   Male 12 8.0 149.6 (77.2-261.4) 
Female 3 3.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 25 24.6 101.7 (65.8-150.1)   Male 8 14.7 54.2 (23.4-106.9) 
Female 16 19.4 82.6 (47.2-134.1)   Female 26 44.8 58.1 (37.9-85.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 13 20.5 63.3 (33.7-108.2)             
Female 4 7.3 nc (nc-nc)   Female 55 57.0 96.6 (72.7-125.7) 
Lung and Bronchus            All Sites / Types     
Male 147 112.5 130.7 (110.4-153.6)   Male 789 817.6 96.5 (89.9-103.5) 
Female 141 126.0 111.9 (94.2-132.0)   Female 864 872.3 99.1 (92.6-105.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Chilmark 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.7 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.2 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 5 4.8 103.7 (33.4-242.1)   Female 0 0.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 1.8 337.4 (123.2-734.4)             
Female 3 1.4 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.4 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 10 5.7 175.5 (84.0-322.8) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.8 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 1 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 0.6 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.5 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 3.1 nc (nc-nc)   Male 26 21.2 122.7 (80.1-179.8) 
Female 2 2.4 nc (nc-nc)   Female 14 16.5 85.1 (46.5-142.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Clarksburg 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 2.4 nc (nc-nc)   Male 0 1.5 nc (nc-nc) 
Female 2 0.7 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.4 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 2 1.3 nc (nc-nc) 
Female 3 8.0 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 1.1 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 2.6 nc (nc-nc)             
Female 6 2.2 277.7 (101.4-604.4)   Female 0 0.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 0.6 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 8 8.6 92.5 (39.8-182.3) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.3 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 3 0.6 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.9 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.8 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 2 1.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 5 4.5 110.7 (35.7-258.3)   Male 28 31.8 87.9 (58.4-127.1) 
Female 5 3.9 128.3 (41.4-299.5)   Female 25 26.7 93.5 (60.5-138.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Clinton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 16 13.2 120.9 (69.1-196.3)   Male 6 8.9 67.5 (24.6-146.9) 
Female 1 5.0 nc (nc-nc)   Female 6 7.5 79.8 (29.1-173.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.7 nc (nc-nc)   Male 1 2.6 nc (nc-nc) 
Female 4 2.3 nc (nc-nc)   Female 1 2.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 4 7.9 nc (nc-nc) 
Female 63 56.3 112.0 (86.0-143.3)   Female 9 6.8 131.4 (60.0-249.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 6.4 94.2 (34.4-205.0) 
Female 2 2.1 nc (nc-nc)   Female 2 2.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 14 15.0 93.3 (51.0-156.5)             
Female 18 15.7 114.9 (68.1-181.6)   Female 1 5.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 3.6 nc (nc-nc)   Male 4 4.5 nc (nc-nc) 
Female 4 1.0 nc (nc-nc)   Female 7 4.9 141.8 (56.8-292.3) 
Hodgkin Lymphoma            Prostate     
Male 0 1.2 nc (nc-nc)   Male 52 47.9 108.5 (81.0-142.3) 
Female 0 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 7.5 nc (nc-nc)   Male 5 3.1 159.0 (51.2-371.1) 
Female 7 4.4 157.9 (63.2-325.3)   Female 2 2.0 nc (nc-nc) 
Larynx            Testis     
Male 3 2.0 nc (nc-nc)   Male 0 2.1 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 5.4 91.8 (29.6-214.3)   Male 2 3.6 nc (nc-nc) 
Female 6 4.1 144.8 (52.9-315.1)   Female 7 11.1 63.3 (25.4-130.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 4.7 nc (nc-nc)             
Female 2 1.5 nc (nc-nc)   Female 14 12.7 110.5 (60.3-185.4) 
Lung and Bronchus            All Sites / Types     
Male 31 24.0 129.2 (87.8-183.5)   Male 168 180.5 93.1 (79.5-108.3) 
Female 35 26.0 134.7 (93.8-187.4)   Female 202 190.3 106.2 (92.0-121.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Cohasset 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 9.3 54.0 (17.4-125.9)   Male 9 5.9 153.7 (70.1-291.7) 
Female 4 3.4 nc (nc-nc)   Female 11 4.4 249.4 (124.3-446.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.7 nc (nc-nc)   Male 1 1.7 nc (nc-nc) 
Female 2 1.4 nc (nc-nc)   Female 2 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 5 5.2 96.8 (31.2-225.8) 
Female 37 35.3 104.9 (73.9-144.6)   Female 1 4.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 4.1 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 3 1.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 15 10.1 148.1 (82.8-244.3)             
Female 7 10.3 67.9 (27.2-140.0)   Female 3 3.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 2.4 nc (nc-nc)   Male 2 3.1 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 2 3.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.6 nc (nc-nc)   Male 28 32.2 86.8 (57.7-125.5) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 4.9 123.1 (45.0-268.0)   Male 0 2.1 nc (nc-nc) 
Female 5 2.8 177.0 (57.0-413.1)   Female 0 1.3 nc (nc-nc) 
Larynx            Testis     
Male 0 1.3 nc (nc-nc)   Male 2 0.9 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 3.6 nc (nc-nc)   Male 3 2.1 nc (nc-nc) 
Female 2 2.6 nc (nc-nc)   Female 8 5.9 134.5 (57.9-265.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 3.1 nc (nc-nc)             
Female 1 1.0 nc (nc-nc)   Female 8 7.9 101.1 (43.5-199.2) 
Lung and Bronchus            All Sites / Types     
Male 8 16.7 47.8 (20.6-94.3)   Male 103 120.8 85.3 (69.6-103.4) 
Female 8 17.1 46.8 (20.2-92.3)   Female 122 120.0 101.6 (84.4-121.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Colrain 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 2.2 nc (nc-nc)   Male 0 1.4 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.4 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 2 1.3 nc (nc-nc) 
Female 8 7.5 106.8 (46.0-210.4)   Female 0 0.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 1.1 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 2.5 nc (nc-nc)             
Female 2 2.0 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.6 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.2 nc (nc-nc)   Male 7 8.5 82.1 (32.9-169.2) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.2 nc (nc-nc)   Male 2 0.5 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 1 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.9 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.8 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 5 1.8 282.5 (91.0-659.3) 
Lung and Bronchus            All Sites / Types     
Male 4 4.1 nc (nc-nc)   Male 27 30.4 88.9 (58.6-129.3) 
Female 4 3.4 nc (nc-nc)   Female 30 24.7 121.3 (81.9-173.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Concord 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 26 26.5 98.1 (64.0-143.7)   Male 33 16.1 204.5 (140.8-287.3) 
Female 6 9.6 62.7 (22.9-136.6)   Female 16 11.5 139.6 (79.7-226.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 4.3 116.2 (37.4-271.2)   Male 2 4.8 nc (nc-nc) 
Female 5 3.6 139.3 (44.9-325.0)   Female 3 4.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.8 nc (nc-nc)   Male 12 14.3 83.8 (43.2-146.3) 
Female 107 91.0 117.6 (96.4-142.1)   Female 12 12.0 100.0 (51.6-174.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 10.9 73.5 (31.7-144.8) 
Female 3 2.7 nc (nc-nc)   Female 1 4.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 19 28.3 67.1 (40.4-104.7)             
Female 33 28.9 114.4 (78.7-160.6)   Female 11 8.5 130.1 (64.9-232.9) 
Esophagus            Pancreas     
Male 3 6.6 nc (nc-nc)   Male 14 8.7 160.1 (87.5-268.7) 
Female 0 1.8 nc (nc-nc)   Female 7 9.4 74.2 (29.7-152.9) 
Hodgkin Lymphoma            Prostate     
Male 1 1.6 nc (nc-nc)   Male 90 85.3 105.5 (84.9-129.7) 
Female 0 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 15 12.9 115.9 (64.8-191.3)   Male 0 6.0 nc (nc-nc) 
Female 7 7.5 93.4 (37.4-192.5)   Female 0 3.7 nc (nc-nc) 
Larynx            Testis     
Male 0 3.6 nc (nc-nc)   Male 2 2.5 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 9.9 101.0 (48.3-185.7)   Male 4 5.5 nc (nc-nc) 
Female 5 7.1 70.3 (22.7-164.1)   Female 12 13.9 86.4 (44.6-151.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 8.2 60.8 (19.6-142.0)             
Female 4 2.7 nc (nc-nc)   Female 24 20.8 115.3 (73.9-171.6) 
Lung and Bronchus            All Sites / Types     
Male 19 46.4 40.9 (24.6-63.9)   Male 299 330.1 90.6 (80.6-101.4) 
Female 24 47.1 51.0 (32.7-75.9)   Female 310 320.2 96.8 (86.3-108.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Conway 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 2.3 nc (nc-nc)   Male 2 1.5 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.4 nc (nc-nc)   Male 2 0.5 nc (nc-nc) 
Female 2 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 2 1.3 nc (nc-nc) 
Female 10 9.1 110.0 (52.7-202.4)   Female 0 1.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 1.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 2.6 nc (nc-nc)             
Female 2 2.1 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.7 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 8 9.6 83.3 (35.8-164.1) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.4 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Larynx            Testis     
Male 1 0.4 nc (nc-nc)   Male 1 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.9 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.9 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 2 2.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 4.3 nc (nc-nc)   Male 32 32.5 98.3 (67.2-138.8) 
Female 1 3.8 nc (nc-nc)   Female 23 28.7 80.3 (50.9-120.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Cummington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.2 nc (nc-nc)   Male 2 0.8 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 3 0.7 nc (nc-nc) 
Female 9 4.2 213.0 (97.2-404.3)   Female 1 0.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 1.3 nc (nc-nc)             
Female 4 1.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 0 4.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.7 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 1 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.5 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.4 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 5 1.0 502.5 (161.9-1172.6) 
Lung and Bronchus            All Sites / Types     
Male 1 2.2 nc (nc-nc)   Male 13 16.1 80.5 (42.8-137.7) 
Female 1 1.8 nc (nc-nc)   Female 24 13.8 174.1 (111.5-259.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Dalton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 9.1 120.8 (60.2-216.2)   Male 11 5.6 197.0 (98.2-352.5) 
Female 4 3.4 nc (nc-nc)   Female 3 4.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.5 nc (nc-nc)   Male 0 1.7 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 4 4.9 nc (nc-nc) 
Female 27 33.4 80.8 (53.2-117.5)   Female 4 4.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 3.8 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 3 1.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 12 9.7 123.5 (63.7-215.7)             
Female 11 10.2 108.2 (53.9-193.5)   Female 4 3.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 2.3 nc (nc-nc)   Male 1 3.0 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 1 3.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.6 nc (nc-nc)   Male 32 30.2 106.0 (72.5-149.6) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 4.5 nc (nc-nc)   Male 1 2.1 nc (nc-nc) 
Female 1 2.7 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Larynx            Testis     
Male 0 1.3 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 3.5 nc (nc-nc)   Male 1 1.9 nc (nc-nc) 
Female 2 2.6 nc (nc-nc)   Female 2 5.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 2.9 nc (nc-nc)             
Female 1 1.0 nc (nc-nc)   Female 9 7.6 117.8 (53.7-223.6) 
Lung and Bronchus            All Sites / Types     
Male 14 16.1 86.8 (47.4-145.7)   Male 102 115.0 88.7 (72.3-107.7) 
Female 22 17.0 129.5 (81.1-196.0)   Female 104 116.7 89.1 (72.8-108.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
80 
Danvers 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 39 33.9 114.9 (81.7-157.1)   Male 23 21.0 109.5 (69.4-164.2) 
Female 9 13.4 67.2 (30.7-127.6)   Female 17 17.3 98.1 (57.1-157.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 12 5.7 209.0 (107.9-365.2)   Male 3 6.3 nc (nc-nc) 
Female 4 5.3 nc (nc-nc)   Female 2 5.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.0 nc (nc-nc)   Male 13 18.6 69.9 (37.2-119.6) 
Female 143 132.9 107.6 (90.7-126.7)   Female 27 17.2 157.2 (103.5-228.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 14 14.3 98.1 (53.6-164.7) 
Female 4 4.4 nc (nc-nc)   Female 6 7.0 85.3 (31.2-185.7) 
Colon / Rectum            Ovary     
Male 29 36.4 79.6 (53.3-114.4)             
Female 40 40.8 98.1 (70.1-133.6)   Female 13 12.3 106.0 (56.4-181.3) 
Esophagus            Pancreas     
Male 11 8.6 127.7 (63.6-228.4)   Male 13 11.3 115.5 (61.4-197.4) 
Female 1 2.5 nc (nc-nc)   Female 12 13.2 91.1 (47.0-159.1) 
Hodgkin Lymphoma            Prostate     
Male 1 2.2 nc (nc-nc)   Male 140 111.7 125.4 (105.5-147.9) 
Female 4 2.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 22 17.0 129.4 (81.1-195.9)   Male 5 7.7 64.5 (20.8-150.6) 
Female 9 10.8 83.0 (37.9-157.6)   Female 7 5.2 135.3 (54.2-278.7) 
Larynx            Testis     
Male 3 4.7 nc (nc-nc)   Male 9 3.5 257.3 (117.4-488.5) 
Female 0 1.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 18 12.9 139.6 (82.7-220.6)   Male 10 7.4 135.1 (64.7-248.5) 
Female 16 10.3 156.0 (89.1-253.3)   Female 19 22.8 83.4 (50.2-130.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 12 10.8 111.6 (57.6-194.9)             
Female 5 3.9 129.2 (41.6-301.5)   Female 34 29.9 113.7 (78.8-159.0) 
Lung and Bronchus            All Sites / Types     
Male 66 60.2 109.7 (84.8-139.5)   Male 477 429.4 111.1 (101.3-121.5) 
Female 58 67.0 86.6 (65.7-111.9)   Female 467 464.1 100.6 (91.7-110.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
81 
Dartmouth 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 54 39.7 136.2 (102.3-177.7)   Male 21 24.9 84.5 (52.3-129.1) 
Female 19 14.6 130.0 (78.2-203.0)   Female 16 19.3 82.8 (47.3-134.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 8 7.0 113.8 (49.0-224.3)   Male 5 7.3 68.1 (21.9-158.9) 
Female 6 6.0 99.9 (36.5-217.5)   Female 6 6.1 98.0 (35.8-213.3) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.2 nc (nc-nc)   Male 21 22.2 94.6 (58.5-144.6) 
Female 120 146.3 82.0 (68.0-98.1)   Female 23 18.9 121.4 (76.9-182.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 17 17.1 99.2 (57.8-158.8) 
Female 6 4.8 125.1 (45.7-272.3)   Female 10 7.8 128.7 (61.6-236.6) 
Colon / Rectum            Ovary     
Male 39 42.7 91.4 (65.0-125.0)             
Female 51 44.2 115.4 (85.9-151.7)   Female 11 13.6 80.6 (40.2-144.3) 
Esophagus            Pancreas     
Male 11 10.3 106.8 (53.2-191.1)   Male 13 13.3 97.8 (52.0-167.3) 
Female 2 2.8 nc (nc-nc)   Female 7 14.4 48.6 (19.5-100.2) 
Hodgkin Lymphoma            Prostate     
Male 3 3.2 nc (nc-nc)   Male 179 136.2 131.4 (112.8-152.1) 
Female 2 2.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 27 20.3 133.3 (87.8-193.9)   Male 13 9.1 143.1 (76.1-244.8) 
Female 16 11.9 134.3 (76.7-218.2)   Female 8 5.6 142.4 (61.3-280.6) 
Larynx            Testis     
Male 4 5.6 nc (nc-nc)   Male 5 5.2 95.6 (30.8-223.0) 
Female 1 1.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 19 15.5 122.8 (73.9-191.8)   Male 12 9.2 130.2 (67.2-227.5) 
Female 9 11.3 79.8 (36.4-151.5)   Female 34 25.7 132.1 (91.5-184.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 8 12.8 62.7 (27.0-123.6)             
Female 2 4.3 nc (nc-nc)   Female 34 33.5 101.6 (70.4-142.0) 
Lung and Bronchus            All Sites / Types     
Male 74 70.5 105.0 (82.4-131.8)   Male 572 513.6 111.4 (102.4-120.9) 
Female 43 73.6 58.4 (42.3-78.7)   Female 467 511.5 91.3 (83.2-100.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
82 
Dedham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 37 32.7 113.0 (79.6-155.8)   Male 21 19.9 105.3 (65.2-161.0) 
Female 9 12.7 70.7 (32.3-134.2)   Female 23 15.9 144.3 (91.4-216.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 5.4 128.7 (51.6-265.3)   Male 5 5.9 84.5 (27.2-197.2) 
Female 4 4.9 nc (nc-nc)   Female 1 5.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.0 nc (nc-nc)   Male 20 17.8 112.7 (68.8-174.0) 
Female 132 120.9 109.2 (91.3-129.4)   Female 14 16.0 87.4 (47.7-146.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 14 13.3 105.6 (57.7-177.2) 
Female 6 3.9 152.1 (55.5-331.1)   Female 4 6.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 32 34.8 91.9 (62.8-129.7)             
Female 34 38.6 88.0 (61.0-123.0)   Female 13 11.2 115.8 (61.6-198.0) 
Esophagus            Pancreas     
Male 6 8.1 74.1 (27.1-161.4)   Male 13 10.7 120.9 (64.3-206.8) 
Female 2 2.4 nc (nc-nc)   Female 16 12.6 127.4 (72.8-207.0) 
Hodgkin Lymphoma            Prostate     
Male 1 2.2 nc (nc-nc)   Male 87 103.3 84.2 (67.5-103.9) 
Female 3 1.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 13 15.9 82.0 (43.6-140.3)   Male 8 7.4 108.2 (46.6-213.1) 
Female 12 10.0 119.9 (61.9-209.5)   Female 6 4.9 121.4 (44.3-264.2) 
Larynx            Testis     
Male 3 4.4 nc (nc-nc)   Male 3 3.5 nc (nc-nc) 
Female 0 1.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 12.4 72.4 (33.0-137.4)   Male 6 6.9 86.5 (31.6-188.3) 
Female 5 9.7 51.7 (16.7-120.6)   Female 30 20.4 147.0 (99.1-209.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 10 10.0 100.2 (48.0-184.4)             
Female 6 3.6 166.7 (60.9-362.8)   Female 26 27.0 96.4 (63.0-141.3) 
Lung and Bronchus            All Sites / Types     
Male 58 56.9 102.0 (77.5-131.9)   Male 386 405.6 95.2 (85.9-105.2) 
Female 72 62.4 115.4 (90.3-145.4)   Female 444 429.0 103.5 (94.1-113.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
83 
Deerfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 6.3 nc (nc-nc)   Male 5 4.1 121.6 (39.2-283.7) 
Female 4 2.2 nc (nc-nc)   Female 4 3.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.2 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 4 3.6 nc (nc-nc) 
Female 22 25.0 88.1 (55.2-133.4)   Female 4 3.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 3.0 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 7.0 86.0 (31.4-187.1)             
Female 2 6.7 nc (nc-nc)   Female 0 2.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.8 nc (nc-nc)   Male 2 2.2 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 2.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.4 nc (nc-nc)   Male 23 24.3 94.7 (60.0-142.1) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 3.5 199.5 (79.9-411.1)   Male 0 1.5 nc (nc-nc) 
Female 3 2.0 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Larynx            Testis     
Male 0 1.0 nc (nc-nc)   Male 3 0.7 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 2.5 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 1 1.7 nc (nc-nc)   Female 4 4.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 2.2 nc (nc-nc)             
Female 0 0.7 nc (nc-nc)   Female 2 5.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 11.7 nc (nc-nc)   Male 64 86.2 74.2 (57.1-94.8) 
Female 4 11.7 nc (nc-nc)   Female 57 83.2 68.5 (51.9-88.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
84 
Dennis 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 32 31.1 102.8 (70.3-145.1)   Male 31 17.4 178.0 (120.9-252.7) 
Female 11 11.1 98.9 (49.3-176.9)   Female 26 12.3 211.3 (138.0-309.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 4.1 nc (nc-nc)   Male 5 5.4 92.5 (29.8-215.9) 
Female 2 3.8 nc (nc-nc)   Female 2 4.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.9 nc (nc-nc)   Male 17 15.3 111.3 (64.8-178.1) 
Female 124 98.2 126.3 (105.1-150.6)   Female 13 13.6 95.6 (50.9-163.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 19 10.9 174.0 (104.7-271.7) 
Female 1 2.7 nc (nc-nc)   Female 4 5.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 32 30.7 104.1 (71.2-147.0)             
Female 32 31.8 100.6 (68.8-142.0)   Female 10 9.2 108.3 (51.8-199.1) 
Esophagus            Pancreas     
Male 8 7.5 106.8 (46.0-210.5)   Male 13 10.0 130.1 (69.2-222.5) 
Female 3 2.1 nc (nc-nc)   Female 10 10.9 92.0 (44.0-169.2) 
Hodgkin Lymphoma            Prostate     
Male 1 1.3 nc (nc-nc)   Male 121 96.5 125.3 (104.0-149.8) 
Female 2 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 9 13.5 66.6 (30.4-126.4)   Male 2 6.7 nc (nc-nc) 
Female 8 8.5 94.2 (40.6-185.7)   Female 4 4.0 nc (nc-nc) 
Larynx            Testis     
Male 2 4.0 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 2 1.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 13 10.7 122.0 (64.9-208.7)   Male 1 4.9 nc (nc-nc) 
Female 7 7.7 90.4 (36.2-186.3)   Female 17 13.3 128.3 (74.7-205.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 10 8.6 115.6 (55.3-212.6)             
Female 3 3.2 nc (nc-nc)   Female 26 23.4 111.3 (72.7-163.1) 
Lung and Bronchus            All Sites / Types     
Male 51 54.9 93.0 (69.2-122.2)   Male 407 365.4 111.4 (100.8-122.7) 
Female 55 57.0 96.4 (72.6-125.5)   Female 396 355.7 111.3 (100.6-122.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
85 
Dighton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 7.2 97.1 (38.9-200.1)   Male 6 4.8 124.8 (45.6-271.6) 
Female 1 2.5 nc (nc-nc)   Female 5 3.8 133.0 (42.9-310.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.4 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 3 4.3 nc (nc-nc) 
Female 16 29.2 54.7 (31.2-88.8)   Female 0 3.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 3.5 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 2 1.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 13 8.2 158.2 (84.1-270.5)             
Female 4 7.8 nc (nc-nc)   Female 2 2.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 2.0 nc (nc-nc)   Male 5 2.5 199.1 (64.2-464.6) 
Female 0 0.5 nc (nc-nc)   Female 1 2.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.6 nc (nc-nc)   Male 30 27.4 109.5 (73.8-156.3) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 4.1 144.7 (52.8-314.9)   Male 2 1.7 nc (nc-nc) 
Female 4 2.3 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Larynx            Testis     
Male 1 1.1 nc (nc-nc)   Male 2 1.0 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 3.0 nc (nc-nc)   Male 4 1.9 nc (nc-nc) 
Female 2 2.1 nc (nc-nc)   Female 5 5.6 88.7 (28.6-207.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 2.5 nc (nc-nc)             
Female 2 0.8 nc (nc-nc)   Female 6 6.6 91.4 (33.4-198.9) 
Lung and Bronchus            All Sites / Types     
Male 9 13.1 68.6 (31.3-130.1)   Male 98 99.6 98.3 (79.8-119.9) 
Female 12 13.1 91.4 (47.2-159.7)   Female 74 96.7 76.6 (60.1-96.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
86 
Douglas 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 9 6.2 144.4 (65.9-274.0)   Male 6 4.8 125.6 (45.9-273.4) 
Female 3 2.1 nc (nc-nc)   Female 6 3.9 155.3 (56.7-338.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.6 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.2 nc (nc-nc)   Male 3 4.2 nc (nc-nc) 
Female 29 29.7 97.7 (65.4-140.3)   Female 2 3.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 3.8 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 2 1.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 7.9 76.1 (27.8-165.6)             
Female 5 6.8 73.2 (23.6-170.9)   Female 2 2.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 5 1.9 258.4 (83.3-603.1)   Male 4 2.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 1 2.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.7 nc (nc-nc)   Male 24 27.3 87.9 (56.3-130.8) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 4.4 137.9 (50.3-300.1)   Male 1 1.6 nc (nc-nc) 
Female 2 2.2 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Larynx            Testis     
Male 1 1.1 nc (nc-nc)   Male 2 1.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 2.8 nc (nc-nc)   Male 3 2.3 nc (nc-nc) 
Female 4 1.9 nc (nc-nc)   Female 5 6.7 75.1 (24.2-175.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 2.6 nc (nc-nc)             
Female 0 0.7 nc (nc-nc)   Female 9 6.5 138.3 (63.1-262.6) 
Lung and Bronchus            All Sites / Types     
Male 11 12.0 91.9 (45.8-164.5)   Male 102 97.1 105.1 (85.7-127.5) 
Female 13 11.3 114.9 (61.1-196.6)   Female 91 93.0 97.8 (78.8-120.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
87 
Dover 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 6.6 nc (nc-nc)   Male 10 4.3 230.2 (110.2-423.3) 
Female 0 1.9 nc (nc-nc)   Female 3 3.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.3 nc (nc-nc)   Male 0 1.3 nc (nc-nc) 
Female 2 0.9 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 8 3.8 209.3 (90.1-412.5) 
Female 28 24.4 114.6 (76.1-165.7)   Female 2 2.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 3.2 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 7.4 67.4 (21.7-157.4)             
Female 4 6.0 nc (nc-nc)   Female 0 2.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.9 nc (nc-nc)   Male 1 2.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 2 1.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 24 26.0 92.5 (59.2-137.6) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 3.8 nc (nc-nc)   Male 0 1.6 nc (nc-nc) 
Female 1 1.9 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Larynx            Testis     
Male 0 1.1 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 2.6 nc (nc-nc)   Male 4 1.6 nc (nc-nc) 
Female 0 1.6 nc (nc-nc)   Female 5 4.4 113.6 (36.6-265.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 2.4 nc (nc-nc)             
Female 0 0.6 nc (nc-nc)   Female 3 5.6 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 5 12.4 40.2 (13.0-93.8)   Male 84 91.6 91.7 (73.1-113.5) 
Female 6 10.7 55.8 (20.4-121.5)   Female 66 78.2 84.4 (65.3-107.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
88 
Dracut 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 39 29.0 134.4 (95.5-183.7)   Male 11 19.5 56.4 (28.1-101.0) 
Female 18 10.5 171.3 (101.5-270.8)   Female 17 16.0 106.3 (61.9-170.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 8 5.8 137.0 (59.0-270.0)   Male 6 5.6 106.2 (38.8-231.2) 
Female 6 4.9 121.9 (44.5-265.3)   Female 4 4.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.9 nc (nc-nc)   Male 18 17.2 104.4 (61.9-165.0) 
Female 133 121.8 109.2 (91.4-129.4)   Female 8 14.5 55.3 (23.8-109.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 9 14.1 64.0 (29.2-121.5) 
Female 6 4.4 134.9 (49.3-293.6)   Female 8 6.1 131.3 (56.5-258.7) 
Colon / Rectum            Ovary     
Male 40 32.8 121.9 (87.1-166.0)             
Female 44 32.4 135.7 (98.6-182.2)   Female 14 11.0 127.3 (69.5-213.6) 
Esophagus            Pancreas     
Male 12 8.0 150.4 (77.6-262.7)   Male 5 10.0 50.0 (16.1-116.6) 
Female 1 2.0 nc (nc-nc)   Female 13 10.2 127.9 (68.0-218.8) 
Hodgkin Lymphoma            Prostate     
Male 2 2.6 nc (nc-nc)   Male 98 107.3 91.3 (74.2-111.3) 
Female 3 2.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 20 16.5 120.9 (73.8-186.8)   Male 4 6.9 nc (nc-nc) 
Female 8 9.5 84.1 (36.2-165.7)   Female 5 4.0 124.0 (40.0-289.3) 
Larynx            Testis     
Male 4 4.4 nc (nc-nc)   Male 1 4.4 nc (nc-nc) 
Female 2 1.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 22 11.9 184.9 (115.8-279.9)   Male 6 7.9 75.9 (27.7-165.3) 
Female 10 8.7 115.3 (55.2-212.0)   Female 28 24.0 116.6 (77.5-168.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 10.2 nc (nc-nc)             
Female 4 3.3 nc (nc-nc)   Female 18 27.5 65.4 (38.8-103.4) 
Lung and Bronchus            All Sites / Types     
Male 57 53.0 107.5 (81.4-139.3)   Male 401 398.2 100.7 (91.1-111.0) 
Female 73 55.6 131.4 (103.0-165.2)   Female 459 405.8 113.1 (103.0-123.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
89 
Dudley 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 11.0 72.8 (31.3-143.4)   Male 4 7.3 nc (nc-nc) 
Female 4 3.7 nc (nc-nc)   Female 4 5.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 2.2 nc (nc-nc)   Male 2 2.1 nc (nc-nc) 
Female 2 1.8 nc (nc-nc)   Female 0 1.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.4 nc (nc-nc)   Male 3 6.5 nc (nc-nc) 
Female 36 43.5 82.7 (57.9-114.5)   Female 4 5.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 5.3 nc (nc-nc) 
Female 0 1.6 nc (nc-nc)   Female 1 2.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 14 12.4 113.2 (61.8-189.9)             
Female 12 11.6 103.1 (53.2-180.2)   Female 8 3.9 202.7 (87.3-399.4) 
Esophagus            Pancreas     
Male 4 3.0 nc (nc-nc)   Male 5 3.8 132.8 (42.8-309.9) 
Female 2 0.7 nc (nc-nc)   Female 3 3.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 1.0 nc (nc-nc)   Male 32 40.0 80.0 (54.7-112.9) 
Female 1 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 6.2 97.3 (35.5-211.7)   Male 4 2.6 nc (nc-nc) 
Female 3 3.4 nc (nc-nc)   Female 0 1.5 nc (nc-nc) 
Larynx            Testis     
Male 3 1.7 nc (nc-nc)   Male 0 1.7 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 4.5 198.6 (90.6-377.1)   Male 1 3.0 nc (nc-nc) 
Female 3 3.1 nc (nc-nc)   Female 12 8.7 138.0 (71.2-241.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 3.8 nc (nc-nc)             
Female 0 1.2 nc (nc-nc)   Female 16 9.8 162.8 (93.0-264.4) 
Lung and Bronchus            All Sites / Types     
Male 28 19.9 140.7 (93.5-203.4)   Male 146 149.8 97.4 (82.3-114.6) 
Female 23 19.5 117.9 (74.7-176.9)   Female 147 145.1 101.3 (85.6-119.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
90 
Dunstable 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 2.8 nc (nc-nc)   Male 2 2.0 nc (nc-nc) 
Female 3 0.9 nc (nc-nc)   Female 3 1.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.6 nc (nc-nc)   Male 2 0.6 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 16 12.9 124.0 (70.8-201.3)   Female 1 1.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 1.6 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 2 0.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 3.4 205.5 (82.3-423.5)             
Female 1 2.9 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 0.9 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 2 0.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.3 nc (nc-nc)   Male 8 12.2 65.6 (28.2-129.2) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 1.9 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Larynx            Testis     
Male 1 0.5 nc (nc-nc)   Male 2 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 1.2 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 2 2.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.1 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 3 2.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 5.4 nc (nc-nc)   Male 42 42.3 99.2 (71.5-134.1) 
Female 6 5.0 119.9 (43.8-260.9)   Female 41 39.7 103.3 (74.1-140.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
91 
Duxbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 24 18.5 129.6 (83.0-192.8)   Male 26 11.7 221.6 (144.7-324.7) 
Female 2 6.7 nc (nc-nc)   Female 14 9.0 155.2 (84.8-260.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 3.3 150.1 (48.4-350.2)   Male 5 3.5 141.8 (45.7-330.9) 
Female 1 2.9 nc (nc-nc)   Female 2 2.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.6 nc (nc-nc)   Male 11 10.4 105.8 (52.7-189.3) 
Female 78 72.4 107.8 (85.2-134.5)   Female 3 8.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 8.5 58.6 (18.9-136.7) 
Female 0 2.4 nc (nc-nc)   Female 4 3.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 11 20.3 54.1 (27.0-96.8)             
Female 12 20.4 58.8 (30.3-102.7)   Female 9 6.6 137.0 (62.5-260.0) 
Esophagus            Pancreas     
Male 8 5.0 158.6 (68.3-312.6)   Male 4 6.4 nc (nc-nc) 
Female 0 1.3 nc (nc-nc)   Female 5 6.6 76.1 (24.5-177.5) 
Hodgkin Lymphoma            Prostate     
Male 4 1.2 nc (nc-nc)   Male 78 68.8 113.4 (89.7-141.6) 
Female 2 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 12 10.0 120.3 (62.1-210.1)   Male 0 4.3 nc (nc-nc) 
Female 3 5.7 nc (nc-nc)   Female 2 2.6 nc (nc-nc) 
Larynx            Testis     
Male 0 2.8 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 7.2 83.5 (30.5-181.7)   Male 0 4.3 nc (nc-nc) 
Female 5 5.3 95.1 (30.6-221.9)   Female 15 12.2 122.6 (68.6-202.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 6.3 nc (nc-nc)             
Female 0 2.0 nc (nc-nc)   Female 9 16.6 54.1 (24.7-102.7) 
Lung and Bronchus            All Sites / Types     
Male 23 33.6 68.4 (43.3-102.6)   Male 247 247.1 100.0 (87.9-113.2) 
Female 18 34.1 52.9 (31.3-83.5)   Female 207 243.5 85.0 (73.8-97.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
92 
East Bridgewater 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 15 13.5 111.0 (62.1-183.1)   Male 11 9.2 119.5 (59.6-213.9) 
Female 8 4.9 163.6 (70.4-322.3)   Female 11 7.4 147.9 (73.7-264.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 2.8 nc (nc-nc)   Male 1 2.7 nc (nc-nc) 
Female 1 2.3 nc (nc-nc)   Female 0 2.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 8 8.1 99.1 (42.7-195.2) 
Female 47 57.7 81.5 (59.9-108.3)   Female 11 6.8 161.5 (80.5-289.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 6.8 103.2 (41.3-212.6) 
Female 2 2.1 nc (nc-nc)   Female 2 2.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 14 15.4 90.9 (49.6-152.4)             
Female 13 15.0 86.7 (46.1-148.2)   Female 5 5.2 96.3 (31.0-224.8) 
Esophagus            Pancreas     
Male 5 3.8 130.6 (42.1-304.7)   Male 2 4.7 nc (nc-nc) 
Female 2 0.9 nc (nc-nc)   Female 7 4.7 147.8 (59.2-304.6) 
Hodgkin Lymphoma            Prostate     
Male 2 1.2 nc (nc-nc)   Male 47 52.7 89.2 (65.6-118.7) 
Female 1 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 11 8.0 138.0 (68.8-247.0)   Male 3 3.2 nc (nc-nc) 
Female 3 4.5 nc (nc-nc)   Female 0 1.9 nc (nc-nc) 
Larynx            Testis     
Male 2 2.1 nc (nc-nc)   Male 2 1.9 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 5.6 nc (nc-nc)   Male 6 3.8 159.5 (58.3-347.3) 
Female 3 4.0 nc (nc-nc)   Female 13 11.1 116.8 (62.1-199.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 4.9 nc (nc-nc)             
Female 0 1.5 nc (nc-nc)   Female 15 13.2 113.5 (63.5-187.3) 
Lung and Bronchus            All Sites / Types     
Male 32 25.2 127.0 (86.8-179.2)   Male 189 189.9 99.5 (85.9-114.8) 
Female 30 26.2 114.4 (77.2-163.3)   Female 196 190.8 102.7 (88.8-118.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
93 
East Brookfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 2.5 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 2 0.8 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.5 nc (nc-nc)   Male 2 0.5 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 2 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 8 9.0 89.4 (38.5-176.1)   Female 0 1.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 2.8 178.3 (57.5-416.1)             
Female 1 2.4 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.7 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 8 9.7 82.7 (35.6-163.0) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.4 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.4 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.0 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 2 1.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.9 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 3 2.0 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 4.6 nc (nc-nc)   Male 30 34.4 87.1 (58.8-124.3) 
Female 4 4.1 nc (nc-nc)   Female 30 29.8 100.8 (68.0-144.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
94 
East Longmeadow 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 22 22.0 99.8 (62.5-151.1)   Male 18 13.1 137.1 (81.2-216.6) 
Female 4 8.9 nc (nc-nc)   Female 7 10.6 66.1 (26.5-136.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 3.5 nc (nc-nc)   Male 0 3.9 nc (nc-nc) 
Female 0 3.3 nc (nc-nc)   Female 3 3.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.7 nc (nc-nc)   Male 11 11.8 93.6 (46.7-167.5) 
Female 73 81.0 90.1 (70.6-113.3)   Female 9 11.0 81.9 (37.4-155.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 8.7 80.3 (32.2-165.5) 
Female 0 2.6 nc (nc-nc)   Female 5 4.4 113.2 (36.5-264.1) 
Colon / Rectum            Ovary     
Male 15 23.3 64.2 (35.9-106.0)             
Female 20 27.1 73.9 (45.1-114.1)   Female 8 7.6 105.7 (45.5-208.4) 
Esophagus            Pancreas     
Male 2 5.4 nc (nc-nc)   Male 5 7.2 69.5 (22.4-162.3) 
Female 2 1.7 nc (nc-nc)   Female 13 8.8 147.1 (78.3-251.6) 
Hodgkin Lymphoma            Prostate     
Male 0 1.3 nc (nc-nc)   Male 66 68.2 96.7 (74.8-123.1) 
Female 2 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 13 10.4 125.2 (66.6-214.1)   Male 6 5.0 121.1 (44.2-263.7) 
Female 11 6.7 163.0 (81.3-291.7)   Female 3 3.5 nc (nc-nc) 
Larynx            Testis     
Male 4 2.9 nc (nc-nc)   Male 2 1.9 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 8.2 85.0 (34.0-175.1)   Male 3 4.4 nc (nc-nc) 
Female 2 6.7 nc (nc-nc)   Female 9 13.0 69.4 (31.7-131.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 6.6 nc (nc-nc)             
Female 0 2.5 nc (nc-nc)   Female 12 17.9 67.1 (34.6-117.2) 
Lung and Bronchus            All Sites / Types     
Male 34 38.0 89.5 (62.0-125.1)   Male 241 268.8 89.7 (78.7-101.7) 
Female 44 42.4 103.7 (75.4-139.2)   Female 254 290.9 87.3 (76.9-98.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
95 
Eastham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 11.9 42.2 (13.6-98.4)   Male 8 6.6 121.8 (52.4-239.9) 
Female 4 3.8 nc (nc-nc)   Female 16 4.3 375.5 (214.5-609.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.5 nc (nc-nc)   Male 3 2.1 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)   Female 3 1.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 2 5.8 nc (nc-nc) 
Female 46 34.5 133.2 (97.5-177.7)   Female 8 4.7 171.5 (73.8-337.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 4.1 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 0 1.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 11.6 60.1 (24.1-123.9)             
Female 11 10.7 102.6 (51.1-183.5)   Female 5 3.2 155.4 (50.1-362.6) 
Esophagus            Pancreas     
Male 0 2.8 nc (nc-nc)   Male 2 3.8 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 6 3.7 164.2 (60.0-357.4) 
Hodgkin Lymphoma            Prostate     
Male 0 0.5 nc (nc-nc)   Male 41 36.6 112.0 (80.3-151.9) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 5.1 nc (nc-nc)   Male 1 2.6 nc (nc-nc) 
Female 1 2.9 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Larynx            Testis     
Male 0 1.5 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 4.0 223.9 (102.2-425.1)   Male 1 1.8 nc (nc-nc) 
Female 2 2.6 nc (nc-nc)   Female 2 4.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 3.3 nc (nc-nc)             
Female 0 1.1 nc (nc-nc)   Female 7 8.3 84.0 (33.7-173.2) 
Lung and Bronchus            All Sites / Types     
Male 22 20.8 105.9 (66.4-160.4)   Male 124 138.3 89.6 (74.6-106.9) 
Female 17 19.6 86.5 (50.4-138.6)   Female 145 123.1 117.8 (99.4-138.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Easthampton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 18.3 65.5 (33.8-114.4)   Male 6 12.0 50.2 (18.3-109.3) 
Female 3 6.9 nc (nc-nc)   Female 7 9.9 70.8 (28.3-145.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 3.4 nc (nc-nc)   Male 2 3.5 nc (nc-nc) 
Female 2 3.0 nc (nc-nc)   Female 3 2.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.6 nc (nc-nc)   Male 6 10.6 56.8 (20.7-123.6) 
Female 70 74.9 93.5 (72.9-118.1)   Female 8 9.2 86.7 (37.3-170.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 9 8.7 104.0 (47.5-197.5) 
Female 2 2.6 nc (nc-nc)   Female 8 3.9 206.6 (89.0-407.1) 
Colon / Rectum            Ovary     
Male 33 20.4 161.7 (111.3-227.1)             
Female 29 21.1 137.3 (92.0-197.3)   Female 2 6.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 5 5.0 100.6 (32.4-234.8)   Male 4 6.3 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)   Female 7 6.7 104.1 (41.7-214.4) 
Hodgkin Lymphoma            Prostate     
Male 2 1.4 nc (nc-nc)   Male 67 66.8 100.2 (77.7-127.3) 
Female 0 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 10.0 79.9 (34.4-157.4)   Male 4 4.3 nc (nc-nc) 
Female 8 5.9 135.0 (58.1-266.0)   Female 2 2.7 nc (nc-nc) 
Larynx            Testis     
Male 4 2.7 nc (nc-nc)   Male 2 2.4 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 7.2 96.7 (38.7-199.3)   Male 1 4.6 nc (nc-nc) 
Female 5 5.4 91.8 (29.6-214.2)   Female 10 14.1 71.1 (34.1-130.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 6.4 nc (nc-nc)             
Female 2 2.1 nc (nc-nc)   Female 14 17.3 81.0 (44.2-135.9) 
Lung and Bronchus            All Sites / Types     
Male 31 32.9 94.2 (64.0-133.7)   Male 224 246.3 91.0 (79.4-103.7) 
Female 32 35.2 90.9 (62.2-128.4)   Female 235 254.5 92.4 (80.9-104.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
97 
Easton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 22 22.5 97.7 (61.2-147.9)   Male 19 15.1 125.6 (75.6-196.2) 
Female 9 7.6 118.0 (53.9-224.1)   Female 17 11.9 142.3 (82.8-227.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 4.5 155.5 (62.3-320.4)   Male 4 4.4 nc (nc-nc) 
Female 6 3.8 159.3 (58.2-346.7)   Female 3 3.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 3 0.7 nc (nc-nc)   Male 10 13.3 74.9 (35.9-137.8) 
Female 117 92.1 127.1 (105.1-152.3)   Female 14 10.7 130.3 (71.2-218.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 9 11.1 80.8 (36.9-153.4) 
Female 1 3.3 nc (nc-nc)   Female 3 4.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 21 25.4 82.6 (51.1-126.2)             
Female 34 23.6 144.2 (99.9-201.5)   Female 8 8.3 95.9 (41.3-189.0) 
Esophagus            Pancreas     
Male 7 6.3 110.5 (44.3-227.7)   Male 6 7.9 76.4 (27.9-166.3) 
Female 3 1.5 nc (nc-nc)   Female 7 7.4 94.9 (38.0-195.6) 
Hodgkin Lymphoma            Prostate     
Male 2 2.0 nc (nc-nc)   Male 74 87.0 85.1 (66.8-106.8) 
Female 2 1.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 15 13.0 115.3 (64.5-190.2)   Male 5 5.4 92.9 (29.9-216.7) 
Female 8 7.1 113.0 (48.7-222.7)   Female 2 2.9 nc (nc-nc) 
Larynx            Testis     
Male 3 3.5 nc (nc-nc)   Male 5 3.1 159.7 (51.5-372.7) 
Female 0 1.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 14 9.2 152.5 (83.3-256.0)   Male 10 6.1 164.5 (78.7-302.5) 
Female 7 6.4 109.2 (43.8-225.0)   Female 24 18.2 132.1 (84.6-196.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 8.1 86.1 (34.5-177.5)             
Female 2 2.4 nc (nc-nc)   Female 18 21.1 85.1 (50.4-134.5) 
Lung and Bronchus            All Sites / Types     
Male 37 41.8 88.5 (62.3-122.0)   Male 303 313.8 96.6 (86.0-108.1) 
Female 39 40.9 95.4 (67.8-130.4)   Female 354 302.9 116.9 (105.0-129.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Edgartown 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 5.4 130.5 (52.3-268.9)   Male 11 3.5 315.1 (157.1-563.8) 
Female 2 1.6 nc (nc-nc)   Female 4 2.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.0 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 2 3.0 nc (nc-nc) 
Female 18 18.5 97.6 (57.8-154.2)   Female 3 2.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 2.5 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 3 0.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 5.9 84.9 (27.4-198.2)             
Female 4 4.8 nc (nc-nc)   Female 0 1.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.5 nc (nc-nc)   Male 0 1.9 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 3 1.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.4 nc (nc-nc)   Male 29 20.4 142.4 (95.3-204.5) 
Female 1 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 3.0 nc (nc-nc)   Male 2 1.3 nc (nc-nc) 
Female 0 1.5 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Larynx            Testis     
Male 0 0.8 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 2.1 nc (nc-nc)   Male 0 1.3 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)   Female 5 3.3 149.8 (48.3-349.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.9 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 5 4.4 113.8 (36.7-265.6) 
Lung and Bronchus            All Sites / Types     
Male 8 9.9 80.8 (34.8-159.2)   Male 80 72.8 109.9 (87.1-136.7) 
Female 11 8.7 126.5 (63.1-226.3)   Female 66 61.2 107.9 (83.4-137.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Egremont 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 2.3 nc (nc-nc)   Male 4 1.4 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 3 7.7 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.0 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 2.4 210.4 (67.8-491.0)             
Female 3 2.2 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.6 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 2 0.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 6 8.3 72.0 (26.3-156.7) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.2 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.8 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.7 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 0 1.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 4 4.3 nc (nc-nc)   Male 27 29.6 91.2 (60.1-132.6) 
Female 4 4.1 nc (nc-nc)   Female 16 26.5 60.3 (34.5-98.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Erving 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 2.1 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.4 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 4 7.9 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 1.0 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 2.3 262.1 (95.7-570.5)             
Female 1 2.1 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.6 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 3 7.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.1 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 2 0.6 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.8 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 1 1.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.7 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 3 1.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 3.7 nc (nc-nc)   Male 17 27.9 60.9 (35.5-97.5) 
Female 2 3.7 nc (nc-nc)   Female 19 26.6 71.5 (43.0-111.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Essex 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 4.4 136.0 (49.7-296.0)   Male 5 2.9 174.7 (56.3-407.6) 
Female 0 1.3 nc (nc-nc)   Female 2 2.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.8 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 2.5 nc (nc-nc) 
Female 8 15.3 52.2 (22.5-102.8)   Female 0 1.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 2.1 nc (nc-nc) 
Female 2 0.5 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 4.9 nc (nc-nc)             
Female 2 4.1 nc (nc-nc)   Female 4 1.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.2 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.3 nc (nc-nc)   Male 7 16.2 43.2 (17.3-89.0) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 2.4 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Larynx            Testis     
Male 1 0.7 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 1.7 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 2 2.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.6 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 3 3.5 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 10 8.0 124.8 (59.8-229.6)   Male 55 59.3 92.8 (69.9-120.8) 
Female 8 7.0 114.8 (49.4-226.2)   Female 44 50.8 86.6 (62.9-116.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Everett 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 34 35.2 96.6 (66.9-135.0)   Male 18 24.0 75.0 (44.4-118.5) 
Female 9 13.7 65.6 (29.9-124.6)   Female 6 21.1 28.4 (10.4-61.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 7.5 66.6 (21.5-155.3)   Male 8 6.8 118.2 (50.9-233.0) 
Female 3 6.5 nc (nc-nc)   Female 5 5.8 85.8 (27.6-200.2) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.1 nc (nc-nc)   Male 15 21.3 70.4 (39.4-116.1) 
Female 135 152.5 88.5 (74.2-104.8)   Female 15 18.7 80.1 (44.8-132.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 19 16.6 114.4 (68.9-178.7) 
Female 15 5.9 255.8 (143.0-421.9)   Female 6 7.7 77.5 (28.3-168.6) 
Colon / Rectum            Ovary     
Male 42 39.7 105.7 (76.2-142.9)             
Female 40 42.5 94.2 (67.3-128.3)   Female 12 13.9 86.1 (44.4-150.4) 
Esophagus            Pancreas     
Male 8 9.3 85.8 (36.9-169.0)   Male 15 12.0 125.5 (70.2-207.0) 
Female 2 2.6 nc (nc-nc)   Female 17 13.4 127.2 (74.1-203.8) 
Hodgkin Lymphoma            Prostate     
Male 1 3.7 nc (nc-nc)   Male 101 122.1 82.7 (67.4-100.5) 
Female 5 3.1 162.5 (52.4-379.3)             
Kidney & Renal Pelvis            Stomach     
Male 24 19.8 120.9 (77.5-179.9)   Male 16 8.3 191.8 (109.6-311.5) 
Female 15 12.1 123.8 (69.2-204.1)   Female 9 5.4 168.2 (76.8-319.3) 
Larynx            Testis     
Male 4 5.2 nc (nc-nc)   Male 5 7.0 71.0 (22.9-165.7) 
Female 2 1.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 15.0 46.8 (18.7-96.4)   Male 8 10.1 79.2 (34.1-156.0) 
Female 14 11.6 120.2 (65.7-201.7)   Female 27 32.1 84.1 (55.4-122.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 17 12.0 141.5 (82.4-226.6)             
Female 8 4.1 193.4 (83.3-381.2)   Female 28 33.6 83.2 (55.3-120.3) 
Lung and Bronchus            All Sites / Types     
Male 86 63.2 136.1 (108.8-168.0)   Male 465 477.4 97.4 (88.7-106.7) 
Female 104 70.9 146.8 (119.9-177.8)   Female 515 520.6 98.9 (90.6-107.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Fairhaven 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 26 22.0 118.1 (77.2-173.1)   Male 7 13.5 52.0 (20.8-107.2) 
Female 15 8.7 171.4 (95.9-282.8)   Female 13 10.8 120.7 (64.2-206.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 3.6 nc (nc-nc)   Male 6 4.0 149.0 (54.4-324.2) 
Female 5 3.3 152.5 (49.1-355.9)   Female 2 3.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.7 nc (nc-nc)   Male 9 11.9 75.4 (34.4-143.1) 
Female 79 82.1 96.2 (76.2-119.9)   Female 10 11.0 91.2 (43.7-167.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 9.1 87.7 (37.8-172.9) 
Female 4 2.6 nc (nc-nc)   Female 4 4.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 17 23.5 72.4 (42.2-116.0)             
Female 26 26.4 98.4 (64.3-144.2)   Female 9 7.7 117.2 (53.5-222.4) 
Esophagus            Pancreas     
Male 3 5.6 nc (nc-nc)   Male 6 7.3 82.3 (30.1-179.2) 
Female 1 1.6 nc (nc-nc)   Female 11 8.7 127.0 (63.3-227.3) 
Hodgkin Lymphoma            Prostate     
Male 1 1.4 nc (nc-nc)   Male 92 72.7 126.6 (102.0-155.2) 
Female 1 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 17 10.9 156.5 (91.1-250.6)   Male 8 5.0 160.2 (69.0-315.8) 
Female 10 6.8 146.8 (70.3-270.0)   Female 4 3.4 nc (nc-nc) 
Larynx            Testis     
Male 8 3.0 262.7 (113.1-517.7)   Male 1 2.2 nc (nc-nc) 
Female 3 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 13 8.3 157.3 (83.7-269.0)   Male 5 4.7 106.8 (34.4-249.2) 
Female 8 6.5 122.5 (52.7-241.3)   Female 17 13.5 126.3 (73.5-202.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 6.9 nc (nc-nc)             
Female 1 2.5 nc (nc-nc)   Female 17 18.6 91.4 (53.2-146.4) 
Lung and Bronchus            All Sites / Types     
Male 60 38.7 155.0 (118.3-199.5)   Male 321 276.9 115.9 (103.6-129.3) 
Female 54 42.7 126.4 (94.9-164.9)   Female 319 292.3 109.1 (97.5-121.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
104 
Fall River 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 105 92.1 114.1 (93.3-138.1)   Male 32 59.0 54.2 (37.1-76.5) 
Female 34 38.4 88.6 (61.4-123.8)   Female 22 51.9 42.4 (26.6-64.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 19 17.3 110.1 (66.3-172.0)   Male 14 17.2 81.6 (44.6-136.9) 
Female 11 16.1 68.3 (34.0-122.2)   Female 16 16.0 100.1 (57.2-162.5) 
Breast            Non-Hodgkin Lymphoma     
Male 3 2.9 nc (nc-nc)   Male 47 52.4 89.7 (65.9-119.3) 
Female 287 379.7 75.6 (67.1-84.9)   Female 60 49.7 120.7 (92.1-155.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 43 40.5 106.2 (76.9-143.1) 
Female 17 13.3 127.9 (74.4-204.7)   Female 16 20.2 79.1 (45.2-128.5) 
Colon / Rectum            Ovary     
Male 123 100.5 122.4 (101.8-146.1)             
Female 131 116.9 112.0 (93.7-132.9)   Female 22 35.4 62.1 (38.9-94.1) 
Esophagus            Pancreas     
Male 21 23.9 87.9 (54.4-134.3)   Male 37 30.9 119.6 (84.2-164.9) 
Female 5 7.3 68.8 (22.2-160.6)   Female 33 37.8 87.3 (60.1-122.6) 
Hodgkin Lymphoma            Prostate     
Male 11 7.7 143.5 (71.5-256.8)   Male 274 314.6 87.1 (77.1-98.0) 
Female 6 6.9 87.1 (31.8-189.7)             
Kidney & Renal Pelvis            Stomach     
Male 44 48.3 91.1 (66.2-122.3)   Male 39 21.3 183.2 (130.2-250.4) 
Female 35 31.2 112.1 (78.1-155.9)   Female 30 14.9 201.3 (135.8-287.5) 
Larynx            Testis     
Male 21 13.1 159.8 (98.9-244.3)   Male 17 13.4 126.5 (73.6-202.5) 
Female 11 4.7 235.3 (117.3-421.0)             
Leukemia            Thyroid     
Male 35 36.8 95.1 (66.2-132.3)   Male 19 22.5 84.3 (50.8-131.7) 
Female 43 30.5 140.9 (102.0-189.9)   Female 82 71.0 115.6 (91.9-143.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 29 29.9 96.9 (64.9-139.1)             
Female 14 11.1 126.2 (68.9-211.8)   Female 99 85.3 116.1 (94.4-141.4) 
Lung and Bronchus            All Sites / Types     
Male 250 163.9 152.6 (134.2-172.7)   Male 1287 1202.6 107.0 (101.3-113.0) 
Female 212 190.7 111.2 (96.7-127.2)   Female 1321 1341.5 98.5 (93.2-103.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
105 
Falmouth 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 58 56.8 102.1 (77.5-132.0)   Male 28 33.0 84.8 (56.4-122.6) 
Female 17 20.6 82.3 (47.9-131.8)   Female 33 24.3 135.8 (93.4-190.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 15 8.2 181.9 (101.7-300.0)   Male 9 10.1 89.0 (40.6-169.0) 
Female 9 7.5 120.4 (54.9-228.5)   Female 9 8.6 104.8 (47.8-199.0) 
Breast            Non-Hodgkin Lymphoma     
Male 3 1.7 nc (nc-nc)   Male 30 28.9 103.7 (69.9-148.0) 
Female 215 193.0 111.4 (97.0-127.3)   Female 27 25.8 104.6 (68.9-152.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 30 21.6 139.2 (93.9-198.7) 
Female 5 5.6 88.7 (28.6-207.0)   Female 7 10.5 66.9 (26.8-137.9) 
Colon / Rectum            Ovary     
Male 59 57.7 102.2 (77.8-131.9)             
Female 52 60.1 86.5 (64.6-113.5)   Female 22 18.0 122.4 (76.7-185.3) 
Esophagus            Pancreas     
Male 13 14.1 92.1 (49.0-157.4)   Male 13 18.6 70.0 (37.3-119.8) 
Female 6 4.0 151.5 (55.3-329.8)   Female 19 20.2 94.2 (56.7-147.1) 
Hodgkin Lymphoma            Prostate     
Male 4 2.8 nc (nc-nc)   Male 213 184.5 115.5 (100.5-132.1) 
Female 3 2.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 27 26.2 103.0 (67.9-149.9)   Male 11 12.5 87.8 (43.8-157.1) 
Female 12 16.3 73.8 (38.1-128.9)   Female 3 7.6 nc (nc-nc) 
Larynx            Testis     
Male 9 7.7 117.3 (53.5-222.8)   Male 3 3.6 nc (nc-nc) 
Female 4 2.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 18 20.1 89.4 (52.9-141.3)   Male 12 10.1 118.6 (61.2-207.2) 
Female 9 14.8 60.6 (27.7-115.1)   Female 14 28.5 49.2 (26.9-82.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 18 16.8 107.4 (63.6-169.7)             
Female 3 6.0 nc (nc-nc)   Female 36 45.3 79.4 (55.6-110.0) 
Lung and Bronchus            All Sites / Types     
Male 68 101.1 67.2 (52.2-85.3)   Male 701 690.6 101.5 (94.1-109.3) 
Female 112 106.1 105.6 (86.9-127.1)   Female 666 685.0 97.2 (90.0-104.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
106 
Fitchburg 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 36 36.8 97.9 (68.5-135.5)   Male 16 24.3 65.8 (37.6-106.9) 
Female 15 14.4 104.1 (58.2-171.7)   Female 14 20.8 67.4 (36.8-113.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 7.4 80.7 (29.5-175.7)   Male 13 7.0 185.3 (98.6-316.9) 
Female 7 6.5 106.9 (42.8-220.3)   Female 8 6.1 131.9 (56.8-260.0) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.2 nc (nc-nc)   Male 19 21.7 87.5 (52.7-136.7) 
Female 130 150.5 86.4 (72.2-102.6)   Female 19 19.2 99.2 (59.7-154.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 27 17.0 158.9 (104.7-231.2) 
Female 9 5.4 165.2 (75.4-313.7)   Female 10 7.9 127.1 (60.8-233.7) 
Colon / Rectum            Ovary     
Male 31 41.0 75.7 (51.4-107.4)             
Female 44 44.5 98.9 (71.9-132.8)   Female 12 14.0 85.5 (44.1-149.4) 
Esophagus            Pancreas     
Male 11 9.7 112.9 (56.3-202.1)   Male 12 12.4 96.6 (49.8-168.7) 
Female 2 2.7 nc (nc-nc)   Female 9 14.2 63.4 (28.9-120.3) 
Hodgkin Lymphoma            Prostate     
Male 4 3.5 nc (nc-nc)   Male 112 128.3 87.3 (71.9-105.0) 
Female 0 3.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 22 20.1 109.4 (68.5-165.6)   Male 13 8.6 150.7 (80.1-257.7) 
Female 11 12.2 90.4 (45.1-161.8)   Female 6 5.6 106.4 (38.8-231.5) 
Larynx            Testis     
Male 1 5.4 nc (nc-nc)   Male 6 6.2 96.4 (35.2-209.8) 
Female 2 1.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 15 15.3 98.2 (54.9-161.9)   Male 4 9.8 nc (nc-nc) 
Female 11 12.0 92.0 (45.9-164.7)   Female 23 29.8 77.2 (48.9-115.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 10 12.5 79.8 (38.2-146.8)             
Female 3 4.3 nc (nc-nc)   Female 38 33.6 113.0 (79.9-155.0) 
Lung and Bronchus            All Sites / Types     
Male 87 66.0 131.8 (105.6-162.6)   Male 485 492.8 98.4 (89.8-107.6) 
Female 87 72.4 120.2 (96.3-148.3)   Female 502 524.0 95.8 (87.6-104.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
107 
Florida 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 1.1 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 2 3.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 1.2 nc (nc-nc)             
Female 0 0.8 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 2 4.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.6 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.4 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.4 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 2.0 nc (nc-nc)   Male 8 14.7 54.4 (23.4-107.3) 
Female 3 1.4 nc (nc-nc)   Female 10 10.2 98.0 (46.9-180.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
108 
Foxborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 15 17.7 84.8 (47.4-139.8)   Male 22 11.8 186.1 (116.6-281.8) 
Female 5 6.2 80.3 (25.9-187.4)   Female 14 9.3 150.7 (82.3-252.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 3.5 143.6 (46.3-335.1)   Male 3 3.5 nc (nc-nc) 
Female 5 2.9 173.7 (56.0-405.3)   Female 1 2.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.6 nc (nc-nc)   Male 13 10.4 124.9 (66.4-213.6) 
Female 81 72.5 111.8 (88.8-138.9)   Female 6 8.6 70.1 (25.6-152.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 8.6 81.5 (32.6-167.9) 
Female 2 2.6 nc (nc-nc)   Female 2 3.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 19 20.1 94.7 (57.0-147.9)             
Female 16 19.1 83.7 (47.8-135.9)   Female 10 6.5 153.7 (73.6-282.7) 
Esophagus            Pancreas     
Male 3 4.9 nc (nc-nc)   Male 5 6.1 81.8 (26.4-190.8) 
Female 0 1.2 nc (nc-nc)   Female 5 6.0 83.3 (26.8-194.4) 
Hodgkin Lymphoma            Prostate     
Male 2 1.5 nc (nc-nc)   Male 70 66.4 105.5 (82.2-133.3) 
Female 0 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 10.1 79.1 (34.1-156.0)   Male 6 4.2 142.4 (52.0-309.9) 
Female 8 5.6 141.7 (61.0-279.3)   Female 1 2.4 nc (nc-nc) 
Larynx            Testis     
Male 0 2.7 nc (nc-nc)   Male 2 2.4 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 7.1 112.3 (48.4-221.4)   Male 5 4.7 106.3 (34.3-248.1) 
Female 7 5.1 137.9 (55.2-284.1)   Female 20 13.7 145.5 (88.8-224.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 6.3 nc (nc-nc)             
Female 1 1.9 nc (nc-nc)   Female 18 16.4 109.9 (65.1-173.7) 
Lung and Bronchus            All Sites / Types     
Male 30 32.7 91.8 (61.9-131.0)   Male 251 243.2 103.2 (90.8-116.8) 
Female 32 33.3 96.0 (65.7-135.6)   Female 257 240.1 107.1 (94.4-121.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
109 
Framingham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 50 68.4 73.1 (54.3-96.4)   Male 41 44.8 91.5 (65.6-124.1) 
Female 29 26.5 109.3 (73.2-156.9)   Female 29 37.8 76.7 (51.4-110.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 14 13.3 105.5 (57.6-177.1)   Male 17 12.9 131.6 (76.6-210.7) 
Female 4 11.7 nc (nc-nc)   Female 14 11.1 125.6 (68.6-210.8) 
Breast            Non-Hodgkin Lymphoma     
Male 2 2.1 nc (nc-nc)   Male 38 39.7 95.7 (67.7-131.3) 
Female 282 276.5 102.0 (90.4-114.6)   Female 36 35.1 102.6 (71.8-142.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 29 30.9 93.8 (62.8-134.7) 
Female 15 10.1 148.7 (83.2-245.3)   Female 7 14.4 48.6 (19.5-100.1) 
Colon / Rectum            Ovary     
Male 71 75.5 94.0 (73.4-118.6)             
Female 88 82.0 107.4 (86.1-132.3)   Female 26 25.6 101.8 (66.4-149.1) 
Esophagus            Pancreas     
Male 15 17.9 83.7 (46.8-138.1)   Male 29 23.1 125.7 (84.2-180.5) 
Female 8 5.0 159.1 (68.5-313.6)   Female 26 26.2 99.4 (64.9-145.6) 
Hodgkin Lymphoma            Prostate     
Male 5 6.0 83.1 (26.8-193.9)   Male 221 235.1 94.0 (82.0-107.3) 
Female 7 5.1 136.6 (54.7-281.4)             
Kidney & Renal Pelvis            Stomach     
Male 44 36.9 119.3 (86.7-160.1)   Male 19 16.0 119.0 (71.6-185.9) 
Female 16 22.2 72.0 (41.1-116.9)   Female 15 10.4 143.9 (80.5-237.4) 
Larynx            Testis     
Male 5 9.9 50.6 (16.3-118.0)   Male 8 10.9 73.2 (31.5-144.3) 
Female 3 3.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 29 27.8 104.5 (69.9-150.0)   Male 20 17.7 113.1 (69.0-174.6) 
Female 22 21.6 101.7 (63.7-154.0)   Female 52 54.1 96.1 (71.7-126.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 24 22.7 105.8 (67.8-157.4)             
Female 10 7.8 128.5 (61.5-236.3)   Female 62 61.6 100.7 (77.2-129.1) 
Lung and Bronchus            All Sites / Types     
Male 106 122.1 86.8 (71.1-105.0)   Male 852 904.6 94.2 (88.0-100.7) 
Female 134 132.3 101.3 (84.9-120.0)   Female 989 959.6 103.1 (96.7-109.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
110 
Franklin 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 28 24.9 112.5 (74.7-162.5)   Male 17 17.8 95.6 (55.6-153.0) 
Female 9 9.0 99.7 (45.5-189.4)   Female 17 15.1 112.4 (65.4-180.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 5.8 nc (nc-nc)   Male 9 5.1 178.0 (81.2-338.0) 
Female 4 4.8 nc (nc-nc)   Female 3 4.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.8 nc (nc-nc)   Male 8 15.8 50.5 (21.7-99.5) 
Female 120 116.9 102.6 (85.1-122.7)   Female 14 13.0 107.4 (58.7-180.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 13 13.4 97.0 (51.6-166.0) 
Female 4 4.5 nc (nc-nc)   Female 1 5.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 32 30.0 106.7 (72.9-150.6)             
Female 32 28.9 110.6 (75.6-156.1)   Female 8 10.3 77.6 (33.4-152.8) 
Esophagus            Pancreas     
Male 9 7.1 126.9 (57.9-241.0)   Male 13 8.8 148.0 (78.7-253.0) 
Female 3 1.7 nc (nc-nc)   Female 6 8.7 68.8 (25.1-149.7) 
Hodgkin Lymphoma            Prostate     
Male 2 2.6 nc (nc-nc)   Male 106 95.2 111.4 (91.2-134.7) 
Female 6 2.1 290.6 (106.1-632.4)             
Kidney & Renal Pelvis            Stomach     
Male 13 15.5 83.8 (44.6-143.4)   Male 7 6.2 113.5 (45.5-233.9) 
Female 12 8.8 137.0 (70.7-239.4)   Female 3 3.6 nc (nc-nc) 
Larynx            Testis     
Male 9 4.0 225.8 (103.0-428.7)   Male 5 4.4 113.2 (36.5-264.1) 
Female 0 1.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 11 11.0 100.2 (50.0-179.3)   Male 12 7.8 153.1 (79.0-267.5) 
Female 5 8.0 62.3 (20.1-145.3)   Female 30 24.5 122.5 (82.6-174.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 11 9.5 115.9 (57.8-207.4)             
Female 2 2.9 nc (nc-nc)   Female 29 25.6 113.2 (75.8-162.6) 
Lung and Bronchus            All Sites / Types     
Male 35 45.8 76.4 (53.2-106.2)   Male 369 358.4 103.0 (92.7-114.0) 
Female 40 48.1 83.1 (59.3-113.1)   Female 377 375.7 100.4 (90.5-111.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
111 
Freetown 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 9.3 75.6 (30.3-155.7)   Male 3 6.4 nc (nc-nc) 
Female 3 3.0 nc (nc-nc)   Female 3 4.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.9 nc (nc-nc)   Male 3 1.9 nc (nc-nc) 
Female 1 1.5 nc (nc-nc)   Female 2 1.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 4 5.6 nc (nc-nc) 
Female 46 37.8 121.5 (89.0-162.1)   Female 9 4.3 209.8 (95.8-398.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 4.9 nc (nc-nc) 
Female 2 1.4 nc (nc-nc)   Female 3 1.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 8 10.7 75.0 (32.3-147.8)             
Female 9 9.2 97.9 (44.7-185.8)   Female 4 3.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 2.7 nc (nc-nc)   Male 2 3.3 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 4 2.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.8 nc (nc-nc)   Male 41 38.8 105.7 (75.9-143.4) 
Female 1 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 5.7 123.5 (49.5-254.6)   Male 2 2.3 nc (nc-nc) 
Female 2 2.9 nc (nc-nc)   Female 2 1.1 nc (nc-nc) 
Larynx            Testis     
Male 2 1.5 nc (nc-nc)   Male 0 1.3 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 3.8 nc (nc-nc)   Male 2 2.7 nc (nc-nc) 
Female 1 2.5 nc (nc-nc)   Female 7 7.3 95.3 (38.2-196.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 3.6 nc (nc-nc)             
Female 0 1.0 nc (nc-nc)   Female 11 8.9 122.9 (61.3-220.0) 
Lung and Bronchus            All Sites / Types     
Male 22 17.5 125.4 (78.6-189.9)   Male 128 134.3 95.3 (79.5-113.3) 
Female 22 16.4 134.3 (84.1-203.3)   Female 143 122.2 117.0 (98.6-137.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Gardner 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 21 22.9 91.7 (56.7-140.2)   Male 6 15.0 40.1 (14.6-87.3) 
Female 10 8.5 118.1 (56.6-217.3)   Female 9 11.3 79.7 (36.4-151.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 4.3 nc (nc-nc)   Male 6 4.3 138.1 (50.4-300.5) 
Female 5 3.5 143.3 (46.2-334.4)   Female 2 3.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.7 nc (nc-nc)   Male 12 13.3 90.3 (46.6-157.8) 
Female 72 84.2 85.5 (66.9-107.7)   Female 14 10.9 128.2 (70.0-215.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 14 10.5 133.1 (72.7-223.3) 
Female 0 2.9 nc (nc-nc)   Female 4 4.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 22 25.5 86.2 (54.0-130.5)             
Female 31 26.0 119.4 (81.1-169.5)   Female 7 7.8 89.7 (35.9-184.7) 
Esophagus            Pancreas     
Male 8 6.0 132.7 (57.1-261.4)   Male 10 7.7 129.2 (61.9-237.7) 
Female 2 1.6 nc (nc-nc)   Female 9 8.3 108.1 (49.3-205.3) 
Hodgkin Lymphoma            Prostate     
Male 1 1.9 nc (nc-nc)   Male 70 78.9 88.7 (69.1-112.1) 
Female 1 1.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 13 12.4 105.2 (55.9-179.9)   Male 2 5.4 nc (nc-nc) 
Female 11 6.9 160.1 (79.8-286.4)   Female 5 3.3 151.1 (48.7-352.7) 
Larynx            Testis     
Male 1 3.3 nc (nc-nc)   Male 5 3.3 152.9 (49.3-356.9) 
Female 0 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 9.2 98.0 (44.7-186.1)   Male 2 5.8 nc (nc-nc) 
Female 9 6.7 134.9 (61.5-256.0)   Female 12 15.3 78.3 (40.4-136.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 10 7.7 129.3 (61.9-237.8)             
Female 3 2.4 nc (nc-nc)   Female 26 18.8 138.4 (90.4-202.8) 
Lung and Bronchus            All Sites / Types     
Male 42 40.8 102.9 (74.2-139.1)   Male 273 302.8 90.2 (79.8-101.5) 
Female 44 41.8 105.1 (76.4-141.2)   Female 308 295.5 104.2 (92.9-116.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Georgetown 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 7.8 nc (nc-nc)   Male 7 5.5 128.3 (51.4-264.3) 
Female 2 2.6 nc (nc-nc)   Female 5 4.2 117.9 (38.0-275.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.7 nc (nc-nc)   Male 0 1.6 nc (nc-nc) 
Female 2 1.3 nc (nc-nc)   Female 3 1.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 8 4.8 167.3 (72.0-329.7) 
Female 38 33.8 112.5 (79.6-154.4)   Female 5 3.7 133.9 (43.1-312.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 4.2 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 9 9.1 98.4 (44.9-186.8)             
Female 7 8.0 87.1 (34.9-179.4)   Female 1 3.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 2.3 nc (nc-nc)   Male 2 2.8 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 1 2.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.7 nc (nc-nc)   Male 39 31.8 122.7 (87.2-167.7) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 9 4.8 187.0 (85.3-355.0)   Male 1 1.9 nc (nc-nc) 
Female 2 2.5 nc (nc-nc)   Female 2 1.0 nc (nc-nc) 
Larynx            Testis     
Male 0 1.3 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 3.3 nc (nc-nc)   Male 3 2.3 nc (nc-nc) 
Female 1 2.2 nc (nc-nc)   Female 5 6.7 74.5 (24.0-173.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 3.0 nc (nc-nc)             
Female 1 0.8 nc (nc-nc)   Female 8 7.7 103.9 (44.7-204.8) 
Lung and Bronchus            All Sites / Types     
Male 8 14.8 54.2 (23.3-106.8)   Male 109 113.0 96.5 (79.2-116.4) 
Female 25 14.2 175.8 (113.8-259.6)   Female 125 107.6 116.2 (96.7-138.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Gill 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 1.8 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 7 7.2 96.8 (38.8-199.4)   Female 0 0.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.9 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 2.0 nc (nc-nc)             
Female 3 1.9 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.5 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 1 0.1 nc (nc-nc)   Female 2 0.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.1 nc (nc-nc)   Male 10 7.5 132.6 (63.5-243.8) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.1 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 0.7 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.7 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 6 3.4 178.2 (65.1-387.8)   Male 29 25.6 113.2 (75.8-162.6) 
Female 7 3.2 220.8 (88.5-455.0)   Female 27 23.6 114.6 (75.5-166.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Gloucester 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 44 37.7 116.6 (84.7-156.6)   Male 34 24.1 141.1 (97.7-197.2) 
Female 20 14.3 140.2 (85.6-216.5)   Female 27 19.0 142.3 (93.7-207.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 6.6 75.7 (24.4-176.7)   Male 6 7.2 83.5 (30.5-181.7) 
Female 5 5.8 86.3 (27.8-201.4)   Female 3 6.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.2 nc (nc-nc)   Male 24 21.1 113.7 (72.8-169.2) 
Female 164 148.8 110.2 (94.0-128.5)   Female 18 18.7 96.4 (57.1-152.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 23 17.3 132.7 (84.1-199.1) 
Female 2 4.8 nc (nc-nc)   Female 10 7.8 128.6 (61.6-236.5) 
Colon / Rectum            Ovary     
Male 51 41.2 123.8 (92.2-162.8)             
Female 33 42.8 77.0 (53.0-108.2)   Female 15 13.7 109.6 (61.3-180.7) 
Esophagus            Pancreas     
Male 13 10.3 126.5 (67.3-216.4)   Male 18 12.9 139.3 (82.5-220.1) 
Female 2 2.7 nc (nc-nc)   Female 14 13.9 100.7 (55.0-169.0) 
Hodgkin Lymphoma            Prostate     
Male 4 2.6 nc (nc-nc)   Male 141 139.9 100.8 (84.8-118.9) 
Female 4 2.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 18 20.3 88.8 (52.6-140.4)   Male 9 8.8 102.4 (46.7-194.5) 
Female 16 12.0 133.4 (76.2-216.6)   Female 4 5.4 nc (nc-nc) 
Larynx            Testis     
Male 9 5.7 158.3 (72.2-300.4)   Male 3 3.9 nc (nc-nc) 
Female 3 1.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 25 14.4 173.5 (112.3-256.2)   Male 8 8.9 90.3 (38.9-177.9) 
Female 6 10.8 55.4 (20.2-120.5)   Female 30 25.1 119.4 (80.5-170.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 11 13.0 84.6 (42.2-151.4)             
Female 4 4.3 nc (nc-nc)   Female 27 34.8 77.6 (51.2-113.0) 
Lung and Bronchus            All Sites / Types     
Male 87 69.0 126.0 (100.9-155.5)   Male 576 503.5 114.4 (105.2-124.1) 
Female 99 73.9 134.1 (109.0-163.2)   Female 542 509.5 106.4 (97.6-115.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Goshen 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 1.2 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 3 0.7 nc (nc-nc) 
Female 3 5.0 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.6 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 1.4 nc (nc-nc)             
Female 0 1.2 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.4 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 2 4.9 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.7 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 1 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.5 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.5 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 2.3 nc (nc-nc)   Male 12 17.2 69.7 (36.0-121.8) 
Female 0 2.2 nc (nc-nc)   Female 9 16.0 56.1 (25.6-106.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Gosnold 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.0 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 0.1 nc (nc-nc)             
Female 1 0.1 nc (nc-nc)   Female 0 0.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.0 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.1 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.0 nc (nc-nc) 
Larynx            Testis     
Male 0 0.0 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.0 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.0 nc (nc-nc)             
Female 0 0.0 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 0.2 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Grafton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 16 15.7 101.9 (58.2-165.5)   Male 8 10.9 73.2 (31.5-144.2) 
Female 4 5.6 nc (nc-nc)   Female 9 9.1 99.0 (45.2-187.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 9 3.4 266.2 (121.5-505.3)   Male 5 3.1 160.1 (51.6-373.6) 
Female 3 2.8 nc (nc-nc)   Female 1 2.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 5 9.7 51.7 (16.7-120.7) 
Female 75 68.7 109.2 (85.9-136.9)   Female 10 7.9 126.5 (60.5-232.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 12 8.1 148.6 (76.7-259.5) 
Female 2 2.7 nc (nc-nc)   Female 3 3.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 14 18.3 76.3 (41.7-128.1)             
Female 18 17.5 103.1 (61.1-162.9)   Female 6 6.1 97.7 (35.7-212.7) 
Esophagus            Pancreas     
Male 6 4.4 136.1 (49.7-296.3)   Male 6 5.5 109.2 (39.9-237.6) 
Female 0 1.1 nc (nc-nc)   Female 4 5.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 1.5 nc (nc-nc)   Male 61 59.5 102.5 (78.4-131.7) 
Female 0 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 9.4 105.9 (50.7-194.8)   Male 2 3.8 nc (nc-nc) 
Female 3 5.3 nc (nc-nc)   Female 1 2.2 nc (nc-nc) 
Larynx            Testis     
Male 2 2.5 nc (nc-nc)   Male 3 2.6 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 16 6.7 239.8 (137.0-389.4)   Male 6 4.7 128.9 (47.1-280.6) 
Female 8 4.8 165.5 (71.2-326.0)   Female 11 14.4 76.4 (38.1-136.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 5.8 104.1 (38.0-226.5)             
Female 0 1.8 nc (nc-nc)   Female 12 15.3 78.2 (40.4-136.6) 
Lung and Bronchus            All Sites / Types     
Male 33 28.7 115.0 (79.2-161.5)   Male 229 221.4 103.4 (90.5-117.7) 
Female 33 29.5 111.8 (77.0-157.0)   Female 222 224.9 98.7 (86.1-112.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Granby 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 6.9 nc (nc-nc)   Male 0 4.6 nc (nc-nc) 
Female 2 2.3 nc (nc-nc)   Female 1 3.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 1.3 nc (nc-nc)   Male 0 1.4 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 5 4.1 122.9 (39.6-286.7) 
Female 17 27.6 61.6 (35.9-98.7)   Female 2 3.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 3.4 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 7.8 89.6 (35.9-184.5)             
Female 5 7.1 70.4 (22.7-164.3)   Female 6 2.5 243.0 (88.7-528.9) 
Esophagus            Pancreas     
Male 2 1.9 nc (nc-nc)   Male 3 2.4 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 1 2.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.6 nc (nc-nc)   Male 24 26.4 90.8 (58.2-135.2) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 4.0 nc (nc-nc)   Male 0 1.7 nc (nc-nc) 
Female 4 2.1 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Larynx            Testis     
Male 2 1.1 nc (nc-nc)   Male 2 0.9 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 2.8 nc (nc-nc)   Male 0 1.8 nc (nc-nc) 
Female 0 1.9 nc (nc-nc)   Female 6 5.2 115.4 (42.1-251.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 2.5 nc (nc-nc)             
Female 1 0.7 nc (nc-nc)   Female 9 6.3 142.9 (65.2-271.2) 
Lung and Bronchus            All Sites / Types     
Male 13 12.8 101.3 (53.9-173.2)   Male 78 95.7 81.5 (64.4-101.7) 
Female 12 12.5 96.3 (49.7-168.3)   Female 74 90.4 81.8 (64.3-102.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Granville 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 1.9 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.4 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 3 1.1 nc (nc-nc) 
Female 8 7.0 114.8 (49.4-226.2)   Female 0 0.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 0.9 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 2.1 nc (nc-nc)             
Female 3 1.7 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.5 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 10 7.2 138.9 (66.5-255.5) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 1.1 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.7 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 4 1.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.7 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 3 1.6 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 3.4 nc (nc-nc)   Male 31 26.0 119.4 (81.1-169.5) 
Female 4 3.0 nc (nc-nc)   Female 27 22.4 120.6 (79.5-175.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Great Barrington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 15 9.6 155.8 (87.2-257.1)   Male 12 5.9 202.5 (104.5-353.8) 
Female 7 3.7 190.9 (76.5-393.3)   Female 5 4.7 106.6 (34.3-248.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 1.6 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 0 1.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 3 5.2 nc (nc-nc) 
Female 31 36.4 85.2 (57.9-121.0)   Female 5 4.7 105.7 (34.1-246.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 4.1 nc (nc-nc) 
Female 2 1.1 nc (nc-nc)   Female 1 2.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 10.3 58.5 (21.4-127.4)             
Female 8 11.0 72.5 (31.2-143.0)   Female 2 3.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 2.5 nc (nc-nc)   Male 0 3.2 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 1 3.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.6 nc (nc-nc)   Male 36 33.3 108.2 (75.8-149.8) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 4.8 124.4 (45.4-270.7)   Male 3 2.2 nc (nc-nc) 
Female 2 3.0 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Larynx            Testis     
Male 0 1.4 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 3.6 nc (nc-nc)   Male 0 2.1 nc (nc-nc) 
Female 4 2.8 nc (nc-nc)   Female 10 5.9 168.1 (80.5-309.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 3.1 nc (nc-nc)             
Female 1 1.1 nc (nc-nc)   Female 8 8.6 92.9 (40.0-183.2) 
Lung and Bronchus            All Sites / Types     
Male 18 17.2 104.7 (62.0-165.5)   Male 127 123.4 102.9 (85.8-122.5) 
Female 20 18.4 108.7 (66.3-167.8)   Female 118 127.0 92.9 (76.9-111.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Greenfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 20 20.7 96.6 (59.0-149.2)   Male 13 13.0 100.1 (53.2-171.2) 
Female 8 8.6 93.1 (40.1-183.4)   Female 4 11.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 3.7 nc (nc-nc)   Male 3 3.8 nc (nc-nc) 
Female 7 3.4 204.3 (81.8-421.0)   Female 3 3.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.6 nc (nc-nc)   Male 5 11.6 43.2 (13.9-100.8) 
Female 79 84.2 93.8 (74.3-117.0)   Female 11 11.0 99.9 (49.8-178.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 9.1 88.1 (37.9-173.6) 
Female 4 2.8 nc (nc-nc)   Female 3 4.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 26 22.6 115.1 (75.2-168.7)             
Female 29 26.3 110.4 (73.9-158.5)   Female 10 7.9 126.9 (60.8-233.4) 
Esophagus            Pancreas     
Male 5 5.4 93.4 (30.1-218.0)   Male 7 6.9 100.8 (40.4-207.6) 
Female 0 1.6 nc (nc-nc)   Female 6 8.5 70.3 (25.7-153.0) 
Hodgkin Lymphoma            Prostate     
Male 6 1.5 397.1 (145.0-864.3)   Male 60 70.4 85.2 (65.0-109.7) 
Female 1 1.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 10.6 75.5 (32.5-148.8)   Male 3 4.8 nc (nc-nc) 
Female 5 6.9 72.8 (23.4-169.8)   Female 5 3.4 148.7 (47.9-347.0) 
Larynx            Testis     
Male 2 2.9 nc (nc-nc)   Male 1 2.5 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 8.1 nc (nc-nc)   Male 1 4.8 nc (nc-nc) 
Female 6 6.6 90.4 (33.0-196.8)   Female 3 14.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 6.8 nc (nc-nc)             
Female 5 2.5 201.9 (65.1-471.3)   Female 19 19.2 98.7 (59.4-154.2) 
Lung and Bronchus            All Sites / Types     
Male 33 36.3 90.9 (62.6-127.7)   Male 236 267.1 88.3 (77.4-100.4) 
Female 42 41.9 100.3 (72.3-135.6)   Female 276 296.3 93.2 (82.5-104.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Groton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 10 9.6 104.3 (49.9-191.8)   Male 3 6.8 nc (nc-nc) 
Female 1 3.2 nc (nc-nc)   Female 2 5.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 2.1 nc (nc-nc)   Male 2 2.0 nc (nc-nc) 
Female 1 1.7 nc (nc-nc)   Female 3 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.3 nc (nc-nc)   Male 4 6.1 nc (nc-nc) 
Female 42 42.8 98.1 (70.7-132.7)   Female 3 4.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 5.3 nc (nc-nc) 
Female 1 1.6 nc (nc-nc)   Female 1 2.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 17 11.6 146.4 (85.2-234.4)             
Female 11 10.3 106.5 (53.1-190.6)   Female 5 3.8 132.9 (42.8-310.2) 
Esophagus            Pancreas     
Male 0 2.8 nc (nc-nc)   Male 4 3.4 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 1 3.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.9 nc (nc-nc)   Male 36 38.6 93.2 (65.2-129.0) 
Female 0 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 6.0 nc (nc-nc)   Male 0 2.4 nc (nc-nc) 
Female 1 3.1 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Larynx            Testis     
Male 2 1.6 nc (nc-nc)   Male 4 1.4 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 4.1 121.8 (39.3-284.2)   Male 4 2.9 nc (nc-nc) 
Female 2 2.8 nc (nc-nc)   Female 9 8.6 105.2 (48.0-199.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 3.8 nc (nc-nc)             
Female 1 1.0 nc (nc-nc)   Female 10 9.5 105.1 (50.3-193.3) 
Lung and Bronchus            All Sites / Types     
Male 13 17.7 73.4 (39.0-125.5)   Male 129 139.7 92.3 (77.1-109.7) 
Female 9 17.0 53.0 (24.2-100.6)   Female 115 134.7 85.4 (70.5-102.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Groveland 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 9 7.2 125.7 (57.4-238.7)   Male 7 4.7 149.3 (59.8-307.6) 
Female 2 2.7 nc (nc-nc)   Female 9 3.8 237.0 (108.1-449.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.4 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 8 4.2 192.7 (83.0-379.8) 
Female 34 30.1 112.8 (78.1-157.7)   Female 6 3.6 164.9 (60.2-359.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 3.4 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 1 1.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 8.1 nc (nc-nc)             
Female 9 8.3 108.7 (49.6-206.4)   Female 3 2.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 1.9 nc (nc-nc)   Male 1 2.5 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 4 2.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.5 nc (nc-nc)   Male 22 26.2 83.8 (52.5-126.9) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 4.0 nc (nc-nc)   Male 3 1.7 nc (nc-nc) 
Female 3 2.4 nc (nc-nc)   Female 3 1.0 nc (nc-nc) 
Larynx            Testis     
Male 2 1.1 nc (nc-nc)   Male 2 0.8 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 2.8 nc (nc-nc)   Male 1 1.8 nc (nc-nc) 
Female 2 2.2 nc (nc-nc)   Female 8 5.3 149.5 (64.4-294.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.5 nc (nc-nc)             
Female 0 0.8 nc (nc-nc)   Female 4 6.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 11 13.0 84.3 (42.0-150.9)   Male 93 96.7 96.1 (77.6-117.8) 
Female 16 14.3 111.7 (63.8-181.5)   Female 114 101.0 112.9 (93.1-135.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hadley 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 7.2 nc (nc-nc)   Male 2 4.4 nc (nc-nc) 
Female 6 3.0 199.2 (72.7-433.5)   Female 3 3.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.2 nc (nc-nc)   Male 2 1.3 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 7 3.9 179.5 (71.9-369.8) 
Female 26 27.5 94.6 (61.8-138.6)   Female 5 3.7 134.1 (43.2-312.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 3.0 232.1 (93.0-478.3) 
Female 0 0.9 nc (nc-nc)   Female 0 1.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 7.7 nc (nc-nc)             
Female 8 9.2 87.4 (37.6-172.3)   Female 2 2.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.8 nc (nc-nc)   Male 2 2.4 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 1 3.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.5 nc (nc-nc)   Male 18 24.1 74.6 (44.2-117.9) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 3.5 nc (nc-nc)   Male 2 1.6 nc (nc-nc) 
Female 2 2.3 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Larynx            Testis     
Male 0 1.0 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 2.7 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 4 2.2 nc (nc-nc)   Female 3 4.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.3 nc (nc-nc)             
Female 0 0.8 nc (nc-nc)   Female 5 6.2 80.5 (25.9-187.8) 
Lung and Bronchus            All Sites / Types     
Male 4 12.6 nc (nc-nc)   Male 68 91.1 74.7 (58.0-94.6) 
Female 10 14.4 69.2 (33.1-127.3)   Female 84 98.9 85.0 (67.8-105.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Halifax 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 8.1 74.2 (27.1-161.4)   Male 6 5.4 111.2 (40.6-242.1) 
Female 1 2.9 nc (nc-nc)   Female 4 4.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.6 nc (nc-nc)   Male 3 1.6 nc (nc-nc) 
Female 0 1.3 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 7 4.7 147.9 (59.2-304.7) 
Female 37 33.9 109.1 (76.8-150.4)   Female 8 4.0 200.8 (86.5-395.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 4.0 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 14 9.1 153.7 (83.9-257.8)             
Female 11 8.8 125.5 (62.6-224.6)   Female 5 3.1 163.7 (52.7-382.0) 
Esophagus            Pancreas     
Male 4 2.3 nc (nc-nc)   Male 7 2.8 247.8 (99.3-510.6) 
Female 0 0.6 nc (nc-nc)   Female 3 2.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.6 nc (nc-nc)   Male 37 31.0 119.2 (83.9-164.4) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 4.6 216.0 (103.4-397.2)   Male 1 1.9 nc (nc-nc) 
Female 3 2.6 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Larynx            Testis     
Male 1 1.3 nc (nc-nc)   Male 2 1.0 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 3.2 nc (nc-nc)   Male 7 2.1 327.5 (131.2-674.9) 
Female 4 2.3 nc (nc-nc)   Female 9 6.3 141.9 (64.7-269.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 2.9 208.7 (76.2-454.3)             
Female 0 0.9 nc (nc-nc)   Female 11 7.9 139.8 (69.7-250.1) 
Lung and Bronchus            All Sites / Types     
Male 21 15.0 140.3 (86.8-214.5)   Male 145 111.8 129.7 (109.5-152.6) 
Female 24 15.5 154.6 (99.0-230.1)   Female 135 111.9 120.6 (101.2-142.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hamilton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 9 7.8 114.8 (52.4-217.9)   Male 6 5.3 113.8 (41.5-247.7) 
Female 3 2.7 nc (nc-nc)   Female 5 4.1 122.2 (39.4-285.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 1.6 nc (nc-nc)   Male 5 1.5 324.4 (104.5-757.1) 
Female 3 1.3 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 7 4.6 150.6 (60.3-310.2) 
Female 28 32.1 87.2 (57.9-126.0)   Female 7 3.7 187.9 (75.3-387.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 3.9 179.0 (71.7-368.8) 
Female 1 1.1 nc (nc-nc)   Female 2 1.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 9 9.0 100.4 (45.8-190.6)             
Female 9 8.3 108.0 (49.3-205.0)   Female 3 2.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 2.2 nc (nc-nc)   Male 0 2.7 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 3 2.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.7 nc (nc-nc)   Male 25 30.0 83.3 (53.9-123.0) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 4.5 154.6 (62.0-318.6)   Male 2 1.9 nc (nc-nc) 
Female 3 2.5 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Larynx            Testis     
Male 0 1.2 nc (nc-nc)   Male 2 1.1 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 3.2 280.1 (127.8-531.7)   Male 5 2.1 237.2 (76.4-553.5) 
Female 3 2.2 nc (nc-nc)   Female 8 6.1 130.6 (56.3-257.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.9 nc (nc-nc)             
Female 0 0.8 nc (nc-nc)   Female 8 7.3 109.2 (47.0-215.2) 
Lung and Bronchus            All Sites / Types     
Male 13 14.5 89.8 (47.8-153.6)   Male 122 109.1 111.8 (92.9-133.5) 
Female 10 14.2 70.5 (33.8-129.7)   Female 108 105.2 102.6 (84.2-123.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hampden 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 7.0 85.7 (31.3-186.5)   Male 4 4.4 nc (nc-nc) 
Female 0 2.5 nc (nc-nc)   Female 5 3.3 150.1 (48.4-350.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.2 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 5 3.9 128.2 (41.3-299.2) 
Female 26 26.5 98.0 (64.0-143.7)   Female 0 3.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 3.2 nc (nc-nc) 
Female 2 0.8 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 7.6 nc (nc-nc)             
Female 5 7.6 65.4 (21.1-152.7)   Female 1 2.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 1.9 nc (nc-nc)   Male 5 2.4 209.0 (67.4-487.8) 
Female 0 0.5 nc (nc-nc)   Female 2 2.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.5 nc (nc-nc)   Male 26 26.3 99.0 (64.7-145.1) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 3.8 nc (nc-nc)   Male 3 1.6 nc (nc-nc) 
Female 2 2.1 nc (nc-nc)   Female 2 1.0 nc (nc-nc) 
Larynx            Testis     
Male 1 1.1 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 2.6 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 1 1.9 nc (nc-nc)   Female 5 4.4 114.6 (36.9-267.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 2.4 nc (nc-nc)             
Female 0 0.8 nc (nc-nc)   Female 4 6.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 14 12.9 108.8 (59.4-182.5)   Male 89 93.5 95.2 (76.4-117.1) 
Female 10 13.1 76.6 (36.7-140.9)   Female 73 90.5 80.7 (63.3-101.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
129 
Hancock 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 1.1 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 1 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 2 3.5 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 1.2 nc (nc-nc)             
Female 1 0.9 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 3 3.9 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.6 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 1 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.4 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 2.0 nc (nc-nc)   Male 9 14.3 63.1 (28.8-119.7) 
Female 2 1.7 nc (nc-nc)   Female 9 11.7 76.6 (35.0-145.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hanover 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 10 13.8 72.7 (34.8-133.6)   Male 14 9.3 150.4 (82.2-252.4) 
Female 3 5.2 nc (nc-nc)   Female 8 7.6 105.3 (45.3-207.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 2.8 nc (nc-nc)   Male 2 2.7 nc (nc-nc) 
Female 1 2.4 nc (nc-nc)   Female 3 2.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 10 8.2 122.0 (58.4-224.4) 
Female 74 60.5 122.3 (96.1-153.6)   Female 7 7.1 98.6 (39.5-203.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 6.9 86.6 (31.6-188.6) 
Female 2 2.1 nc (nc-nc)   Female 1 3.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 17 15.7 108.1 (62.9-173.1)             
Female 21 15.7 133.4 (82.5-203.9)   Female 4 5.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 3.9 nc (nc-nc)   Male 2 4.8 nc (nc-nc) 
Female 2 1.0 nc (nc-nc)   Female 3 5.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 1.1 nc (nc-nc)   Male 56 53.7 104.2 (78.7-135.4) 
Female 0 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 8.1 74.1 (27.1-161.3)   Male 5 3.3 151.1 (48.7-352.5) 
Female 6 4.7 127.4 (46.5-277.3)   Female 0 2.0 nc (nc-nc) 
Larynx            Testis     
Male 5 2.2 229.3 (73.9-535.0)   Male 2 1.8 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 5.6 106.3 (38.8-231.4)   Male 7 3.8 186.4 (74.7-384.0) 
Female 1 4.2 nc (nc-nc)   Female 12 11.1 107.9 (55.7-188.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 5.0 nc (nc-nc)             
Female 0 1.6 nc (nc-nc)   Female 16 13.8 116.1 (66.3-188.6) 
Lung and Bronchus            All Sites / Types     
Male 21 25.7 81.8 (50.6-125.0)   Male 188 193.1 97.4 (83.9-112.3) 
Female 32 27.8 115.1 (78.7-162.4)   Female 211 199.3 105.8 (92.0-121.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hanson 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 9.5 125.8 (65.0-219.8)   Male 4 6.6 nc (nc-nc) 
Female 2 3.2 nc (nc-nc)   Female 6 5.2 115.5 (42.2-251.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 2.0 nc (nc-nc)   Male 2 1.9 nc (nc-nc) 
Female 0 1.6 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 2 5.8 nc (nc-nc) 
Female 35 40.9 85.6 (59.6-119.0)   Female 5 4.6 108.9 (35.1-254.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 5.0 139.8 (56.0-288.0) 
Female 2 1.5 nc (nc-nc)   Female 1 2.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 19 11.1 171.0 (102.9-267.1)             
Female 10 9.9 101.5 (48.6-186.7)   Female 3 3.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 2.8 nc (nc-nc)   Male 5 3.4 147.8 (47.6-344.8) 
Female 1 0.6 nc (nc-nc)   Female 1 3.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.9 nc (nc-nc)   Male 48 38.6 124.5 (91.8-165.1) 
Female 0 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 5.8 119.9 (48.0-247.0)   Male 0 2.3 nc (nc-nc) 
Female 4 3.1 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Larynx            Testis     
Male 1 1.6 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 4.0 125.5 (40.5-293.0)   Male 2 2.8 nc (nc-nc) 
Female 3 2.7 nc (nc-nc)   Female 16 8.2 196.1 (112.0-318.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 3.6 nc (nc-nc)             
Female 4 1.0 nc (nc-nc)   Female 20 9.4 211.9 (129.4-327.3) 
Lung and Bronchus            All Sites / Types     
Male 25 18.0 139.1 (90.0-205.4)   Male 156 137.4 113.6 (96.4-132.8) 
Female 17 17.4 97.6 (56.8-156.3)   Female 139 131.4 105.8 (89.0-124.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hardwick 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 3.3 151.9 (48.9-354.4)   Male 2 2.1 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 0 1.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.6 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.9 nc (nc-nc) 
Female 13 11.8 110.3 (58.7-188.7)   Female 2 1.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 1.6 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 3.7 nc (nc-nc)             
Female 5 3.1 161.7 (52.1-377.3)   Female 0 1.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 0.9 nc (nc-nc)   Male 2 1.1 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 2 1.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.3 nc (nc-nc)   Male 8 12.3 65.2 (28.1-128.5) 
Female 1 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 1.8 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Larynx            Testis     
Male 0 0.5 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.3 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 2 0.8 nc (nc-nc)   Female 2 2.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.1 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 4 2.7 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 8 6.0 133.0 (57.3-262.2)   Male 44 44.7 98.5 (71.5-132.2) 
Female 7 5.3 131.8 (52.8-271.6)   Female 40 39.1 102.3 (73.1-139.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Harvard 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 6.5 77.1 (24.8-179.9)   Male 7 4.8 147.1 (59.0-303.2) 
Female 0 1.8 nc (nc-nc)   Female 3 3.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.5 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 2 0.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 8 4.2 190.8 (82.1-375.9) 
Female 17 24.5 69.4 (40.4-111.2)   Female 2 2.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 3.7 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 7.8 nc (nc-nc)             
Female 7 5.7 123.6 (49.5-254.8)   Female 2 2.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 2.0 nc (nc-nc)   Male 2 2.4 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 1.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.7 nc (nc-nc)   Male 20 28.0 71.5 (43.7-110.5) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 4.2 nc (nc-nc)   Male 0 1.6 nc (nc-nc) 
Female 1 1.8 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Larynx            Testis     
Male 0 1.1 nc (nc-nc)   Male 0 1.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 2.8 180.5 (58.2-421.2)   Male 2 2.2 nc (nc-nc) 
Female 1 1.5 nc (nc-nc)   Female 6 4.5 133.3 (48.7-290.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 2.7 nc (nc-nc)             
Female 0 0.6 nc (nc-nc)   Female 7 5.8 120.3 (48.2-247.8) 
Lung and Bronchus            All Sites / Types     
Male 4 12.4 nc (nc-nc)   Male 78 98.2 79.5 (62.8-99.2) 
Female 4 10.2 nc (nc-nc)   Female 56 76.8 72.9 (55.1-94.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Harwich 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 38 24.4 155.6 (110.1-213.5)   Male 16 13.8 115.7 (66.1-187.9) 
Female 8 9.0 88.8 (38.2-175.0)   Female 21 10.1 207.7 (128.5-317.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 3.4 nc (nc-nc)   Male 5 4.3 117.1 (37.7-273.3) 
Female 3 3.1 nc (nc-nc)   Female 5 3.7 135.2 (43.6-315.5) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.7 nc (nc-nc)   Male 14 12.2 115.0 (62.8-193.0) 
Female 107 79.9 133.9 (109.7-161.8)   Female 10 11.0 90.9 (43.5-167.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 8.8 91.0 (39.2-179.3) 
Female 1 2.3 nc (nc-nc)   Female 2 4.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 24 24.4 98.3 (63.0-146.3)             
Female 34 26.1 130.1 (90.1-181.8)   Female 10 7.5 133.3 (63.8-245.1) 
Esophagus            Pancreas     
Male 5 5.9 84.7 (27.3-197.8)   Male 8 7.9 101.6 (43.8-200.2) 
Female 2 1.7 nc (nc-nc)   Female 9 8.8 101.8 (46.5-193.3) 
Hodgkin Lymphoma            Prostate     
Male 5 1.1 462.7 (149.1-1079.8)   Male 105 75.9 138.3 (113.1-167.5) 
Female 1 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 9 10.8 83.5 (38.1-158.5)   Male 10 5.3 188.0 (90.0-345.7) 
Female 7 6.9 102.0 (40.9-210.1)   Female 3 3.3 nc (nc-nc) 
Larynx            Testis     
Male 4 3.2 nc (nc-nc)   Male 0 1.3 nc (nc-nc) 
Female 3 1.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 11 8.5 129.3 (64.5-231.4)   Male 5 4.0 124.5 (40.1-290.6) 
Female 2 6.4 nc (nc-nc)   Female 1 11.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 6.9 nc (nc-nc)             
Female 3 2.5 nc (nc-nc)   Female 21 18.7 112.3 (69.5-171.7) 
Lung and Bronchus            All Sites / Types     
Male 52 42.9 121.3 (90.6-159.1)   Male 351 289.0 121.5 (109.1-134.9) 
Female 35 45.4 77.1 (53.7-107.2)   Female 321 289.0 111.1 (99.3-123.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hatfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 4.8 nc (nc-nc)   Male 4 3.0 nc (nc-nc) 
Female 2 1.6 nc (nc-nc)   Female 2 2.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 0.8 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 0 2.7 nc (nc-nc) 
Female 15 17.5 85.8 (48.0-141.5)   Female 1 2.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 2.2 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 5.2 95.8 (30.9-223.5)             
Female 10 4.8 209.9 (100.5-386.0)   Female 3 1.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 1.3 nc (nc-nc)   Male 0 1.7 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 1.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.3 nc (nc-nc)   Male 16 17.7 90.2 (51.5-146.4) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 2.5 nc (nc-nc)   Male 2 1.1 nc (nc-nc) 
Female 3 1.4 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Larynx            Testis     
Male 0 0.7 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 1.8 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 2 3.0 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.6 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 5 4.1 121.3 (39.1-283.0) 
Lung and Bronchus            All Sites / Types     
Male 7 8.8 79.5 (31.8-163.8)   Male 59 63.7 92.6 (70.5-119.4) 
Female 4 8.4 nc (nc-nc)   Female 58 58.5 99.1 (75.3-128.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Haverhill 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 60 55.2 108.7 (82.9-139.9)   Male 36 37.4 96.3 (67.5-133.4) 
Female 25 22.2 112.4 (72.7-165.9)   Female 27 33.3 81.0 (53.4-117.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 14 11.4 122.3 (66.8-205.2)   Male 8 10.7 74.5 (32.1-146.9) 
Female 10 10.3 97.3 (46.6-179.0)   Female 8 9.5 84.3 (36.3-166.2) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.8 nc (nc-nc)   Male 40 33.2 120.6 (86.1-164.2) 
Female 253 247.4 102.2 (90.0-115.7)   Female 45 30.2 149.2 (108.8-199.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 38 27.0 141.0 (99.8-193.5) 
Female 6 9.2 65.4 (23.9-142.4)   Female 18 12.6 143.0 (84.7-226.0) 
Colon / Rectum            Ovary     
Male 81 63.2 128.2 (101.8-159.4)             
Female 74 69.2 106.9 (84.0-134.2)   Female 23 22.6 101.7 (64.4-152.6) 
Esophagus            Pancreas     
Male 14 15.0 93.1 (50.8-156.2)   Male 25 19.0 131.3 (85.0-193.9) 
Female 4 4.2 nc (nc-nc)   Female 30 21.8 137.6 (92.8-196.4) 
Hodgkin Lymphoma            Prostate     
Male 7 5.1 136.0 (54.5-280.3)   Male 175 201.1 87.0 (74.6-100.9) 
Female 4 4.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 37 31.6 117.2 (82.5-161.6)   Male 21 13.2 159.1 (98.5-243.3) 
Female 23 19.5 118.0 (74.8-177.1)   Female 8 8.7 91.7 (39.5-180.6) 
Larynx            Testis     
Male 9 8.4 107.6 (49.1-204.3)   Male 9 9.1 98.4 (44.9-186.9) 
Female 4 2.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 20 23.1 86.5 (52.8-133.6)   Male 15 15.4 97.3 (54.4-160.5) 
Female 19 18.5 102.6 (61.7-160.2)   Female 48 49.4 97.1 (71.6-128.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 18 19.6 91.9 (54.5-145.3)             
Female 4 6.7 nc (nc-nc)   Female 61 55.5 109.9 (84.1-141.2) 
Lung and Bronchus            All Sites / Types     
Male 106 99.7 106.3 (87.0-128.6)   Male 785 758.4 103.5 (96.4-111.0) 
Female 145 113.2 128.1 (108.1-150.7)   Female 908 838.5 108.3 (101.4-115.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hawley 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 0.6 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 3 1.7 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 0.6 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.2 nc (nc-nc)   Male 1 0.2 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 0 2.3 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.3 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.1 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 1 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.2 nc (nc-nc)             
Female 0 0.0 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 1.1 nc (nc-nc)   Male 3 7.8 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 5 5.7 87.8 (28.3-205.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Heath 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 1.2 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 1 3.6 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 1.3 nc (nc-nc)             
Female 1 0.9 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 6 4.4 136.1 (49.7-296.3) 
Female 2 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.6 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.4 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.4 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 2.1 nc (nc-nc)   Male 15 15.5 96.8 (54.1-159.7) 
Female 1 1.8 nc (nc-nc)   Female 8 12.2 65.6 (28.2-129.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hingham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 25 29.8 83.9 (54.3-123.9)   Male 37 17.9 206.3 (145.3-284.4) 
Female 10 12.2 81.8 (39.2-150.5)   Female 28 14.7 191.0 (126.9-276.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 4.9 nc (nc-nc)   Male 6 5.4 111.1 (40.6-241.8) 
Female 5 4.7 107.5 (34.6-250.8)   Female 5 5.0 99.3 (32.0-231.8) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.9 nc (nc-nc)   Male 18 16.0 112.7 (66.8-178.2) 
Female 112 114.1 98.1 (80.8-118.1)   Female 28 15.3 183.3 (121.8-265.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 16 12.0 132.9 (75.9-215.9) 
Female 2 3.6 nc (nc-nc)   Female 8 6.2 129.5 (55.7-255.1) 
Colon / Rectum            Ovary     
Male 26 31.5 82.5 (53.9-120.9)             
Female 44 37.1 118.7 (86.3-159.4)   Female 14 10.6 132.4 (72.3-222.2) 
Esophagus            Pancreas     
Male 6 7.4 80.7 (29.5-175.6)   Male 5 9.8 51.1 (16.5-119.2) 
Female 4 2.3 nc (nc-nc)   Female 10 12.1 82.7 (39.6-152.1) 
Hodgkin Lymphoma            Prostate     
Male 2 1.7 nc (nc-nc)   Male 110 95.7 114.9 (94.4-138.5) 
Female 2 1.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 12 14.4 83.1 (42.9-145.1)   Male 4 6.7 nc (nc-nc) 
Female 12 9.5 126.1 (65.1-220.3)   Female 1 4.7 nc (nc-nc) 
Larynx            Testis     
Male 2 4.1 nc (nc-nc)   Male 4 2.5 nc (nc-nc) 
Female 0 1.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 12 11.3 106.5 (55.0-186.1)   Male 6 6.0 99.7 (36.4-217.0) 
Female 12 9.3 129.4 (66.8-226.0)   Female 26 18.0 144.3 (94.2-211.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 9.1 nc (nc-nc)             
Female 0 3.4 nc (nc-nc)   Female 20 25.6 78.2 (47.8-120.8) 
Lung and Bronchus            All Sites / Types     
Male 34 52.2 65.2 (45.1-91.1)   Male 354 369.2 95.9 (86.2-106.4) 
Female 44 59.7 73.7 (53.5-98.9)   Female 421 406.1 103.7 (94.0-114.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hinsdale 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 2.9 nc (nc-nc)   Male 1 1.8 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.5 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 2 0.4 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.6 nc (nc-nc) 
Female 16 10.0 160.6 (91.7-260.7)   Female 2 1.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 1.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 3.2 nc (nc-nc)             
Female 2 2.6 nc (nc-nc)   Female 2 0.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.8 nc (nc-nc)   Male 2 1.0 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 5 10.7 46.8 (15.1-109.2) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 1.5 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.4 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.1 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 2 1.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 1.0 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 5 2.4 212.4 (68.4-495.6) 
Lung and Bronchus            All Sites / Types     
Male 11 5.4 204.4 (101.9-365.7)   Male 36 38.5 93.5 (65.4-129.4) 
Female 7 4.8 147.2 (59.0-303.3)   Female 44 33.1 132.8 (96.5-178.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Holbrook 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 22 12.0 183.1 (114.7-277.2)   Male 4 7.8 nc (nc-nc) 
Female 9 4.3 207.2 (94.6-393.4)   Female 11 6.2 177.7 (88.6-318.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 2.2 nc (nc-nc)   Male 2 2.3 nc (nc-nc) 
Female 3 1.9 nc (nc-nc)   Female 5 1.9 269.9 (87.0-629.8) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 11 6.9 159.7 (79.6-285.8) 
Female 50 47.3 105.6 (78.4-139.3)   Female 7 5.8 120.3 (48.2-247.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 5.5 nc (nc-nc) 
Female 3 1.7 nc (nc-nc)   Female 2 2.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 17 13.3 128.2 (74.7-205.3)             
Female 17 13.3 128.1 (74.6-205.1)   Female 7 4.3 162.6 (65.1-334.9) 
Esophagus            Pancreas     
Male 6 3.2 187.7 (68.5-408.5)   Male 6 4.1 147.4 (53.8-320.9) 
Female 1 0.8 nc (nc-nc)   Female 3 4.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.9 nc (nc-nc)   Male 54 42.3 127.8 (96.0-166.7) 
Female 2 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 6.5 122.9 (52.9-242.3)   Male 4 2.8 nc (nc-nc) 
Female 5 3.8 132.5 (42.7-309.2)   Female 1 1.7 nc (nc-nc) 
Larynx            Testis     
Male 2 1.8 nc (nc-nc)   Male 2 1.6 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 4.8 105.2 (33.9-245.4)   Male 2 3.0 nc (nc-nc) 
Female 7 3.5 200.8 (80.5-413.8)   Female 8 8.8 90.5 (39.0-178.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 8 4.1 196.5 (84.6-387.2)             
Female 1 1.3 nc (nc-nc)   Female 10 10.7 93.4 (44.7-171.7) 
Lung and Bronchus            All Sites / Types     
Male 24 21.9 109.7 (70.3-163.3)   Male 204 159.4 128.0 (111.0-146.8) 
Female 45 22.7 198.6 (144.8-265.7)   Female 204 160.7 126.9 (110.1-145.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Holden 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 19 19.5 97.5 (58.7-152.3)   Male 21 12.7 165.5 (102.4-253.0) 
Female 6 7.0 85.9 (31.4-187.0)   Female 6 9.9 60.4 (22.1-131.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 3.7 nc (nc-nc)   Male 5 3.7 133.6 (43.1-311.9) 
Female 5 3.1 160.9 (51.9-375.6)   Female 2 3.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.6 nc (nc-nc)   Male 9 11.2 80.5 (36.7-152.8) 
Female 81 77.3 104.8 (83.2-130.2)   Female 7 9.4 74.4 (29.8-153.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 13 9.1 142.2 (75.6-243.1) 
Female 0 2.7 nc (nc-nc)   Female 5 3.9 126.8 (40.9-295.9) 
Colon / Rectum            Ovary     
Male 15 21.7 69.1 (38.7-114.0)             
Female 23 21.4 107.4 (68.1-161.2)   Female 7 7.0 99.7 (39.9-205.3) 
Esophagus            Pancreas     
Male 8 5.3 151.3 (65.1-298.2)   Male 10 6.7 149.6 (71.6-275.1) 
Female 1 1.3 nc (nc-nc)   Female 2 6.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 1.4 nc (nc-nc)   Male 73 71.3 102.3 (80.2-128.7) 
Female 2 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 10.7 65.4 (26.2-134.7)   Male 2 4.6 nc (nc-nc) 
Female 7 6.1 114.7 (45.9-236.3)   Female 2 2.7 nc (nc-nc) 
Larynx            Testis     
Male 2 2.9 nc (nc-nc)   Male 6 2.3 264.5 (96.6-575.6) 
Female 0 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 7.7 103.6 (44.6-204.1)   Male 2 4.8 nc (nc-nc) 
Female 3 5.6 nc (nc-nc)   Female 8 14.2 56.5 (24.3-111.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 6.8 73.8 (23.8-172.2)             
Female 3 2.1 nc (nc-nc)   Female 27 17.6 153.0 (100.8-222.7) 
Lung and Bronchus            All Sites / Types     
Male 37 35.4 104.4 (73.5-143.9)   Male 269 262.1 102.6 (90.7-115.7) 
Female 28 36.2 77.4 (51.4-111.9)   Female 255 260.2 98.0 (86.3-110.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Holland 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 2.6 nc (nc-nc)   Male 1 1.8 nc (nc-nc) 
Female 3 0.7 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.5 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 5 9.8 51.0 (16.4-119.1)   Female 1 1.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.4 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 3.1 nc (nc-nc)             
Female 1 2.3 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.8 nc (nc-nc)   Male 2 0.9 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.2 nc (nc-nc)   Male 10 11.2 89.6 (42.9-164.9) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 1.6 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.4 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.1 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 2 0.6 nc (nc-nc)   Female 3 2.0 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.0 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 4 2.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 4 5.0 nc (nc-nc)   Male 26 38.5 67.6 (44.2-99.1) 
Female 5 4.0 124.1 (40.0-289.6)   Female 33 31.1 106.1 (73.0-149.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Holliston 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 15 13.9 107.8 (60.3-177.8)   Male 10 9.5 105.3 (50.4-193.6) 
Female 2 4.7 nc (nc-nc)   Female 4 7.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 2.8 176.7 (56.9-412.3)   Male 3 2.8 nc (nc-nc) 
Female 2 2.3 nc (nc-nc)   Female 2 2.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 9 8.4 107.7 (49.1-204.5) 
Female 63 59.0 106.8 (82.1-136.7)   Female 3 6.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 7.2 97.5 (39.0-200.8) 
Female 3 2.1 nc (nc-nc)   Female 3 2.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 18 16.1 111.9 (66.3-176.8)             
Female 13 14.7 88.7 (47.2-151.7)   Female 4 5.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 7 4.0 174.7 (70.0-359.9)   Male 4 4.9 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 4 4.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 1.1 nc (nc-nc)   Male 72 55.4 130.0 (101.7-163.7) 
Female 0 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 8.3 96.2 (41.4-189.6)   Male 3 3.4 nc (nc-nc) 
Female 4 4.5 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Larynx            Testis     
Male 2 2.2 nc (nc-nc)   Male 4 1.8 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 5.7 123.3 (49.4-254.1)   Male 3 3.9 nc (nc-nc) 
Female 4 3.9 nc (nc-nc)   Female 11 11.1 99.2 (49.5-177.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 5.2 95.5 (30.8-222.8)             
Female 1 1.5 nc (nc-nc)   Female 22 13.6 161.4 (101.1-244.3) 
Lung and Bronchus            All Sites / Types     
Male 15 26.1 57.6 (32.2-94.9)   Male 219 197.4 111.0 (96.7-126.7) 
Female 21 25.9 81.1 (50.2-124.0)   Female 180 190.6 94.4 (81.1-109.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Holyoke 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 33 40.4 81.8 (56.3-114.9)   Male 20 25.2 79.4 (48.5-122.7) 
Female 13 16.1 80.6 (42.9-137.9)   Female 15 21.9 68.4 (38.2-112.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 8 7.5 106.7 (46.0-210.4)   Male 3 7.4 nc (nc-nc) 
Female 4 7.0 nc (nc-nc)   Female 1 6.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.2 nc (nc-nc)   Male 19 22.5 84.3 (50.7-131.6) 
Female 124 158.8 78.1 (64.9-93.1)   Female 17 20.9 81.4 (47.4-130.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 25 17.0 146.8 (95.0-216.7) 
Female 12 5.6 213.7 (110.3-373.4)   Female 6 8.5 70.7 (25.8-153.9) 
Colon / Rectum            Ovary     
Male 38 43.6 87.2 (61.7-119.7)             
Female 46 49.5 93.0 (68.1-124.0)   Female 15 14.9 100.6 (56.3-166.0) 
Esophagus            Pancreas     
Male 8 10.2 78.6 (33.8-154.9)   Male 15 13.4 111.7 (62.5-184.2) 
Female 3 3.0 nc (nc-nc)   Female 25 16.0 156.4 (101.2-230.9) 
Hodgkin Lymphoma            Prostate     
Male 4 3.2 nc (nc-nc)   Male 116 132.0 87.9 (72.6-105.4) 
Female 4 3.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 21 20.3 103.5 (64.1-158.3)   Male 4 9.2 nc (nc-nc) 
Female 8 13.1 61.2 (26.4-120.6)   Female 9 6.3 142.0 (64.8-269.5) 
Larynx            Testis     
Male 8 5.6 144.1 (62.1-284.0)   Male 3 5.5 nc (nc-nc) 
Female 2 1.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 12 16.3 73.8 (38.1-128.8)   Male 3 9.3 nc (nc-nc) 
Female 10 13.2 76.0 (36.4-139.7)   Female 19 30.1 63.1 (38.0-98.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 24 12.7 189.1 (121.1-281.4)             
Female 7 4.6 150.9 (60.5-311.0)   Female 42 35.6 118.1 (85.1-159.7) 
Lung and Bronchus            All Sites / Types     
Male 74 70.5 105.0 (82.5-131.9)   Male 488 514.5 94.9 (86.6-103.7) 
Female 71 78.8 90.1 (70.4-113.7)   Female 499 563.4 88.6 (81.0-96.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hopedale 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 6.3 111.8 (44.8-230.5)   Male 7 4.1 172.3 (69.0-355.1) 
Female 1 2.4 nc (nc-nc)   Female 2 3.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.2 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 2 3.6 nc (nc-nc) 
Female 24 25.7 93.4 (59.8-139.0)   Female 0 3.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 2.9 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 7.1 70.8 (22.8-165.3)             
Female 12 7.5 159.9 (82.5-279.3)   Female 2 2.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 1.6 nc (nc-nc)   Male 2 2.1 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 2.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.5 nc (nc-nc)   Male 28 21.0 133.4 (88.6-192.8) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 3.4 nc (nc-nc)   Male 2 1.5 nc (nc-nc) 
Female 3 2.0 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Larynx            Testis     
Male 0 0.9 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 2.5 nc (nc-nc)   Male 3 1.6 nc (nc-nc) 
Female 0 1.9 nc (nc-nc)   Female 6 4.8 125.6 (45.9-273.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 2.1 nc (nc-nc)             
Female 0 0.7 nc (nc-nc)   Female 7 5.7 123.7 (49.6-254.9) 
Lung and Bronchus            All Sites / Types     
Male 11 11.0 100.4 (50.0-179.6)   Male 90 82.0 109.8 (88.3-134.9) 
Female 14 11.9 118.1 (64.5-198.2)   Female 77 87.2 88.3 (69.7-110.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hopkinton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 11.0 73.0 (31.4-143.8)   Male 14 8.3 169.7 (92.7-284.7) 
Female 6 3.8 157.7 (57.6-343.2)   Female 11 6.9 159.2 (79.4-284.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 8 2.7 291.7 (125.6-574.7)   Male 1 2.3 nc (nc-nc) 
Female 5 2.2 227.9 (73.5-531.9)   Female 1 1.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 5 7.3 68.1 (21.9-158.9) 
Female 52 55.2 94.2 (70.4-123.6)   Female 6 5.8 104.1 (38.0-226.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 6.6 90.4 (33.0-196.7) 
Female 2 2.1 nc (nc-nc)   Female 1 2.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 13.8 50.6 (20.3-104.2)             
Female 13 12.6 103.2 (54.9-176.5)   Female 2 4.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 3.4 nc (nc-nc)   Male 3 4.0 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 6 3.7 163.8 (59.8-356.6) 
Hodgkin Lymphoma            Prostate     
Male 0 1.2 nc (nc-nc)   Male 57 46.7 122.0 (92.4-158.1) 
Female 2 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 7.5 66.6 (21.5-155.5)   Male 5 2.8 176.8 (57.0-412.7) 
Female 1 4.0 nc (nc-nc)   Female 0 1.5 nc (nc-nc) 
Larynx            Testis     
Male 3 1.9 nc (nc-nc)   Male 4 1.9 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 5.0 nc (nc-nc)   Male 5 3.8 130.4 (42.0-304.3) 
Female 1 3.5 nc (nc-nc)   Female 17 11.7 145.7 (84.8-233.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 4.6 nc (nc-nc)             
Female 2 1.3 nc (nc-nc)   Female 10 12.1 82.8 (39.6-152.2) 
Lung and Bronchus            All Sites / Types     
Male 9 20.8 43.4 (19.8-82.3)   Male 156 168.3 92.7 (78.7-108.5) 
Female 19 20.9 91.0 (54.8-142.1)   Female 171 170.7 100.2 (85.7-116.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hubbardston 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 4.1 nc (nc-nc)   Male 2 2.9 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 2 2.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.9 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 2 2.6 nc (nc-nc) 
Female 22 16.7 131.9 (82.6-199.7)   Female 1 1.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 2.3 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 5 0.8 638.0 (205.6-1489.0) 
Colon / Rectum            Ovary     
Male 1 4.9 nc (nc-nc)             
Female 6 3.8 158.5 (57.9-345.0)   Female 3 1.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.2 nc (nc-nc)   Male 2 1.5 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.4 nc (nc-nc)   Male 12 16.9 71.1 (36.7-124.2) 
Female 1 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 2.6 nc (nc-nc)   Male 3 1.0 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Larynx            Testis     
Male 0 0.7 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.7 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 6 3.5 170.8 (62.4-371.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.6 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 5 3.8 132.6 (42.7-309.5) 
Lung and Bronchus            All Sites / Types     
Male 4 7.7 nc (nc-nc)   Male 43 59.9 71.8 (51.9-96.7) 
Female 5 6.4 77.8 (25.1-181.6)   Female 64 51.9 123.4 (95.0-157.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hudson 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 22 20.9 105.2 (65.9-159.2)   Male 11 13.7 80.0 (39.9-143.2) 
Female 8 7.4 108.7 (46.8-214.2)   Female 9 10.8 83.7 (38.2-158.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 4.0 150.0 (54.8-326.4)   Male 2 4.0 nc (nc-nc) 
Female 2 3.3 nc (nc-nc)   Female 4 3.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.7 nc (nc-nc)   Male 8 12.1 66.3 (28.5-130.6) 
Female 84 83.3 100.9 (80.5-124.9)   Female 7 10.0 70.0 (28.0-144.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 14 9.7 143.8 (78.6-241.3) 
Female 2 2.9 nc (nc-nc)   Female 4 4.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 30 23.2 129.3 (87.2-184.6)             
Female 23 22.2 103.7 (65.7-155.6)   Female 11 7.5 146.8 (73.2-262.6) 
Esophagus            Pancreas     
Male 8 5.7 141.3 (60.8-278.5)   Male 5 7.1 70.0 (22.5-163.3) 
Female 1 1.4 nc (nc-nc)   Female 7 7.1 98.9 (39.6-203.7) 
Hodgkin Lymphoma            Prostate     
Male 0 1.7 nc (nc-nc)   Male 81 75.8 106.9 (84.9-132.9) 
Female 1 1.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 11.5 60.7 (24.3-125.0)   Male 3 4.9 nc (nc-nc) 
Female 9 6.6 136.0 (62.1-258.2)   Female 5 2.7 181.9 (58.6-424.5) 
Larynx            Testis     
Male 3 3.1 nc (nc-nc)   Male 2 2.8 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 8.4 107.8 (49.2-204.6)   Male 3 5.3 nc (nc-nc) 
Female 3 5.9 nc (nc-nc)   Female 22 15.7 140.3 (87.9-212.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 7.2 69.6 (22.4-162.4)             
Female 0 2.3 nc (nc-nc)   Female 26 19.0 137.1 (89.5-200.9) 
Lung and Bronchus            All Sites / Types     
Male 36 38.3 94.0 (65.9-130.2)   Male 276 281.4 98.1 (86.8-110.3) 
Female 36 39.7 90.6 (63.4-125.4)   Female 281 279.0 100.7 (89.3-113.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hull 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 18 12.4 145.0 (85.9-229.1)   Male 11 8.3 132.7 (66.1-237.4) 
Female 5 4.5 110.3 (35.5-257.3)   Female 11 6.8 162.4 (81.0-290.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 2.3 nc (nc-nc)   Male 2 2.5 nc (nc-nc) 
Female 3 2.0 nc (nc-nc)   Female 3 2.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.4 nc (nc-nc)   Male 7 7.2 97.2 (38.9-200.2) 
Female 56 54.6 102.6 (77.5-133.2)   Female 10 6.3 158.8 (76.0-292.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 6.2 nc (nc-nc) 
Female 3 1.8 nc (nc-nc)   Female 6 2.7 221.1 (80.7-481.2) 
Colon / Rectum            Ovary     
Male 10 14.0 71.4 (34.2-131.4)             
Female 9 13.7 65.8 (30.0-125.0)   Female 4 4.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 3.6 nc (nc-nc)   Male 4 4.4 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 7 4.4 160.4 (64.3-330.6) 
Hodgkin Lymphoma            Prostate     
Male 1 0.9 nc (nc-nc)   Male 53 50.0 105.9 (79.3-138.5) 
Female 1 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 7.2 138.8 (66.5-255.3)   Male 1 3.0 nc (nc-nc) 
Female 6 4.2 142.6 (52.1-310.4)   Female 0 1.7 nc (nc-nc) 
Larynx            Testis     
Male 5 2.0 250.3 (80.7-584.2)   Male 4 1.4 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 4.8 nc (nc-nc)   Male 4 3.2 nc (nc-nc) 
Female 4 3.5 nc (nc-nc)   Female 4 9.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 14 4.6 303.0 (165.5-508.4)             
Female 1 1.5 nc (nc-nc)   Female 15 13.0 115.1 (64.3-189.8) 
Lung and Bronchus            All Sites / Types     
Male 28 23.4 119.9 (79.6-173.3)   Male 198 174.2 113.6 (98.4-130.6) 
Female 33 24.9 132.4 (91.1-185.9)   Female 195 177.8 109.7 (94.8-126.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Huntington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 2.3 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.5 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.1 nc (nc-nc)   Male 2 1.4 nc (nc-nc) 
Female 7 9.0 78.2 (31.3-161.1)   Female 2 1.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 1.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 2.7 nc (nc-nc)             
Female 3 2.2 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.7 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 6 9.6 62.7 (22.9-136.5) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 1.4 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 2 0.4 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 0.9 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 3 1.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.9 nc (nc-nc)             
Female 1 0.2 nc (nc-nc)   Female 1 2.1 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 6 4.2 141.6 (51.7-308.1)   Male 38 33.1 114.8 (81.2-157.6) 
Female 3 3.8 nc (nc-nc)   Female 23 29.0 79.4 (50.3-119.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
152 
Ipswich 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 22 17.3 126.9 (79.5-192.1)   Male 15 11.0 136.4 (76.3-224.9) 
Female 8 6.7 119.8 (51.6-236.1)   Female 9 8.7 103.1 (47.1-195.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 3.0 165.7 (53.4-386.7)   Male 2 3.3 nc (nc-nc) 
Female 2 2.7 nc (nc-nc)   Female 1 2.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.5 nc (nc-nc)   Male 8 9.7 82.7 (35.6-163.0) 
Female 82 69.2 118.5 (94.3-147.2)   Female 9 8.7 103.7 (47.3-196.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 7.9 101.2 (43.6-199.5) 
Female 1 2.2 nc (nc-nc)   Female 5 3.6 138.7 (44.7-323.6) 
Colon / Rectum            Ovary     
Male 10 18.9 52.9 (25.3-97.2)             
Female 18 20.2 89.3 (52.9-141.1)   Female 9 6.3 142.1 (64.9-269.9) 
Esophagus            Pancreas     
Male 5 4.7 106.4 (34.3-248.3)   Male 8 5.9 135.4 (58.3-266.7) 
Female 2 1.3 nc (nc-nc)   Female 9 6.5 138.0 (63.0-261.9) 
Hodgkin Lymphoma            Prostate     
Male 0 1.1 nc (nc-nc)   Male 77 63.5 121.2 (95.6-151.5) 
Female 1 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 9.2 75.7 (30.3-155.9)   Male 2 4.0 nc (nc-nc) 
Female 7 5.6 125.7 (50.3-258.9)   Female 6 2.5 236.6 (86.4-515.0) 
Larynx            Testis     
Male 2 2.6 nc (nc-nc)   Male 4 1.7 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 6.6 121.1 (52.1-238.6)   Male 5 4.0 124.8 (40.2-291.3) 
Female 8 5.1 157.4 (67.8-310.2)   Female 10 11.4 87.5 (41.9-160.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 5.9 nc (nc-nc)             
Female 5 2.0 252.0 (81.2-588.2)   Female 18 16.0 112.5 (66.6-177.8) 
Lung and Bronchus            All Sites / Types     
Male 32 31.6 101.3 (69.3-143.0)   Male 247 229.9 107.5 (94.5-121.7) 
Female 27 34.2 79.0 (52.0-114.9)   Female 255 236.7 107.7 (94.9-121.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
153 
Kingston 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 13 13.3 97.4 (51.8-166.6)   Male 12 8.8 136.9 (70.7-239.1) 
Female 6 5.6 106.8 (39.0-232.4)   Female 11 7.5 146.6 (73.1-262.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.6 nc (nc-nc)   Male 0 2.6 nc (nc-nc) 
Female 3 2.4 nc (nc-nc)   Female 2 2.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 3 7.7 nc (nc-nc) 
Female 64 57.9 110.6 (85.2-141.2)   Female 9 7.3 123.2 (56.2-233.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 6.3 94.6 (34.5-205.9) 
Female 2 2.0 nc (nc-nc)   Female 2 3.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 14 15.0 93.2 (50.9-156.5)             
Female 15 17.3 86.6 (48.4-142.8)   Female 2 5.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 3.6 nc (nc-nc)   Male 13 4.6 283.1 (150.6-484.2) 
Female 4 1.1 nc (nc-nc)   Female 8 5.5 144.2 (62.1-284.1) 
Hodgkin Lymphoma            Prostate     
Male 0 1.0 nc (nc-nc)   Male 47 49.0 95.9 (70.5-127.6) 
Female 0 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 7.4 107.6 (46.3-212.1)   Male 8 3.2 253.3 (109.1-499.1) 
Female 4 4.6 nc (nc-nc)   Female 0 2.2 nc (nc-nc) 
Larynx            Testis     
Male 0 2.0 nc (nc-nc)   Male 3 1.7 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 5.3 130.9 (52.5-269.8)   Male 4 3.4 nc (nc-nc) 
Female 5 4.4 112.4 (36.2-262.3)   Female 15 10.2 146.6 (82.0-241.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 4.6 nc (nc-nc)             
Female 1 1.6 nc (nc-nc)   Female 17 12.9 131.7 (76.7-210.8) 
Lung and Bronchus            All Sites / Types     
Male 30 24.3 123.6 (83.4-176.4)   Male 186 180.6 103.0 (88.7-118.9) 
Female 23 27.8 82.8 (52.5-124.2)   Female 215 199.2 107.9 (94.0-123.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
154 
Lakeville 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 13 10.8 120.3 (64.0-205.8)   Male 7 7.4 95.2 (38.1-196.2) 
Female 4 3.7 nc (nc-nc)   Female 4 5.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 2.2 227.4 (73.3-530.8)   Male 1 2.2 nc (nc-nc) 
Female 2 1.8 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 7 6.5 107.9 (43.2-222.4) 
Female 42 45.2 92.9 (66.9-125.6)   Female 3 5.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 5.5 108.4 (39.6-235.8) 
Female 1 1.6 nc (nc-nc)   Female 4 2.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 17 12.4 136.8 (79.6-219.0)             
Female 11 11.6 94.9 (47.3-169.8)   Female 4 4.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 3.1 nc (nc-nc)   Male 4 3.8 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 5 3.6 138.8 (44.7-323.8) 
Hodgkin Lymphoma            Prostate     
Male 2 0.9 nc (nc-nc)   Male 43 42.7 100.6 (72.8-135.6) 
Female 1 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 6.4 77.9 (25.1-181.7)   Male 5 2.6 191.4 (61.7-446.7) 
Female 4 3.4 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Larynx            Testis     
Male 1 1.7 nc (nc-nc)   Male 2 1.4 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 4.4 nc (nc-nc)   Male 3 3.0 nc (nc-nc) 
Female 2 3.1 nc (nc-nc)   Female 12 8.7 138.4 (71.4-241.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 4.0 nc (nc-nc)             
Female 1 1.2 nc (nc-nc)   Female 13 10.2 127.0 (67.6-217.2) 
Lung and Bronchus            All Sites / Types     
Male 14 20.1 69.5 (38.0-116.6)   Male 157 152.7 102.8 (87.4-120.2) 
Female 14 19.7 70.9 (38.7-119.0)   Female 143 147.2 97.1 (81.9-114.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
155 
Lancaster 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 13 7.3 176.9 (94.1-302.5)   Male 6 5.3 114.1 (41.7-248.4) 
Female 5 2.7 187.6 (60.5-437.8)   Female 3 3.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.7 nc (nc-nc)   Male 2 1.5 nc (nc-nc) 
Female 2 1.2 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 5 4.7 107.0 (34.5-249.7) 
Female 28 30.0 93.3 (62.0-134.9)   Female 3 3.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 3.8 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 0 1.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 8.6 58.0 (18.7-135.4)             
Female 3 8.1 nc (nc-nc)   Female 3 2.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 2.1 nc (nc-nc)   Male 3 2.6 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 4 2.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.9 nc (nc-nc)   Male 46 27.9 164.6 (120.5-219.5) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 4.5 111.2 (35.8-259.5)   Male 1 1.8 nc (nc-nc) 
Female 1 2.4 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Larynx            Testis     
Male 4 1.2 nc (nc-nc)   Male 4 1.6 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 3.2 nc (nc-nc)   Male 4 2.4 nc (nc-nc) 
Female 4 2.1 nc (nc-nc)   Female 5 5.6 89.6 (28.9-209.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 2.7 nc (nc-nc)             
Female 2 0.8 nc (nc-nc)   Female 4 6.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 10 13.6 73.6 (35.3-135.4)   Male 122 105.4 115.8 (96.1-138.2) 
Female 9 14.0 64.5 (29.4-122.4)   Female 84 100.5 83.6 (66.7-103.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
156 
Lanesborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 4.0 nc (nc-nc)   Male 6 2.6 230.8 (84.3-502.4) 
Female 0 1.3 nc (nc-nc)   Female 3 1.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.7 nc (nc-nc)   Male 2 0.8 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 2.3 nc (nc-nc) 
Female 9 15.0 60.1 (27.4-114.2)   Female 3 1.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 1.9 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 4.5 nc (nc-nc)             
Female 2 3.9 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 1.1 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.3 nc (nc-nc)   Male 14 15.5 90.6 (49.5-152.0) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 2.2 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 3 1.2 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Larynx            Testis     
Male 1 0.6 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.5 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 2 1.0 nc (nc-nc)   Female 0 2.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.4 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 1 3.5 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 9 7.4 121.5 (55.4-230.6)   Male 53 54.7 96.9 (72.6-126.8) 
Female 5 6.9 72.9 (23.5-170.1)   Female 32 49.3 64.9 (44.4-91.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
157 
Lawrence 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 49 49.7 98.7 (73.0-130.5)   Male 13 35.3 36.8 (19.6-63.0) 
Female 16 19.8 80.7 (46.1-131.1)   Female 13 33.7 38.5 (20.5-65.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 8 12.3 65.2 (28.1-128.6)   Male 10 9.8 101.8 (48.7-187.2) 
Female 10 11.0 91.1 (43.6-167.5)   Female 16 8.6 186.5 (106.5-302.8) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.6 nc (nc-nc)   Male 29 31.7 91.5 (61.3-131.4) 
Female 176 239.3 73.6 (63.1-85.3)   Female 33 28.4 116.3 (80.0-163.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 28 25.5 109.9 (73.0-158.9) 
Female 17 9.7 174.7 (101.7-279.8)   Female 11 11.9 92.4 (46.1-165.3) 
Colon / Rectum            Ovary     
Male 60 58.1 103.3 (78.8-132.9)             
Female 59 62.5 94.4 (71.8-121.7)   Female 11 21.9 50.3 (25.1-90.0) 
Esophagus            Pancreas     
Male 10 13.8 72.5 (34.7-133.4)   Male 19 17.3 109.7 (66.0-171.4) 
Female 9 3.8 236.1 (107.8-448.3)   Female 16 19.3 82.9 (47.3-134.6) 
Hodgkin Lymphoma            Prostate     
Male 3 6.2 nc (nc-nc)   Male 243 185.3 131.1 (115.1-148.7) 
Female 5 5.5 90.5 (29.2-211.2)             
Kidney & Renal Pelvis            Stomach     
Male 20 30.0 66.6 (40.7-102.9)   Male 22 12.1 182.4 (114.3-276.2) 
Female 17 18.6 91.2 (53.1-146.0)   Female 11 7.8 140.3 (70.0-251.1) 
Larynx            Testis     
Male 9 7.7 117.1 (53.4-222.3)   Male 9 11.7 77.0 (35.1-146.2) 
Female 4 2.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 18 23.0 78.2 (46.3-123.6)   Male 17 15.9 107.0 (62.3-171.3) 
Female 21 18.4 114.1 (70.6-174.4)   Female 60 54.5 110.0 (83.9-141.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 27 18.2 148.6 (97.9-216.2)             
Female 14 6.2 225.0 (122.9-377.6)   Female 45 53.0 84.9 (61.9-113.6) 
Lung and Bronchus            All Sites / Types     
Male 86 90.2 95.4 (76.3-117.8)   Male 736 710.0 103.7 (96.3-111.4) 
Female 89 103.6 85.9 (69.0-105.7)   Female 708 802.6 88.2 (81.8-95.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
158 
Lee 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 15 8.2 183.3 (102.5-302.4)   Male 7 5.1 137.4 (55.1-283.2) 
Female 2 3.1 nc (nc-nc)   Female 9 3.9 229.8 (104.9-436.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.4 nc (nc-nc)   Male 0 1.5 nc (nc-nc) 
Female 4 1.2 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 2 4.5 nc (nc-nc) 
Female 24 30.2 79.4 (50.8-118.1)   Female 4 3.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 3.5 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 3 1.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 8.7 68.6 (25.0-149.3)             
Female 8 9.2 87.0 (37.5-171.4)   Female 0 2.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 2.1 nc (nc-nc)   Male 2 2.8 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 3.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.5 nc (nc-nc)   Male 32 28.7 111.5 (76.3-157.4) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 4.2 nc (nc-nc)   Male 2 1.9 nc (nc-nc) 
Female 2 2.5 nc (nc-nc)   Female 3 1.2 nc (nc-nc) 
Larynx            Testis     
Male 4 1.2 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 2 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 3.1 nc (nc-nc)   Male 3 1.8 nc (nc-nc) 
Female 0 2.3 nc (nc-nc)   Female 7 5.0 139.2 (55.8-286.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 2.6 nc (nc-nc)             
Female 2 0.9 nc (nc-nc)   Female 3 7.0 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 17 14.8 115.0 (66.9-184.1)   Male 114 105.7 107.8 (88.9-129.5) 
Female 18 15.4 116.5 (69.0-184.1)   Female 98 105.7 92.7 (75.2-113.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
159 
Leicester 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 10 11.3 88.6 (42.4-162.9)   Male 11 7.5 145.9 (72.7-261.1) 
Female 3 4.1 nc (nc-nc)   Female 10 6.0 165.8 (79.4-305.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.2 nc (nc-nc)   Male 3 2.2 nc (nc-nc) 
Female 3 1.9 nc (nc-nc)   Female 0 1.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.4 nc (nc-nc)   Male 4 6.7 nc (nc-nc) 
Female 54 46.1 117.1 (88.0-152.8)   Female 4 5.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 5.5 nc (nc-nc) 
Female 4 1.6 nc (nc-nc)   Female 3 2.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 10 12.7 78.6 (37.7-144.6)             
Female 10 12.6 79.5 (38.1-146.3)   Female 4 4.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 3.1 nc (nc-nc)   Male 0 3.9 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 6 4.0 150.2 (54.8-326.9) 
Hodgkin Lymphoma            Prostate     
Male 0 0.9 nc (nc-nc)   Male 30 42.6 70.4 (47.5-100.5) 
Female 1 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 6.4 77.8 (25.1-181.5)   Male 1 2.7 nc (nc-nc) 
Female 3 3.6 nc (nc-nc)   Female 0 1.6 nc (nc-nc) 
Larynx            Testis     
Male 1 1.7 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 4.6 153.7 (61.6-316.6)   Male 2 3.0 nc (nc-nc) 
Female 3 3.3 nc (nc-nc)   Female 3 8.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 4.0 nc (nc-nc)             
Female 0 1.3 nc (nc-nc)   Female 14 10.5 134.0 (73.2-224.8) 
Lung and Bronchus            All Sites / Types     
Male 29 20.8 139.7 (93.5-200.6)   Male 139 155.5 89.4 (75.2-105.6) 
Female 30 21.7 138.6 (93.5-197.8)   Female 166 155.1 107.0 (91.3-124.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
160 
Lenox 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 13 9.1 143.4 (76.3-245.2)   Male 9 5.1 176.6 (80.6-335.2) 
Female 1 4.1 nc (nc-nc)   Female 5 4.3 116.3 (37.5-271.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.3 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 3 1.3 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 2 4.5 nc (nc-nc) 
Female 37 32.5 113.8 (80.1-156.8)   Female 3 4.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 3.2 nc (nc-nc) 
Female 2 0.9 nc (nc-nc)   Female 0 1.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 16 9.2 174.4 (99.6-283.3)             
Female 16 12.5 128.5 (73.4-208.6)   Female 5 3.2 158.6 (51.1-370.1) 
Esophagus            Pancreas     
Male 1 2.1 nc (nc-nc)   Male 1 2.9 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 3 4.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.4 nc (nc-nc)   Male 30 26.8 111.8 (75.4-159.6) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 3.9 nc (nc-nc)   Male 1 2.0 nc (nc-nc) 
Female 4 2.8 nc (nc-nc)   Female 0 1.6 nc (nc-nc) 
Larynx            Testis     
Male 1 1.1 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 3.2 217.9 (87.3-448.9)   Male 1 1.5 nc (nc-nc) 
Female 2 2.9 nc (nc-nc)   Female 3 4.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 2.5 nc (nc-nc)             
Female 2 1.1 nc (nc-nc)   Female 10 7.3 136.1 (65.2-250.4) 
Lung and Bronchus            All Sites / Types     
Male 9 15.5 58.2 (26.6-110.5)   Male 106 105.6 100.4 (82.2-121.4) 
Female 14 18.5 75.5 (41.3-126.7)   Female 120 123.3 97.3 (80.7-116.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
161 
Leominster 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 52 42.4 122.7 (91.6-160.9)   Male 21 27.8 75.6 (46.8-115.6) 
Female 27 16.6 163.0 (107.4-237.1)   Female 21 23.3 90.3 (55.9-138.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 8 8.2 97.9 (42.1-192.9)   Male 12 8.1 148.3 (76.6-259.1) 
Female 8 7.2 111.6 (48.0-219.8)   Female 6 7.0 85.9 (31.4-187.0) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.3 nc (nc-nc)   Male 28 24.6 113.8 (75.6-164.5) 
Female 165 174.6 94.5 (80.6-110.1)   Female 24 21.9 109.6 (70.2-163.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 19 19.6 96.7 (58.2-151.1) 
Female 8 6.2 129.6 (55.8-255.4)   Female 12 9.0 132.7 (68.5-231.8) 
Colon / Rectum            Ovary     
Male 42 47.2 88.9 (64.1-120.2)             
Female 37 50.8 72.8 (51.3-100.4)   Female 24 16.1 149.5 (95.8-222.5) 
Esophagus            Pancreas     
Male 11 11.3 97.2 (48.5-174.0)   Male 16 14.4 111.0 (63.4-180.2) 
Female 3 3.1 nc (nc-nc)   Female 16 16.2 98.5 (56.3-160.0) 
Hodgkin Lymphoma            Prostate     
Male 4 3.5 nc (nc-nc)   Male 155 150.0 103.3 (87.7-120.9) 
Female 5 3.0 168.3 (54.2-392.7)             
Kidney & Renal Pelvis            Stomach     
Male 20 23.2 86.3 (52.7-133.3)   Male 10 10.0 100.4 (48.1-184.7) 
Female 14 14.0 100.1 (54.7-167.9)   Female 6 6.4 93.2 (34.0-202.8) 
Larynx            Testis     
Male 8 6.3 127.6 (54.9-251.4)   Male 3 5.9 nc (nc-nc) 
Female 1 2.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 18 17.1 105.3 (62.4-166.4)   Male 7 10.8 64.6 (25.9-133.2) 
Female 12 13.3 90.5 (46.7-158.0)   Female 19 32.9 57.8 (34.8-90.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 14.5 41.5 (15.2-90.3)             
Female 2 4.9 nc (nc-nc)   Female 38 39.2 96.9 (68.5-133.0) 
Lung and Bronchus            All Sites / Types     
Male 95 76.5 124.2 (100.5-151.8)   Male 573 566.4 101.2 (93.1-109.8) 
Female 72 83.8 85.9 (67.2-108.2)   Female 563 600.4 93.8 (86.2-101.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
162 
Leverett 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 2.7 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.5 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 3 1.5 nc (nc-nc) 
Female 17 9.5 178.5 (103.9-285.8)   Female 1 1.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 1.3 nc (nc-nc) 
Female 2 0.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 2.9 nc (nc-nc)             
Female 0 2.3 nc (nc-nc)   Female 2 0.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.8 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 8 11.1 72.0 (31.0-141.9) 
Female 1 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 1.5 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.0 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 2 0.6 nc (nc-nc)   Female 3 1.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.0 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 4 2.4 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 5.1 nc (nc-nc)   Male 28 37.2 75.3 (50.0-108.8) 
Female 3 4.3 nc (nc-nc)   Female 38 30.8 123.3 (87.2-169.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
163 
Lexington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 28 44.1 63.5 (42.2-91.7)   Male 30 26.8 112.1 (75.6-160.0) 
Female 8 15.9 50.3 (21.7-99.2)   Female 24 20.2 118.7 (76.1-176.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 9 7.2 124.5 (56.8-236.4)   Male 8 8.1 99.1 (42.7-195.3) 
Female 5 6.3 78.9 (25.4-184.2)   Female 7 6.7 105.2 (42.1-216.7) 
Breast            Non-Hodgkin Lymphoma     
Male 3 1.4 nc (nc-nc)   Male 21 23.7 88.6 (54.8-135.4) 
Female 175 160.2 109.2 (93.6-126.7)   Female 23 20.4 112.6 (71.3-168.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 13 18.2 71.2 (37.9-121.8) 
Female 2 5.1 nc (nc-nc)   Female 7 8.4 83.2 (33.3-171.4) 
Colon / Rectum            Ovary     
Male 37 47.0 78.7 (55.4-108.5)             
Female 32 48.1 66.6 (45.5-94.0)   Female 17 14.7 115.7 (67.4-185.3) 
Esophagus            Pancreas     
Male 3 11.2 nc (nc-nc)   Male 11 14.6 75.3 (37.5-134.7) 
Female 4 3.0 nc (nc-nc)   Female 17 15.6 108.9 (63.4-174.4) 
Hodgkin Lymphoma            Prostate     
Male 0 2.5 nc (nc-nc)   Male 152 144.6 105.1 (89.1-123.2) 
Female 1 2.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 20 21.6 92.4 (56.4-142.7)   Male 6 10.0 60.0 (21.9-130.6) 
Female 7 13.0 53.9 (21.6-111.0)   Female 8 6.1 131.2 (56.5-258.6) 
Larynx            Testis     
Male 5 6.1 81.9 (26.4-191.2)   Male 3 3.5 nc (nc-nc) 
Female 0 2.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 19 16.6 114.8 (69.1-179.2)   Male 12 9.0 132.8 (68.6-232.1) 
Female 13 12.1 107.3 (57.1-183.4)   Female 38 26.2 145.3 (102.8-199.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 13.8 36.2 (11.7-84.4)             
Female 3 4.6 nc (nc-nc)   Female 31 36.4 85.1 (57.8-120.8) 
Lung and Bronchus            All Sites / Types     
Male 44 77.9 56.5 (41.0-75.8)   Male 468 552.0 84.8 (77.3-92.8) 
Female 49 80.1 61.1 (45.2-80.8)   Female 515 553.2 93.1 (85.2-101.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
164 
Leyden 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 0.8 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 3.5 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 1.0 nc (nc-nc)             
Female 0 0.8 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 3 3.8 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.5 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.4 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 2 0.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 1.6 nc (nc-nc)   Male 8 12.4 64.5 (27.8-127.2) 
Female 2 1.4 nc (nc-nc)   Female 5 10.7 46.9 (15.1-109.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
165 
Lincoln 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 8.9 nc (nc-nc)   Male 3 5.4 nc (nc-nc) 
Female 5 2.6 189.7 (61.1-442.8)   Female 8 3.7 217.1 (93.5-427.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.5 nc (nc-nc)   Male 3 1.6 nc (nc-nc) 
Female 2 1.2 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.3 nc (nc-nc)   Male 5 4.8 104.6 (33.7-244.0) 
Female 36 29.4 122.6 (85.9-169.7)   Female 4 3.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 3.7 nc (nc-nc) 
Female 2 1.0 nc (nc-nc)   Female 2 1.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 9.4 74.6 (29.9-153.7)             
Female 8 7.9 101.2 (43.6-199.4)   Female 4 2.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 2.3 nc (nc-nc)   Male 4 3.0 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 4 2.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.5 nc (nc-nc)   Male 44 30.0 146.7 (106.5-196.9) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 4.4 nc (nc-nc)   Male 0 2.0 nc (nc-nc) 
Female 2 2.3 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Larynx            Testis     
Male 0 1.3 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 3.3 nc (nc-nc)   Male 3 1.8 nc (nc-nc) 
Female 4 2.1 nc (nc-nc)   Female 4 5.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.8 nc (nc-nc)             
Female 0 0.8 nc (nc-nc)   Female 8 6.9 116.7 (50.3-230.0) 
Lung and Bronchus            All Sites / Types     
Male 8 16.0 50.1 (21.6-98.8)   Male 106 112.5 94.3 (77.2-114.0) 
Female 6 14.0 42.7 (15.6-93.0)   Female 110 98.4 111.8 (91.9-134.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
166 
Littleton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 9.5 115.3 (57.5-206.2)   Male 5 6.3 79.3 (25.6-185.1) 
Female 1 3.5 nc (nc-nc)   Female 2 5.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.8 nc (nc-nc)   Male 1 1.9 nc (nc-nc) 
Female 0 1.6 nc (nc-nc)   Female 0 1.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 5 5.6 89.4 (28.8-208.7) 
Female 33 40.1 82.3 (56.7-115.6)   Female 5 4.8 105.2 (33.9-245.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 4.6 nc (nc-nc) 
Female 0 1.4 nc (nc-nc)   Female 0 2.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 10.8 64.6 (25.9-133.1)             
Female 10 10.9 91.9 (44.0-169.0)   Female 4 3.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 2.6 nc (nc-nc)   Male 5 3.3 152.2 (49.0-355.2) 
Female 0 0.7 nc (nc-nc)   Female 6 3.4 175.5 (64.1-382.1) 
Hodgkin Lymphoma            Prostate     
Male 1 0.7 nc (nc-nc)   Male 33 34.7 95.1 (65.5-133.6) 
Female 0 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 5.4 111.9 (40.9-243.5)   Male 3 2.3 nc (nc-nc) 
Female 4 3.1 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Larynx            Testis     
Male 1 1.4 nc (nc-nc)   Male 4 1.2 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 3.8 nc (nc-nc)   Male 0 2.5 nc (nc-nc) 
Female 4 2.9 nc (nc-nc)   Female 7 7.4 95.1 (38.1-196.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 3.3 nc (nc-nc)             
Female 2 1.1 nc (nc-nc)   Female 13 8.9 145.5 (77.4-248.9) 
Lung and Bronchus            All Sites / Types     
Male 18 17.3 104.2 (61.7-164.6)   Male 118 129.2 91.3 (75.6-109.4) 
Female 10 18.3 54.7 (26.2-100.6)   Female 111 132.9 83.5 (68.7-100.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
167 
Longmeadow 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 21.9 54.7 (28.2-95.6)   Male 18 13.2 136.2 (80.7-215.3) 
Female 9 8.3 108.1 (49.3-205.2)   Female 14 10.3 136.2 (74.4-228.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 3.6 nc (nc-nc)   Male 4 4.0 nc (nc-nc) 
Female 3 3.2 nc (nc-nc)   Female 3 3.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.7 nc (nc-nc)   Male 10 11.7 85.1 (40.8-156.6) 
Female 87 80.1 108.6 (87.0-133.9)   Female 12 10.5 114.1 (58.9-199.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 9.0 55.3 (17.8-129.1) 
Female 1 2.5 nc (nc-nc)   Female 1 4.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 11 23.3 47.3 (23.6-84.6)             
Female 14 25.3 55.3 (30.2-92.9)   Female 4 7.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 5.6 nc (nc-nc)   Male 0 7.3 nc (nc-nc) 
Female 2 1.6 nc (nc-nc)   Female 3 8.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 1.3 nc (nc-nc)   Male 70 72.5 96.6 (75.3-122.1) 
Female 0 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 10.7 93.4 (44.7-171.9)   Male 5 5.0 100.8 (32.5-235.2) 
Female 4 6.6 nc (nc-nc)   Female 3 3.2 nc (nc-nc) 
Larynx            Testis     
Male 4 3.0 nc (nc-nc)   Male 6 1.7 348.2 (127.2-758.0) 
Female 1 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 11 8.2 133.6 (66.6-239.1)   Male 5 4.4 112.7 (36.3-262.9) 
Female 5 6.3 79.1 (25.5-184.6)   Female 8 12.9 62.2 (26.8-122.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 6.8 nc (nc-nc)             
Female 4 2.4 nc (nc-nc)   Female 9 18.2 49.5 (22.6-93.9) 
Lung and Bronchus            All Sites / Types     
Male 22 38.6 57.0 (35.7-86.4)   Male 223 274.3 81.3 (71.0-92.7) 
Female 22 40.7 54.1 (33.9-81.9)   Female 235 281.8 83.4 (73.1-94.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
168 
Lowell 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 85 80.9 105.1 (83.9-129.9)   Male 37 56.9 65.1 (45.8-89.7) 
Female 41 31.4 130.7 (93.8-177.4)   Female 32 49.9 64.1 (43.8-90.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 13 18.6 70.0 (37.2-119.7)   Male 19 16.0 119.1 (71.7-185.9) 
Female 15 15.8 94.9 (53.1-156.6)   Female 16 13.4 119.2 (68.1-193.6) 
Breast            Non-Hodgkin Lymphoma     
Male 4 2.6 nc (nc-nc)   Male 57 50.6 112.6 (85.3-145.9) 
Female 318 355.8 89.4 (79.8-99.8)   Female 33 43.5 75.9 (52.3-106.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 52 41.0 126.9 (94.8-166.5) 
Female 20 13.8 144.7 (88.4-223.5)   Female 12 18.1 66.3 (34.2-115.9) 
Colon / Rectum            Ovary     
Male 101 93.7 107.8 (87.8-131.0)             
Female 97 97.8 99.1 (80.4-121.0)   Female 27 32.8 82.3 (54.2-119.8) 
Esophagus            Pancreas     
Male 20 22.5 89.0 (54.4-137.5)   Male 24 28.2 85.2 (54.6-126.8) 
Female 5 6.0 83.3 (26.8-194.4)   Female 20 30.6 65.3 (39.9-100.9) 
Hodgkin Lymphoma            Prostate     
Male 11 9.5 115.7 (57.7-207.0)   Male 227 302.9 74.9 (65.5-85.4) 
Female 5 7.8 64.2 (20.7-149.8)             
Kidney & Renal Pelvis            Stomach     
Male 47 48.2 97.6 (71.7-129.8)   Male 23 19.5 117.7 (74.6-176.6) 
Female 34 28.2 120.7 (83.6-168.7)   Female 20 12.3 162.4 (99.2-250.8) 
Larynx            Testis     
Male 19 12.5 151.4 (91.1-236.5)   Male 13 17.9 72.8 (38.7-124.5) 
Female 8 4.2 189.5 (81.6-373.4)             
Leukemia            Thyroid     
Male 28 35.8 78.3 (52.0-113.1)   Male 23 25.0 91.8 (58.2-137.8) 
Female 43 27.5 156.2 (113.0-210.4)   Female 76 77.0 98.7 (77.7-123.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 64 29.5 217.3 (167.3-277.4)             
Female 9 9.6 93.7 (42.8-178.0)   Female 86 79.3 108.5 (86.7-133.9) 
Lung and Bronchus            All Sites / Types     
Male 193 147.9 130.5 (112.7-150.2)   Male 1179 1146.8 102.8 (97.0-108.8) 
Female 186 161.9 114.9 (99.0-132.6)   Female 1213 1212.7 100.0 (94.5-105.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
169 
Ludlow 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 34 25.5 133.2 (92.2-186.1)   Male 16 16.5 97.2 (55.5-157.9) 
Female 5 9.5 52.6 (17.0-122.8)   Female 17 12.5 136.3 (79.4-218.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 4.7 150.5 (60.3-310.1)   Male 2 4.8 nc (nc-nc) 
Female 3 3.8 nc (nc-nc)   Female 3 4.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.8 nc (nc-nc)   Male 15 14.5 103.2 (57.7-170.3) 
Female 89 96.3 92.4 (74.2-113.8)   Female 9 12.3 73.3 (33.4-139.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 9 11.5 78.6 (35.9-149.2) 
Female 4 3.2 nc (nc-nc)   Female 2 5.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 36 28.0 128.7 (90.1-178.2)             
Female 27 28.8 93.7 (61.8-136.4)   Female 8 8.9 90.4 (38.9-178.1) 
Esophagus            Pancreas     
Male 4 6.8 nc (nc-nc)   Male 6 8.6 69.5 (25.4-151.4) 
Female 3 1.8 nc (nc-nc)   Female 10 9.3 107.4 (51.4-197.5) 
Hodgkin Lymphoma            Prostate     
Male 2 2.0 nc (nc-nc)   Male 84 89.7 93.7 (74.7-116.0) 
Female 1 1.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 16 13.6 117.6 (67.2-191.1)   Male 5 5.9 84.3 (27.2-196.8) 
Female 4 7.8 nc (nc-nc)   Female 2 3.6 nc (nc-nc) 
Larynx            Testis     
Male 1 3.7 nc (nc-nc)   Male 4 3.5 nc (nc-nc) 
Female 2 1.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 10.0 80.3 (34.6-158.2)   Male 3 6.3 nc (nc-nc) 
Female 6 7.3 82.3 (30.1-179.1)   Female 6 16.6 36.2 (13.2-78.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 9 8.5 106.4 (48.6-202.1)             
Female 3 2.8 nc (nc-nc)   Female 21 21.8 96.5 (59.7-147.5) 
Lung and Bronchus            All Sites / Types     
Male 28 46.1 60.8 (40.4-87.9)   Male 311 336.7 92.4 (82.4-103.2) 
Female 35 48.2 72.6 (50.5-100.9)   Female 283 333.6 84.8 (75.2-95.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
170 
Lunenburg 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 11.5 43.3 (14.0-101.1)   Male 5 7.7 65.0 (21.0-151.8) 
Female 4 3.8 nc (nc-nc)   Female 3 5.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.2 nc (nc-nc)   Male 5 2.3 220.2 (71.0-513.8) 
Female 3 1.8 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 4 6.7 nc (nc-nc) 
Female 50 45.3 110.4 (81.9-145.6)   Female 3 5.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 5.7 nc (nc-nc) 
Female 1 1.6 nc (nc-nc)   Female 0 2.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 15 13.0 115.2 (64.4-190.0)             
Female 14 11.6 121.2 (66.2-203.4)   Female 3 4.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 3.3 nc (nc-nc)   Male 3 4.0 nc (nc-nc) 
Female 2 0.7 nc (nc-nc)   Female 2 3.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.9 nc (nc-nc)   Male 48 44.6 107.6 (79.3-142.7) 
Female 2 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 6.6 nc (nc-nc)   Male 3 2.8 nc (nc-nc) 
Female 2 3.5 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Larynx            Testis     
Male 0 1.8 nc (nc-nc)   Male 2 1.4 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 4.6 nc (nc-nc)   Male 3 3.0 nc (nc-nc) 
Female 2 3.0 nc (nc-nc)   Female 3 8.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 4.2 nc (nc-nc)             
Female 2 1.2 nc (nc-nc)   Female 16 10.5 152.1 (86.9-247.0) 
Lung and Bronchus            All Sites / Types     
Male 24 21.4 112.0 (71.7-166.7)   Male 152 159.8 95.1 (80.6-111.5) 
Female 13 20.4 63.7 (33.9-109.0)   Female 134 148.1 90.5 (75.8-107.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Lynn 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 69 77.1 89.5 (69.6-113.2)   Male 42 52.1 80.6 (58.1-109.0) 
Female 24 29.6 81.0 (51.9-120.6)   Female 30 45.4 66.1 (44.6-94.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 15 16.4 91.3 (51.0-150.5)   Male 24 14.9 161.4 (103.4-240.2) 
Female 17 14.3 119.0 (69.3-190.5)   Female 9 12.7 71.0 (32.4-134.8) 
Breast            Non-Hodgkin Lymphoma     
Male 4 2.5 nc (nc-nc)   Male 54 46.3 116.6 (87.6-152.1) 
Female 323 331.3 97.5 (87.2-108.7)   Female 46 40.6 113.4 (83.0-151.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 55 36.9 149.2 (112.4-194.2) 
Female 15 12.4 120.8 (67.5-199.2)   Female 18 16.9 106.6 (63.1-168.4) 
Colon / Rectum            Ovary     
Male 111 87.3 127.2 (104.6-153.2)             
Female 113 91.4 123.6 (101.8-148.6)   Female 27 30.5 88.7 (58.4-129.0) 
Esophagus            Pancreas     
Male 27 20.8 129.9 (85.6-188.9)   Male 25 26.4 94.5 (61.2-139.6) 
Female 9 5.7 158.1 (72.1-300.1)   Female 25 28.9 86.6 (56.0-127.8) 
Hodgkin Lymphoma            Prostate     
Male 5 7.8 64.4 (20.7-150.2)   Male 314 277.3 113.2 (101.1-126.5) 
Female 3 6.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 35 43.6 80.3 (55.9-111.7)   Male 13 18.3 71.1 (37.8-121.5) 
Female 26 26.4 98.6 (64.4-144.5)   Female 20 11.5 174.3 (106.4-269.3) 
Larynx            Testis     
Male 17 11.5 147.2 (85.7-235.7)   Male 11 14.1 77.8 (38.8-139.2) 
Female 4 4.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 45 32.9 137.0 (99.9-183.3)   Male 12 21.6 55.6 (28.7-97.0) 
Female 28 25.2 111.1 (73.8-160.5)   Female 51 68.2 74.8 (55.7-98.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 56 26.9 208.5 (157.5-270.7)             
Female 11 9.0 121.6 (60.6-217.6)   Female 70 74.6 93.8 (73.1-118.6) 
Lung and Bronchus            All Sites / Types     
Male 205 139.3 147.2 (127.7-168.8)   Male 1229 1055.5 116.4 (110.0-123.1) 
Female 179 153.9 116.3 (99.9-134.6)   Female 1156 1128.2 102.5 (96.6-108.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
172 
Lynnfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 13 15.5 84.1 (44.7-143.8)   Male 23 9.6 239.6 (151.8-359.5) 
Female 9 5.4 166.9 (76.2-316.9)   Female 12 7.1 169.1 (87.3-295.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 2.6 nc (nc-nc)   Male 5 2.9 174.2 (56.1-406.6) 
Female 5 2.2 225.6 (72.7-526.4)   Female 4 2.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.5 nc (nc-nc)   Male 14 8.5 165.3 (90.3-277.4) 
Female 56 56.2 99.6 (75.3-129.4)   Female 12 7.0 170.8 (88.2-298.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 6.6 nc (nc-nc) 
Female 0 1.8 nc (nc-nc)   Female 2 2.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 18 16.6 108.3 (64.1-171.1)             
Female 22 16.3 134.7 (84.4-203.9)   Female 9 5.1 176.1 (80.4-334.4) 
Esophagus            Pancreas     
Male 2 4.0 nc (nc-nc)   Male 7 5.2 135.0 (54.1-278.1) 
Female 0 1.0 nc (nc-nc)   Female 6 5.3 113.7 (41.5-247.5) 
Hodgkin Lymphoma            Prostate     
Male 1 1.0 nc (nc-nc)   Male 57 53.0 107.6 (81.5-139.4) 
Female 2 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 12 7.9 151.7 (78.3-265.1)   Male 3 3.5 nc (nc-nc) 
Female 2 4.5 nc (nc-nc)   Female 2 2.1 nc (nc-nc) 
Larynx            Testis     
Male 3 2.2 nc (nc-nc)   Male 4 1.4 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 5.9 170.1 (81.4-312.8)   Male 3 3.4 nc (nc-nc) 
Female 6 4.2 144.2 (52.7-313.9)   Female 12 9.5 126.7 (65.4-221.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 5.0 nc (nc-nc)             
Female 2 1.6 nc (nc-nc)   Female 17 12.7 133.4 (77.7-213.6) 
Lung and Bronchus            All Sites / Types     
Male 22 27.8 79.1 (49.5-119.7)   Male 211 198.5 106.3 (92.5-121.7) 
Female 27 27.6 97.8 (64.4-142.2)   Female 224 191.9 116.7 (101.9-133.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Malden 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 40 51.6 77.5 (55.4-105.6)   Male 9 35.4 25.4 (11.6-48.3) 
Female 32 20.3 158.0 (108.0-223.0)   Female 20 31.7 63.0 (38.5-97.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 10.9 64.2 (25.7-132.3)   Male 5 10.0 49.9 (16.1-116.5) 
Female 9 9.6 93.6 (42.7-177.7)   Female 7 8.7 80.7 (32.3-166.4) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.6 nc (nc-nc)   Male 32 31.2 102.5 (70.1-144.7) 
Female 193 227.7 84.8 (73.2-97.6)   Female 20 27.9 71.8 (43.8-110.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 21 24.9 84.4 (52.2-129.1) 
Female 9 8.9 101.7 (46.4-193.0)   Female 8 11.6 69.1 (29.8-136.2) 
Colon / Rectum            Ovary     
Male 71 58.6 121.2 (94.6-152.9)             
Female 80 62.7 127.6 (101.2-158.8)   Female 19 20.9 90.9 (54.7-141.9) 
Esophagus            Pancreas     
Male 20 14.0 143.1 (87.4-221.0)   Male 22 17.7 124.2 (77.8-188.0) 
Female 10 3.9 256.7 (122.9-472.1)   Female 19 19.7 96.2 (57.9-150.3) 
Hodgkin Lymphoma            Prostate     
Male 5 5.4 93.3 (30.1-217.8)   Male 135 186.2 72.5 (60.8-85.8) 
Female 3 4.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 35 29.5 118.5 (82.5-164.8)   Male 16 12.3 130.3 (74.4-211.5) 
Female 18 18.0 99.8 (59.1-157.7)   Female 6 7.9 76.3 (27.9-166.1) 
Larynx            Testis     
Male 11 7.8 141.4 (70.5-253.0)   Male 9 10.2 88.2 (40.2-167.4) 
Female 6 2.7 219.6 (80.2-478.0)             
Leukemia            Thyroid     
Male 23 21.7 106.0 (67.2-159.0)   Male 17 15.0 113.7 (66.2-182.0) 
Female 17 17.0 99.9 (58.2-159.9)   Female 51 48.4 105.3 (78.4-138.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 24 18.0 133.1 (85.2-198.0)             
Female 8 6.2 129.6 (55.8-255.4)   Female 56 51.1 109.7 (82.8-142.4) 
Lung and Bronchus            All Sites / Types     
Male 122 93.8 130.1 (108.0-155.4)   Male 671 710.1 94.5 (87.5-101.9) 
Female 114 105.2 108.4 (89.4-130.2)   Female 778 775.6 100.3 (93.4-107.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Manchester by the Sea 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 7.5 67.0 (21.6-156.3)   Male 16 4.6 347.2 (198.3-563.9) 
Female 2 2.6 nc (nc-nc)   Female 7 3.4 203.8 (81.7-420.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 1.2 nc (nc-nc)   Male 2 1.4 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 3 1.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.2 nc (nc-nc)   Male 4 4.0 nc (nc-nc) 
Female 37 28.0 132.1 (93.0-182.0)   Female 2 3.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 3.2 nc (nc-nc) 
Female 2 0.9 nc (nc-nc)   Female 4 1.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 7.9 75.6 (27.6-164.5)             
Female 3 7.7 nc (nc-nc)   Female 2 2.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 2.0 nc (nc-nc)   Male 1 2.5 nc (nc-nc) 
Female 2 0.5 nc (nc-nc)   Female 2 2.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 35 26.7 131.0 (91.2-182.2) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 3.8 nc (nc-nc)   Male 0 1.7 nc (nc-nc) 
Female 1 2.2 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Larynx            Testis     
Male 1 1.1 nc (nc-nc)   Male 2 0.6 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 2.8 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 1 2.0 nc (nc-nc)   Female 9 4.5 199.0 (90.8-377.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.5 nc (nc-nc)             
Female 0 0.8 nc (nc-nc)   Female 5 6.6 76.0 (24.5-177.3) 
Lung and Bronchus            All Sites / Types     
Male 7 13.6 51.4 (20.6-105.8)   Male 100 96.7 103.4 (84.1-125.8) 
Female 9 14.0 64.4 (29.4-122.3)   Female 101 94.3 107.1 (87.3-130.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
175 
Mansfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 18 16.9 106.7 (63.2-168.6)   Male 22 12.5 175.6 (110.0-265.8) 
Female 1 6.0 nc (nc-nc)   Female 18 10.7 167.7 (99.4-265.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 4.2 120.0 (38.7-280.1)   Male 3 3.5 nc (nc-nc) 
Female 8 3.4 238.2 (102.6-469.5)   Female 1 2.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 3 0.6 nc (nc-nc)   Male 12 11.2 107.5 (55.5-187.8) 
Female 88 82.8 106.3 (85.3-131.0)   Female 3 9.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 11 9.7 113.4 (56.5-202.9) 
Female 1 3.3 nc (nc-nc)   Female 2 3.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 27 20.9 129.0 (85.0-187.7)             
Female 27 19.8 136.1 (89.7-198.1)   Female 9 7.2 124.5 (56.8-236.4) 
Esophagus            Pancreas     
Male 4 5.0 nc (nc-nc)   Male 3 6.1 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 8 5.8 136.9 (59.0-269.8) 
Hodgkin Lymphoma            Prostate     
Male 0 1.9 nc (nc-nc)   Male 60 67.6 88.8 (67.7-114.2) 
Female 3 1.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 13 11.1 117.2 (62.3-200.4)   Male 6 4.3 140.3 (51.2-305.4) 
Female 8 6.1 132.0 (56.8-260.0)   Female 2 2.4 nc (nc-nc) 
Larynx            Testis     
Male 0 2.8 nc (nc-nc)   Male 6 3.4 177.8 (64.9-386.9) 
Female 1 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 7.7 104.1 (44.8-205.1)   Male 15 5.8 258.7 (144.7-426.7) 
Female 8 5.5 144.4 (62.2-284.5)   Female 19 18.0 105.7 (63.6-165.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 6.8 nc (nc-nc)             
Female 3 2.0 nc (nc-nc)   Female 10 17.9 55.8 (26.7-102.6) 
Lung and Bronchus            All Sites / Types     
Male 30 31.3 95.8 (64.6-136.7)   Male 270 251.8 107.2 (94.8-120.8) 
Female 41 32.3 127.0 (91.1-172.3)   Female 285 261.5 109.0 (96.7-122.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
176 
Marblehead 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 20 25.5 78.6 (48.0-121.4)   Male 40 16.0 249.2 (178.0-339.4) 
Female 13 9.1 142.1 (75.6-243.0)   Female 24 12.6 190.8 (122.2-283.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 4.5 nc (nc-nc)   Male 7 4.8 145.4 (58.3-299.6) 
Female 6 3.9 152.8 (55.8-332.6)   Female 7 3.9 177.9 (71.3-366.6) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.8 nc (nc-nc)   Male 16 14.1 113.2 (64.7-183.8) 
Female 128 101.2 126.5 (105.5-150.4)   Female 15 12.2 122.5 (68.5-202.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 12 11.5 104.0 (53.7-181.6) 
Female 2 3.3 nc (nc-nc)   Female 5 5.2 96.8 (31.2-226.0) 
Colon / Rectum            Ovary     
Male 26 27.7 93.9 (61.3-137.6)             
Female 18 27.6 65.2 (38.6-103.0)   Female 10 9.2 109.1 (52.2-200.7) 
Esophagus            Pancreas     
Male 4 6.9 nc (nc-nc)   Male 13 8.7 149.4 (79.5-255.5) 
Female 1 1.8 nc (nc-nc)   Female 12 8.9 135.0 (69.7-235.8) 
Hodgkin Lymphoma            Prostate     
Male 0 1.6 nc (nc-nc)   Male 103 93.8 109.8 (89.6-133.2) 
Female 0 1.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 11 13.6 81.0 (40.4-144.9)   Male 6 5.9 101.4 (37.0-220.7) 
Female 7 8.0 87.6 (35.1-180.5)   Female 2 3.5 nc (nc-nc) 
Larynx            Testis     
Male 1 3.8 nc (nc-nc)   Male 2 2.2 nc (nc-nc) 
Female 0 1.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 15 9.8 153.8 (86.0-253.6)   Male 8 5.8 138.2 (59.5-272.4) 
Female 9 7.1 126.3 (57.6-239.8)   Female 17 17.3 98.4 (57.3-157.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 8.6 58.3 (18.8-136.0)             
Female 4 2.8 nc (nc-nc)   Female 16 23.6 67.8 (38.7-110.1) 
Lung and Bronchus            All Sites / Types     
Male 34 46.4 73.3 (50.8-102.5)   Male 357 337.2 105.9 (95.2-117.4) 
Female 43 48.1 89.4 (64.7-120.4)   Female 377 338.5 111.4 (100.4-123.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
177 
Marion 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 7.4 95.2 (38.1-196.2)   Male 5 4.4 112.6 (36.3-262.7) 
Female 4 2.8 nc (nc-nc)   Female 2 3.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 1.2 nc (nc-nc)   Male 2 1.3 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 8 3.9 205.1 (88.3-404.1) 
Female 33 26.7 123.6 (85.0-173.6)   Female 3 3.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 3.0 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 7.8 64.3 (20.7-150.1)             
Female 8 8.2 97.6 (42.0-192.3)   Female 2 2.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.9 nc (nc-nc)   Male 1 2.5 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 3 2.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 28 25.0 112.1 (74.5-162.1) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 3.6 nc (nc-nc)   Male 0 1.7 nc (nc-nc) 
Female 3 2.2 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Larynx            Testis     
Male 1 1.0 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 2.7 294.3 (126.7-579.8)   Male 3 1.5 nc (nc-nc) 
Female 2 2.1 nc (nc-nc)   Female 5 4.2 120.3 (38.8-280.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 2.3 nc (nc-nc)             
Female 0 0.8 nc (nc-nc)   Female 5 6.2 80.8 (26.1-188.7) 
Lung and Bronchus            All Sites / Types     
Male 4 13.1 nc (nc-nc)   Male 91 92.7 98.2 (79.0-120.5) 
Female 17 13.9 122.2 (71.2-195.7)   Female 98 93.6 104.7 (85.0-127.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
178 
Marlborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 34 35.6 95.6 (66.2-133.6)   Male 22 24.4 90.3 (56.6-136.8) 
Female 11 14.1 78.3 (39.0-140.0)   Female 16 20.7 77.2 (44.1-125.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 7.4 94.1 (37.7-194.0)   Male 8 6.9 115.3 (49.6-227.2) 
Female 5 6.4 78.7 (25.4-183.6)   Female 6 6.0 100.8 (36.8-219.5) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.1 nc (nc-nc)   Male 22 21.5 102.2 (64.0-154.7) 
Female 137 153.1 89.5 (75.1-105.8)   Female 17 18.9 90.0 (52.4-144.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 16 17.4 91.7 (52.4-149.0) 
Female 9 5.7 158.0 (72.1-300.0)   Female 15 7.8 191.9 (107.3-316.5) 
Colon / Rectum            Ovary     
Male 47 40.8 115.2 (84.7-153.2)             
Female 58 43.6 133.1 (101.1-172.1)   Female 16 14.0 114.4 (65.4-185.9) 
Esophagus            Pancreas     
Male 12 9.7 123.5 (63.8-215.8)   Male 9 12.3 73.3 (33.4-139.1) 
Female 3 2.7 nc (nc-nc)   Female 11 13.7 80.0 (39.9-143.2) 
Hodgkin Lymphoma            Prostate     
Male 6 3.5 173.1 (63.2-376.8)   Male 128 129.8 98.6 (82.3-117.3) 
Female 2 2.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 30 20.6 146.0 (98.5-208.4)   Male 9 8.5 105.6 (48.2-200.5) 
Female 9 12.2 74.1 (33.8-140.6)   Female 5 5.5 90.7 (29.2-211.7) 
Larynx            Testis     
Male 6 5.4 111.0 (40.5-241.7)   Male 5 6.4 78.4 (25.3-182.9) 
Female 2 1.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 19 14.9 127.7 (76.8-199.4)   Male 9 10.2 88.0 (40.1-167.0) 
Female 11 11.6 94.8 (47.2-169.6)   Female 40 30.6 130.8 (93.4-178.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 13 12.6 103.4 (55.0-176.8)             
Female 6 4.2 143.4 (52.4-312.1)   Female 37 33.9 109.1 (76.8-150.4) 
Lung and Bronchus            All Sites / Types     
Male 51 64.6 79.0 (58.8-103.9)   Male 493 491.0 100.4 (91.7-109.7) 
Female 67 71.3 93.9 (72.8-119.3)   Female 533 522.5 102.0 (93.5-111.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
179 
Marshfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 23 26.6 86.4 (54.8-129.7)   Male 39 18.0 217.0 (154.3-296.7) 
Female 12 9.3 129.4 (66.8-226.0)   Female 27 14.1 191.1 (125.9-278.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 5.3 132.0 (52.9-271.9)   Male 7 5.3 132.2 (53.0-272.3) 
Female 7 4.4 158.4 (63.5-326.5)   Female 2 4.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.9 nc (nc-nc)   Male 11 15.7 69.8 (34.8-125.0) 
Female 142 113.1 125.6 (105.8-148.0)   Female 11 13.0 84.5 (42.1-151.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 13.5 74.0 (35.4-136.1) 
Female 5 3.9 127.4 (41.1-297.3)   Female 5 5.6 89.7 (28.9-209.3) 
Colon / Rectum            Ovary     
Male 34 30.3 112.2 (77.7-156.8)             
Female 32 28.2 113.4 (77.5-160.1)   Female 12 10.1 118.6 (61.2-207.1) 
Esophagus            Pancreas     
Male 4 7.7 nc (nc-nc)   Male 13 9.4 138.7 (73.8-237.2) 
Female 2 1.8 nc (nc-nc)   Female 7 8.9 78.5 (31.4-161.7) 
Hodgkin Lymphoma            Prostate     
Male 4 2.1 nc (nc-nc)   Male 122 106.8 114.2 (94.9-136.4) 
Female 2 1.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 25 15.7 159.1 (103.0-234.9)   Male 4 6.4 nc (nc-nc) 
Female 6 8.7 68.9 (25.2-150.0)   Female 4 3.5 nc (nc-nc) 
Larynx            Testis     
Male 0 4.3 nc (nc-nc)   Male 3 3.3 nc (nc-nc) 
Female 2 1.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 10.7 83.8 (38.3-159.1)   Male 7 7.2 97.3 (39.0-200.4) 
Female 3 7.6 nc (nc-nc)   Female 26 21.0 123.9 (80.9-181.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 10 9.9 101.1 (48.4-185.9)             
Female 1 3.0 nc (nc-nc)   Female 27 26.4 102.4 (67.5-149.1) 
Lung and Bronchus            All Sites / Types     
Male 49 50.0 98.0 (72.5-129.6)   Male 403 376.1 107.2 (97.0-118.2) 
Female 69 50.9 135.6 (105.5-171.6)   Female 431 368.0 117.1 (106.3-128.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
180 
Mashpee 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 31 22.7 136.3 (92.6-193.4)   Male 22 13.4 164.4 (103.0-248.9) 
Female 9 8.3 108.7 (49.6-206.4)   Female 15 10.1 148.0 (82.8-244.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 3.4 nc (nc-nc)   Male 6 4.1 146.8 (53.6-319.6) 
Female 2 3.1 nc (nc-nc)   Female 2 3.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.7 nc (nc-nc)   Male 17 11.7 144.9 (84.4-232.1) 
Female 86 80.3 107.1 (85.7-132.3)   Female 14 10.5 133.4 (72.9-223.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 13 8.7 149.9 (79.8-256.4) 
Female 2 2.4 nc (nc-nc)   Female 5 4.3 117.3 (37.8-273.8) 
Colon / Rectum            Ovary     
Male 19 23.1 82.1 (49.4-128.3)             
Female 28 24.0 116.6 (77.5-168.5)   Female 9 7.4 121.7 (55.5-231.0) 
Esophagus            Pancreas     
Male 6 5.7 105.7 (38.6-230.2)   Male 8 7.4 108.0 (46.5-212.8) 
Female 0 1.6 nc (nc-nc)   Female 8 8.0 99.8 (43.0-196.6) 
Hodgkin Lymphoma            Prostate     
Male 1 1.2 nc (nc-nc)   Male 82 73.9 110.9 (88.2-137.7) 
Female 1 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 11 10.7 103.1 (51.4-184.5)   Male 5 5.0 99.5 (32.1-232.2) 
Female 8 6.7 118.7 (51.1-234.0)   Female 1 3.0 nc (nc-nc) 
Larynx            Testis     
Male 4 3.1 nc (nc-nc)   Male 4 1.7 nc (nc-nc) 
Female 4 1.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 8.1 85.9 (34.4-177.1)   Male 2 4.2 nc (nc-nc) 
Female 10 6.1 164.9 (78.9-303.2)   Female 11 12.5 88.3 (44.0-158.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 6.7 nc (nc-nc)             
Female 2 2.4 nc (nc-nc)   Female 14 18.7 74.7 (40.8-125.4) 
Lung and Bronchus            All Sites / Types     
Male 31 40.8 75.9 (51.6-107.8)   Male 297 278.3 106.7 (94.9-119.6) 
Female 59 43.6 135.3 (103.0-174.6)   Female 310 281.7 110.0 (98.1-123.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Mattapoisett 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 9.2 119.1 (59.4-213.2)   Male 6 5.7 105.9 (38.7-230.6) 
Female 3 3.0 nc (nc-nc)   Female 6 4.0 149.8 (54.7-326.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.5 nc (nc-nc)   Male 0 1.7 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 4 5.0 nc (nc-nc) 
Female 38 32.5 116.8 (82.6-160.3)   Female 5 4.0 124.6 (40.2-290.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 11 4.0 276.7 (137.9-495.1) 
Female 1 1.0 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 9.8 61.1 (22.3-133.1)             
Female 11 8.9 123.1 (61.4-220.4)   Female 5 3.0 168.8 (54.4-393.8) 
Esophagus            Pancreas     
Male 1 2.4 nc (nc-nc)   Male 2 3.1 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 3 2.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.5 nc (nc-nc)   Male 46 33.1 139.2 (101.9-185.6) 
Female 1 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 4.7 nc (nc-nc)   Male 4 2.1 nc (nc-nc) 
Female 0 2.6 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Larynx            Testis     
Male 0 1.3 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 3.4 nc (nc-nc)   Male 2 1.9 nc (nc-nc) 
Female 2 2.3 nc (nc-nc)   Female 5 5.3 94.4 (30.4-220.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 3.0 nc (nc-nc)             
Female 1 0.9 nc (nc-nc)   Female 11 7.7 143.2 (71.4-256.3) 
Lung and Bronchus            All Sites / Types     
Male 15 16.7 89.6 (50.1-147.9)   Male 128 119.3 107.3 (89.5-127.5) 
Female 12 16.3 73.7 (38.1-128.8)   Female 113 109.9 102.8 (84.8-123.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Maynard 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 10 9.9 101.2 (48.4-186.1)   Male 4 6.7 nc (nc-nc) 
Female 1 3.8 nc (nc-nc)   Female 7 5.8 121.2 (48.6-249.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.0 nc (nc-nc)   Male 0 2.0 nc (nc-nc) 
Female 1 1.8 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 7 5.9 118.1 (47.3-243.3) 
Female 46 44.4 103.7 (75.9-138.3)   Female 3 5.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 4.9 nc (nc-nc) 
Female 0 1.6 nc (nc-nc)   Female 1 2.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 20 11.3 176.3 (107.6-272.3)             
Female 18 11.7 154.0 (91.2-243.5)   Female 2 4.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 2.8 nc (nc-nc)   Male 3 3.4 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 4 3.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.8 nc (nc-nc)   Male 36 37.3 96.6 (67.6-133.7) 
Female 1 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 5.8 nc (nc-nc)   Male 2 2.4 nc (nc-nc) 
Female 5 3.4 144.9 (46.7-338.2)   Female 0 1.5 nc (nc-nc) 
Larynx            Testis     
Male 0 1.5 nc (nc-nc)   Male 2 1.5 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 4.1 nc (nc-nc)   Male 4 2.8 nc (nc-nc) 
Female 4 3.1 nc (nc-nc)   Female 10 8.7 114.9 (55.0-211.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 3.6 nc (nc-nc)             
Female 2 1.2 nc (nc-nc)   Female 8 10.0 79.7 (34.3-157.0) 
Lung and Bronchus            All Sites / Types     
Male 12 18.2 66.1 (34.1-115.5)   Male 132 137.4 96.1 (80.4-114.0) 
Female 20 19.9 100.3 (61.2-154.9)   Female 150 146.9 102.1 (86.4-119.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
183 
Medfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 9 11.6 77.5 (35.3-147.0)   Male 9 7.9 113.4 (51.8-215.4) 
Female 6 4.0 150.2 (54.8-326.9)   Female 9 6.2 144.9 (66.1-275.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.4 nc (nc-nc)   Male 5 2.3 215.0 (69.3-501.7) 
Female 4 2.0 nc (nc-nc)   Female 3 1.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 6 7.0 85.2 (31.1-185.5) 
Female 49 50.1 97.8 (72.3-129.3)   Female 3 5.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 6.0 116.1 (46.5-239.2) 
Female 0 1.8 nc (nc-nc)   Female 1 2.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 18 13.6 132.0 (78.2-208.7)             
Female 16 12.6 126.5 (72.3-205.5)   Female 5 4.4 112.5 (36.2-262.5) 
Esophagus            Pancreas     
Male 0 3.3 nc (nc-nc)   Male 3 4.1 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 1 3.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.9 nc (nc-nc)   Male 60 44.9 133.7 (102.0-172.1) 
Female 1 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 6.9 86.7 (31.7-188.7)   Male 1 2.8 nc (nc-nc) 
Female 3 3.8 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Larynx            Testis     
Male 1 1.9 nc (nc-nc)   Male 0 1.4 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 4.8 124.7 (45.5-271.5)   Male 2 3.2 nc (nc-nc) 
Female 7 3.4 207.0 (82.9-426.6)   Female 9 9.5 95.0 (43.4-180.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 4.4 nc (nc-nc)             
Female 1 1.3 nc (nc-nc)   Female 10 11.2 88.9 (42.6-163.6) 
Lung and Bronchus            All Sites / Types     
Male 12 21.5 55.9 (28.8-97.6)   Male 164 163.6 100.2 (85.5-116.8) 
Female 12 21.3 56.2 (29.0-98.2)   Female 150 161.1 93.1 (78.8-109.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
184 
Medford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 65 60.4 107.6 (83.0-137.1)   Male 29 38.4 75.6 (50.6-108.6) 
Female 22 24.3 90.7 (56.8-137.3)   Female 23 33.3 69.1 (43.8-103.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 14 11.0 127.8 (69.8-214.4)   Male 8 11.1 72.1 (31.0-142.0) 
Female 11 10.1 109.0 (54.3-195.0)   Female 12 10.1 118.8 (61.3-207.5) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.8 nc (nc-nc)   Male 29 34.0 85.3 (57.1-122.4) 
Female 235 240.1 97.9 (85.8-111.2)   Female 22 31.5 69.9 (43.8-105.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 36 25.5 141.0 (98.7-195.2) 
Female 9 8.5 105.3 (48.1-199.9)   Female 13 12.8 101.7 (54.1-174.0) 
Colon / Rectum            Ovary     
Male 75 65.2 115.1 (90.5-144.3)             
Female 81 73.7 109.8 (87.2-136.5)   Female 27 22.4 120.3 (79.2-175.0) 
Esophagus            Pancreas     
Male 12 15.2 78.8 (40.7-137.6)   Male 19 20.0 94.9 (57.1-148.2) 
Female 5 4.6 108.5 (35.0-253.3)   Female 11 23.8 46.2 (23.0-82.6) 
Hodgkin Lymphoma            Prostate     
Male 6 5.2 116.1 (42.4-252.6)   Male 157 196.2 80.0 (68.0-93.6) 
Female 4 4.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 31 30.6 101.3 (68.8-143.8)   Male 14 13.8 101.3 (55.3-170.0) 
Female 25 19.8 126.5 (81.8-186.7)   Female 10 9.4 106.6 (51.0-196.1) 
Larynx            Testis     
Male 13 8.4 155.6 (82.7-266.0)   Male 11 9.4 116.5 (58.1-208.5) 
Female 2 3.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 26 23.8 109.3 (71.4-160.1)   Male 9 14.5 62.1 (28.3-117.9) 
Female 25 19.1 130.9 (84.7-193.3)   Female 47 46.0 102.1 (75.0-135.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 17 19.0 89.4 (52.0-143.1)             
Female 8 7.0 114.1 (49.1-224.8)   Female 60 53.8 111.4 (85.0-143.4) 
Lung and Bronchus            All Sites / Types     
Male 110 106.3 103.5 (85.0-124.7)   Male 741 771.8 96.0 (89.2-103.2) 
Female 124 121.4 102.1 (84.9-121.8)   Female 852 850.3 100.2 (93.6-107.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
185 
Medway 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 15 10.9 137.2 (76.7-226.3)   Male 6 7.7 77.4 (28.3-168.6) 
Female 2 4.2 nc (nc-nc)   Female 4 6.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 2.4 nc (nc-nc)   Male 3 2.2 nc (nc-nc) 
Female 2 2.1 nc (nc-nc)   Female 2 1.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 13 6.9 188.8 (100.4-322.9) 
Female 47 51.6 91.1 (66.9-121.1)   Female 7 5.9 119.2 (47.7-245.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 5.9 nc (nc-nc) 
Female 1 1.9 nc (nc-nc)   Female 1 2.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 19 13.1 145.3 (87.5-227.0)             
Female 14 13.4 104.1 (56.9-174.7)   Female 7 4.6 153.2 (61.4-315.7) 
Esophagus            Pancreas     
Male 7 3.2 221.8 (88.9-457.1)   Male 2 3.9 nc (nc-nc) 
Female 2 0.8 nc (nc-nc)   Female 2 4.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 1.0 nc (nc-nc)   Male 44 42.8 102.9 (74.8-138.1) 
Female 0 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 6.8 nc (nc-nc)   Male 1 2.7 nc (nc-nc) 
Female 0 3.9 nc (nc-nc)   Female 0 1.7 nc (nc-nc) 
Larynx            Testis     
Male 1 1.8 nc (nc-nc)   Male 0 1.7 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 4.7 nc (nc-nc)   Male 2 3.3 nc (nc-nc) 
Female 3 3.6 nc (nc-nc)   Female 12 10.2 117.6 (60.7-205.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 4.2 nc (nc-nc)             
Female 0 1.3 nc (nc-nc)   Female 8 11.3 70.7 (30.4-139.2) 
Lung and Bronchus            All Sites / Types     
Male 19 20.3 93.7 (56.4-146.4)   Male 164 157.6 104.1 (88.7-121.3) 
Female 28 21.9 128.1 (85.1-185.2)   Female 152 167.6 90.7 (76.9-106.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
186 
Melrose 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 24 29.9 80.3 (51.5-119.5)   Male 23 19.3 119.0 (75.4-178.5) 
Female 17 12.3 138.6 (80.7-222.0)   Female 19 16.7 113.8 (68.5-177.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 10 5.5 180.6 (86.4-332.1)   Male 4 5.7 nc (nc-nc) 
Female 7 5.2 135.7 (54.4-279.6)   Female 2 5.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.9 nc (nc-nc)   Male 22 17.0 129.1 (80.9-195.5) 
Female 132 127.0 104.0 (87.0-123.3)   Female 16 16.1 99.5 (56.9-161.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 17 13.6 125.0 (72.8-200.1) 
Female 2 4.4 nc (nc-nc)   Female 5 6.6 75.5 (24.3-176.1) 
Colon / Rectum            Ovary     
Male 44 32.9 133.7 (97.1-179.5)             
Female 34 37.3 91.1 (63.1-127.3)   Female 13 11.6 111.7 (59.4-191.1) 
Esophagus            Pancreas     
Male 10 8.0 125.5 (60.1-230.8)   Male 11 10.2 108.3 (54.0-193.7) 
Female 1 2.3 nc (nc-nc)   Female 16 12.0 133.2 (76.1-216.4) 
Hodgkin Lymphoma            Prostate     
Male 0 2.3 nc (nc-nc)   Male 95 106.3 89.4 (72.3-109.3) 
Female 1 2.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 16 16.1 99.2 (56.6-161.1)   Male 6 7.0 86.1 (31.4-187.3) 
Female 9 10.3 87.7 (40.0-166.5)   Female 5 4.7 106.0 (34.2-247.3) 
Larynx            Testis     
Male 10 4.4 227.7 (109.0-418.8)   Male 2 3.8 nc (nc-nc) 
Female 2 1.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 20 11.8 169.6 (103.6-262.0)   Male 12 7.4 162.7 (84.0-284.3) 
Female 6 9.7 62.2 (22.7-135.3)   Female 27 23.1 117.0 (77.1-170.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 10.0 49.9 (16.1-116.5)             
Female 2 3.6 nc (nc-nc)   Female 32 28.8 111.3 (76.1-157.1) 
Lung and Bronchus            All Sites / Types     
Male 54 53.9 100.2 (75.3-130.7)   Male 418 396.3 105.5 (95.6-116.1) 
Female 50 62.2 80.4 (59.7-106.1)   Female 431 438.3 98.3 (89.3-108.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
187 
Mendon 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 5.4 nc (nc-nc)   Male 4 3.8 nc (nc-nc) 
Female 2 1.7 nc (nc-nc)   Female 2 2.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.2 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.2 nc (nc-nc)   Male 3 3.4 nc (nc-nc) 
Female 24 23.2 103.2 (66.1-153.6)   Female 7 2.5 277.5 (111.2-571.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 3.0 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 6.5 nc (nc-nc)             
Female 3 5.5 nc (nc-nc)   Female 1 2.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.6 nc (nc-nc)   Male 1 1.9 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 2 1.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.5 nc (nc-nc)   Male 27 22.1 122.2 (80.5-177.8) 
Female 1 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 3.4 nc (nc-nc)   Male 0 1.3 nc (nc-nc) 
Female 2 1.7 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Larynx            Testis     
Male 0 0.9 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 2.3 nc (nc-nc)   Male 0 1.6 nc (nc-nc) 
Female 2 1.5 nc (nc-nc)   Female 4 4.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.1 nc (nc-nc)             
Female 1 0.6 nc (nc-nc)   Female 5 5.2 96.4 (31.1-224.9) 
Lung and Bronchus            All Sites / Types     
Male 4 10.2 nc (nc-nc)   Male 60 79.1 75.9 (57.9-97.7) 
Female 7 9.5 73.8 (29.6-152.1)   Female 71 73.3 96.9 (75.6-122.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
188 
Merrimac 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 6.7 74.9 (24.2-174.9)   Male 5 4.5 111.4 (35.9-259.9) 
Female 2 2.4 nc (nc-nc)   Female 5 3.6 139.3 (44.9-325.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.3 nc (nc-nc)   Male 2 1.3 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.2 nc (nc-nc)   Male 1 3.9 nc (nc-nc) 
Female 24 28.8 83.3 (53.4-124.0)   Female 2 3.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 3.3 nc (nc-nc) 
Female 2 1.0 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 8 7.6 105.0 (45.2-207.0)             
Female 6 7.4 81.5 (29.8-177.3)   Female 5 2.6 195.8 (63.1-456.9) 
Esophagus            Pancreas     
Male 2 1.9 nc (nc-nc)   Male 2 2.3 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 2.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.5 nc (nc-nc)   Male 25 25.5 97.9 (63.3-144.5) 
Female 1 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 3.9 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 3 2.2 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Larynx            Testis     
Male 2 1.0 nc (nc-nc)   Male 3 0.8 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 2.7 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 1 1.9 nc (nc-nc)   Female 3 5.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 2.4 nc (nc-nc)             
Female 2 0.7 nc (nc-nc)   Female 4 6.5 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 14 12.4 113.0 (61.7-189.5)   Male 88 92.7 95.0 (76.2-117.0) 
Female 16 12.8 124.8 (71.3-202.7)   Female 86 93.6 91.9 (73.5-113.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
189 
Methuen 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 54 47.7 113.2 (85.0-147.7)   Male 25 31.1 80.4 (52.0-118.8) 
Female 25 18.9 132.1 (85.5-195.0)   Female 27 26.8 100.8 (66.4-146.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 8 9.2 87.0 (37.5-171.5)   Male 11 9.0 121.7 (60.7-217.7) 
Female 9 8.3 108.0 (49.3-205.0)   Female 5 8.0 62.5 (20.1-145.9) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.5 nc (nc-nc)   Male 27 27.6 97.8 (64.4-142.3) 
Female 197 201.1 98.0 (84.8-112.6)   Female 27 25.2 107.3 (70.7-156.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 18 21.9 82.1 (48.7-129.8) 
Female 8 7.2 111.8 (48.1-220.2)   Female 8 10.4 76.9 (33.1-151.5) 
Colon / Rectum            Ovary     
Male 56 53.1 105.4 (79.6-136.9)             
Female 52 58.4 89.1 (66.5-116.8)   Female 10 18.5 54.2 (25.9-99.6) 
Esophagus            Pancreas     
Male 12 12.6 95.1 (49.1-166.1)   Male 19 16.2 117.2 (70.5-183.0) 
Female 1 3.6 nc (nc-nc)   Female 17 18.6 91.5 (53.3-146.6) 
Hodgkin Lymphoma            Prostate     
Male 4 4.0 nc (nc-nc)   Male 186 166.9 111.4 (96.0-128.7) 
Female 3 3.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 27 25.8 104.8 (69.0-152.4)   Male 13 11.2 116.3 (61.9-198.9) 
Female 16 16.1 99.5 (56.9-161.7)   Female 7 7.4 94.9 (38.0-195.5) 
Larynx            Testis     
Male 8 7.0 114.9 (49.5-226.3)   Male 11 6.7 163.0 (81.3-291.7) 
Female 3 2.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 21 19.3 108.7 (67.3-166.2)   Male 14 12.1 115.8 (63.2-194.3) 
Female 16 15.3 104.4 (59.6-169.5)   Female 34 38.2 89.1 (61.7-124.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 15 16.1 93.1 (52.1-153.5)             
Female 4 5.6 nc (nc-nc)   Female 48 45.1 106.5 (78.5-141.2) 
Lung and Bronchus            All Sites / Types     
Male 98 85.2 115.0 (93.4-140.2)   Male 663 633.7 104.6 (96.8-112.9) 
Female 113 95.6 118.1 (97.4-142.0)   Female 699 690.2 101.3 (93.9-109.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
190 
Middleborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 34 25.7 132.2 (91.6-184.8)   Male 19 16.8 113.3 (68.2-177.0) 
Female 15 8.9 168.4 (94.2-277.8)   Female 14 13.0 107.3 (58.6-180.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 4.9 123.4 (45.1-268.7)   Male 5 4.9 101.5 (32.7-236.8) 
Female 4 4.1 nc (nc-nc)   Female 5 3.8 130.1 (41.9-303.5) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.8 nc (nc-nc)   Male 17 14.8 115.2 (67.1-184.4) 
Female 110 101.0 108.9 (89.5-131.3)   Female 9 12.2 74.1 (33.8-140.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 12.0 66.8 (28.8-131.7) 
Female 7 3.5 197.6 (79.2-407.1)   Female 9 5.1 176.8 (80.7-335.6) 
Colon / Rectum            Ovary     
Male 41 28.4 144.3 (103.5-195.8)             
Female 31 26.9 115.1 (78.2-163.3)   Female 14 9.2 153.0 (83.6-256.7) 
Esophagus            Pancreas     
Male 8 7.0 114.0 (49.1-224.5)   Male 12 8.8 135.9 (70.1-237.4) 
Female 2 1.7 nc (nc-nc)   Female 6 8.6 69.4 (25.3-151.0) 
Hodgkin Lymphoma            Prostate     
Male 2 2.0 nc (nc-nc)   Male 106 95.3 111.2 (91.1-134.5) 
Female 0 1.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 14 14.2 98.5 (53.8-165.2)   Male 6 6.0 99.4 (36.3-216.4) 
Female 1 8.0 nc (nc-nc)   Female 0 3.4 nc (nc-nc) 
Larynx            Testis     
Male 1 3.9 nc (nc-nc)   Male 6 3.2 185.3 (67.7-403.4) 
Female 3 1.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 15 10.2 147.0 (82.2-242.5)   Male 6 6.5 92.8 (33.9-202.0) 
Female 14 7.2 194.8 (106.4-326.8)   Female 20 18.9 105.9 (64.6-163.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 13 8.8 148.4 (79.0-253.8)             
Female 8 2.7 291.3 (125.4-574.1)   Female 30 23.3 128.7 (86.8-183.8) 
Lung and Bronchus            All Sites / Types     
Male 45 47.1 95.5 (69.7-127.8)   Male 391 347.2 112.6 (101.7-124.3) 
Female 67 47.4 141.3 (109.5-179.4)   Female 396 338.0 117.2 (105.9-129.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
191 
Middlefield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 0.7 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 1 2.4 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 0.8 nc (nc-nc)             
Female 1 0.6 nc (nc-nc)   Female 1 0.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.2 nc (nc-nc)   Male 1 0.2 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 1 3.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.4 nc (nc-nc)   Male 1 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.3 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 1.3 nc (nc-nc)   Male 9 10.0 89.9 (41.0-170.7) 
Female 2 1.0 nc (nc-nc)   Female 7 7.6 92.6 (37.1-190.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
192 
Middleton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 16 9.6 167.3 (95.5-271.6)   Male 8 6.5 122.3 (52.7-241.1) 
Female 6 3.2 189.7 (69.3-412.9)   Female 6 4.5 133.7 (48.8-291.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.0 nc (nc-nc)   Male 5 1.9 267.0 (86.0-623.0) 
Female 3 1.4 nc (nc-nc)   Female 2 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 10 5.8 172.6 (82.6-317.4) 
Female 36 35.9 100.4 (70.3-139.0)   Female 5 4.3 117.2 (37.8-273.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 4.7 107.1 (34.5-249.9) 
Female 2 1.2 nc (nc-nc)   Female 3 1.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 11 10.9 100.5 (50.1-179.9)             
Female 10 9.6 104.0 (49.8-191.3)   Female 0 3.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 2.6 nc (nc-nc)   Male 4 3.3 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 2 3.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 1.0 nc (nc-nc)   Male 45 34.6 130.0 (94.8-173.9) 
Female 2 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 5.5 nc (nc-nc)   Male 4 2.3 nc (nc-nc) 
Female 3 2.8 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Larynx            Testis     
Male 1 1.5 nc (nc-nc)   Male 4 1.7 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 3.9 127.2 (41.0-296.8)   Male 4 2.8 nc (nc-nc) 
Female 3 2.5 nc (nc-nc)   Female 3 6.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 3.3 nc (nc-nc)             
Female 1 1.0 nc (nc-nc)   Female 6 8.0 74.8 (27.3-162.8) 
Lung and Bronchus            All Sites / Types     
Male 16 17.4 91.8 (52.4-149.0)   Male 161 131.5 122.4 (104.2-142.9) 
Female 20 16.9 118.1 (72.1-182.4)   Female 120 119.1 100.8 (83.6-120.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Milford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 48 28.2 170.2 (125.5-225.7)   Male 10 18.7 53.3 (25.5-98.1) 
Female 13 10.1 128.4 (68.3-219.5)   Female 15 15.0 100.3 (56.1-165.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 5.6 nc (nc-nc)   Male 7 5.4 129.3 (51.8-266.5) 
Female 0 4.6 nc (nc-nc)   Female 7 4.3 161.9 (64.9-333.5) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.9 nc (nc-nc)   Male 18 16.6 108.2 (64.1-171.0) 
Female 87 112.3 77.5 (62.0-95.5)   Female 17 13.7 123.9 (72.1-198.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 13 13.3 97.5 (51.8-166.7) 
Female 2 4.1 nc (nc-nc)   Female 10 5.7 174.7 (83.6-321.4) 
Colon / Rectum            Ovary     
Male 25 31.8 78.7 (50.9-116.2)             
Female 29 31.4 92.4 (61.9-132.8)   Female 9 10.2 87.9 (40.1-166.8) 
Esophagus            Pancreas     
Male 10 7.6 132.0 (63.2-242.7)   Male 11 9.6 114.0 (56.8-204.0) 
Female 2 1.9 nc (nc-nc)   Female 6 9.9 60.5 (22.1-131.7) 
Hodgkin Lymphoma            Prostate     
Male 7 2.5 280.4 (112.3-577.7)   Male 107 101.2 105.8 (86.7-127.8) 
Female 1 1.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 17 15.7 108.2 (63.0-173.3)   Male 13 6.7 194.7 (103.6-333.0) 
Female 11 8.9 124.0 (61.8-221.9)   Female 1 3.9 nc (nc-nc) 
Larynx            Testis     
Male 3 4.2 nc (nc-nc)   Male 3 4.4 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 12 11.6 103.9 (53.6-181.4)   Male 4 7.5 nc (nc-nc) 
Female 11 8.4 131.3 (65.5-235.0)   Female 19 22.0 86.5 (52.0-135.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 9.7 nc (nc-nc)             
Female 2 3.1 nc (nc-nc)   Female 25 25.3 99.0 (64.0-146.1) 
Lung and Bronchus            All Sites / Types     
Male 49 50.6 96.8 (71.6-128.0)   Male 390 381.3 102.3 (92.4-112.9) 
Female 60 51.9 115.6 (88.2-148.8)   Female 358 380.4 94.1 (84.6-104.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Millbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 14 15.2 92.0 (50.2-154.3)   Male 4 9.9 nc (nc-nc) 
Female 8 5.7 141.0 (60.7-277.8)   Female 4 7.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 2.8 nc (nc-nc)   Male 3 2.9 nc (nc-nc) 
Female 1 2.4 nc (nc-nc)   Female 5 2.4 207.8 (67.0-484.9) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 14 8.7 160.9 (87.9-270.0) 
Female 56 60.4 92.7 (70.0-120.4)   Female 5 7.5 66.4 (21.4-154.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 6.9 115.3 (49.6-227.1) 
Female 5 2.1 238.5 (76.9-556.5)   Female 2 3.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 10 16.7 59.8 (28.6-109.9)             
Female 14 17.2 81.2 (44.4-136.3)   Female 7 5.5 127.0 (50.9-261.8) 
Esophagus            Pancreas     
Male 7 4.1 172.0 (68.9-354.4)   Male 6 5.2 116.2 (42.4-253.0) 
Female 2 1.1 nc (nc-nc)   Female 10 5.5 180.7 (86.5-332.3) 
Hodgkin Lymphoma            Prostate     
Male 1 1.2 nc (nc-nc)   Male 60 54.2 110.7 (84.5-142.5) 
Female 1 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 14 8.3 169.4 (92.5-284.3)   Male 3 3.6 nc (nc-nc) 
Female 8 4.9 164.8 (70.9-324.7)   Female 1 2.2 nc (nc-nc) 
Larynx            Testis     
Male 3 2.3 nc (nc-nc)   Male 4 1.9 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 6.0 83.9 (27.0-195.8)   Male 4 3.8 nc (nc-nc) 
Female 7 4.5 156.0 (62.5-321.5)   Female 10 11.1 90.3 (43.2-166.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 5.1 97.8 (31.5-228.2)             
Female 2 1.7 nc (nc-nc)   Female 12 13.7 87.6 (45.2-153.0) 
Lung and Bronchus            All Sites / Types     
Male 44 27.7 159.0 (115.5-213.4)   Male 228 202.1 112.8 (98.6-128.4) 
Female 32 29.4 108.9 (74.5-153.7)   Female 208 206.6 100.7 (87.5-115.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Millis 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 7.9 152.9 (78.9-267.0)   Male 7 5.4 129.2 (51.8-266.3) 
Female 4 2.7 nc (nc-nc)   Female 5 4.3 116.8 (37.6-272.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 1.6 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 0 1.3 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 5 4.8 104.9 (33.8-244.8) 
Female 36 33.9 106.1 (74.3-146.9)   Female 2 3.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 4.1 146.1 (53.3-317.9) 
Female 1 1.2 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 10 9.1 110.0 (52.7-202.3)             
Female 13 8.3 156.3 (83.1-267.2)   Female 1 3.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 2.3 nc (nc-nc)   Male 4 2.8 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 3 2.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.7 nc (nc-nc)   Male 39 31.3 124.5 (88.5-170.1) 
Female 2 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 4.7 147.5 (59.1-304.0)   Male 1 1.9 nc (nc-nc) 
Female 1 2.6 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Larynx            Testis     
Male 0 1.3 nc (nc-nc)   Male 2 1.1 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 3.2 nc (nc-nc)   Male 4 2.2 nc (nc-nc) 
Female 3 2.3 nc (nc-nc)   Female 13 6.6 197.2 (104.9-337.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 3.0 nc (nc-nc)             
Female 0 0.9 nc (nc-nc)   Female 5 7.8 64.2 (20.7-149.9) 
Lung and Bronchus            All Sites / Types     
Male 14 14.7 95.4 (52.1-160.1)   Male 133 112.0 118.7 (99.4-140.7) 
Female 13 14.8 88.1 (46.8-150.6)   Female 114 109.4 104.2 (85.9-125.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Millville 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 2.2 nc (nc-nc)   Male 1 1.7 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 1 1.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.6 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 7 11.2 62.5 (25.0-128.8)   Female 2 1.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 1.3 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 2.7 nc (nc-nc)             
Female 1 2.7 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.7 nc (nc-nc)   Male 2 0.8 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.3 nc (nc-nc)   Male 10 9.0 110.8 (53.1-203.8) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.5 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.4 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.0 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 1 2.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.9 nc (nc-nc)             
Female 1 0.3 nc (nc-nc)   Female 1 2.4 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 4.1 nc (nc-nc)   Male 32 33.2 96.3 (65.8-135.9) 
Female 8 4.6 175.3 (75.5-345.4)   Female 28 35.9 77.9 (51.8-112.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Milton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 20 30.2 66.3 (40.5-102.4)   Male 34 19.0 179.4 (124.2-250.7) 
Female 4 12.3 nc (nc-nc)   Female 23 16.1 142.5 (90.3-213.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 5.5 91.6 (29.5-213.7)   Male 8 5.6 142.0 (61.1-279.8) 
Female 6 5.1 117.6 (43.0-256.0)   Female 8 5.1 155.7 (67.1-306.9) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.9 nc (nc-nc)   Male 12 16.9 71.0 (36.7-124.1) 
Female 112 124.4 90.0 (74.1-108.3)   Female 12 15.9 75.5 (39.0-131.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 13.3 75.4 (36.1-138.6) 
Female 6 4.1 146.5 (53.5-318.8)   Female 5 6.6 76.2 (24.6-177.8) 
Colon / Rectum            Ovary     
Male 24 32.9 73.0 (46.8-108.7)             
Female 44 37.4 117.7 (85.5-158.1)   Female 14 11.5 121.9 (66.6-204.6) 
Esophagus            Pancreas     
Male 4 7.8 nc (nc-nc)   Male 7 10.1 69.1 (27.7-142.3) 
Female 4 2.3 nc (nc-nc)   Female 13 12.0 108.2 (57.5-185.0) 
Hodgkin Lymphoma            Prostate     
Male 0 2.2 nc (nc-nc)   Male 122 103.2 118.2 (98.1-141.1) 
Female 3 2.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 14 15.6 90.0 (49.2-151.0)   Male 1 7.0 nc (nc-nc) 
Female 12 10.1 118.8 (61.3-207.5)   Female 4 4.7 nc (nc-nc) 
Larynx            Testis     
Male 1 4.3 nc (nc-nc)   Male 5 3.4 149.0 (48.0-347.7) 
Female 0 1.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 11 11.9 92.4 (46.1-165.4)   Male 7 6.9 101.2 (40.6-208.6) 
Female 11 9.6 114.4 (57.0-204.6)   Female 35 21.6 161.8 (112.7-225.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 10.0 50.2 (16.2-117.2)             
Female 2 3.6 nc (nc-nc)   Female 31 28.2 110.1 (74.8-156.2) 
Lung and Bronchus            All Sites / Types     
Male 32 53.5 59.8 (40.9-84.5)   Male 351 390.9 89.8 (80.7-99.7) 
Female 45 61.6 73.1 (53.3-97.8)   Female 416 431.5 96.4 (87.4-106.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Monroe 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.0 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 0.1 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.0 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 2 0.5 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.1 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.0 nc (nc-nc) 
Larynx            Testis     
Male 0 0.0 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.0 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.0 nc (nc-nc)             
Female 0 0.0 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 0.2 nc (nc-nc)   Male 3 1.7 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 2.1 nc (nc-nc) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
199 
Monson 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 8.9 78.3 (31.4-161.3)   Male 8 6.1 130.3 (56.1-256.8) 
Female 2 3.1 nc (nc-nc)   Female 1 4.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 1.8 nc (nc-nc)   Male 0 1.8 nc (nc-nc) 
Female 3 1.5 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 4 5.4 nc (nc-nc) 
Female 45 37.8 118.9 (86.7-159.1)   Female 4 4.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 4.7 nc (nc-nc) 
Female 2 1.3 nc (nc-nc)   Female 2 1.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 10 10.4 96.0 (46.0-176.6)             
Female 7 9.6 72.9 (29.2-150.1)   Female 2 3.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 2.6 nc (nc-nc)   Male 5 3.2 157.6 (50.8-367.8) 
Female 0 0.6 nc (nc-nc)   Female 2 3.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.7 nc (nc-nc)   Male 31 36.4 85.2 (57.9-121.0) 
Female 1 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 5.4 148.4 (63.9-292.4)   Male 3 2.2 nc (nc-nc) 
Female 1 2.9 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Larynx            Testis     
Male 0 1.5 nc (nc-nc)   Male 2 1.2 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 3.6 137.9 (44.5-321.9)   Male 1 2.5 nc (nc-nc) 
Female 2 2.5 nc (nc-nc)   Female 2 7.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 3.4 146.4 (47.2-341.6)             
Female 0 1.0 nc (nc-nc)   Female 8 8.7 91.8 (39.5-180.9) 
Lung and Bronchus            All Sites / Types     
Male 17 16.7 101.6 (59.2-162.7)   Male 122 128.1 95.3 (79.1-113.7) 
Female 11 16.6 66.1 (33.0-118.3)   Female 105 123.1 85.3 (69.7-103.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
200 
Montague 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 10.1 79.0 (34.0-155.7)   Male 7 6.5 107.2 (43.0-220.9) 
Female 7 3.9 180.9 (72.5-372.8)   Female 2 5.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 1.8 nc (nc-nc)   Male 1 1.9 nc (nc-nc) 
Female 2 1.6 nc (nc-nc)   Female 0 1.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 4 5.7 nc (nc-nc) 
Female 41 39.7 103.3 (74.1-140.2)   Female 3 5.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 4.6 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)   Female 3 2.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 9 11.1 81.0 (36.9-153.7)             
Female 15 11.7 128.2 (71.7-211.4)   Female 5 3.7 136.4 (43.9-318.3) 
Esophagus            Pancreas     
Male 3 2.7 nc (nc-nc)   Male 2 3.4 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 2 3.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.8 nc (nc-nc)   Male 30 36.1 83.0 (56.0-118.5) 
Female 0 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 5.4 110.7 (40.4-241.0)   Male 4 2.4 nc (nc-nc) 
Female 2 3.2 nc (nc-nc)   Female 0 1.5 nc (nc-nc) 
Larynx            Testis     
Male 3 1.5 nc (nc-nc)   Male 2 1.2 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 4.0 nc (nc-nc)   Male 1 2.5 nc (nc-nc) 
Female 2 3.0 nc (nc-nc)   Female 3 7.0 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 3.5 nc (nc-nc)             
Female 0 1.1 nc (nc-nc)   Female 11 9.1 120.6 (60.1-215.8) 
Lung and Bronchus            All Sites / Types     
Male 16 18.3 87.2 (49.8-141.7)   Male 110 134.3 81.9 (67.3-98.7) 
Female 15 19.7 76.0 (42.5-125.4)   Female 121 137.4 88.1 (73.1-105.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
201 
Monterey 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.8 nc (nc-nc)   Male 3 1.1 nc (nc-nc) 
Female 2 0.5 nc (nc-nc)   Female 2 0.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 2 5.6 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.7 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 1.8 nc (nc-nc)             
Female 1 1.5 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.5 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 3 6.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.9 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.6 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.6 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 3.2 nc (nc-nc)   Male 10 22.5 44.4 (21.2-81.6) 
Female 1 2.9 nc (nc-nc)   Female 10 18.8 53.1 (25.4-97.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
202 
Montgomery 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 1.0 nc (nc-nc)   Male 2 0.7 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 3 3.8 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 1.2 nc (nc-nc)             
Female 1 0.9 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 8 4.2 188.6 (81.2-371.7) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 0.6 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 1 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.4 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.4 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 1.9 nc (nc-nc)   Male 18 14.7 122.1 (72.3-193.0) 
Female 2 1.6 nc (nc-nc)   Female 8 12.1 65.9 (28.4-129.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
203 
Mount Washington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 0.3 nc (nc-nc)   Male 1 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.0 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 0.3 nc (nc-nc)             
Female 2 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.0 nc (nc-nc) 
Larynx            Testis     
Male 0 0.0 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.1 nc (nc-nc)             
Female 0 0.0 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 0.5 nc (nc-nc)   Male 3 3.9 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 3 3.5 nc (nc-nc) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
204 
Nahant 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 5.7 87.0 (28.0-203.1)   Male 12 3.5 345.7 (178.4-603.9) 
Female 3 1.9 nc (nc-nc)   Female 2 2.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.9 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 2 0.7 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 4 3.1 nc (nc-nc) 
Female 18 19.7 91.2 (54.0-144.1)   Female 1 2.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 2.4 nc (nc-nc) 
Female 2 0.6 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 6.1 nc (nc-nc)             
Female 7 5.8 119.8 (48.0-246.9)   Female 2 1.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.5 nc (nc-nc)   Male 2 1.9 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 2 1.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.3 nc (nc-nc)   Male 20 20.2 99.0 (60.4-152.9) 
Female 2 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 2.9 nc (nc-nc)   Male 0 1.3 nc (nc-nc) 
Female 1 1.6 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Larynx            Testis     
Male 2 0.8 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 2.1 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 2 1.4 nc (nc-nc)   Female 3 3.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 1.8 nc (nc-nc)             
Female 1 0.6 nc (nc-nc)   Female 4 4.6 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 7 10.3 68.0 (27.2-140.1)   Male 71 73.2 97.0 (75.8-122.4) 
Female 5 9.7 51.4 (16.6-119.8)   Female 62 67.6 91.7 (70.3-117.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
205 
Nantucket 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 10.1 69.5 (27.8-143.1)   Male 26 7.0 372.7 (243.4-546.1) 
Female 3 3.4 nc (nc-nc)   Female 18 5.3 341.9 (202.5-540.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.1 nc (nc-nc)   Male 4 2.0 nc (nc-nc) 
Female 1 1.6 nc (nc-nc)   Female 0 1.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 3 6.1 nc (nc-nc) 
Female 55 39.5 139.3 (104.9-181.3)   Female 5 4.7 107.1 (34.5-249.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 5.0 158.7 (68.3-312.6) 
Female 0 1.5 nc (nc-nc)   Female 4 2.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 13 11.5 112.8 (60.0-192.8)             
Female 11 10.4 105.8 (52.7-189.2)   Female 3 3.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 2.8 nc (nc-nc)   Male 5 3.5 142.2 (45.8-331.9) 
Female 4 0.6 nc (nc-nc)   Female 4 3.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 3 1.0 nc (nc-nc)   Male 47 38.4 122.4 (90.0-162.8) 
Female 0 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 6.0 nc (nc-nc)   Male 1 2.4 nc (nc-nc) 
Female 0 3.1 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Larynx            Testis     
Male 1 1.6 nc (nc-nc)   Male 1 1.8 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 4.2 191.5 (82.5-377.4)   Male 5 2.9 169.6 (54.7-395.9) 
Female 2 2.8 nc (nc-nc)   Female 9 8.0 112.1 (51.1-212.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 3.6 nc (nc-nc)             
Female 0 1.0 nc (nc-nc)   Female 11 9.0 122.9 (61.2-219.8) 
Lung and Bronchus            All Sites / Types     
Male 15 18.6 80.6 (45.1-133.0)   Male 173 141.4 122.3 (104.8-142.0) 
Female 12 17.7 67.7 (34.9-118.2)   Female 154 131.5 117.2 (99.4-137.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
206 
Natick 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 39 35.1 111.2 (79.1-152.0)   Male 21 22.9 91.6 (56.7-140.0) 
Female 11 13.2 83.6 (41.7-149.6)   Female 21 19.1 109.9 (68.0-168.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 13 6.7 193.7 (103.0-331.3)   Male 7 6.7 104.7 (42.0-215.8) 
Female 10 5.9 170.2 (81.5-313.1)   Female 6 5.6 106.9 (39.0-232.7) 
Breast            Non-Hodgkin Lymphoma     
Male 3 1.1 nc (nc-nc)   Male 17 20.3 83.9 (48.8-134.3) 
Female 159 146.1 108.8 (92.6-127.1)   Female 15 17.7 84.6 (47.3-139.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 16 16.2 98.8 (56.4-160.5) 
Female 1 5.2 nc (nc-nc)   Female 10 7.4 135.2 (64.7-248.7) 
Colon / Rectum            Ovary     
Male 47 39.1 120.2 (88.3-159.9)             
Female 31 40.4 76.8 (52.2-109.0)   Female 21 13.2 158.7 (98.2-242.6) 
Esophagus            Pancreas     
Male 11 9.3 118.0 (58.8-211.1)   Male 13 11.9 109.0 (58.0-186.4) 
Female 3 2.5 nc (nc-nc)   Female 7 12.8 54.6 (21.9-112.5) 
Hodgkin Lymphoma            Prostate     
Male 1 2.7 nc (nc-nc)   Male 121 123.2 98.2 (81.5-117.3) 
Female 3 2.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 16 19.1 83.7 (47.8-135.9)   Male 10 8.2 121.5 (58.2-223.4) 
Female 9 11.6 77.8 (35.5-147.8)   Female 2 5.1 nc (nc-nc) 
Larynx            Testis     
Male 4 5.2 nc (nc-nc)   Male 3 4.6 nc (nc-nc) 
Female 5 1.8 282.4 (91.0-658.9)             
Leukemia            Thyroid     
Male 12 14.1 85.1 (43.9-148.6)   Male 15 8.9 169.1 (94.6-278.9) 
Female 9 10.7 84.3 (38.5-160.1)   Female 24 27.8 86.4 (55.4-128.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 11.9 nc (nc-nc)             
Female 3 4.0 nc (nc-nc)   Female 29 32.9 88.2 (59.1-126.7) 
Lung and Bronchus            All Sites / Types     
Male 52 63.0 82.5 (61.6-108.2)   Male 477 466.5 102.2 (93.3-111.9) 
Female 73 68.4 106.7 (83.6-134.1)   Female 492 492.5 99.9 (91.3-109.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
207 
Needham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 40 35.5 112.6 (80.4-153.3)   Male 34 22.0 154.6 (107.1-216.1) 
Female 10 13.4 74.7 (35.8-137.4)   Female 18 17.3 104.2 (61.7-164.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 8 6.2 128.7 (55.4-253.7)   Male 8 6.5 122.2 (52.6-240.8) 
Female 9 5.5 163.9 (74.8-311.2)   Female 5 5.6 89.5 (28.9-209.0) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.1 nc (nc-nc)   Male 26 19.6 132.7 (86.7-194.5) 
Female 153 134.8 113.5 (96.2-133.0)   Female 16 17.2 93.0 (53.1-151.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 13 15.2 85.4 (45.4-146.1) 
Female 2 4.4 nc (nc-nc)   Female 6 7.1 84.8 (31.0-184.6) 
Colon / Rectum            Ovary     
Male 29 38.5 75.2 (50.4-108.1)             
Female 33 41.1 80.2 (55.2-112.7)   Female 12 12.4 97.1 (50.1-169.6) 
Esophagus            Pancreas     
Male 7 9.1 77.2 (30.9-159.1)   Male 11 11.8 92.8 (46.3-166.1) 
Female 4 2.5 nc (nc-nc)   Female 17 13.2 128.5 (74.8-205.7) 
Hodgkin Lymphoma            Prostate     
Male 4 2.3 nc (nc-nc)   Male 156 117.6 132.7 (112.7-155.2) 
Female 1 1.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 14 17.9 78.0 (42.6-130.9)   Male 7 8.1 85.9 (34.4-177.1) 
Female 10 10.9 91.7 (43.9-168.6)   Female 2 5.2 nc (nc-nc) 
Larynx            Testis     
Male 5 5.0 100.9 (32.5-235.4)   Male 4 3.4 nc (nc-nc) 
Female 0 1.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 13.8 50.6 (20.3-104.3)   Male 9 7.8 115.5 (52.7-219.3) 
Female 15 10.5 142.4 (79.6-234.8)   Female 39 22.8 171.0 (121.6-233.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 11.4 44.0 (14.2-102.6)             
Female 1 3.9 nc (nc-nc)   Female 29 30.2 96.1 (64.3-138.0) 
Lung and Bronchus            All Sites / Types     
Male 41 62.4 65.7 (47.2-89.2)   Male 455 451.5 100.8 (91.7-110.5) 
Female 40 65.9 60.7 (43.3-82.6)   Female 465 466.7 99.6 (90.8-109.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
208 
New Ashford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 2 1.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.2 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 0.3 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.1 nc (nc-nc)   Male 1 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 0 1.3 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.0 nc (nc-nc) 
Larynx            Testis     
Male 0 0.1 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.1 nc (nc-nc)             
Female 0 0.0 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 0.6 nc (nc-nc)   Male 2 4.3 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 5 3.6 139.8 (45.1-326.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
209 
New Bedford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 110 96.8 113.6 (93.4-136.9)   Male 33 61.9 53.3 (36.7-74.9) 
Female 38 39.7 95.6 (67.7-131.3)   Female 23 53.8 42.8 (27.1-64.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 16 18.3 87.5 (50.0-142.1)   Male 20 18.0 111.2 (67.9-171.7) 
Female 21 16.9 124.5 (77.0-190.3)   Female 14 16.5 84.6 (46.2-142.0) 
Breast            Non-Hodgkin Lymphoma     
Male 4 3.0 nc (nc-nc)   Male 51 55.0 92.7 (69.0-121.9) 
Female 339 392.8 86.3 (77.4-96.0)   Female 36 51.4 70.0 (49.0-96.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 59 42.2 139.9 (106.5-180.5) 
Female 24 13.7 174.8 (111.9-260.0)   Female 30 20.9 143.4 (96.7-204.7) 
Colon / Rectum            Ovary     
Male 119 105.3 113.0 (93.6-135.2)             
Female 107 120.9 88.5 (72.5-106.9)   Female 37 36.7 100.8 (71.0-139.0) 
Esophagus            Pancreas     
Male 34 24.9 136.3 (94.4-190.5)   Male 36 32.4 111.1 (77.8-153.8) 
Female 9 7.5 119.7 (54.6-227.3)   Female 63 39.1 161.1 (123.8-206.2) 
Hodgkin Lymphoma            Prostate     
Male 9 8.2 110.3 (50.3-209.5)   Male 379 326.2 116.2 (104.8-128.5) 
Female 4 7.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 71 50.4 140.9 (110.1-177.8)   Male 37 22.3 165.8 (116.7-228.5) 
Female 46 32.4 142.0 (104.0-189.5)   Female 27 15.4 175.1 (115.4-254.8) 
Larynx            Testis     
Male 21 13.7 153.1 (94.8-234.1)   Male 8 14.3 56.0 (24.1-110.3) 
Female 14 4.8 288.9 (157.8-484.7)             
Leukemia            Thyroid     
Male 37 39.0 95.0 (66.9-130.9)   Male 20 23.5 85.1 (51.9-131.4) 
Female 23 31.8 72.3 (45.8-108.5)   Female 74 73.5 100.6 (79.0-126.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 69 31.3 220.3 (171.4-278.9)             
Female 11 11.5 95.7 (47.7-171.2)   Female 93 88.3 105.4 (85.0-129.1) 
Lung and Bronchus            All Sites / Types     
Male 244 171.9 141.9 (124.7-160.9)   Male 1477 1258.4 117.4 (111.5-123.5) 
Female 199 197.6 100.7 (87.2-115.7)   Female 1365 1389.3 98.2 (93.1-103.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
210 
New Braintree 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 0.9 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 2 4.2 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.5 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 1.1 nc (nc-nc)             
Female 3 1.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 2 4.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.6 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 1 0.2 nc (nc-nc)   Male 1 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.4 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.4 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 3 1.0 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 1.7 nc (nc-nc)   Male 11 14.0 78.7 (39.3-140.9) 
Female 0 1.8 nc (nc-nc)   Female 12 13.7 87.6 (45.2-153.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
211 
New Marlborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 2.4 nc (nc-nc)   Male 3 1.5 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 3 1.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.4 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.3 nc (nc-nc) 
Female 10 7.7 129.4 (62.0-238.0)   Female 1 1.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.1 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 2 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 2.6 nc (nc-nc)             
Female 1 2.1 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.7 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 5 9.3 54.0 (17.4-126.1) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.3 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 1 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.9 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.8 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 3 1.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 4.5 nc (nc-nc)   Male 18 32.1 56.1 (33.2-88.7) 
Female 2 3.8 nc (nc-nc)   Female 23 26.1 88.1 (55.8-132.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
212 
New Salem 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 1.2 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 3 4.5 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.6 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 1 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 1.4 nc (nc-nc)             
Female 0 1.0 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.4 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 4 5.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.7 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.5 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.5 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 4 1.1 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 2.2 nc (nc-nc)   Male 11 17.1 64.5 (32.1-115.3) 
Female 0 1.8 nc (nc-nc)   Female 10 13.8 72.3 (34.6-133.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
213 
Newbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 7.9 76.2 (27.8-165.9)   Male 16 5.3 301.0 (171.9-488.8) 
Female 3 2.6 nc (nc-nc)   Female 3 4.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.5 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 3 1.2 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 5 4.6 107.6 (34.7-251.2) 
Female 44 32.1 137.2 (99.7-184.2)   Female 4 3.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 4.1 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 11 9.0 122.5 (61.0-219.1)             
Female 10 8.0 124.4 (59.6-228.8)   Female 4 2.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 2.3 nc (nc-nc)   Male 2 2.8 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 2.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.6 nc (nc-nc)   Male 40 32.5 123.0 (87.8-167.5) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 4.7 nc (nc-nc)   Male 1 1.9 nc (nc-nc) 
Female 2 2.4 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Larynx            Testis     
Male 2 1.3 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 3.1 nc (nc-nc)   Male 3 2.1 nc (nc-nc) 
Female 2 2.1 nc (nc-nc)   Female 7 5.8 121.1 (48.5-249.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 3.0 nc (nc-nc)             
Female 1 0.8 nc (nc-nc)   Female 8 7.5 106.2 (45.7-209.3) 
Lung and Bronchus            All Sites / Types     
Male 9 14.9 60.5 (27.6-114.9)   Male 113 112.3 100.7 (83.0-121.0) 
Female 11 14.2 77.3 (38.5-138.3)   Female 113 103.7 108.9 (89.8-131.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
214 
Newburyport 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 22 20.7 106.3 (66.6-160.9)   Male 24 13.5 178.2 (114.2-265.2) 
Female 8 8.5 93.9 (40.4-185.0)   Female 16 11.6 137.7 (78.6-223.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 3.8 nc (nc-nc)   Male 1 4.0 nc (nc-nc) 
Female 2 3.5 nc (nc-nc)   Female 6 3.6 165.0 (60.2-359.1) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.7 nc (nc-nc)   Male 14 11.8 118.7 (64.9-199.2) 
Female 91 91.5 99.4 (80.1-122.1)   Female 8 11.3 71.0 (30.6-139.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 17 9.8 173.7 (101.1-278.1) 
Female 0 3.0 nc (nc-nc)   Female 3 4.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 25 23.0 108.9 (70.5-160.8)             
Female 26 26.0 99.9 (65.3-146.5)   Female 9 8.4 107.6 (49.1-204.2) 
Esophagus            Pancreas     
Male 6 5.7 105.1 (38.4-228.8)   Male 7 7.1 98.0 (39.3-202.0) 
Female 2 1.6 nc (nc-nc)   Female 8 8.4 95.7 (41.2-188.6) 
Hodgkin Lymphoma            Prostate     
Male 2 1.4 nc (nc-nc)   Male 85 77.7 109.5 (87.4-135.4) 
Female 2 1.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 11 11.5 96.0 (47.9-171.8)   Male 6 4.9 123.2 (45.0-268.1) 
Female 4 7.3 nc (nc-nc)   Female 6 3.3 183.6 (67.1-399.7) 
Larynx            Testis     
Male 2 3.2 nc (nc-nc)   Male 2 2.2 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 8.1 99.3 (42.8-195.7)   Male 9 5.1 176.6 (80.6-335.2) 
Female 5 6.6 75.6 (24.4-176.5)   Female 18 15.8 113.9 (67.5-180.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 7.2 nc (nc-nc)             
Female 3 2.6 nc (nc-nc)   Female 16 21.2 75.3 (43.0-122.3) 
Lung and Bronchus            All Sites / Types     
Male 30 38.1 78.8 (53.2-112.5)   Male 293 280.0 104.6 (93.0-117.3) 
Female 43 43.6 98.7 (71.4-132.9)   Female 306 309.8 98.8 (88.0-110.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
215 
Newton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 93 98.2 94.7 (76.4-116.0)   Male 69 61.3 112.5 (87.5-142.4) 
Female 42 36.8 114.1 (82.2-154.3)   Female 67 50.3 133.3 (103.3-169.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 21 17.4 120.9 (74.8-184.9)   Male 25 18.2 137.4 (88.9-202.8) 
Female 17 15.7 108.1 (62.9-173.1)   Female 18 15.5 116.1 (68.7-183.4) 
Breast            Non-Hodgkin Lymphoma     
Male 3 3.0 nc (nc-nc)   Male 56 54.5 102.7 (77.6-133.4) 
Female 457 381.0 119.9 (109.2-131.5)   Female 53 48.3 109.7 (82.1-143.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 40 42.6 93.9 (67.1-127.9) 
Female 12 12.9 92.8 (47.9-162.1)   Female 26 20.0 130.0 (84.9-190.5) 
Colon / Rectum            Ovary     
Male 90 105.8 85.0 (68.4-104.5)             
Female 91 112.1 81.1 (65.3-99.6)   Female 39 35.3 110.4 (78.5-151.0) 
Esophagus            Pancreas     
Male 9 25.5 35.2 (16.1-66.9)   Male 34 33.0 103.2 (71.4-144.2) 
Female 7 7.0 99.8 (40.0-205.7)   Female 48 36.2 132.5 (97.7-175.7) 
Hodgkin Lymphoma            Prostate     
Male 2 7.1 nc (nc-nc)   Male 362 337.6 107.2 (96.5-118.9) 
Female 4 6.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 51 50.3 101.5 (75.6-133.4)   Male 18 22.5 79.9 (47.3-126.2) 
Female 22 30.7 71.7 (44.9-108.6)   Female 15 14.2 105.4 (59.0-173.9) 
Larynx            Testis     
Male 9 14.0 64.3 (29.4-122.1)   Male 13 11.1 117.2 (62.3-200.4) 
Female 1 4.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 46 38.3 120.2 (88.0-160.4)   Male 34 22.2 153.1 (106.0-214.0) 
Female 25 29.2 85.7 (55.5-126.6)   Female 82 68.8 119.3 (94.8-148.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 28 31.9 87.9 (58.4-127.0)             
Female 11 10.9 100.8 (50.3-180.5)   Female 87 87.4 99.6 (79.8-122.9) 
Lung and Bronchus            All Sites / Types     
Male 127 174.6 72.8 (60.6-86.6)   Male 1203 1268.4 94.8 (89.6-100.4) 
Female 148 185.0 80.0 (67.6-94.0)   Female 1400 1316.6 106.3 (100.8-112.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
216 
Norfolk 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 10.6 75.6 (32.6-149.0)   Male 12 8.3 145.2 (75.0-253.7) 
Female 3 2.6 nc (nc-nc)   Female 6 4.4 135.5 (49.5-294.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.6 nc (nc-nc)   Male 3 2.3 nc (nc-nc) 
Female 0 1.4 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.4 nc (nc-nc)   Male 7 7.2 96.9 (38.8-199.7) 
Female 53 35.7 148.3 (111.1-194.0)   Female 0 3.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 6.7 nc (nc-nc) 
Female 0 1.3 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 12 13.5 88.6 (45.7-154.8)             
Female 7 8.2 85.4 (34.2-176.0)   Female 1 3.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 3.4 nc (nc-nc)   Male 2 4.0 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 3 2.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 1.2 nc (nc-nc)   Male 49 47.6 103.0 (76.2-136.2) 
Female 1 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 7.5 79.6 (29.1-173.3)   Male 6 2.8 217.0 (79.2-472.4) 
Female 2 2.6 nc (nc-nc)   Female 2 1.0 nc (nc-nc) 
Larynx            Testis     
Male 3 1.9 nc (nc-nc)   Male 3 2.2 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 4.7 nc (nc-nc)   Male 2 4.0 nc (nc-nc) 
Female 3 2.3 nc (nc-nc)   Female 6 7.2 83.8 (30.6-182.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 4.6 151.5 (60.7-312.2)             
Female 0 0.9 nc (nc-nc)   Female 7 8.2 85.7 (34.3-176.6) 
Lung and Bronchus            All Sites / Types     
Male 20 20.4 98.1 (59.9-151.5)   Male 157 167.3 93.8 (79.7-109.7) 
Female 10 14.2 70.3 (33.6-129.3)   Female 113 111.6 101.3 (83.5-121.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
217 
North Adams 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 19 15.6 121.9 (73.3-190.3)   Male 6 9.8 61.5 (22.5-133.9) 
Female 13 6.4 203.1 (108.0-347.3)   Female 5 8.2 60.9 (19.6-142.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 2.7 182.1 (58.7-424.9)   Male 5 2.9 173.4 (55.9-404.7) 
Female 1 2.6 nc (nc-nc)   Female 2 2.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.5 nc (nc-nc)   Male 8 8.7 92.4 (39.8-182.0) 
Female 52 60.8 85.5 (63.8-112.1)   Female 6 8.1 73.7 (26.9-160.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 6.7 120.2 (51.7-236.8) 
Female 1 2.0 nc (nc-nc)   Female 2 3.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 26 16.7 155.4 (101.5-227.7)             
Female 24 19.3 124.4 (79.7-185.1)   Female 6 5.7 104.7 (38.2-227.9) 
Esophagus            Pancreas     
Male 10 4.0 249.0 (119.2-458.0)   Male 2 5.2 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 11 6.3 174.9 (87.2-313.0) 
Hodgkin Lymphoma            Prostate     
Male 0 1.2 nc (nc-nc)   Male 52 52.7 98.6 (73.6-129.3) 
Female 1 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 14 7.9 176.8 (96.6-296.7)   Male 5 3.6 140.3 (45.2-327.4) 
Female 2 5.1 nc (nc-nc)   Female 3 2.5 nc (nc-nc) 
Larynx            Testis     
Male 2 2.2 nc (nc-nc)   Male 2 2.0 nc (nc-nc) 
Female 4 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 6.1 82.6 (26.6-192.8)   Male 3 3.5 nc (nc-nc) 
Female 7 5.0 141.4 (56.6-291.3)   Female 11 10.7 103.1 (51.4-184.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 11 5.0 219.1 (109.2-392.1)             
Female 3 1.8 nc (nc-nc)   Female 11 13.8 80.0 (39.9-143.1) 
Lung and Bronchus            All Sites / Types     
Male 41 27.8 147.4 (105.7-199.9)   Male 240 200.5 119.7 (105.0-135.8) 
Female 42 31.9 131.8 (95.0-178.2)   Female 220 217.6 101.1 (88.2-115.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
218 
North Andover 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 37 27.6 134.1 (94.4-184.8)   Male 23 18.2 126.4 (80.1-189.7) 
Female 14 11.3 123.6 (67.5-207.3)   Female 15 15.8 94.9 (53.1-156.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 5.5 109.5 (40.0-238.4)   Male 4 5.3 nc (nc-nc) 
Female 5 5.0 100.9 (32.5-235.4)   Female 5 4.8 105.0 (33.8-245.1) 
Breast            Non-Hodgkin Lymphoma     
Male 4 0.9 nc (nc-nc)   Male 13 16.2 80.2 (42.7-137.1) 
Female 117 119.9 97.6 (80.7-117.0)   Female 17 15.0 113.7 (66.2-182.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 12 13.1 91.5 (47.2-159.8) 
Female 4 4.3 nc (nc-nc)   Female 4 6.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 27 31.2 86.4 (56.9-125.8)             
Female 40 35.4 112.9 (80.6-153.7)   Female 11 11.0 100.4 (50.1-179.7) 
Esophagus            Pancreas     
Male 7 7.4 94.2 (37.7-194.1)   Male 13 9.5 137.3 (73.1-234.9) 
Female 1 2.1 nc (nc-nc)   Female 13 11.2 115.9 (61.6-198.1) 
Hodgkin Lymphoma            Prostate     
Male 5 2.3 217.6 (70.1-507.8)   Male 115 98.9 116.3 (96.0-139.6) 
Female 4 2.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 19 15.3 124.0 (74.6-193.6)   Male 6 6.5 91.8 (33.5-199.7) 
Female 5 9.5 52.7 (17.0-122.9)   Female 5 4.5 110.7 (35.7-258.3) 
Larynx            Testis     
Male 1 4.1 nc (nc-nc)   Male 5 3.8 132.3 (42.6-308.8) 
Female 0 1.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 12 11.3 105.9 (54.6-185.0)   Male 9 7.2 124.9 (57.0-237.1) 
Female 9 9.2 97.5 (44.5-185.1)   Female 31 22.4 138.5 (94.1-196.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 9.5 nc (nc-nc)             
Female 4 3.3 nc (nc-nc)   Female 17 26.5 64.2 (37.4-102.8) 
Lung and Bronchus            All Sites / Types     
Male 35 49.5 70.7 (49.3-98.4)   Male 391 372.1 105.1 (94.9-116.0) 
Female 59 55.6 106.2 (80.8-137.0)   Female 412 410.2 100.4 (91.0-110.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
219 
North Attleborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 18 24.3 74.2 (44.0-117.3)   Male 19 17.2 110.5 (66.5-172.6) 
Female 6 8.9 67.6 (24.7-147.1)   Female 20 14.5 137.6 (84.0-212.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 5.4 129.8 (52.0-267.5)   Male 1 4.9 nc (nc-nc) 
Female 6 4.5 132.7 (48.4-288.8)   Female 5 3.9 128.9 (41.5-300.8) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.8 nc (nc-nc)   Male 18 15.2 118.5 (70.2-187.3) 
Female 106 110.2 96.2 (78.7-116.3)   Female 12 12.6 95.1 (49.1-166.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 12 12.9 93.2 (48.1-162.8) 
Female 2 4.3 nc (nc-nc)   Female 7 5.4 130.3 (52.2-268.4) 
Colon / Rectum            Ovary     
Male 38 28.7 132.2 (93.6-181.5)             
Female 27 28.1 96.2 (63.4-140.0)   Female 7 9.8 71.1 (28.5-146.6) 
Esophagus            Pancreas     
Male 7 7.0 100.6 (40.3-207.3)   Male 6 8.6 69.9 (25.5-152.2) 
Female 1 1.7 nc (nc-nc)   Female 10 8.6 116.0 (55.5-213.4) 
Hodgkin Lymphoma            Prostate     
Male 3 2.4 nc (nc-nc)   Male 103 95.0 108.4 (88.5-131.5) 
Female 1 1.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 15.0 66.8 (32.0-122.9)   Male 4 6.0 nc (nc-nc) 
Female 7 8.4 83.4 (33.4-171.8)   Female 1 3.5 nc (nc-nc) 
Larynx            Testis     
Male 9 3.9 230.9 (105.4-438.4)   Male 4 4.3 nc (nc-nc) 
Female 0 1.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 10.4 76.7 (33.0-151.2)   Male 4 7.5 nc (nc-nc) 
Female 5 7.7 64.7 (20.8-150.9)   Female 30 23.0 130.3 (87.9-186.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 9 9.2 98.0 (44.7-186.1)             
Female 1 2.8 nc (nc-nc)   Female 25 24.6 101.7 (65.8-150.2) 
Lung and Bronchus            All Sites / Types     
Male 47 44.9 104.7 (76.9-139.2)   Male 356 349.1 102.0 (91.6-113.1) 
Female 44 46.9 93.8 (68.2-126.0)   Female 342 360.0 95.0 (85.2-105.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
220 
North Brookfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 5.1 nc (nc-nc)   Male 5 3.4 148.6 (47.9-346.7) 
Female 1 1.8 nc (nc-nc)   Female 2 2.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.0 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 3 3.0 nc (nc-nc) 
Female 20 19.8 101.1 (61.7-156.2)   Female 1 2.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 2.5 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 2 1.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 5.7 104.6 (38.2-227.6)             
Female 3 5.5 nc (nc-nc)   Female 4 1.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 1.4 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 1.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 21 19.1 110.0 (68.0-168.1) 
Female 2 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 2.9 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 0 1.6 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Larynx            Testis     
Male 1 0.8 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 2.0 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 0 1.4 nc (nc-nc)   Female 2 3.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.8 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 6 4.5 134.2 (49.0-292.1) 
Lung and Bronchus            All Sites / Types     
Male 7 9.2 75.8 (30.3-156.1)   Male 65 69.5 93.5 (72.1-119.1) 
Female 6 9.2 64.9 (23.7-141.3)   Female 53 66.8 79.4 (59.5-103.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
221 
North Reading 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 15.2 72.4 (36.1-129.6)   Male 17 10.3 164.8 (95.9-263.8) 
Female 9 5.2 173.6 (79.2-329.6)   Female 14 8.0 175.2 (95.7-294.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 3.1 195.5 (71.4-425.4)   Male 3 3.0 nc (nc-nc) 
Female 2 2.5 nc (nc-nc)   Female 0 2.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.5 nc (nc-nc)   Male 11 9.1 121.3 (60.5-217.0) 
Female 70 62.8 111.5 (86.9-140.8)   Female 8 7.2 110.6 (47.6-217.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 7.6 nc (nc-nc) 
Female 2 2.2 nc (nc-nc)   Female 1 3.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 20 17.5 114.5 (69.9-176.9)             
Female 16 16.1 99.2 (56.7-161.2)   Female 3 5.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 6 4.3 140.5 (51.3-305.9)   Male 2 5.3 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 4 5.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 3 1.3 nc (nc-nc)   Male 55 58.1 94.7 (71.3-123.2) 
Female 2 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 8.9 90.1 (38.8-177.5)   Male 2 3.7 nc (nc-nc) 
Female 2 4.8 nc (nc-nc)   Female 0 2.0 nc (nc-nc) 
Larynx            Testis     
Male 3 2.4 nc (nc-nc)   Male 1 2.0 nc (nc-nc) 
Female 2 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 6.2 145.3 (66.3-275.8)   Male 2 4.2 nc (nc-nc) 
Female 6 4.3 139.3 (50.9-303.3)   Female 16 12.1 132.1 (75.5-214.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 5.6 nc (nc-nc)             
Female 2 1.6 nc (nc-nc)   Female 15 14.2 105.9 (59.3-174.8) 
Lung and Bronchus            All Sites / Types     
Male 20 28.1 71.1 (43.4-109.9)   Male 204 211.9 96.3 (83.5-110.4) 
Female 16 27.8 57.6 (32.9-93.6)   Female 203 205.1 99.0 (85.8-113.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
222 
Northampton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 30 30.0 100.1 (67.5-142.9)   Male 10 19.4 51.5 (24.6-94.7) 
Female 9 11.6 77.6 (35.4-147.3)   Female 12 17.2 69.8 (36.0-121.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 5.5 109.2 (39.9-237.7)   Male 0 5.7 nc (nc-nc) 
Female 7 5.2 133.8 (53.6-275.6)   Female 6 4.9 121.4 (44.3-264.2) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.9 nc (nc-nc)   Male 16 17.1 93.4 (53.4-151.7) 
Female 142 125.5 113.2 (95.3-133.4)   Female 15 15.6 96.0 (53.7-158.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 14.0 71.4 (34.2-131.3) 
Female 3 4.5 nc (nc-nc)   Female 9 6.5 137.6 (62.8-261.2) 
Colon / Rectum            Ovary     
Male 33 33.1 99.6 (68.5-139.8)             
Female 33 35.7 92.3 (63.5-129.7)   Female 17 11.8 144.5 (84.1-231.4) 
Esophagus            Pancreas     
Male 9 8.2 110.4 (50.4-209.5)   Male 9 10.3 87.5 (39.9-166.2) 
Female 3 2.2 nc (nc-nc)   Female 15 11.4 131.5 (73.6-216.9) 
Hodgkin Lymphoma            Prostate     
Male 4 2.3 nc (nc-nc)   Male 82 110.2 74.4 (59.2-92.4) 
Female 2 2.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 12 16.2 73.9 (38.2-129.2)   Male 3 7.0 nc (nc-nc) 
Female 12 9.9 120.9 (62.4-211.3)   Female 5 4.5 110.2 (35.5-257.2) 
Larynx            Testis     
Male 3 4.5 nc (nc-nc)   Male 4 3.9 nc (nc-nc) 
Female 1 1.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 11.7 76.6 (35.0-145.5)   Male 5 7.5 67.0 (21.6-156.4) 
Female 8 9.4 85.4 (36.8-168.2)   Female 11 24.8 44.4 (22.1-79.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 11 10.4 105.7 (52.7-189.2)             
Female 1 3.5 nc (nc-nc)   Female 31 29.0 106.8 (72.5-151.5) 
Lung and Bronchus            All Sites / Types     
Male 40 54.1 73.9 (52.8-100.7)   Male 317 402.6 78.7 (70.3-87.9) 
Female 53 58.5 90.5 (67.8-118.4)   Female 425 430.5 98.7 (89.5-108.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
223 
Northborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 19 14.2 133.5 (80.3-208.4)   Male 6 9.7 62.2 (22.7-135.3) 
Female 8 5.4 147.9 (63.7-291.4)   Female 7 7.9 89.1 (35.7-183.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 2.9 nc (nc-nc)   Male 4 2.8 nc (nc-nc) 
Female 1 2.4 nc (nc-nc)   Female 2 2.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 6 8.5 70.4 (25.7-153.2) 
Female 59 61.9 95.4 (72.6-123.0)   Female 4 7.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 7.2 nc (nc-nc) 
Female 0 2.2 nc (nc-nc)   Female 5 3.1 161.7 (52.1-377.4) 
Colon / Rectum            Ovary     
Male 10 16.4 61.0 (29.2-112.2)             
Female 22 16.8 131.0 (82.0-198.3)   Female 4 5.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 5 4.0 125.2 (40.4-292.3)   Male 9 5.0 181.7 (82.9-345.0) 
Female 0 1.0 nc (nc-nc)   Female 5 5.3 95.0 (30.6-221.8) 
Hodgkin Lymphoma            Prostate     
Male 1 1.2 nc (nc-nc)   Male 56 53.9 103.8 (78.4-134.8) 
Female 2 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 8.3 nc (nc-nc)   Male 4 3.4 nc (nc-nc) 
Female 3 4.8 nc (nc-nc)   Female 2 2.1 nc (nc-nc) 
Larynx            Testis     
Male 3 2.2 nc (nc-nc)   Male 0 1.9 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 11 5.8 188.5 (93.9-337.2)   Male 2 3.9 nc (nc-nc) 
Female 4 4.4 nc (nc-nc)   Female 8 11.4 69.9 (30.1-137.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 5.2 nc (nc-nc)             
Female 0 1.6 nc (nc-nc)   Female 17 13.8 122.9 (71.5-196.7) 
Lung and Bronchus            All Sites / Types     
Male 17 26.2 64.8 (37.7-103.7)   Male 175 198.1 88.4 (75.8-102.5) 
Female 18 28.2 63.9 (37.9-101.0)   Female 186 205.3 90.6 (78.1-104.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
224 
Northbridge 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 19 15.3 123.9 (74.6-193.5)   Male 5 10.1 49.5 (16.0-115.5) 
Female 8 6.2 129.8 (55.9-255.8)   Female 6 8.7 69.3 (25.3-150.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 3.0 nc (nc-nc)   Male 6 2.9 205.2 (74.9-446.7) 
Female 1 2.7 nc (nc-nc)   Female 4 2.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.5 nc (nc-nc)   Male 6 9.0 66.6 (24.3-145.0) 
Female 56 64.9 86.3 (65.2-112.1)   Female 7 8.1 86.0 (34.5-177.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 7.2 139.4 (66.8-256.5) 
Female 2 2.3 nc (nc-nc)   Female 5 3.4 148.9 (48.0-347.6) 
Colon / Rectum            Ovary     
Male 19 17.4 109.4 (65.8-170.8)             
Female 31 19.2 161.4 (109.7-229.1)   Female 6 5.9 101.0 (36.9-219.8) 
Esophagus            Pancreas     
Male 6 4.1 148.0 (54.0-322.1)   Male 2 5.2 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 10 6.1 163.9 (78.5-301.5) 
Hodgkin Lymphoma            Prostate     
Male 2 1.3 nc (nc-nc)   Male 58 53.2 109.0 (82.7-140.9) 
Female 0 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 18 8.4 213.8 (126.7-337.9)   Male 1 3.6 nc (nc-nc) 
Female 3 5.2 nc (nc-nc)   Female 2 2.4 nc (nc-nc) 
Larynx            Testis     
Male 1 2.2 nc (nc-nc)   Male 2 2.2 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 6.3 142.5 (65.0-270.6)   Male 3 4.0 nc (nc-nc) 
Female 3 5.0 nc (nc-nc)   Female 13 12.4 105.2 (56.0-180.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 5.2 115.1 (42.0-250.5)             
Female 3 1.8 nc (nc-nc)   Female 16 14.3 111.6 (63.7-181.2) 
Lung and Bronchus            All Sites / Types     
Male 29 27.2 106.6 (71.4-153.1)   Male 225 204.6 110.0 (96.1-125.3) 
Female 30 30.4 98.7 (66.6-140.9)   Female 222 223.1 99.5 (86.8-113.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
225 
Northfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 3.9 nc (nc-nc)   Male 2 2.5 nc (nc-nc) 
Female 2 1.2 nc (nc-nc)   Female 3 1.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.7 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 2.2 nc (nc-nc) 
Female 13 14.0 92.6 (49.3-158.4)   Female 0 1.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 1.8 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 4.3 nc (nc-nc)             
Female 3 3.8 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.1 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.3 nc (nc-nc)   Male 10 14.4 69.5 (33.3-127.8) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 2.1 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Larynx            Testis     
Male 1 0.6 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.5 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 2 1.0 nc (nc-nc)   Female 2 2.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.4 nc (nc-nc)             
Female 1 0.4 nc (nc-nc)   Female 4 3.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 4 7.1 nc (nc-nc)   Male 38 52.0 73.0 (51.7-100.2) 
Female 4 6.5 nc (nc-nc)   Female 40 46.8 85.4 (61.0-116.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
226 
Norton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 15.8 69.6 (34.7-124.5)   Male 13 11.2 116.3 (61.8-198.8) 
Female 8 5.8 137.8 (59.3-271.5)   Female 13 9.4 137.8 (73.3-235.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 3.5 143.3 (46.2-334.3)   Male 4 3.2 nc (nc-nc) 
Female 5 3.0 168.4 (54.3-393.1)   Female 2 2.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.5 nc (nc-nc)   Male 7 9.9 70.7 (28.3-145.6) 
Female 63 72.0 87.5 (67.2-112.0)   Female 12 8.3 144.8 (74.7-252.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 9 8.5 106.3 (48.5-201.7) 
Female 2 2.7 nc (nc-nc)   Female 4 3.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 26 18.7 138.9 (90.7-203.5)             
Female 29 18.1 160.2 (107.3-230.1)   Female 7 6.5 107.8 (43.2-222.2) 
Esophagus            Pancreas     
Male 6 4.6 130.7 (47.7-284.4)   Male 9 5.6 159.9 (73.0-303.6) 
Female 2 1.1 nc (nc-nc)   Female 8 5.6 142.2 (61.2-280.2) 
Hodgkin Lymphoma            Prostate     
Male 2 1.6 nc (nc-nc)   Male 65 63.4 102.5 (79.1-130.7) 
Female 0 1.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 11 9.8 112.4 (56.0-201.1)   Male 4 3.9 nc (nc-nc) 
Female 7 5.5 127.9 (51.2-263.5)   Female 2 2.3 nc (nc-nc) 
Larynx            Testis     
Male 3 2.6 nc (nc-nc)   Male 5 2.8 180.6 (58.2-421.5) 
Female 0 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 6.8 103.3 (41.4-212.9)   Male 8 4.9 164.1 (70.7-323.4) 
Female 6 5.0 119.9 (43.8-260.9)   Female 15 14.8 101.5 (56.8-167.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 12 6.0 198.8 (102.6-347.3)             
Female 0 1.8 nc (nc-nc)   Female 23 16.3 141.1 (89.4-211.8) 
Lung and Bronchus            All Sites / Types     
Male 28 29.5 95.0 (63.1-137.2)   Male 252 229.5 109.8 (96.7-124.2) 
Female 30 31.1 96.6 (65.2-137.9)   Female 252 235.2 107.1 (94.3-121.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
227 
Norwell 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 10 12.3 81.3 (38.9-149.5)   Male 5 7.9 63.1 (20.3-147.3) 
Female 1 4.6 nc (nc-nc)   Female 14 6.2 226.0 (123.4-379.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 2.3 nc (nc-nc)   Male 2 2.4 nc (nc-nc) 
Female 2 2.0 nc (nc-nc)   Female 4 2.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.4 nc (nc-nc)   Male 4 7.0 nc (nc-nc) 
Female 43 49.3 87.2 (63.1-117.4)   Female 7 6.1 115.0 (46.1-237.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 5.8 nc (nc-nc) 
Female 1 1.6 nc (nc-nc)   Female 7 2.5 276.6 (110.8-570.0) 
Colon / Rectum            Ovary     
Male 11 13.6 80.7 (40.2-144.4)             
Female 9 14.1 63.8 (29.1-121.1)   Female 8 4.5 179.0 (77.1-352.8) 
Esophagus            Pancreas     
Male 1 3.4 nc (nc-nc)   Male 4 4.3 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 7 4.5 154.4 (61.9-318.2) 
Hodgkin Lymphoma            Prostate     
Male 1 0.8 nc (nc-nc)   Male 45 45.9 98.1 (71.6-131.3) 
Female 3 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 6.7 nc (nc-nc)   Male 1 2.9 nc (nc-nc) 
Female 4 3.9 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Larynx            Testis     
Male 2 1.9 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 4.8 123.9 (45.2-269.6)   Male 2 3.0 nc (nc-nc) 
Female 4 3.7 nc (nc-nc)   Female 6 8.4 71.4 (26.1-155.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 4.3 nc (nc-nc)             
Female 1 1.4 nc (nc-nc)   Female 15 11.2 134.1 (75.0-221.2) 
Lung and Bronchus            All Sites / Types     
Male 14 22.5 62.2 (34.0-104.4)   Male 132 165.6 79.7 (66.7-94.5) 
Female 15 23.6 63.6 (35.6-104.9)   Female 168 167.0 100.6 (85.9-117.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
228 
Norwood 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 21 34.6 60.6 (37.5-92.7)   Male 31 21.5 144.1 (97.9-204.5) 
Female 11 13.9 79.0 (39.4-141.3)   Female 23 18.0 128.0 (81.1-192.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 10 6.0 166.5 (79.7-306.2)   Male 10 6.3 157.7 (75.5-290.1) 
Female 8 5.5 145.1 (62.5-286.0)   Female 7 5.8 121.5 (48.7-250.3) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.1 nc (nc-nc)   Male 24 19.1 125.9 (80.7-187.4) 
Female 147 134.1 109.6 (92.6-128.9)   Female 16 17.7 90.3 (51.6-146.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 15 14.3 104.6 (58.5-172.5) 
Female 5 4.5 110.7 (35.7-258.3)   Female 4 7.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 51 37.0 137.9 (102.7-181.4)             
Female 53 42.2 125.5 (94.0-164.2)   Female 15 12.5 120.3 (67.3-198.5) 
Esophagus            Pancreas     
Male 10 8.7 114.7 (54.9-211.0)   Male 16 11.4 139.9 (79.9-227.2) 
Female 4 2.6 nc (nc-nc)   Female 18 13.7 131.3 (77.8-207.5) 
Hodgkin Lymphoma            Prostate     
Male 5 2.5 198.3 (63.9-462.8)   Male 88 112.4 78.3 (62.8-96.5) 
Female 2 2.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 18 17.2 104.5 (61.9-165.1)   Male 11 7.9 139.9 (69.7-250.3) 
Female 16 11.1 144.1 (82.3-234.0)   Female 7 5.4 130.1 (52.1-268.0) 
Larynx            Testis     
Male 7 4.8 146.7 (58.8-302.3)   Male 7 4.3 162.4 (65.0-334.6) 
Female 4 1.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 18 13.4 134.8 (79.8-213.0)   Male 13 7.7 168.1 (89.4-287.4) 
Female 8 10.8 74.4 (32.0-146.6)   Female 28 23.6 118.6 (78.8-171.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 14 10.8 129.6 (70.8-217.5)             
Female 2 4.0 nc (nc-nc)   Female 33 29.9 110.3 (75.9-154.9) 
Lung and Bronchus            All Sites / Types     
Male 64 61.0 104.9 (80.8-134.0)   Male 483 437.0 110.5 (100.9-120.8) 
Female 83 69.1 120.2 (95.7-149.0)   Female 526 475.7 110.6 (101.3-120.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
229 
Oak Bluffs 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 5.6 89.9 (29.0-209.7)   Male 10 3.6 277.2 (132.7-509.7) 
Female 0 2.2 nc (nc-nc)   Female 0 2.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.0 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 3 3.2 nc (nc-nc) 
Female 22 22.1 99.5 (62.3-150.7)   Female 1 2.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 2.6 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 6.1 97.8 (35.7-212.9)             
Female 5 6.8 74.0 (23.9-172.8)   Female 2 2.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.5 nc (nc-nc)   Male 4 1.9 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 1 2.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 19 20.2 94.3 (56.7-147.2) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 3.0 nc (nc-nc)   Male 0 1.3 nc (nc-nc) 
Female 1 1.8 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Larynx            Testis     
Male 1 0.8 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 2.2 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 1 1.7 nc (nc-nc)   Female 4 3.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 1.9 264.4 (85.2-617.0)             
Female 0 0.6 nc (nc-nc)   Female 7 5.1 137.9 (55.2-284.0) 
Lung and Bronchus            All Sites / Types     
Male 5 10.1 49.4 (15.9-115.3)   Male 69 74.3 92.9 (72.3-117.6) 
Female 12 11.1 108.4 (55.9-189.3)   Female 69 77.2 89.3 (69.5-113.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
230 
Oakham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 2.0 nc (nc-nc)   Male 0 1.4 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.4 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.1 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 6 7.7 77.5 (28.3-168.6)   Female 2 0.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 1.1 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 2.3 nc (nc-nc)             
Female 2 1.8 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.6 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 12 8.1 147.6 (76.2-257.8) 
Female 1 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.2 nc (nc-nc)   Male 2 0.5 nc (nc-nc) 
Female 2 0.6 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 0.8 nc (nc-nc)   Male 2 0.6 nc (nc-nc) 
Female 2 0.5 nc (nc-nc)   Female 0 1.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.8 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 3.7 nc (nc-nc)   Male 26 28.7 90.5 (59.1-132.6) 
Female 1 3.1 nc (nc-nc)   Female 20 24.3 82.3 (50.3-127.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Orange 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 10 8.6 115.7 (55.4-212.8)   Male 4 5.7 nc (nc-nc) 
Female 2 3.2 nc (nc-nc)   Female 3 4.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 1.6 nc (nc-nc)   Male 1 1.7 nc (nc-nc) 
Female 3 1.4 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 7 5.0 140.3 (56.2-289.0) 
Female 38 34.8 109.4 (77.4-150.1)   Female 3 4.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 4.1 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 9.6 73.1 (29.3-150.7)             
Female 5 9.6 52.1 (16.8-121.6)   Female 1 3.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 2.4 nc (nc-nc)   Male 2 3.0 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 1 3.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.7 nc (nc-nc)   Male 34 32.5 104.8 (72.5-146.4) 
Female 1 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 4.8 104.0 (33.5-242.6)   Male 0 2.0 nc (nc-nc) 
Female 3 2.8 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Larynx            Testis     
Male 0 1.3 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 3.4 nc (nc-nc)   Male 2 2.2 nc (nc-nc) 
Female 0 2.5 nc (nc-nc)   Female 7 6.4 109.4 (43.8-225.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 3.0 nc (nc-nc)             
Female 0 1.0 nc (nc-nc)   Female 13 8.0 163.3 (86.9-279.3) 
Lung and Bronchus            All Sites / Types     
Male 19 15.9 119.5 (71.9-186.6)   Male 120 117.7 102.0 (84.5-121.9) 
Female 12 16.7 71.8 (37.0-125.4)   Female 108 117.7 91.8 (75.3-110.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Orleans 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 16 16.3 97.9 (55.9-159.0)   Male 22 8.8 249.5 (156.3-377.8) 
Female 5 5.5 91.4 (29.5-213.3)   Female 10 5.6 177.0 (84.7-325.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 2.0 nc (nc-nc)   Male 3 2.8 nc (nc-nc) 
Female 1 1.7 nc (nc-nc)   Female 1 2.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 10 7.7 129.1 (61.8-237.4) 
Female 64 45.1 142.1 (109.4-181.4)   Female 5 6.5 76.9 (24.8-179.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 5.3 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 4 2.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 15 15.8 95.2 (53.2-157.0)             
Female 16 15.5 102.9 (58.8-167.2)   Female 3 4.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 3.8 nc (nc-nc)   Male 2 5.2 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 6 5.4 111.5 (40.7-242.7) 
Hodgkin Lymphoma            Prostate     
Male 0 0.6 nc (nc-nc)   Male 42 48.4 86.8 (62.5-117.3) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 6.7 nc (nc-nc)   Male 2 3.5 nc (nc-nc) 
Female 2 4.0 nc (nc-nc)   Female 2 2.0 nc (nc-nc) 
Larynx            Testis     
Male 2 2.0 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 5.4 128.8 (51.6-265.4)   Male 1 2.3 nc (nc-nc) 
Female 2 3.7 nc (nc-nc)   Female 3 5.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 4.3 nc (nc-nc)             
Female 1 1.5 nc (nc-nc)   Female 15 10.7 140.0 (78.3-231.0) 
Lung and Bronchus            All Sites / Types     
Male 14 28.4 49.3 (26.9-82.7)   Male 162 185.5 87.3 (74.4-101.8) 
Female 19 27.5 69.1 (41.6-107.9)   Female 175 167.4 104.6 (89.6-121.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Otis 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 2.5 nc (nc-nc)   Male 2 1.6 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 2 1.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.4 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 10 8.3 121.2 (58.0-222.9)   Female 3 1.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.1 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 2.7 nc (nc-nc)             
Female 1 2.1 nc (nc-nc)   Female 2 0.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.7 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 13 9.4 138.8 (73.8-237.4) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.3 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.9 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 2 1.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.8 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 0 2.0 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 5 4.6 108.7 (35.0-253.7)   Male 29 33.2 87.4 (58.5-125.5) 
Female 6 3.9 155.2 (56.7-337.8)   Female 29 27.0 107.2 (71.8-154.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Oxford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 16 13.1 122.5 (70.0-199.0)   Male 9 9.0 100.3 (45.8-190.3) 
Female 8 4.7 171.8 (74.0-338.5)   Female 7 7.4 95.2 (38.1-196.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 2.7 nc (nc-nc)   Male 2 2.6 nc (nc-nc) 
Female 1 2.3 nc (nc-nc)   Female 3 2.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 10 7.9 126.0 (60.3-231.8) 
Female 52 56.7 91.8 (68.5-120.4)   Female 6 6.6 91.5 (33.4-199.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 6.7 119.4 (51.4-235.2) 
Female 0 2.1 nc (nc-nc)   Female 4 2.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 15.2 39.6 (14.5-86.2)             
Female 16 14.5 110.3 (63.0-179.1)   Female 5 5.1 98.3 (31.7-229.5) 
Esophagus            Pancreas     
Male 4 3.7 nc (nc-nc)   Male 2 4.6 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 5 4.5 111.1 (35.8-259.3) 
Hodgkin Lymphoma            Prostate     
Male 0 1.2 nc (nc-nc)   Male 47 50.9 92.4 (67.9-122.9) 
Female 2 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 7.8 nc (nc-nc)   Male 2 3.2 nc (nc-nc) 
Female 6 4.4 137.6 (50.2-299.4)   Female 2 1.8 nc (nc-nc) 
Larynx            Testis     
Male 5 2.1 240.5 (77.5-561.1)   Male 4 2.0 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 5.4 184.5 (88.3-339.3)   Male 4 3.7 nc (nc-nc) 
Female 5 3.9 127.8 (41.2-298.2)   Female 10 11.3 88.6 (42.4-163.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 4.9 143.4 (57.5-295.6)             
Female 0 1.5 nc (nc-nc)   Female 20 12.9 155.3 (94.8-239.9) 
Lung and Bronchus            All Sites / Types     
Male 39 24.1 161.8 (115.0-221.1)   Male 192 184.6 104.0 (89.8-119.8) 
Female 31 25.0 123.8 (84.1-175.8)   Female 201 185.8 108.2 (93.8-124.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Palmer 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 22 13.3 165.9 (103.9-251.2)   Male 12 8.7 137.2 (70.8-239.7) 
Female 9 5.1 175.6 (80.2-333.5)   Female 8 7.0 113.8 (49.0-224.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.5 nc (nc-nc)   Male 0 2.6 nc (nc-nc) 
Female 1 2.1 nc (nc-nc)   Female 1 2.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 0 7.8 nc (nc-nc) 
Female 60 53.4 112.4 (85.8-144.7)   Female 10 6.7 148.9 (71.3-273.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 6.3 94.7 (34.6-206.2) 
Female 2 1.8 nc (nc-nc)   Female 0 2.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 9 15.0 60.1 (27.4-114.0)             
Female 13 15.8 82.1 (43.6-140.3)   Female 4 4.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 3.6 nc (nc-nc)   Male 6 4.5 132.1 (48.2-287.5) 
Female 1 1.0 nc (nc-nc)   Female 8 5.0 158.7 (68.3-312.7) 
Hodgkin Lymphoma            Prostate     
Male 2 1.1 nc (nc-nc)   Male 36 48.1 74.9 (52.4-103.6) 
Female 1 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 7.3 108.9 (46.9-214.5)   Male 6 3.1 191.3 (69.9-416.4) 
Female 3 4.3 nc (nc-nc)   Female 2 2.0 nc (nc-nc) 
Larynx            Testis     
Male 5 2.0 250.5 (80.7-584.5)   Male 0 1.8 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 5.3 nc (nc-nc)   Male 2 3.5 nc (nc-nc) 
Female 5 4.0 123.7 (39.9-288.6)   Female 7 9.7 71.8 (28.8-148.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 4.7 107.4 (34.6-250.7)             
Female 3 1.5 nc (nc-nc)   Female 11 12.0 92.0 (45.9-164.6) 
Lung and Bronchus            All Sites / Types     
Male 29 23.9 121.1 (81.1-173.9)   Male 171 179.3 95.4 (81.6-110.8) 
Female 19 25.6 74.3 (44.7-116.0)   Female 180 183.6 98.0 (84.2-113.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Paxton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 5.4 nc (nc-nc)   Male 5 3.4 145.2 (46.8-339.0) 
Female 2 1.7 nc (nc-nc)   Female 1 2.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.0 nc (nc-nc)   Male 2 1.0 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 1 3.1 nc (nc-nc) 
Female 22 19.1 115.4 (72.3-174.7)   Female 0 2.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 2.4 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 5.9 nc (nc-nc)             
Female 6 5.1 117.2 (42.8-255.1)   Female 2 1.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.4 nc (nc-nc)   Male 1 1.8 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 24 19.1 125.4 (80.3-186.7) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 2.9 nc (nc-nc)   Male 2 1.3 nc (nc-nc) 
Female 0 1.5 nc (nc-nc)   Female 2 0.6 nc (nc-nc) 
Larynx            Testis     
Male 3 0.8 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 2.1 nc (nc-nc)   Male 4 1.3 nc (nc-nc) 
Female 2 1.4 nc (nc-nc)   Female 2 3.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 1.8 nc (nc-nc)             
Female 1 0.5 nc (nc-nc)   Female 5 4.4 114.6 (36.9-267.5) 
Lung and Bronchus            All Sites / Types     
Male 7 9.7 71.9 (28.8-148.1)   Male 71 71.4 99.5 (77.7-125.5) 
Female 6 8.8 67.8 (24.8-147.7)   Female 58 63.7 91.1 (69.1-117.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Peabody 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 82 72.9 112.5 (89.5-139.7)   Male 38 43.6 87.2 (61.7-119.7) 
Female 36 29.2 123.4 (86.4-170.8)   Female 36 35.2 102.3 (71.6-141.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 12 11.5 103.9 (53.6-181.6)   Male 18 13.0 138.2 (81.9-218.4) 
Female 12 10.8 111.3 (57.4-194.4)   Female 20 12.0 167.2 (102.1-258.2) 
Breast            Non-Hodgkin Lymphoma     
Male 5 2.2 228.3 (73.6-532.8)   Male 46 38.7 118.8 (87.0-158.4) 
Female 267 266.6 100.1 (88.5-112.9)   Female 53 36.2 146.4 (109.6-191.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 37 28.5 129.7 (91.3-178.8) 
Female 12 8.4 142.9 (73.8-249.7)   Female 14 14.6 96.2 (52.5-161.4) 
Colon / Rectum            Ovary     
Male 72 76.4 94.2 (73.7-118.7)             
Female 91 87.8 103.6 (83.4-127.2)   Female 21 24.9 84.2 (52.1-128.7) 
Esophagus            Pancreas     
Male 15 17.8 84.3 (47.2-139.1)   Male 18 23.7 75.8 (44.9-119.8) 
Female 4 5.5 nc (nc-nc)   Female 34 28.8 118.0 (81.7-164.9) 
Hodgkin Lymphoma            Prostate     
Male 4 4.5 nc (nc-nc)   Male 272 226.1 120.3 (106.4-135.5) 
Female 6 4.0 150.9 (55.1-328.4)             
Kidney & Renal Pelvis            Stomach     
Male 39 34.3 113.7 (80.8-155.4)   Male 13 16.3 79.7 (42.4-136.3) 
Female 19 22.4 84.7 (51.0-132.3)   Female 9 11.2 80.1 (36.6-152.1) 
Larynx            Testis     
Male 17 9.7 175.8 (102.3-281.4)   Male 13 7.1 184.1 (97.9-314.9) 
Female 2 3.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 30 27.1 110.7 (74.7-158.1)   Male 17 14.6 116.8 (68.0-187.1) 
Female 30 21.7 138.0 (93.1-197.0)   Female 38 43.2 88.0 (62.3-120.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 25 21.7 115.3 (74.6-170.2)             
Female 9 8.2 110.1 (50.2-209.0)   Female 56 59.8 93.7 (70.8-121.7) 
Lung and Bronchus            All Sites / Types     
Male 130 126.5 102.7 (85.8-122.0)   Male 996 888.9 112.0 (105.2-119.2) 
Female 172 142.8 120.4 (103.1-139.8)   Female 1024 960.0 106.7 (100.2-113.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Pelham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 2.0 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 2 0.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 6 6.9 87.5 (32.0-190.5)   Female 0 0.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.9 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 2.1 nc (nc-nc)             
Female 1 1.8 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.5 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 7 7.2 97.4 (39.0-200.6) 
Female 1 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.0 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.7 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.7 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 3.6 nc (nc-nc)   Male 16 25.7 62.2 (35.6-101.1) 
Female 0 3.2 nc (nc-nc)   Female 12 22.6 53.2 (27.4-92.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Pembroke 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 24 16.2 148.1 (94.8-220.3)   Male 15 11.4 131.8 (73.7-217.4) 
Female 6 5.6 107.3 (39.2-233.5)   Female 11 9.2 119.4 (59.5-213.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 3.5 nc (nc-nc)   Male 2 3.3 nc (nc-nc) 
Female 2 2.9 nc (nc-nc)   Female 0 2.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 15 10.0 150.2 (84.0-247.7) 
Female 91 72.6 125.3 (100.9-153.8)   Female 6 8.1 74.0 (27.0-161.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 8.6 93.0 (40.1-183.3) 
Female 2 2.7 nc (nc-nc)   Female 1 3.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 27 19.0 142.0 (93.6-206.6)             
Female 19 17.4 109.0 (65.6-170.2)   Female 4 6.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 4.7 nc (nc-nc)   Male 2 5.8 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 5 5.4 93.0 (30.0-217.1) 
Hodgkin Lymphoma            Prostate     
Male 0 1.5 nc (nc-nc)   Male 74 65.5 113.1 (88.8-141.9) 
Female 2 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 12 10.0 120.0 (61.9-209.6)   Male 3 4.0 nc (nc-nc) 
Female 6 5.5 109.7 (40.1-238.8)   Female 1 2.1 nc (nc-nc) 
Larynx            Testis     
Male 4 2.7 nc (nc-nc)   Male 2 2.5 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 6.8 131.9 (60.2-250.5)   Male 3 4.8 nc (nc-nc) 
Female 6 4.8 125.1 (45.7-272.3)   Female 22 14.5 151.2 (94.7-229.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 6.2 80.5 (26.0-188.0)             
Female 0 1.8 nc (nc-nc)   Female 17 16.6 102.5 (59.7-164.1) 
Lung and Bronchus            All Sites / Types     
Male 36 30.5 117.9 (82.6-163.2)   Male 262 234.3 111.8 (98.7-126.2) 
Female 44 30.9 142.5 (103.5-191.3)   Female 268 232.7 115.2 (101.8-129.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Pepperell 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 10.1 69.2 (27.7-142.5)   Male 8 7.3 109.8 (47.3-216.4) 
Female 2 3.5 nc (nc-nc)   Female 2 5.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 2.3 nc (nc-nc)   Male 2 2.1 nc (nc-nc) 
Female 2 1.8 nc (nc-nc)   Female 2 1.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 8 6.4 124.5 (53.6-245.4) 
Female 47 46.3 101.6 (74.7-135.1)   Female 5 5.1 98.8 (31.8-230.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 5.7 nc (nc-nc) 
Female 2 1.7 nc (nc-nc)   Female 4 2.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 10 12.2 81.7 (39.1-150.3)             
Female 16 11.0 145.9 (83.3-236.9)   Female 2 4.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 5 3.0 164.6 (53.0-384.1)   Male 3 3.7 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 5 3.3 150.3 (48.4-350.8) 
Hodgkin Lymphoma            Prostate     
Male 2 1.0 nc (nc-nc)   Male 36 42.4 84.9 (59.5-117.6) 
Female 1 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 6.5 92.6 (33.8-201.5)   Male 3 2.5 nc (nc-nc) 
Female 3 3.4 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Larynx            Testis     
Male 0 1.7 nc (nc-nc)   Male 2 1.6 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 4.4 160.6 (64.3-330.9)   Male 6 3.2 187.7 (68.5-408.6) 
Female 5 3.0 167.1 (53.8-389.9)   Female 4 9.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 4.1 nc (nc-nc)             
Female 0 1.1 nc (nc-nc)   Female 11 10.6 104.1 (51.9-186.3) 
Lung and Bronchus            All Sites / Types     
Male 19 19.1 99.5 (59.9-155.4)   Male 147 150.5 97.7 (82.5-114.8) 
Female 16 19.0 84.2 (48.1-136.7)   Female 138 146.7 94.1 (79.0-111.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Peru 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 0.9 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 3.3 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 1.1 nc (nc-nc)             
Female 1 0.8 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 3 3.9 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.6 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 1 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.4 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.4 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 1.7 nc (nc-nc)   Male 10 13.2 75.6 (36.2-139.1) 
Female 0 1.2 nc (nc-nc)   Female 4 10.2 nc (nc-nc) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Petersham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 1.8 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 4 6.2 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.8 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 1.9 nc (nc-nc)             
Female 0 1.7 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.5 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 4 6.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.0 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 1 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.7 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 2 0.4 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.6 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 3 1.5 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 3.3 nc (nc-nc)   Male 13 23.8 54.7 (29.1-93.5) 
Female 0 3.0 nc (nc-nc)   Female 15 20.7 72.6 (40.6-119.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Phillipston 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 1.6 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.4 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 5 6.5 76.5 (24.6-178.4)   Female 0 0.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.9 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 1.9 nc (nc-nc)             
Female 0 1.5 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.5 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 2 0.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 7 6.7 104.1 (41.7-214.5) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.0 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.7 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.6 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 4 1.5 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 3.0 nc (nc-nc)   Male 17 23.8 71.4 (41.6-114.4) 
Female 3 2.6 nc (nc-nc)   Female 18 20.2 88.9 (52.7-140.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
244 
Pittsfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 57 57.2 99.6 (75.4-129.0)   Male 29 35.3 82.1 (54.9-117.9) 
Female 26 21.6 120.1 (78.5-176.0)   Female 31 27.9 111.1 (75.4-157.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 15 9.7 154.0 (86.1-254.1)   Male 9 10.5 85.7 (39.1-162.7) 
Female 7 8.7 80.9 (32.4-166.7)   Female 5 9.0 55.5 (17.9-129.5) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.8 nc (nc-nc)   Male 34 31.3 108.7 (75.2-151.8) 
Female 210 211.9 99.1 (86.2-113.5)   Female 33 27.7 119.3 (82.1-167.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 28 23.9 117.1 (77.8-169.2) 
Female 9 6.9 129.7 (59.2-246.3)   Female 6 11.3 53.2 (19.4-115.8) 
Colon / Rectum            Ovary     
Male 64 61.0 104.9 (80.7-133.9)             
Female 86 65.2 131.9 (105.5-162.9)   Female 15 19.7 76.3 (42.7-125.9) 
Esophagus            Pancreas     
Male 26 14.5 178.8 (116.8-262.0)   Male 19 19.0 100.2 (60.3-156.5) 
Female 4 4.1 nc (nc-nc)   Female 15 21.2 70.6 (39.5-116.5) 
Hodgkin Lymphoma            Prostate     
Male 4 3.9 nc (nc-nc)   Male 179 188.8 94.8 (81.4-109.8) 
Female 2 3.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 30 28.5 105.2 (71.0-150.2)   Male 7 13.0 53.8 (21.5-110.8) 
Female 21 17.5 120.1 (74.3-183.7)   Female 4 8.3 nc (nc-nc) 
Larynx            Testis     
Male 7 8.0 87.8 (35.2-180.9)   Male 9 6.3 143.5 (65.5-272.4) 
Female 3 2.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 19 21.9 86.9 (52.3-135.7)   Male 14 12.5 112.2 (61.3-188.3) 
Female 9 16.7 54.0 (24.7-102.6)   Female 24 36.4 65.9 (42.2-98.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 21 18.1 116.3 (72.0-177.8)             
Female 7 6.3 111.9 (44.8-230.6)   Female 43 48.0 89.5 (64.8-120.6) 
Lung and Bronchus            All Sites / Types     
Male 112 101.4 110.5 (90.9-132.9)   Male 741 724.1 102.3 (95.1-110.0) 
Female 144 108.7 132.4 (111.7-155.9)   Female 759 745.4 101.8 (94.7-109.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Plainfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 1.0 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 1 3.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 1.0 nc (nc-nc)             
Female 0 0.8 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.3 nc (nc-nc)   Male 2 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 1 3.8 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.5 nc (nc-nc)   Male 1 0.2 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.3 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 5 1.8 277.4 (89.4-647.3)   Male 14 13.1 107.0 (58.5-179.6) 
Female 1 1.5 nc (nc-nc)   Female 8 10.4 76.7 (33.0-151.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Plainville 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 8.1 148.8 (76.8-260.0)   Male 5 5.5 91.4 (29.4-213.2) 
Female 2 3.1 nc (nc-nc)   Female 2 4.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.6 nc (nc-nc)   Male 2 1.6 nc (nc-nc) 
Female 0 1.4 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.3 nc (nc-nc)   Male 9 4.8 186.5 (85.1-354.1) 
Female 32 35.5 90.2 (61.7-127.4)   Female 3 4.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 4.0 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)   Female 4 1.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 8 9.1 87.5 (37.7-172.4)             
Female 10 9.4 106.1 (50.8-195.1)   Female 4 3.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 2.2 nc (nc-nc)   Male 6 2.8 214.7 (78.4-467.3) 
Female 1 0.6 nc (nc-nc)   Female 4 3.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.7 nc (nc-nc)   Male 33 30.5 108.1 (74.4-151.9) 
Female 0 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 4.7 213.4 (102.2-392.5)   Male 1 1.9 nc (nc-nc) 
Female 2 2.8 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Larynx            Testis     
Male 2 1.3 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 3.3 nc (nc-nc)   Male 3 2.2 nc (nc-nc) 
Female 5 2.5 198.8 (64.1-463.9)   Female 7 6.8 102.7 (41.2-211.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 2.9 nc (nc-nc)             
Female 0 1.0 nc (nc-nc)   Female 7 8.0 87.4 (35.0-180.2) 
Lung and Bronchus            All Sites / Types     
Male 14 14.9 93.9 (51.3-157.5)   Male 131 112.0 116.9 (97.8-138.8) 
Female 18 16.6 108.4 (64.2-171.3)   Female 117 118.4 98.8 (81.7-118.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
247 
Plymouth 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 72 60.0 120.0 (93.9-151.1)   Male 62 40.1 154.7 (118.6-198.4) 
Female 21 22.2 94.5 (58.5-144.5)   Female 63 32.3 195.2 (150.0-249.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 10 11.8 85.0 (40.7-156.4)   Male 13 11.7 111.3 (59.2-190.4) 
Female 11 10.0 109.9 (54.8-196.7)   Female 8 9.6 83.5 (35.9-164.5) 
Breast            Non-Hodgkin Lymphoma     
Male 3 1.9 nc (nc-nc)   Male 43 35.2 122.1 (88.3-164.4) 
Female 296 249.6 118.6 (105.5-132.9)   Female 35 30.2 115.8 (80.7-161.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 38 29.2 130.3 (92.2-178.9) 
Female 4 8.8 nc (nc-nc)   Female 13 12.7 102.2 (54.4-174.8) 
Colon / Rectum            Ovary     
Male 84 67.2 124.9 (99.7-154.7)             
Female 82 67.4 121.6 (96.7-150.9)   Female 26 22.8 114.1 (74.5-167.2) 
Esophagus            Pancreas     
Male 23 16.8 137.3 (87.0-206.0)   Male 23 20.9 110.3 (69.9-165.5) 
Female 1 4.3 nc (nc-nc)   Female 20 21.7 92.0 (56.2-142.1) 
Hodgkin Lymphoma            Prostate     
Male 4 5.0 nc (nc-nc)   Male 264 229.7 115.0 (101.5-129.7) 
Female 3 3.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 31 34.3 90.4 (61.4-128.3)   Male 17 14.3 119.2 (69.4-190.8) 
Female 20 19.7 101.8 (62.1-157.2)   Female 9 8.5 106.5 (48.6-202.1) 
Larynx            Testis     
Male 13 9.3 140.1 (74.5-239.5)   Male 3 8.5 nc (nc-nc) 
Female 1 3.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 33 24.2 136.3 (93.8-191.4)   Male 17 16.0 106.0 (61.7-169.8) 
Female 16 17.8 89.7 (51.2-145.6)   Female 70 46.2 151.5 (118.1-191.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 21 21.3 98.8 (61.1-151.1)             
Female 5 6.9 72.9 (23.5-170.2)   Female 58 58.4 99.4 (75.5-128.5) 
Lung and Bronchus            All Sites / Types     
Male 113 110.6 102.2 (84.2-122.9)   Male 956 829.1 115.3 (108.1-122.9) 
Female 123 116.1 105.9 (88.0-126.4)   Female 961 837.5 114.7 (107.6-122.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
248 
Plympton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 3.2 nc (nc-nc)   Male 2 2.2 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 3 1.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.6 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.9 nc (nc-nc) 
Female 9 12.6 71.2 (32.5-135.3)   Female 0 1.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.6 nc (nc-nc) 
Female 2 0.4 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 3.6 nc (nc-nc)             
Female 4 3.0 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 0.9 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 15 13.4 112.1 (62.7-184.9) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 1.9 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Larynx            Testis     
Male 0 0.5 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.3 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 1 2.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.2 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 1 3.0 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 6.1 nc (nc-nc)   Male 38 45.8 83.0 (58.7-113.9) 
Female 7 5.4 128.6 (51.5-265.0)   Female 39 40.3 96.8 (68.8-132.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
249 
Princeton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 3.8 158.7 (58.0-345.5)   Male 2 2.7 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 1 1.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 0.8 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 2 2.3 nc (nc-nc) 
Female 14 15.6 89.7 (49.0-150.5)   Female 3 1.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 2.1 233.7 (75.3-545.3) 
Female 1 0.5 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 4.5 111.8 (36.0-261.0)             
Female 1 3.7 nc (nc-nc)   Female 6 1.4 430.1 (157.0-936.1) 
Esophagus            Pancreas     
Male 3 1.2 nc (nc-nc)   Male 2 1.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.3 nc (nc-nc)   Male 24 16.7 143.8 (92.1-213.9) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 2.4 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 5 1.2 431.7 (139.1-1007.5)   Female 0 0.5 nc (nc-nc) 
Larynx            Testis     
Male 0 0.7 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 1.5 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 3 2.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.6 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 3 3.7 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 7.3 nc (nc-nc)   Male 63 56.4 111.8 (85.9-143.0) 
Female 3 6.5 nc (nc-nc)   Female 49 49.3 99.3 (73.5-131.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
250 
Provincetown 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 5.2 nc (nc-nc)   Male 7 3.4 205.6 (82.4-423.7) 
Female 2 1.6 nc (nc-nc)   Female 3 2.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.9 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 2 0.6 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 3 3.0 nc (nc-nc) 
Female 23 16.8 137.2 (87.0-205.9)   Female 1 2.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 2.6 194.1 (62.5-452.9) 
Female 0 0.5 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 5.9 101.3 (37.0-220.4)             
Female 5 4.7 106.1 (34.2-247.6)   Female 2 1.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.5 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 2 1.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 3 0.3 nc (nc-nc)   Male 14 20.1 69.8 (38.1-117.1) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 2.9 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Larynx            Testis     
Male 0 0.8 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.9 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 2 1.1 nc (nc-nc)   Female 1 2.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 1.9 nc (nc-nc)             
Female 1 0.5 nc (nc-nc)   Female 4 4.1 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 11 9.5 115.8 (57.7-207.3)   Male 77 71.0 108.4 (85.5-135.5) 
Female 10 8.4 119.4 (57.1-219.5)   Female 68 56.8 119.7 (93.0-151.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
251 
Quincy 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 81 98.3 82.4 (65.4-102.4)   Male 49 64.0 76.6 (56.7-101.3) 
Female 31 39.7 78.2 (53.1-111.0)   Female 64 55.6 115.1 (88.6-147.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 16 18.4 87.0 (49.7-141.3)   Male 16 18.5 86.6 (49.4-140.6) 
Female 11 16.7 66.0 (32.9-118.0)   Female 10 16.6 60.1 (28.8-110.6) 
Breast            Non-Hodgkin Lymphoma     
Male 2 3.1 nc (nc-nc)   Male 49 56.4 86.8 (64.2-114.8) 
Female 380 403.4 94.2 (85.0-104.2)   Female 58 51.9 111.7 (84.8-144.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 61 44.0 138.8 (106.1-178.3) 
Female 19 14.5 130.7 (78.6-204.1)   Female 22 21.2 103.5 (64.9-156.8) 
Colon / Rectum            Ovary     
Male 137 107.8 127.0 (106.7-150.2)             
Female 117 121.0 96.7 (80.0-115.9)   Female 37 37.5 98.5 (69.4-135.8) 
Esophagus            Pancreas     
Male 30 25.7 116.5 (78.6-166.4)   Male 30 33.2 90.5 (61.0-129.2) 
Female 9 7.5 119.5 (54.5-226.8)   Female 37 39.0 95.0 (66.9-130.9) 
Hodgkin Lymphoma            Prostate     
Male 7 8.5 82.8 (33.2-170.6)   Male 297 339.5 87.5 (77.8-98.0) 
Female 7 7.3 95.4 (38.2-196.6)             
Kidney & Renal Pelvis            Stomach     
Male 51 52.4 97.4 (72.5-128.1)   Male 25 22.9 109.4 (70.8-161.5) 
Female 39 32.8 118.8 (84.4-162.4)   Female 11 15.4 71.7 (35.7-128.2) 
Larynx            Testis     
Male 14 14.2 98.6 (53.8-165.4)   Male 13 15.5 83.8 (44.6-143.3) 
Female 7 5.0 140.9 (56.4-290.3)             
Leukemia            Thyroid     
Male 26 39.0 66.7 (43.5-97.7)   Male 20 24.9 80.2 (49.0-123.9) 
Female 28 31.3 89.4 (59.4-129.3)   Female 75 77.9 96.3 (75.7-120.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 58 32.4 178.8 (135.8-231.2)             
Female 13 11.6 112.3 (59.7-192.0)   Female 87 91.0 95.6 (76.5-117.9) 
Lung and Bronchus            All Sites / Types     
Male 214 175.9 121.7 (105.9-139.1)   Male 1290 1295.2 99.6 (94.2-105.2) 
Female 239 199.3 119.9 (105.2-136.2)   Female 1413 1412.7 100.0 (94.9-105.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
252 
Randolph 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 36 32.3 111.4 (78.0-154.2)   Male 13 21.4 60.7 (32.3-103.8) 
Female 6 12.6 47.8 (17.5-104.0)   Female 18 18.4 97.7 (57.9-154.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 6.3 94.7 (34.6-206.1)   Male 5 6.2 80.3 (25.9-187.4) 
Female 7 5.6 124.1 (49.7-255.7)   Female 9 5.4 167.5 (76.4-318.1) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.0 nc (nc-nc)   Male 17 18.9 90.0 (52.4-144.1) 
Female 120 139.0 86.3 (71.6-103.2)   Female 17 17.0 100.2 (58.3-160.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 15.4 32.4 (10.5-75.7) 
Female 9 5.0 180.8 (82.5-343.3)   Female 8 7.1 112.6 (48.5-221.9) 
Colon / Rectum            Ovary     
Male 40 36.2 110.5 (78.9-150.4)             
Female 42 38.5 109.1 (78.6-147.4)   Female 10 12.7 78.6 (37.6-144.6) 
Esophagus            Pancreas     
Male 6 8.8 68.0 (24.8-148.1)   Male 13 11.1 116.7 (62.1-199.5) 
Female 3 2.4 nc (nc-nc)   Female 11 12.2 90.1 (44.9-161.3) 
Hodgkin Lymphoma            Prostate     
Male 1 2.8 nc (nc-nc)   Male 123 119.1 103.3 (85.8-123.2) 
Female 0 2.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 22 18.0 122.1 (76.5-184.8)   Male 7 7.6 91.7 (36.7-188.9) 
Female 10 11.0 90.9 (43.5-167.1)   Female 6 4.8 124.3 (45.4-270.5) 
Larynx            Testis     
Male 7 4.9 143.0 (57.3-294.7)   Male 0 4.7 nc (nc-nc) 
Female 0 1.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 13 13.1 99.1 (52.7-169.5)   Male 4 8.5 nc (nc-nc) 
Female 5 10.2 49.2 (15.9-114.9)   Female 24 26.8 89.6 (57.4-133.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 15 11.3 132.2 (73.9-218.0)             
Female 7 3.8 183.3 (73.4-377.7)   Female 31 31.7 97.8 (66.5-138.9) 
Lung and Bronchus            All Sites / Types     
Male 54 58.9 91.7 (68.9-119.7)   Male 414 440.0 94.1 (85.2-103.6) 
Female 53 65.1 81.4 (60.9-106.4)   Female 431 470.6 91.6 (83.1-100.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
253 
Raynham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 17 14.4 117.8 (68.6-188.6)   Male 7 9.5 74.1 (29.7-152.6) 
Female 6 5.2 116.2 (42.4-252.9)   Female 11 7.5 146.2 (72.9-261.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 2.8 nc (nc-nc)   Male 3 2.8 nc (nc-nc) 
Female 3 2.3 nc (nc-nc)   Female 4 2.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 8 8.4 95.8 (41.2-188.7) 
Female 59 58.3 101.2 (77.0-130.5)   Female 8 7.0 113.7 (49.0-224.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 6.8 nc (nc-nc) 
Female 5 2.1 242.9 (78.3-566.9)   Female 2 3.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 16 16.0 99.7 (57.0-161.9)             
Female 19 15.8 120.4 (72.5-188.0)   Female 4 5.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 5 3.9 127.3 (41.0-297.2)   Male 6 4.9 121.5 (44.4-264.4) 
Female 4 1.0 nc (nc-nc)   Female 2 5.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 3 1.1 nc (nc-nc)   Male 53 52.8 100.4 (75.2-131.3) 
Female 0 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 11 8.0 137.6 (68.6-246.2)   Male 3 3.4 nc (nc-nc) 
Female 9 4.6 196.6 (89.7-373.2)   Female 4 2.0 nc (nc-nc) 
Larynx            Testis     
Male 1 2.2 nc (nc-nc)   Male 9 1.8 489.3 (223.3-928.9) 
Female 0 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 5.8 86.5 (27.9-201.9)   Male 6 3.7 163.7 (59.8-356.2) 
Female 6 4.2 143.6 (52.5-312.7)   Female 22 10.9 201.1 (126.0-304.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 5.0 nc (nc-nc)             
Female 2 1.6 nc (nc-nc)   Female 11 13.3 82.5 (41.2-147.7) 
Lung and Bronchus            All Sites / Types     
Male 33 26.3 125.5 (86.4-176.3)   Male 215 194.7 110.4 (96.2-126.2) 
Female 33 27.1 121.8 (83.8-171.1)   Female 235 195.2 120.4 (105.5-136.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
254 
Reading 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 31 26.4 117.2 (79.6-166.4)   Male 25 17.3 144.8 (93.7-213.7) 
Female 6 10.2 59.0 (21.6-128.5)   Female 15 14.3 105.1 (58.8-173.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 5.1 118.2 (43.2-257.3)   Male 4 5.1 nc (nc-nc) 
Female 5 4.4 112.7 (36.3-263.0)   Female 4 4.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.8 nc (nc-nc)   Male 17 15.3 111.1 (64.7-177.8) 
Female 130 110.0 118.2 (98.8-140.4)   Female 9 13.5 66.6 (30.4-126.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 12.3 48.6 (17.8-105.8) 
Female 2 3.8 nc (nc-nc)   Female 5 5.6 88.8 (28.6-207.1) 
Colon / Rectum            Ovary     
Male 31 29.6 104.9 (71.2-148.9)             
Female 31 31.3 99.0 (67.3-140.6)   Female 9 10.0 90.0 (41.1-170.9) 
Esophagus            Pancreas     
Male 11 7.1 155.2 (77.4-277.7)   Male 10 9.0 111.0 (53.1-204.1) 
Female 3 1.9 nc (nc-nc)   Female 7 9.9 70.5 (28.3-145.3) 
Hodgkin Lymphoma            Prostate     
Male 1 2.1 nc (nc-nc)   Male 74 94.1 78.6 (61.7-98.7) 
Female 4 1.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 9 14.5 62.1 (28.4-118.0)   Male 6 6.2 96.4 (35.2-209.9) 
Female 4 8.7 nc (nc-nc)   Female 2 3.9 nc (nc-nc) 
Larynx            Testis     
Male 4 3.9 nc (nc-nc)   Male 2 3.3 nc (nc-nc) 
Female 0 1.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 12 10.6 112.7 (58.2-197.0)   Male 9 6.7 134.9 (61.6-256.2) 
Female 11 8.2 134.8 (67.2-241.2)   Female 32 20.2 158.1 (108.1-223.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 9 9.1 98.9 (45.1-187.7)             
Female 6 3.0 197.2 (72.0-429.3)   Female 31 24.7 125.3 (85.1-177.8) 
Lung and Bronchus            All Sites / Types     
Male 45 47.6 94.5 (68.9-126.4)   Male 329 353.5 93.1 (83.3-103.7) 
Female 50 52.0 96.2 (71.4-126.9)   Female 407 373.2 109.1 (98.7-120.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
255 
Rehoboth 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 10 12.4 80.4 (38.5-147.9)   Male 8 8.5 94.2 (40.6-185.6) 
Female 3 3.9 nc (nc-nc)   Female 3 6.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 2.5 nc (nc-nc)   Male 2 2.5 nc (nc-nc) 
Female 3 1.9 nc (nc-nc)   Female 2 1.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.4 nc (nc-nc)   Male 6 7.5 80.4 (29.4-175.0) 
Female 48 50.1 95.8 (70.6-127.0)   Female 7 5.6 124.1 (49.7-255.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 6.5 nc (nc-nc) 
Female 0 1.8 nc (nc-nc)   Female 2 2.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 11 14.3 76.8 (38.3-137.4)             
Female 12 12.3 97.7 (50.4-170.6)   Female 2 4.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 3.6 nc (nc-nc)   Male 2 4.4 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 5 3.8 131.7 (42.4-307.3) 
Hodgkin Lymphoma            Prostate     
Male 1 1.0 nc (nc-nc)   Male 47 50.4 93.2 (68.5-123.9) 
Female 1 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 7.5 107.3 (46.2-211.4)   Male 1 3.0 nc (nc-nc) 
Female 6 3.8 158.3 (57.8-344.6)   Female 0 1.5 nc (nc-nc) 
Larynx            Testis     
Male 1 2.0 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 5.0 nc (nc-nc)   Male 1 3.5 nc (nc-nc) 
Female 3 3.3 nc (nc-nc)   Female 9 9.6 94.1 (42.9-178.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 4.7 nc (nc-nc)             
Female 2 1.3 nc (nc-nc)   Female 16 11.6 137.8 (78.7-223.7) 
Lung and Bronchus            All Sites / Types     
Male 28 23.3 120.0 (79.7-173.4)   Male 144 177.5 81.1 (68.4-95.5) 
Female 18 21.6 83.2 (49.3-131.5)   Female 151 161.1 93.7 (79.4-109.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
256 
Revere 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 47 54.8 85.7 (63.0-114.0)   Male 22 35.3 62.4 (39.1-94.4) 
Female 19 20.7 91.8 (55.2-143.4)   Female 26 29.0 89.6 (58.5-131.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 13 10.3 126.7 (67.4-216.7)   Male 10 10.2 98.0 (46.9-180.2) 
Female 8 8.9 89.7 (38.6-176.8)   Female 12 8.7 138.2 (71.3-241.3) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.7 nc (nc-nc)   Male 31 31.3 99.1 (67.3-140.7) 
Female 214 212.3 100.8 (87.7-115.2)   Female 28 27.2 103.0 (68.4-148.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 24 23.8 100.8 (64.5-149.9) 
Female 5 7.6 65.7 (21.2-153.3)   Female 12 11.1 108.1 (55.8-188.8) 
Colon / Rectum            Ovary     
Male 73 59.8 122.1 (95.7-153.6)             
Female 43 63.3 67.9 (49.1-91.5)   Female 14 19.7 71.2 (38.9-119.5) 
Esophagus            Pancreas     
Male 8 14.1 56.8 (24.5-112.0)   Male 17 18.3 92.8 (54.0-148.6) 
Female 5 3.9 126.7 (40.8-295.7)   Female 15 20.4 73.7 (41.2-121.6) 
Hodgkin Lymphoma            Prostate     
Male 7 4.7 148.3 (59.4-305.6)   Male 120 183.3 65.5 (54.3-78.3) 
Female 4 3.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 36 28.6 125.8 (88.1-174.1)   Male 23 12.6 181.9 (115.2-272.9) 
Female 35 17.3 202.4 (140.9-281.5)   Female 6 8.0 74.9 (27.3-163.0) 
Larynx            Testis     
Male 10 7.7 129.2 (61.9-237.6)   Male 9 8.5 105.3 (48.0-199.9) 
Female 8 2.6 308.0 (132.6-606.8)             
Leukemia            Thyroid     
Male 30 21.9 137.2 (92.5-195.9)   Male 13 13.6 95.8 (50.9-163.8) 
Female 12 16.6 72.1 (37.2-125.9)   Female 47 40.8 115.1 (84.6-153.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 32 17.6 182.0 (124.5-256.9)             
Female 5 6.1 82.5 (26.6-192.6)   Female 39 47.5 82.0 (58.3-112.1) 
Lung and Bronchus            All Sites / Types     
Male 127 97.3 130.6 (108.8-155.3)   Male 707 711.8 99.3 (92.1-106.9) 
Female 143 104.5 136.8 (115.3-161.2)   Female 758 741.2 102.3 (95.1-109.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
257 
Richmond 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 2.7 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.4 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 6 8.6 69.5 (25.4-151.4)   Female 1 1.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 1.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 2.8 nc (nc-nc)             
Female 4 2.3 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.7 nc (nc-nc)   Male 2 0.9 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 13 10.2 127.1 (67.6-217.4) 
Female 1 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 1.4 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 1 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.0 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 2 1.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.9 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 1 2.1 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 5.1 nc (nc-nc)   Male 28 35.6 78.8 (52.3-113.8) 
Female 2 4.2 nc (nc-nc)   Female 21 28.7 73.2 (45.3-112.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
258 
Rochester 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 5.4 nc (nc-nc)   Male 4 3.7 nc (nc-nc) 
Female 3 1.7 nc (nc-nc)   Female 3 2.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.1 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 2 3.3 nc (nc-nc) 
Female 26 22.1 117.5 (76.7-172.1)   Female 3 2.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 2.9 nc (nc-nc) 
Female 2 0.8 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 6.3 79.3 (25.6-185.1)             
Female 6 5.2 114.4 (41.8-249.0)   Female 2 2.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 1.6 nc (nc-nc)   Male 2 1.9 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 29 22.7 127.7 (85.5-183.4) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 3.3 nc (nc-nc)   Male 0 1.3 nc (nc-nc) 
Female 3 1.6 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Larynx            Testis     
Male 0 0.9 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 2.2 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 2 4.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 2.1 nc (nc-nc)             
Female 0 0.6 nc (nc-nc)   Female 3 5.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 12 10.1 118.5 (61.2-207.0)   Male 73 78.6 92.9 (72.8-116.8) 
Female 3 9.1 nc (nc-nc)   Female 65 70.1 92.7 (71.5-118.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
259 
Rockland 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 22 17.4 126.2 (79.1-191.1)   Male 9 11.5 78.0 (35.6-148.0) 
Female 12 7.0 172.3 (88.9-301.0)   Female 17 10.0 169.2 (98.5-271.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 8 3.4 233.5 (100.5-460.1)   Male 2 3.3 nc (nc-nc) 
Female 4 3.1 nc (nc-nc)   Female 0 3.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.6 nc (nc-nc)   Male 12 10.2 117.6 (60.7-205.5) 
Female 79 76.3 103.6 (82.0-129.1)   Female 13 9.3 139.1 (74.0-237.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 8.3 120.9 (57.9-222.3) 
Female 1 2.7 nc (nc-nc)   Female 6 3.9 154.2 (56.3-335.5) 
Colon / Rectum            Ovary     
Male 25 19.6 127.8 (82.7-188.7)             
Female 28 21.3 131.5 (87.4-190.1)   Female 4 7.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 5 4.7 105.9 (34.1-247.1)   Male 7 6.0 117.0 (46.9-241.1) 
Female 1 1.3 nc (nc-nc)   Female 7 6.8 103.3 (41.4-213.0) 
Hodgkin Lymphoma            Prostate     
Male 0 1.5 nc (nc-nc)   Male 70 63.2 110.8 (86.4-140.0) 
Female 0 1.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 12 9.7 123.8 (63.9-216.2)   Male 3 4.1 nc (nc-nc) 
Female 15 6.1 247.0 (138.1-407.4)   Female 5 2.7 187.3 (60.4-437.1) 
Larynx            Testis     
Male 2 2.6 nc (nc-nc)   Male 4 2.5 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 13 7.1 183.0 (97.4-313.0)   Male 3 4.6 nc (nc-nc) 
Female 13 5.6 230.7 (122.7-394.6)   Female 22 14.5 152.1 (95.3-230.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 6.1 nc (nc-nc)             
Female 4 2.1 nc (nc-nc)   Female 22 17.2 127.6 (79.9-193.2) 
Lung and Bronchus            All Sites / Types     
Male 38 31.6 120.3 (85.1-165.1)   Male 274 236.0 116.1 (102.7-130.7) 
Female 55 36.3 151.7 (114.3-197.5)   Female 329 258.9 127.1 (113.7-141.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
260 
Rockport 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 10.9 100.6 (50.2-180.0)   Male 9 6.6 135.6 (61.9-257.4) 
Female 3 4.4 nc (nc-nc)   Female 8 5.4 148.3 (63.9-292.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.7 nc (nc-nc)   Male 1 2.0 nc (nc-nc) 
Female 2 1.7 nc (nc-nc)   Female 3 1.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 3 0.3 nc (nc-nc)   Male 6 5.8 103.1 (37.7-224.4) 
Female 42 43.2 97.3 (70.1-131.5)   Female 7 5.6 124.7 (49.9-256.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 4.7 149.8 (60.0-308.6) 
Female 0 1.3 nc (nc-nc)   Female 5 2.3 215.6 (69.5-503.1) 
Colon / Rectum            Ovary     
Male 8 11.5 69.4 (29.9-136.8)             
Female 12 13.0 92.0 (47.5-160.8)   Female 2 4.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 2.9 nc (nc-nc)   Male 3 3.7 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 4 4.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.6 nc (nc-nc)   Male 42 39.6 106.0 (76.4-143.3) 
Female 2 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 5.5 126.9 (50.8-261.5)   Male 0 2.5 nc (nc-nc) 
Female 2 3.6 nc (nc-nc)   Female 2 1.6 nc (nc-nc) 
Larynx            Testis     
Male 0 1.6 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 4.0 125.4 (40.4-292.7)   Male 1 2.2 nc (nc-nc) 
Female 2 3.2 nc (nc-nc)   Female 9 6.5 138.3 (63.1-262.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 3.5 nc (nc-nc)             
Female 1 1.3 nc (nc-nc)   Female 10 10.3 97.2 (46.5-178.7) 
Lung and Bronchus            All Sites / Types     
Male 17 19.8 85.8 (50.0-137.4)   Male 140 141.0 99.3 (83.5-117.2) 
Female 8 22.6 35.4 (15.2-69.8)   Female 141 150.6 93.6 (78.8-110.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
261 
Rowe 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 0.8 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 1 2.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 0.8 nc (nc-nc)             
Female 0 0.6 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.2 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 2 2.7 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.1 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.3 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.2 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 1.4 nc (nc-nc)   Male 5 9.7 51.6 (16.6-120.4) 
Female 0 1.2 nc (nc-nc)   Female 2 7.6 nc (nc-nc) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
262 
Rowley 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 5.7 104.9 (38.3-228.3)   Male 3 4.0 nc (nc-nc) 
Female 1 2.0 nc (nc-nc)   Female 4 3.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.2 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 2 1.0 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 4 3.5 nc (nc-nc) 
Female 27 24.8 108.7 (71.6-158.1)   Female 4 2.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 3.1 nc (nc-nc) 
Female 2 0.9 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 6.8 nc (nc-nc)             
Female 6 6.3 95.9 (35.0-208.7)   Female 2 2.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 5 1.7 296.3 (95.5-691.4)   Male 4 2.1 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 2 1.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.5 nc (nc-nc)   Male 25 23.6 105.8 (68.5-156.2) 
Female 1 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 3.6 nc (nc-nc)   Male 0 1.4 nc (nc-nc) 
Female 4 1.9 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Larynx            Testis     
Male 0 1.0 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 2.4 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 0 1.7 nc (nc-nc)   Female 7 4.8 145.3 (58.2-299.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.3 nc (nc-nc)             
Female 0 0.6 nc (nc-nc)   Female 5 5.7 88.2 (28.4-205.9) 
Lung and Bronchus            All Sites / Types     
Male 9 10.8 83.6 (38.2-158.8)   Male 73 83.5 87.4 (68.5-109.9) 
Female 4 10.5 nc (nc-nc)   Female 84 80.0 105.0 (83.7-129.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Royalston 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.5 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 7 5.2 133.7 (53.6-275.4)   Female 1 0.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.8 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 1.7 nc (nc-nc)             
Female 0 1.2 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.4 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 7 6.2 113.0 (45.3-232.7) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.9 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 1 0.2 nc (nc-nc)   Male 1 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.6 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.6 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 2.8 nc (nc-nc)   Male 19 21.4 88.6 (53.3-138.4) 
Female 3 2.1 nc (nc-nc)   Female 18 16.5 109.0 (64.6-172.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Russell 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.6 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.4 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 8 6.9 116.2 (50.0-229.0)   Female 0 0.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.9 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 2 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 1.9 nc (nc-nc)             
Female 5 1.7 295.9 (95.4-690.6)   Female 1 0.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.5 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 4 6.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 1.0 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.7 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.6 nc (nc-nc)             
Female 1 0.2 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 3.1 nc (nc-nc)   Male 12 23.9 50.2 (25.9-87.7) 
Female 2 2.8 nc (nc-nc)   Female 24 22.2 108.0 (69.2-160.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Rutland 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 9 6.2 144.9 (66.1-275.1)   Male 4 4.5 nc (nc-nc) 
Female 1 2.1 nc (nc-nc)   Female 1 3.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.5 nc (nc-nc)   Male 0 1.3 nc (nc-nc) 
Female 2 1.2 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.2 nc (nc-nc)   Male 3 4.0 nc (nc-nc) 
Female 34 29.1 117.0 (81.0-163.5)   Female 3 3.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 3.5 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 9 7.5 119.2 (54.4-226.4)             
Female 7 6.8 102.4 (41.0-211.1)   Female 1 2.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 1.8 nc (nc-nc)   Male 2 2.2 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 3 2.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.7 nc (nc-nc)   Male 25 25.5 98.2 (63.5-145.0) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 4.0 nc (nc-nc)   Male 0 1.6 nc (nc-nc) 
Female 0 2.2 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Larynx            Testis     
Male 3 1.0 nc (nc-nc)   Male 3 1.1 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 2.8 181.4 (58.4-423.3)   Male 1 2.0 nc (nc-nc) 
Female 1 1.9 nc (nc-nc)   Female 6 6.2 96.4 (35.2-209.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 2.4 nc (nc-nc)             
Female 0 0.7 nc (nc-nc)   Female 9 6.4 139.9 (63.8-265.6) 
Lung and Bronchus            All Sites / Types     
Male 10 11.6 86.1 (41.2-158.4)   Male 89 92.3 96.4 (77.4-118.6) 
Female 10 11.7 85.5 (40.9-157.2)   Female 84 92.1 91.2 (72.8-113.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Salem 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 36 38.8 92.7 (64.9-128.3)   Male 26 25.7 101.1 (66.0-148.1) 
Female 11 15.9 69.4 (34.6-124.2)   Female 25 23.6 106.1 (68.6-156.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 9 7.7 117.6 (53.6-223.2)   Male 4 7.4 nc (nc-nc) 
Female 5 7.2 69.4 (22.4-161.9)   Female 7 6.8 103.5 (41.5-213.3) 
Breast            Non-Hodgkin Lymphoma     
Male 3 1.2 nc (nc-nc)   Male 36 22.8 158.2 (110.8-219.0) 
Female 192 172.7 111.2 (96.0-128.1)   Female 21 21.4 98.1 (60.7-149.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 16 18.1 88.3 (50.5-143.5) 
Female 4 6.3 nc (nc-nc)   Female 14 8.9 156.9 (85.7-263.3) 
Colon / Rectum            Ovary     
Male 49 43.2 113.3 (83.8-149.8)             
Female 47 48.6 96.7 (71.1-128.6)   Female 12 16.0 75.0 (38.7-131.1) 
Esophagus            Pancreas     
Male 18 10.4 172.5 (102.2-272.7)   Male 10 13.3 75.4 (36.1-138.7) 
Female 4 3.0 nc (nc-nc)   Female 20 15.5 129.3 (78.9-199.7) 
Hodgkin Lymphoma            Prostate     
Male 5 3.6 140.3 (45.2-327.5)   Male 162 139.1 116.4 (99.2-135.8) 
Female 8 3.4 238.2 (102.6-469.4)             
Kidney & Renal Pelvis            Stomach     
Male 31 21.4 145.0 (98.5-205.8)   Male 16 9.1 175.4 (100.2-284.9) 
Female 17 13.8 123.5 (71.9-197.8)   Female 3 6.1 nc (nc-nc) 
Larynx            Testis     
Male 7 5.8 121.4 (48.6-250.2)   Male 6 6.4 94.2 (34.4-205.1) 
Female 4 2.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 18 15.8 113.6 (67.3-179.5)   Male 13 10.3 126.1 (67.1-215.6) 
Female 15 12.9 116.1 (64.9-191.4)   Female 36 34.4 104.6 (73.2-144.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 18 13.3 135.4 (80.2-214.0)             
Female 4 4.8 nc (nc-nc)   Female 44 39.5 111.4 (80.9-149.5) 
Lung and Bronchus            All Sites / Types     
Male 72 70.2 102.6 (80.3-129.2)   Male 602 523.8 114.9 (105.9-124.5) 
Female 93 81.6 114.0 (92.0-139.7)   Female 631 591.4 106.7 (98.5-115.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Salisbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 13 9.5 136.4 (72.6-233.3)   Male 12 6.4 188.3 (97.2-328.9) 
Female 3 3.4 nc (nc-nc)   Female 3 5.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.8 nc (nc-nc)   Male 2 1.9 nc (nc-nc) 
Female 1 1.5 nc (nc-nc)   Female 2 1.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.3 nc (nc-nc)   Male 5 5.6 89.7 (28.9-209.4) 
Female 45 40.1 112.2 (81.8-150.1)   Female 11 4.7 232.9 (116.1-416.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 11 4.8 231.5 (115.4-414.3) 
Female 2 1.4 nc (nc-nc)   Female 0 2.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 18 10.8 167.1 (99.0-264.0)             
Female 15 10.3 145.6 (81.4-240.1)   Female 8 3.6 221.0 (95.2-435.5) 
Esophagus            Pancreas     
Male 2 2.7 nc (nc-nc)   Male 2 3.3 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 4 3.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.7 nc (nc-nc)   Male 33 37.7 87.4 (60.2-122.8) 
Female 1 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 11 5.5 199.1 (99.2-356.2)   Male 0 2.3 nc (nc-nc) 
Female 4 3.1 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Larynx            Testis     
Male 1 1.5 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 3.8 nc (nc-nc)   Male 0 2.5 nc (nc-nc) 
Female 3 2.7 nc (nc-nc)   Female 2 7.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 3.5 nc (nc-nc)             
Female 1 1.1 nc (nc-nc)   Female 11 9.4 116.6 (58.1-208.7) 
Lung and Bronchus            All Sites / Types     
Male 20 17.9 112.0 (68.4-173.0)   Male 147 133.2 110.4 (93.2-129.7) 
Female 28 18.7 149.4 (99.3-216.0)   Female 158 132.2 119.5 (101.6-139.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Sandisfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 1.7 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 1 4.4 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.8 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 1.8 nc (nc-nc)             
Female 0 1.1 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.5 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 3 6.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.9 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.6 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.6 nc (nc-nc)             
Female 1 0.1 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 3.2 nc (nc-nc)   Male 14 22.5 62.1 (33.9-104.2) 
Female 3 2.1 nc (nc-nc)   Female 9 14.5 62.2 (28.4-118.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Sandwich 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 31 24.3 127.4 (86.6-180.9)   Male 26 15.8 164.5 (107.4-241.0) 
Female 7 8.9 79.0 (31.7-162.9)   Female 22 12.4 176.9 (110.8-267.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 9 4.5 200.3 (91.4-380.3)   Male 3 4.7 nc (nc-nc) 
Female 5 3.9 129.0 (41.6-301.0)   Female 1 3.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.8 nc (nc-nc)   Male 18 13.9 129.6 (76.7-204.8) 
Female 105 99.4 105.7 (86.4-127.9)   Female 16 12.0 133.7 (76.4-217.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 11 11.6 95.0 (47.3-169.9) 
Female 0 3.3 nc (nc-nc)   Female 6 5.0 118.9 (43.4-258.7) 
Colon / Rectum            Ovary     
Male 21 27.0 77.7 (48.1-118.8)             
Female 25 26.9 93.0 (60.2-137.3)   Female 8 9.0 88.8 (38.2-175.0) 
Esophagus            Pancreas     
Male 5 6.7 74.1 (23.9-173.0)   Male 12 8.4 142.6 (73.6-249.1) 
Female 2 1.7 nc (nc-nc)   Female 9 8.6 104.7 (47.8-198.7) 
Hodgkin Lymphoma            Prostate     
Male 2 1.7 nc (nc-nc)   Male 111 92.4 120.1 (98.8-144.6) 
Female 0 1.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 13.5 74.1 (35.5-136.3)   Male 7 5.7 122.1 (48.9-251.6) 
Female 4 7.8 nc (nc-nc)   Female 4 3.4 nc (nc-nc) 
Larynx            Testis     
Male 2 3.7 nc (nc-nc)   Male 1 2.6 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 15 9.5 157.8 (88.2-260.2)   Male 4 6.0 nc (nc-nc) 
Female 5 7.0 71.7 (23.1-167.4)   Female 11 17.4 63.3 (31.6-113.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 8.6 69.9 (25.5-152.2)             
Female 1 2.7 nc (nc-nc)   Female 22 23.0 95.5 (59.8-144.5) 
Lung and Bronchus            All Sites / Types     
Male 21 44.9 46.8 (28.9-71.5)   Male 355 330.9 107.3 (96.4-119.1) 
Female 44 46.9 93.9 (68.2-126.1)   Female 324 331.4 97.8 (87.4-109.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Saugus 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 40 34.0 117.7 (84.1-160.3)   Male 14 21.4 65.5 (35.8-109.9) 
Female 20 12.7 157.1 (95.9-242.6)   Female 16 17.1 93.8 (53.6-152.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 5.8 nc (nc-nc)   Male 4 6.3 nc (nc-nc) 
Female 9 5.2 172.4 (78.7-327.3)   Female 3 5.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.1 nc (nc-nc)   Male 22 18.8 117.2 (73.4-177.5) 
Female 144 131.9 109.2 (92.1-128.5)   Female 17 16.6 102.1 (59.4-163.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 22 14.7 149.4 (93.6-226.2) 
Female 4 4.4 nc (nc-nc)   Female 7 6.9 101.7 (40.7-209.5) 
Colon / Rectum            Ovary     
Male 43 36.5 117.7 (85.2-158.5)             
Female 40 38.1 104.9 (74.9-142.8)   Female 8 12.1 66.1 (28.4-130.2) 
Esophagus            Pancreas     
Male 14 8.9 157.6 (86.1-264.4)   Male 8 11.4 70.2 (30.2-138.3) 
Female 4 2.5 nc (nc-nc)   Female 12 12.4 97.0 (50.1-169.5) 
Hodgkin Lymphoma            Prostate     
Male 5 2.4 211.8 (68.2-494.2)   Male 97 117.6 82.5 (66.9-100.7) 
Female 1 2.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 27 17.5 153.9 (101.4-224.0)   Male 8 7.8 102.6 (44.2-202.1) 
Female 11 10.7 102.6 (51.2-183.6)   Female 2 4.8 nc (nc-nc) 
Larynx            Testis     
Male 6 4.9 122.6 (44.8-266.9)   Male 9 3.8 239.8 (109.4-455.2) 
Female 3 1.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 18 12.9 139.3 (82.5-220.2)   Male 11 7.7 142.6 (71.1-255.1) 
Female 5 9.8 51.2 (16.5-119.6)   Female 18 23.0 78.3 (46.4-123.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 14 11.0 126.7 (69.2-212.7)             
Female 4 3.8 nc (nc-nc)   Female 27 30.4 88.9 (58.6-129.3) 
Lung and Bronchus            All Sites / Types     
Male 67 61.3 109.2 (84.6-138.7)   Male 468 439.7 106.4 (97.0-116.5) 
Female 90 66.3 135.8 (109.2-167.0)   Female 495 454.2 109.0 (99.6-119.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Savoy 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 0.9 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 4 3.0 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 1.0 nc (nc-nc)             
Female 0 0.7 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 1 3.8 nc (nc-nc) 
Female 1 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.5 nc (nc-nc)   Male 1 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.4 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 1.8 nc (nc-nc)   Male 5 13.2 37.9 (12.2-88.6) 
Female 0 1.3 nc (nc-nc)   Female 8 9.8 81.9 (35.3-161.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Scituate 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 26 23.5 110.5 (72.2-161.9)   Male 39 14.8 264.1 (187.8-361.1) 
Female 12 8.4 143.3 (74.0-250.4)   Female 32 11.2 284.5 (194.6-401.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 4.1 122.2 (39.4-285.3)   Male 5 4.4 112.9 (36.4-263.5) 
Female 3 3.5 nc (nc-nc)   Female 4 3.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.7 nc (nc-nc)   Male 11 13.0 84.7 (42.2-151.6) 
Female 98 90.1 108.8 (88.3-132.6)   Female 9 11.1 81.4 (37.1-154.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 17 10.4 163.7 (95.3-262.1) 
Female 1 2.9 nc (nc-nc)   Female 6 4.6 129.9 (47.4-282.8) 
Colon / Rectum            Ovary     
Male 21 25.5 82.3 (50.9-125.9)             
Female 18 25.4 71.0 (42.0-112.2)   Female 8 8.2 98.1 (42.2-193.3) 
Esophagus            Pancreas     
Male 6 6.2 96.3 (35.2-209.7)   Male 8 7.9 100.7 (43.3-198.4) 
Female 0 1.6 nc (nc-nc)   Female 9 8.1 110.6 (50.5-210.0) 
Hodgkin Lymphoma            Prostate     
Male 2 1.5 nc (nc-nc)   Male 63 83.1 75.8 (58.3-97.0) 
Female 2 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 12.3 48.8 (17.8-106.3)   Male 7 5.4 129.0 (51.7-265.8) 
Female 6 7.2 83.3 (30.4-181.4)   Female 3 3.2 nc (nc-nc) 
Larynx            Testis     
Male 1 3.4 nc (nc-nc)   Male 1 2.1 nc (nc-nc) 
Female 2 1.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 9.0 100.2 (45.7-190.1)   Male 2 5.3 nc (nc-nc) 
Female 8 6.5 122.9 (52.9-242.2)   Female 19 15.2 124.7 (75.0-194.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 7.8 nc (nc-nc)             
Female 2 2.5 nc (nc-nc)   Female 14 20.6 67.8 (37.1-113.8) 
Lung and Bronchus            All Sites / Types     
Male 37 42.7 86.7 (61.0-119.5)   Male 295 306.7 96.2 (85.5-107.8) 
Female 47 43.9 107.1 (78.7-142.5)   Female 321 304.4 105.5 (94.2-117.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Seekonk 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 19 16.7 113.5 (68.3-177.2)   Male 11 10.8 101.7 (50.7-182.0) 
Female 2 5.4 nc (nc-nc)   Female 8 8.0 100.0 (43.1-197.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 3.0 nc (nc-nc)   Male 3 3.2 nc (nc-nc) 
Female 2 2.5 nc (nc-nc)   Female 1 2.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.5 nc (nc-nc)   Male 12 9.5 126.4 (65.2-220.7) 
Female 59 63.0 93.6 (71.3-120.8)   Female 5 7.5 67.1 (21.6-156.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 7.7 64.9 (20.9-151.4) 
Female 2 2.2 nc (nc-nc)   Female 5 3.2 158.1 (50.9-368.9) 
Colon / Rectum            Ovary     
Male 10 18.4 54.3 (26.0-99.8)             
Female 10 16.7 59.9 (28.7-110.2)   Female 6 5.7 105.5 (38.5-229.6) 
Esophagus            Pancreas     
Male 3 4.5 nc (nc-nc)   Male 3 5.7 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 7 5.3 133.0 (53.3-274.1) 
Hodgkin Lymphoma            Prostate     
Male 0 1.2 nc (nc-nc)   Male 42 61.0 68.8 (49.6-93.1) 
Female 0 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 9.1 76.9 (30.8-158.5)   Male 5 3.9 127.6 (41.1-297.8) 
Female 1 4.9 nc (nc-nc)   Female 1 2.1 nc (nc-nc) 
Larynx            Testis     
Male 2 2.5 nc (nc-nc)   Male 1 1.9 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 6.5 108.1 (43.3-222.8)   Male 4 4.1 nc (nc-nc) 
Female 3 4.3 nc (nc-nc)   Female 13 11.6 111.9 (59.5-191.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 5.7 nc (nc-nc)             
Female 0 1.7 nc (nc-nc)   Female 9 14.5 62.1 (28.3-117.8) 
Lung and Bronchus            All Sites / Types     
Male 19 30.6 62.0 (37.3-96.8)   Male 170 223.5 76.1 (65.1-88.4) 
Female 32 29.0 110.3 (75.4-155.7)   Female 179 208.7 85.8 (73.7-99.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Sharon 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 14 19.0 73.8 (40.3-123.8)   Male 14 12.7 110.5 (60.4-185.4) 
Female 5 6.4 78.6 (25.3-183.4)   Female 13 9.7 134.0 (71.3-229.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 3.7 nc (nc-nc)   Male 8 3.7 213.5 (91.9-420.6) 
Female 2 3.1 nc (nc-nc)   Female 2 2.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.6 nc (nc-nc)   Male 18 11.2 161.2 (95.5-254.7) 
Female 87 77.4 112.4 (90.1-138.7)   Female 8 8.9 89.7 (38.6-176.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 9.5 62.9 (23.0-136.9) 
Female 1 2.7 nc (nc-nc)   Female 1 3.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 13 21.7 59.9 (31.9-102.5)             
Female 12 19.8 60.7 (31.3-106.0)   Female 9 6.9 129.5 (59.1-245.9) 
Esophagus            Pancreas     
Male 3 5.4 nc (nc-nc)   Male 10 6.6 150.5 (72.1-276.9) 
Female 2 1.2 nc (nc-nc)   Female 8 6.2 130.0 (56.0-256.1) 
Hodgkin Lymphoma            Prostate     
Male 2 1.4 nc (nc-nc)   Male 72 73.7 97.7 (76.5-123.1) 
Female 1 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 11.0 54.7 (20.0-119.2)   Male 3 4.6 nc (nc-nc) 
Female 5 5.9 84.6 (27.3-197.4)   Female 1 2.4 nc (nc-nc) 
Larynx            Testis     
Male 1 3.0 nc (nc-nc)   Male 4 2.1 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 7.6 nc (nc-nc)   Male 8 5.0 160.0 (68.9-315.4) 
Female 4 5.2 nc (nc-nc)   Female 30 14.5 207.3 (139.8-295.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 7.0 nc (nc-nc)             
Female 2 2.0 nc (nc-nc)   Female 12 17.9 67.1 (34.7-117.3) 
Lung and Bronchus            All Sites / Types     
Male 13 35.0 37.1 (19.8-63.5)   Male 226 264.0 85.6 (74.8-97.5) 
Female 32 34.0 94.2 (64.4-133.0)   Female 256 252.0 101.6 (89.5-114.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Sheffield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 4.8 104.2 (33.6-243.3)   Male 4 3.0 nc (nc-nc) 
Female 0 1.7 nc (nc-nc)   Female 3 2.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.8 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 2 0.7 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 0 2.6 nc (nc-nc) 
Female 22 17.2 128.1 (80.2-193.9)   Female 2 2.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 2.1 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 5.2 nc (nc-nc)             
Female 3 4.9 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.3 nc (nc-nc)   Male 0 1.6 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 1.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.3 nc (nc-nc)   Male 17 17.3 98.3 (57.3-157.5) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 2.5 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Larynx            Testis     
Male 0 0.7 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.8 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 1 2.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.6 nc (nc-nc)             
Female 1 0.5 nc (nc-nc)   Female 3 4.0 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 5 8.7 57.2 (18.4-133.6)   Male 46 62.7 73.3 (53.7-97.8) 
Female 16 8.6 185.5 (106.0-301.3)   Female 64 58.8 108.9 (83.9-139.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Shelburne 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 2.7 nc (nc-nc)   Male 3 1.7 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 3 1.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 0.5 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 2 0.4 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.5 nc (nc-nc) 
Female 8 10.1 79.1 (34.1-155.9)   Female 3 1.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.2 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 2.9 nc (nc-nc)             
Female 3 3.0 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.7 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 16 10.1 158.5 (90.5-257.4) 
Female 1 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 1.4 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Larynx            Testis     
Male 0 0.4 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.0 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 2 1.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.9 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 7 2.4 289.4 (116.0-596.4) 
Lung and Bronchus            All Sites / Types     
Male 4 5.0 nc (nc-nc)   Male 41 36.1 113.6 (81.5-154.2) 
Female 3 5.1 nc (nc-nc)   Female 41 35.1 116.7 (83.7-158.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Sherborn 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 4.8 144.7 (58.0-298.1)   Male 5 3.2 157.9 (50.9-368.5) 
Female 1 1.5 nc (nc-nc)   Female 3 2.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 0.9 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 2 2.8 nc (nc-nc) 
Female 21 18.8 111.8 (69.2-170.9)   Female 3 2.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 2.4 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 8 5.5 146.6 (63.1-288.9)             
Female 3 4.7 nc (nc-nc)   Female 3 1.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.4 nc (nc-nc)   Male 3 1.7 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 2 1.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.3 nc (nc-nc)   Male 20 18.4 108.9 (66.5-168.1) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 2.7 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 2 1.4 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Larynx            Testis     
Male 0 0.8 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 1.9 nc (nc-nc)   Male 2 1.2 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 5 3.3 149.8 (48.3-349.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.8 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 5 4.3 116.1 (37.4-271.0) 
Lung and Bronchus            All Sites / Types     
Male 3 9.0 nc (nc-nc)   Male 65 66.2 98.2 (75.8-125.2) 
Female 7 8.3 84.7 (34.0-174.6)   Female 62 60.3 102.9 (78.9-131.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
278 
Shirley 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 6.4 124.7 (53.7-245.8)   Male 4 4.9 nc (nc-nc) 
Female 5 2.0 253.9 (81.8-592.4)   Female 0 3.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.5 nc (nc-nc)   Male 0 1.3 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 4 4.3 nc (nc-nc) 
Female 23 24.3 94.5 (59.9-141.8)   Female 0 2.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 3.6 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 13 7.9 164.6 (87.5-281.4)             
Female 9 6.2 146.2 (66.7-277.5)   Female 2 2.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.9 nc (nc-nc)   Male 3 2.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 3 1.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.8 nc (nc-nc)   Male 24 24.8 96.7 (61.9-143.9) 
Female 1 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 4.2 167.6 (67.2-345.4)   Male 1 1.6 nc (nc-nc) 
Female 1 1.9 nc (nc-nc)   Female 2 0.8 nc (nc-nc) 
Larynx            Testis     
Male 2 1.0 nc (nc-nc)   Male 1 1.7 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 2.9 nc (nc-nc)   Male 2 2.3 nc (nc-nc) 
Female 1 1.6 nc (nc-nc)   Female 4 4.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 8 2.5 314.6 (135.5-619.9)             
Female 0 0.6 nc (nc-nc)   Female 12 5.5 216.3 (111.7-377.9) 
Lung and Bronchus            All Sites / Types     
Male 23 11.8 195.2 (123.7-292.9)   Male 110 95.1 115.7 (95.1-139.5) 
Female 15 10.5 142.8 (79.8-235.5)   Female 86 79.2 108.6 (86.8-134.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
279 
Shrewsbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 43 36.3 118.4 (85.7-159.5)   Male 11 23.9 46.1 (23.0-82.4) 
Female 10 13.5 74.2 (35.5-136.5)   Female 20 19.3 103.4 (63.1-159.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 9 7.1 127.1 (58.0-241.2)   Male 10 6.9 144.2 (69.1-265.3) 
Female 3 6.1 nc (nc-nc)   Female 5 5.7 87.6 (28.2-204.5) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.2 nc (nc-nc)   Male 32 21.2 150.9 (103.2-213.1) 
Female 151 147.4 102.5 (86.8-120.2)   Female 12 18.1 66.5 (34.3-116.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 13 16.8 77.5 (41.2-132.6) 
Female 3 5.3 nc (nc-nc)   Female 5 7.5 66.9 (21.5-156.0) 
Colon / Rectum            Ovary     
Male 38 40.7 93.3 (66.0-128.1)             
Female 34 41.8 81.3 (56.3-113.7)   Female 12 13.3 90.3 (46.6-157.7) 
Esophagus            Pancreas     
Male 14 9.6 145.8 (79.7-244.7)   Male 13 12.3 105.6 (56.2-180.6) 
Female 2 2.6 nc (nc-nc)   Female 8 13.2 60.8 (26.2-119.8) 
Hodgkin Lymphoma            Prostate     
Male 1 3.0 nc (nc-nc)   Male 130 125.8 103.3 (86.3-122.7) 
Female 5 2.4 204.3 (65.8-476.7)             
Kidney & Renal Pelvis            Stomach     
Male 30 19.9 150.6 (101.6-215.1)   Male 5 8.6 58.5 (18.8-136.5) 
Female 11 11.6 94.5 (47.1-169.0)   Female 2 5.3 nc (nc-nc) 
Larynx            Testis     
Male 2 5.3 nc (nc-nc)   Male 7 5.0 138.7 (55.6-285.7) 
Female 0 1.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 12 14.7 81.5 (42.1-142.4)   Male 15 9.4 160.0 (89.5-263.9) 
Female 9 11.0 81.6 (37.2-154.8)   Female 17 28.3 60.1 (35.0-96.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 9 12.2 73.8 (33.7-140.1)             
Female 1 4.0 nc (nc-nc)   Female 25 32.4 77.2 (49.9-113.9) 
Lung and Bronchus            All Sites / Types     
Male 56 65.2 85.9 (64.9-111.5)   Male 495 482.7 102.5 (93.7-112.0) 
Female 57 68.7 83.0 (62.9-107.6)   Female 425 499.3 85.1 (77.2-93.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
280 
Shutesbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 1.8 nc (nc-nc)   Male 0 1.3 nc (nc-nc) 
Female 2 0.5 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.4 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 6 8.0 75.2 (27.4-163.6)   Female 0 0.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.0 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 2.1 nc (nc-nc)             
Female 1 1.7 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.5 nc (nc-nc)   Male 3 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 3 7.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.1 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 1 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.7 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.8 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 3 1.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 3.4 nc (nc-nc)   Male 14 26.4 53.0 (29.0-89.0) 
Female 1 3.0 nc (nc-nc)   Female 17 24.5 69.5 (40.5-111.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
281 
Somerset 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 25 26.2 95.3 (61.7-140.8)   Male 13 15.8 82.3 (43.8-140.7) 
Female 12 10.7 112.3 (58.0-196.1)   Female 8 12.7 62.9 (27.1-123.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 4.2 119.8 (38.6-279.6)   Male 2 4.7 nc (nc-nc) 
Female 3 3.9 nc (nc-nc)   Female 4 4.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.8 nc (nc-nc)   Male 13 14.0 93.0 (49.5-159.1) 
Female 90 97.5 92.3 (74.2-113.5)   Female 12 13.2 90.6 (46.8-158.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 10.5 76.5 (32.9-150.7) 
Female 2 3.0 nc (nc-nc)   Female 7 5.3 131.7 (52.7-271.3) 
Colon / Rectum            Ovary     
Male 25 27.5 91.0 (58.9-134.4)             
Female 30 32.0 93.9 (63.3-134.0)   Female 10 9.1 109.9 (52.6-202.2) 
Esophagus            Pancreas     
Male 5 6.5 76.5 (24.6-178.4)   Male 12 8.6 139.5 (72.0-243.7) 
Female 0 2.0 nc (nc-nc)   Female 10 10.6 94.7 (45.3-174.2) 
Hodgkin Lymphoma            Prostate     
Male 4 1.6 nc (nc-nc)   Male 88 84.4 104.3 (83.6-128.4) 
Female 0 1.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 16 12.6 126.6 (72.3-205.6)   Male 11 5.9 186.7 (93.1-334.1) 
Female 9 8.2 109.8 (50.1-208.4)   Female 5 4.1 121.9 (39.3-284.5) 
Larynx            Testis     
Male 4 3.6 nc (nc-nc)   Male 7 2.4 290.3 (116.3-598.2) 
Female 1 1.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 11 9.7 113.4 (56.5-202.8)   Male 3 5.3 nc (nc-nc) 
Female 12 7.9 152.0 (78.5-265.6)   Female 23 15.5 148.7 (94.2-223.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 7.9 88.3 (35.4-181.9)             
Female 1 3.0 nc (nc-nc)   Female 26 22.0 118.4 (77.3-173.5) 
Lung and Bronchus            All Sites / Types     
Male 52 46.2 112.5 (84.0-147.5)   Male 335 324.4 103.3 (92.5-114.9) 
Female 39 52.4 74.5 (53.0-101.8)   Female 332 350.4 94.7 (84.8-105.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
282 
Somerville 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 43 50.6 85.0 (61.5-114.5)   Male 31 36.8 84.2 (57.2-119.5) 
Female 20 20.1 99.6 (60.8-153.9)   Female 17 36.0 47.2 (27.5-75.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 8 12.1 66.1 (28.5-130.3)   Male 12 9.8 122.3 (63.1-213.7) 
Female 14 10.5 133.6 (73.0-224.2)   Female 11 8.6 128.5 (64.0-229.9) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.6 nc (nc-nc)   Male 37 32.6 113.4 (79.9-156.4) 
Female 190 224.0 84.8 (73.2-97.8)   Female 19 28.4 66.9 (40.3-104.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 29 24.9 116.4 (78.0-167.2) 
Female 8 10.2 78.7 (33.9-155.0)   Female 8 11.6 69.2 (29.8-136.4) 
Colon / Rectum            Ovary     
Male 55 58.2 94.5 (71.2-123.0)             
Female 56 62.6 89.5 (67.6-116.2)   Female 22 21.3 103.4 (64.8-156.6) 
Esophagus            Pancreas     
Male 12 13.6 88.4 (45.6-154.4)   Male 21 17.4 120.9 (74.8-184.9) 
Female 6 3.9 155.8 (56.9-339.2)   Female 21 19.6 107.0 (66.2-163.6) 
Hodgkin Lymphoma            Prostate     
Male 15 7.7 194.7 (108.9-321.1)   Male 151 179.1 84.3 (71.4-98.9) 
Female 4 6.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 34 29.8 114.0 (79.0-159.3)   Male 17 12.2 139.7 (81.3-223.7) 
Female 23 18.0 128.0 (81.1-192.0)   Female 11 7.9 138.9 (69.3-248.6) 
Larynx            Testis     
Male 10 7.6 132.4 (63.4-243.6)   Male 7 16.8 41.8 (16.7-86.1) 
Female 2 2.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 19 22.7 83.8 (50.4-130.9)   Male 19 17.5 108.5 (65.3-169.4) 
Female 19 17.8 106.6 (64.2-166.5)   Female 53 58.8 90.1 (67.5-117.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 25 17.6 142.4 (92.2-210.3)             
Female 13 6.1 214.2 (113.9-366.3)   Female 46 49.6 92.8 (67.9-123.7) 
Lung and Bronchus            All Sites / Types     
Male 111 90.6 122.5 (100.8-147.5)   Male 706 714.7 98.8 (91.6-106.4) 
Female 103 103.2 99.8 (81.4-121.0)   Female 727 789.6 92.1 (85.5-99.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
283 
South Hadley 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 19 21.4 88.8 (53.4-138.7)   Male 22 13.0 169.3 (106.1-256.3) 
Female 13 8.4 154.0 (81.9-263.3)   Female 9 11.1 80.9 (36.9-153.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 3.5 nc (nc-nc)   Male 3 3.9 nc (nc-nc) 
Female 2 3.5 nc (nc-nc)   Female 1 3.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.7 nc (nc-nc)   Male 12 11.5 104.4 (53.9-182.3) 
Female 97 81.5 119.0 (96.5-145.2)   Female 10 10.8 92.3 (44.2-169.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 8.7 57.1 (18.4-133.4) 
Female 5 2.7 188.2 (60.6-439.2)   Female 7 4.4 159.1 (63.7-327.7) 
Colon / Rectum            Ovary     
Male 22 22.6 97.2 (60.9-147.2)             
Female 31 25.5 121.7 (82.7-172.7)   Female 5 7.7 64.8 (20.9-151.3) 
Esophagus            Pancreas     
Male 5 5.4 92.7 (29.9-216.2)   Male 5 7.1 70.8 (22.8-165.3) 
Female 3 1.6 nc (nc-nc)   Female 8 8.3 96.4 (41.5-190.0) 
Hodgkin Lymphoma            Prostate     
Male 0 1.3 nc (nc-nc)   Male 74 70.0 105.6 (82.9-132.6) 
Female 0 1.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 10.4 76.6 (33.0-151.0)   Male 8 4.8 165.6 (71.3-326.3) 
Female 6 6.8 88.9 (32.4-193.4)   Female 2 3.2 nc (nc-nc) 
Larynx            Testis     
Male 8 2.9 271.4 (116.9-534.8)   Male 1 2.0 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 8.0 62.7 (20.2-146.3)   Male 3 4.4 nc (nc-nc) 
Female 7 6.6 106.7 (42.7-219.8)   Female 10 14.7 67.9 (32.5-124.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 6.6 nc (nc-nc)             
Female 0 2.4 nc (nc-nc)   Female 24 18.5 129.8 (83.2-193.2) 
Lung and Bronchus            All Sites / Types     
Male 33 37.7 87.4 (60.2-122.8)   Male 263 267.4 98.4 (86.8-111.0) 
Female 37 42.3 87.5 (61.6-120.7)   Female 295 290.7 101.5 (90.2-113.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
284 
Southampton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 6.3 79.1 (25.5-184.6)   Male 1 4.4 nc (nc-nc) 
Female 2 2.1 nc (nc-nc)   Female 2 3.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.3 nc (nc-nc)   Male 0 1.3 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 2 0.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 3 3.8 nc (nc-nc) 
Female 22 26.6 82.7 (51.8-125.2)   Female 1 3.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 3.4 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 9 7.3 123.0 (56.1-233.5)             
Female 8 6.5 122.3 (52.6-240.9)   Female 3 2.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 1.9 nc (nc-nc)   Male 3 2.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 4 2.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.5 nc (nc-nc)   Male 25 26.7 93.7 (60.6-138.3) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 3.9 nc (nc-nc)   Male 2 1.5 nc (nc-nc) 
Female 4 2.0 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Larynx            Testis     
Male 0 1.1 nc (nc-nc)   Male 2 0.8 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 2.5 nc (nc-nc)   Male 1 1.8 nc (nc-nc) 
Female 0 1.7 nc (nc-nc)   Female 1 5.0 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 2.5 nc (nc-nc)             
Female 0 0.7 nc (nc-nc)   Female 7 6.3 111.4 (44.6-229.5) 
Lung and Bronchus            All Sites / Types     
Male 5 11.9 41.8 (13.5-97.6)   Male 75 91.7 81.8 (64.3-102.5) 
Female 11 11.7 94.4 (47.1-168.9)   Female 71 86.0 82.6 (64.5-104.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
285 
Southborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 9.0 134.0 (69.2-234.1)   Male 6 6.3 95.5 (34.9-207.9) 
Female 2 3.1 nc (nc-nc)   Female 4 4.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 2.0 nc (nc-nc)   Male 5 1.8 273.4 (88.1-638.1) 
Female 0 1.6 nc (nc-nc)   Female 2 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 4 5.5 nc (nc-nc) 
Female 45 39.7 113.3 (82.6-151.6)   Female 4 4.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 4.8 166.8 (71.8-328.8) 
Female 2 1.4 nc (nc-nc)   Female 2 1.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 10.6 56.6 (20.7-123.2)             
Female 13 9.6 135.0 (71.8-230.9)   Female 2 3.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 2.6 nc (nc-nc)   Male 1 3.2 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 6 2.9 203.4 (74.3-442.7) 
Hodgkin Lymphoma            Prostate     
Male 1 0.8 nc (nc-nc)   Male 42 35.7 117.5 (84.7-158.9) 
Female 1 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 5.5 108.1 (39.5-235.3)   Male 3 2.2 nc (nc-nc) 
Female 1 3.0 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Larynx            Testis     
Male 2 1.5 nc (nc-nc)   Male 3 1.2 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 3.8 nc (nc-nc)   Male 5 2.7 188.3 (60.7-439.4) 
Female 2 2.6 nc (nc-nc)   Female 5 7.7 65.0 (21.0-151.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 3.4 nc (nc-nc)             
Female 0 1.0 nc (nc-nc)   Female 8 8.9 90.3 (38.9-178.0) 
Lung and Bronchus            All Sites / Types     
Male 11 16.9 65.3 (32.5-116.8)   Male 138 129.1 106.9 (89.8-126.3) 
Female 19 16.9 112.6 (67.8-175.9)   Female 128 126.6 101.1 (84.4-120.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
286 
Southbridge 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 19 16.8 112.8 (67.9-176.1)   Male 6 10.9 54.8 (20.0-119.3) 
Female 9 6.7 134.1 (61.2-254.6)   Female 4 9.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 3.2 nc (nc-nc)   Male 3 3.2 nc (nc-nc) 
Female 1 2.9 nc (nc-nc)   Female 2 2.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 9 9.7 92.3 (42.1-175.3) 
Female 68 69.0 98.6 (76.5-124.9)   Female 10 8.8 113.5 (54.3-208.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 12 7.7 156.3 (80.7-273.1) 
Female 3 2.4 nc (nc-nc)   Female 2 3.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 19 18.7 101.7 (61.2-158.8)             
Female 20 20.6 96.9 (59.1-149.6)   Female 6 6.4 93.6 (34.2-203.7) 
Esophagus            Pancreas     
Male 4 4.4 nc (nc-nc)   Male 5 5.7 87.6 (28.2-204.4) 
Female 1 1.3 nc (nc-nc)   Female 3 6.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 1.4 nc (nc-nc)   Male 43 58.8 73.1 (52.9-98.5) 
Female 3 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 11 9.1 121.4 (60.5-217.2)   Male 6 3.9 152.4 (55.6-331.7) 
Female 11 5.6 197.3 (98.3-353.0)   Female 5 2.6 190.3 (61.3-444.0) 
Larynx            Testis     
Male 5 2.4 204.6 (65.9-477.4)   Male 2 2.5 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 6.8 87.7 (32.0-191.0)   Male 0 4.3 nc (nc-nc) 
Female 10 5.4 184.7 (88.4-339.7)   Female 7 13.1 53.6 (21.5-110.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 5.6 106.6 (38.9-232.1)             
Female 0 2.0 nc (nc-nc)   Female 15 15.6 96.3 (53.8-158.8) 
Lung and Bronchus            All Sites / Types     
Male 40 30.0 133.5 (95.4-181.8)   Male 220 223.3 98.5 (85.9-112.4) 
Female 33 33.3 99.2 (68.3-139.3)   Female 233 240.1 97.0 (85.0-110.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
287 
Southwick 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 10 10.7 93.4 (44.7-171.7)   Male 5 7.1 70.4 (22.7-164.3) 
Female 3 4.0 nc (nc-nc)   Female 4 5.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.0 nc (nc-nc)   Male 1 2.1 nc (nc-nc) 
Female 2 1.7 nc (nc-nc)   Female 2 1.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 2 6.3 nc (nc-nc) 
Female 32 43.1 74.2 (50.8-104.8)   Female 7 5.3 132.9 (53.2-273.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 5.2 nc (nc-nc) 
Female 0 1.5 nc (nc-nc)   Female 3 2.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 12.2 57.5 (23.0-118.5)             
Female 15 12.3 122.2 (68.4-201.6)   Female 4 3.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 2.9 nc (nc-nc)   Male 3 3.7 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 1 3.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.8 nc (nc-nc)   Male 37 39.9 92.7 (65.3-127.8) 
Female 0 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 6.0 99.3 (36.2-216.0)   Male 2 2.6 nc (nc-nc) 
Female 1 3.4 nc (nc-nc)   Female 1 1.5 nc (nc-nc) 
Larynx            Testis     
Male 0 1.6 nc (nc-nc)   Male 4 1.3 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 4.3 nc (nc-nc)   Male 2 2.8 nc (nc-nc) 
Female 5 3.1 159.2 (51.3-371.4)   Female 4 7.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 3.8 nc (nc-nc)             
Female 2 1.2 nc (nc-nc)   Female 5 9.7 51.8 (16.7-120.8) 
Lung and Bronchus            All Sites / Types     
Male 15 19.5 76.8 (43.0-126.8)   Male 116 146.3 79.3 (65.5-95.1) 
Female 11 20.3 54.1 (27.0-96.8)   Female 111 145.6 76.2 (62.7-91.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
288 
Spencer 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 19 13.3 143.1 (86.1-223.5)   Male 5 8.7 57.2 (18.4-133.5) 
Female 12 4.5 268.0 (138.3-468.2)   Female 4 6.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.5 nc (nc-nc)   Male 1 2.6 nc (nc-nc) 
Female 2 2.0 nc (nc-nc)   Female 2 1.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 5 7.7 65.2 (21.0-152.1) 
Female 45 50.6 89.0 (64.9-119.0)   Female 6 6.1 98.3 (35.9-214.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 6.3 95.1 (34.7-207.0) 
Female 1 1.8 nc (nc-nc)   Female 3 2.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 12 14.8 81.2 (41.9-141.9)             
Female 17 13.6 125.2 (72.9-200.5)   Female 2 4.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 3.7 nc (nc-nc)   Male 3 4.6 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 2 4.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 1.1 nc (nc-nc)   Male 25 49.8 50.2 (32.5-74.2) 
Female 2 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 12 7.4 162.1 (83.6-283.1)   Male 2 3.1 nc (nc-nc) 
Female 7 4.0 175.6 (70.4-361.9)   Female 2 1.7 nc (nc-nc) 
Larynx            Testis     
Male 2 2.0 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 14 5.3 265.9 (145.2-446.1)   Male 2 3.4 nc (nc-nc) 
Female 5 3.6 139.3 (44.9-325.1)   Female 3 9.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 4.7 107.0 (34.5-249.8)             
Female 2 1.4 nc (nc-nc)   Female 15 11.7 127.7 (71.4-210.7) 
Lung and Bronchus            All Sites / Types     
Male 26 24.4 106.4 (69.5-156.0)   Male 153 180.8 84.6 (71.7-99.1) 
Female 19 23.7 80.2 (48.3-125.2)   Female 166 169.6 97.9 (83.5-113.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
289 
Springfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 97 123.0 78.9 (64.0-96.2)   Male 33 82.0 40.2 (27.7-56.5) 
Female 40 49.1 81.5 (58.2-111.0)   Female 34 75.5 45.0 (31.2-62.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 28 26.3 106.5 (70.8-154.0)   Male 22 23.5 93.5 (58.6-141.5) 
Female 24 24.3 98.7 (63.2-146.8)   Female 17 21.0 80.9 (47.1-129.6) 
Breast            Non-Hodgkin Lymphoma     
Male 8 3.9 204.7 (88.1-403.3)   Male 68 73.4 92.6 (71.9-117.4) 
Female 528 548.2 96.3 (88.3-104.9)   Female 62 67.5 91.8 (70.4-117.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 64 57.9 110.6 (85.2-141.3) 
Female 31 20.6 150.8 (102.4-214.0)   Female 21 28.1 74.7 (46.2-114.1) 
Colon / Rectum            Ovary     
Male 148 137.6 107.6 (91.0-126.4)             
Female 151 151.2 99.8 (84.5-117.1)   Female 39 50.6 77.1 (54.8-105.3) 
Esophagus            Pancreas     
Male 37 33.0 112.2 (79.0-154.7)   Male 42 42.0 100.1 (72.1-135.3) 
Female 13 9.4 137.9 (73.4-235.8)   Female 41 47.8 85.8 (61.6-116.4) 
Hodgkin Lymphoma            Prostate     
Male 11 12.4 88.7 (44.2-158.6)   Male 452 439.6 102.8 (93.6-112.8) 
Female 15 11.5 130.3 (72.9-215.0)             
Kidney & Renal Pelvis            Stomach     
Male 81 68.4 118.4 (94.0-147.1)   Male 38 29.0 131.1 (92.8-179.9) 
Female 47 43.7 107.5 (79.0-143.0)   Female 24 19.0 126.3 (80.9-187.9) 
Larynx            Testis     
Male 19 18.3 103.9 (62.5-162.3)   Male 13 21.8 59.5 (31.7-101.8) 
Female 8 6.6 120.8 (52.0-238.1)             
Leukemia            Thyroid     
Male 48 52.7 91.0 (67.1-120.7)   Male 14 33.5 41.8 (22.9-70.2) 
Female 43 42.3 101.6 (73.5-136.9)   Female 74 113.8 65.0 (51.1-81.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 67 42.4 157.9 (122.4-200.6)             
Female 11 15.1 73.1 (36.4-130.8)   Female 116 124.1 93.4 (77.2-112.1) 
Lung and Bronchus            All Sites / Types     
Male 248 221.6 111.9 (98.4-126.7)   Male 1657 1672.5 99.1 (94.4-104.0) 
Female 258 254.8 101.3 (89.3-114.4)   Female 1735 1872.6 92.7 (88.3-97.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Sterling 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 10 8.5 118.0 (56.5-217.1)   Male 5 5.7 87.4 (28.2-203.9) 
Female 4 3.0 nc (nc-nc)   Female 5 4.5 111.6 (36.0-260.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.7 nc (nc-nc)   Male 3 1.7 nc (nc-nc) 
Female 0 1.4 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 7 5.0 139.3 (55.8-287.1) 
Female 34 35.3 96.4 (66.8-134.8)   Female 3 4.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 4.3 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 0 1.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 9.7 72.1 (28.9-148.5)             
Female 7 9.5 73.7 (29.5-151.8)   Female 5 3.2 156.4 (50.4-365.0) 
Esophagus            Pancreas     
Male 3 2.4 nc (nc-nc)   Male 3 3.0 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 3 3.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.7 nc (nc-nc)   Male 46 33.5 137.3 (100.5-183.1) 
Female 1 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 5.0 100.5 (32.4-234.5)   Male 1 2.0 nc (nc-nc) 
Female 6 2.7 221.1 (80.7-481.3)   Female 1 1.2 nc (nc-nc) 
Larynx            Testis     
Male 0 1.4 nc (nc-nc)   Male 2 1.0 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 3.4 146.4 (47.2-341.5)   Male 2 2.3 nc (nc-nc) 
Female 1 2.5 nc (nc-nc)   Female 7 6.5 108.1 (43.3-222.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 3.2 nc (nc-nc)             
Female 0 0.9 nc (nc-nc)   Female 10 8.1 122.9 (58.8-226.1) 
Lung and Bronchus            All Sites / Types     
Male 9 15.8 57.0 (26.0-108.3)   Male 120 119.2 100.7 (83.5-120.4) 
Female 12 15.6 76.8 (39.6-134.2)   Female 107 116.6 91.8 (75.2-110.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
291 
Stockbridge 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 3.5 nc (nc-nc)   Male 5 2.1 234.5 (75.6-547.3) 
Female 2 1.3 nc (nc-nc)   Female 5 1.6 314.3 (101.3-733.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.5 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 3 1.9 nc (nc-nc) 
Female 10 12.7 78.5 (37.6-144.4)   Female 3 1.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.5 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 3.7 163.6 (59.8-356.2)             
Female 6 3.8 156.0 (57.0-339.5)   Female 2 1.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 0.9 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 3 1.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 13 12.9 100.6 (53.5-172.1) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 1.8 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 2 1.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Larynx            Testis     
Male 2 0.5 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 1.3 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 1 1.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.2 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 4 3.1 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 6.5 nc (nc-nc)   Male 47 45.5 103.3 (75.9-137.4) 
Female 2 6.9 nc (nc-nc)   Female 46 44.7 102.9 (75.3-137.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Stoneham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 22 28.1 78.2 (49.0-118.5)   Male 13 17.4 74.6 (39.7-127.6) 
Female 14 11.1 126.1 (68.9-211.6)   Female 19 14.2 133.8 (80.5-208.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 4.7 nc (nc-nc)   Male 6 5.2 115.8 (42.3-252.0) 
Female 4 4.4 nc (nc-nc)   Female 5 4.6 108.2 (34.9-252.4) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.9 nc (nc-nc)   Male 19 15.4 123.7 (74.5-193.2) 
Female 127 108.8 116.7 (97.3-138.8)   Female 13 14.2 91.7 (48.8-156.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 13 11.8 109.7 (58.4-187.6) 
Female 9 3.6 253.2 (115.5-480.6)   Female 7 5.8 120.9 (48.4-249.1) 
Colon / Rectum            Ovary     
Male 33 30.1 109.7 (75.5-154.1)             
Female 34 33.5 101.6 (70.4-142.0)   Female 11 10.1 109.3 (54.5-195.6) 
Esophagus            Pancreas     
Male 8 7.2 111.0 (47.8-218.7)   Male 3 9.4 nc (nc-nc) 
Female 2 2.1 nc (nc-nc)   Female 13 10.9 119.4 (63.5-204.2) 
Hodgkin Lymphoma            Prostate     
Male 4 1.9 nc (nc-nc)   Male 79 94.4 83.7 (66.3-104.3) 
Female 3 1.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 17 14.1 120.2 (70.0-192.4)   Male 12 6.4 187.3 (96.7-327.3) 
Female 10 8.9 111.8 (53.5-205.6)   Female 5 4.3 117.6 (37.9-274.5) 
Larynx            Testis     
Male 6 4.0 151.8 (55.4-330.3)   Male 4 2.9 nc (nc-nc) 
Female 2 1.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 16 10.6 150.3 (85.8-244.1)   Male 11 6.1 178.9 (89.2-320.2) 
Female 10 8.4 118.7 (56.8-218.3)   Female 23 18.5 124.6 (78.9-186.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 8 8.9 89.6 (38.6-176.5)             
Female 4 3.2 nc (nc-nc)   Female 32 24.7 129.6 (88.6-183.0) 
Lung and Bronchus            All Sites / Types     
Male 46 50.1 91.8 (67.2-122.5)   Male 368 357.7 102.9 (92.6-113.9) 
Female 47 55.7 84.3 (62.0-112.2)   Female 418 381.8 109.5 (99.2-120.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
293 
Stoughton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 28 31.3 89.5 (59.4-129.3)   Male 16 20.0 79.8 (45.6-129.6) 
Female 13 12.3 105.6 (56.2-180.6)   Female 24 16.7 143.5 (91.9-213.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 5.7 105.4 (38.5-229.5)   Male 4 5.9 nc (nc-nc) 
Female 6 5.1 116.5 (42.6-253.7)   Female 6 5.2 115.0 (42.0-250.4) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.0 nc (nc-nc)   Male 15 17.7 84.7 (47.4-139.7) 
Female 142 129.2 109.9 (92.6-129.6)   Female 23 16.2 141.9 (89.9-212.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 19 14.1 134.3 (80.8-209.8) 
Female 5 4.3 115.0 (37.1-268.5)   Female 7 6.7 104.4 (41.8-215.0) 
Colon / Rectum            Ovary     
Male 36 34.3 104.8 (73.4-145.2)             
Female 43 37.2 115.7 (83.7-155.9)   Female 15 11.8 126.9 (70.9-209.2) 
Esophagus            Pancreas     
Male 9 8.3 107.8 (49.2-204.7)   Male 11 10.6 103.5 (51.6-185.2) 
Female 7 2.4 295.1 (118.2-608.1)   Female 16 12.0 133.3 (76.1-216.5) 
Hodgkin Lymphoma            Prostate     
Male 5 2.3 214.1 (69.0-499.5)   Male 107 111.6 95.9 (78.6-115.9) 
Female 6 2.0 301.0 (109.9-655.1)             
Kidney & Renal Pelvis            Stomach     
Male 23 16.7 137.5 (87.2-206.4)   Male 6 7.3 82.4 (30.1-179.3) 
Female 16 10.4 153.5 (87.7-249.3)   Female 10 4.7 214.4 (102.6-394.3) 
Larynx            Testis     
Male 10 4.6 217.7 (104.2-400.4)   Male 3 3.8 nc (nc-nc) 
Female 2 1.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 12.2 65.4 (28.1-128.8)   Male 10 7.5 132.7 (63.5-244.1) 
Female 6 9.6 62.6 (22.9-136.3)   Female 37 22.9 161.7 (113.9-222.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 10.4 47.9 (15.4-111.7)             
Female 1 3.7 nc (nc-nc)   Female 22 29.6 74.4 (46.6-112.7) 
Lung and Bronchus            All Sites / Types     
Male 68 56.5 120.3 (93.4-152.5)   Male 425 413.7 102.7 (93.2-113.0) 
Female 63 63.8 98.7 (75.8-126.3)   Female 513 443.1 115.8 (106.0-126.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
294 
Stow 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 10 7.2 139.3 (66.7-256.2)   Male 3 4.8 nc (nc-nc) 
Female 3 2.3 nc (nc-nc)   Female 3 3.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.4 nc (nc-nc)   Male 2 1.4 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 2 1.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 4 4.2 nc (nc-nc) 
Female 32 29.1 109.8 (75.1-155.0)   Female 5 3.3 153.8 (49.6-359.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 3.6 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 4 1.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 8.2 61.0 (19.7-142.4)             
Female 6 7.0 85.1 (31.1-185.3)   Female 6 2.6 233.4 (85.2-508.0) 
Esophagus            Pancreas     
Male 1 2.0 nc (nc-nc)   Male 3 2.5 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 1 2.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.5 nc (nc-nc)   Male 36 27.7 130.1 (91.1-180.1) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 4.2 nc (nc-nc)   Male 0 1.7 nc (nc-nc) 
Female 3 2.2 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Larynx            Testis     
Male 1 1.1 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 2.9 172.1 (55.5-401.7)   Male 2 1.9 nc (nc-nc) 
Female 2 1.9 nc (nc-nc)   Female 2 5.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.6 nc (nc-nc)             
Female 1 0.7 nc (nc-nc)   Female 9 6.7 134.7 (61.4-255.6) 
Lung and Bronchus            All Sites / Types     
Male 3 13.3 nc (nc-nc)   Male 91 99.7 91.2 (73.5-112.0) 
Female 12 12.6 95.3 (49.2-166.4)   Female 100 93.2 107.3 (87.3-130.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
295 
Sturbridge 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 14 10.5 133.3 (72.8-223.6)   Male 9 6.8 131.6 (60.0-249.8) 
Female 6 3.6 168.3 (61.4-366.3)   Female 6 5.2 115.3 (42.1-251.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.0 nc (nc-nc)   Male 2 2.0 nc (nc-nc) 
Female 2 1.6 nc (nc-nc)   Female 2 1.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 4 6.0 nc (nc-nc) 
Female 42 40.5 103.7 (74.8-140.2)   Female 5 4.9 103.0 (33.2-240.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 4.9 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 1 2.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 10 11.6 86.1 (41.2-158.4)             
Female 5 10.8 46.1 (14.9-107.7)   Female 2 3.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 2.9 nc (nc-nc)   Male 4 3.6 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 6 3.5 173.7 (63.4-378.2) 
Hodgkin Lymphoma            Prostate     
Male 2 0.8 nc (nc-nc)   Male 41 38.7 106.1 (76.1-143.9) 
Female 0 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 5.8 120.7 (48.4-248.8)   Male 1 2.5 nc (nc-nc) 
Female 6 3.2 187.8 (68.6-408.7)   Female 2 1.3 nc (nc-nc) 
Larynx            Testis     
Male 1 1.6 nc (nc-nc)   Male 2 1.3 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 4.2 nc (nc-nc)   Male 2 2.6 nc (nc-nc) 
Female 3 2.9 nc (nc-nc)   Female 5 7.6 66.0 (21.3-154.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 3.6 nc (nc-nc)             
Female 2 1.1 nc (nc-nc)   Female 20 9.3 215.5 (131.6-332.9) 
Lung and Bronchus            All Sites / Types     
Male 18 19.2 93.6 (55.4-147.9)   Male 137 141.5 96.9 (81.3-114.5) 
Female 15 18.9 79.2 (44.3-130.7)   Female 139 135.3 102.7 (86.4-121.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
296 
Sudbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 16 17.9 89.5 (51.1-145.3)   Male 21 12.0 174.5 (108.0-266.8) 
Female 2 6.0 nc (nc-nc)   Female 11 9.2 120.1 (59.9-214.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 3.6 192.1 (77.0-395.9)   Male 4 3.6 nc (nc-nc) 
Female 3 2.9 nc (nc-nc)   Female 2 2.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.6 nc (nc-nc)   Male 12 10.7 112.7 (58.1-196.8) 
Female 112 74.2 150.9 (124.2-181.6)   Female 12 8.4 142.4 (73.5-248.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 9.0 nc (nc-nc) 
Female 2 2.6 nc (nc-nc)   Female 2 3.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 22 20.6 106.6 (66.8-161.5)             
Female 11 18.9 58.3 (29.0-104.3)   Female 5 6.6 76.2 (24.6-177.8) 
Esophagus            Pancreas     
Male 3 5.0 nc (nc-nc)   Male 7 6.2 112.1 (44.9-231.0) 
Female 0 1.2 nc (nc-nc)   Female 4 5.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 1.4 nc (nc-nc)   Male 76 68.4 111.1 (87.5-139.0) 
Female 2 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 11 10.5 105.2 (52.4-188.2)   Male 2 4.3 nc (nc-nc) 
Female 6 5.6 106.6 (38.9-232.0)   Female 2 2.3 nc (nc-nc) 
Larynx            Testis     
Male 2 2.8 nc (nc-nc)   Male 2 2.0 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 7.3 109.0 (46.9-214.9)   Male 5 4.8 104.2 (33.6-243.2) 
Female 8 5.1 157.7 (67.9-310.7)   Female 15 13.8 108.3 (60.6-178.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 6.6 nc (nc-nc)             
Female 3 1.9 nc (nc-nc)   Female 14 16.6 84.3 (46.0-141.4) 
Lung and Bronchus            All Sites / Types     
Male 11 33.1 33.3 (16.6-59.5)   Male 228 249.0 91.6 (80.1-104.3) 
Female 35 32.0 109.2 (76.1-151.9)   Female 281 239.6 117.3 (104.0-131.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
297 
Sunderland 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 3.0 nc (nc-nc)   Male 1 2.1 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 0 1.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.6 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 3 1.9 nc (nc-nc) 
Female 13 12.9 100.9 (53.7-172.6)   Female 0 1.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 1.5 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 3.4 nc (nc-nc)             
Female 0 3.5 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.8 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.4 nc (nc-nc)   Male 14 11.3 124.4 (67.9-208.7) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.7 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Larynx            Testis     
Male 1 0.5 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 1.3 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 2 2.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.1 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 2 3.0 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 4 5.4 nc (nc-nc)   Male 40 42.2 94.7 (67.6-129.0) 
Female 1 5.7 nc (nc-nc)   Female 24 43.6 55.0 (35.3-81.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
298 
Sutton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 10 8.7 115.3 (55.2-212.0)   Male 10 6.1 163.4 (78.2-300.5) 
Female 5 2.7 182.9 (58.9-426.8)   Female 4 4.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.9 nc (nc-nc)   Male 3 1.8 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.3 nc (nc-nc)   Male 7 5.4 130.3 (52.2-268.5) 
Female 40 36.7 108.9 (77.8-148.3)   Female 5 4.0 124.5 (40.1-290.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 4.8 nc (nc-nc) 
Female 2 1.4 nc (nc-nc)   Female 5 1.8 285.4 (92.0-666.0) 
Colon / Rectum            Ovary     
Male 7 10.2 68.3 (27.4-140.7)             
Female 8 8.6 92.9 (40.0-183.0)   Female 1 3.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 2.6 nc (nc-nc)   Male 1 3.1 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 1 2.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.8 nc (nc-nc)   Male 30 36.8 81.6 (55.0-116.5) 
Female 0 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 5.5 127.7 (51.2-263.2)   Male 2 2.1 nc (nc-nc) 
Female 5 2.7 183.2 (59.0-427.5)   Female 2 1.1 nc (nc-nc) 
Larynx            Testis     
Male 0 1.5 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 3.6 138.0 (44.5-322.1)   Male 3 2.6 nc (nc-nc) 
Female 1 2.4 nc (nc-nc)   Female 8 7.3 109.2 (47.0-215.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 3.4 nc (nc-nc)             
Female 0 0.9 nc (nc-nc)   Female 14 8.4 166.2 (90.8-278.8) 
Lung and Bronchus            All Sites / Types     
Male 17 16.5 103.2 (60.1-165.3)   Male 123 127.8 96.2 (80.0-114.8) 
Female 13 15.2 85.8 (45.6-146.7)   Female 123 116.2 105.8 (88.0-126.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
299 
Swampscott 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 22 18.1 121.7 (76.2-184.2)   Male 11 11.1 98.8 (49.2-176.8) 
Female 14 7.1 198.4 (108.4-333.0)   Female 12 9.1 131.9 (68.1-230.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 3.1 nc (nc-nc)   Male 2 3.3 nc (nc-nc) 
Female 3 2.8 nc (nc-nc)   Female 4 2.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.6 nc (nc-nc)   Male 19 9.9 192.2 (115.7-300.2) 
Female 83 70.6 117.6 (93.6-145.7)   Female 12 9.1 132.5 (68.4-231.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 7.7 77.7 (28.4-169.1) 
Female 2 2.3 nc (nc-nc)   Female 3 3.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 17 19.5 87.4 (50.9-139.9)             
Female 25 21.6 115.7 (74.8-170.7)   Female 5 6.5 76.6 (24.7-178.9) 
Esophagus            Pancreas     
Male 2 4.7 nc (nc-nc)   Male 4 6.0 nc (nc-nc) 
Female 0 1.3 nc (nc-nc)   Female 7 7.0 100.2 (40.1-206.4) 
Hodgkin Lymphoma            Prostate     
Male 1 1.1 nc (nc-nc)   Male 58 61.0 95.0 (72.2-122.8) 
Female 2 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 11 9.1 120.9 (60.3-216.3)   Male 2 4.1 nc (nc-nc) 
Female 7 5.7 122.7 (49.2-252.8)   Female 2 2.8 nc (nc-nc) 
Larynx            Testis     
Male 1 2.5 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 6.9 86.9 (31.7-189.2)   Male 8 3.9 204.8 (88.2-403.5) 
Female 10 5.4 184.7 (88.4-339.7)   Female 15 11.9 126.5 (70.7-208.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 5.8 nc (nc-nc)             
Female 2 2.0 nc (nc-nc)   Female 23 16.1 143.2 (90.7-214.8) 
Lung and Bronchus            All Sites / Types     
Male 32 31.9 100.3 (68.6-141.5)   Male 226 230.3 98.2 (85.8-111.8) 
Female 36 34.7 103.8 (72.7-143.7)   Female 287 245.0 117.1 (104.0-131.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
300 
Swansea 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 20 20.3 98.7 (60.2-152.4)   Male 9 12.9 69.8 (31.8-132.5) 
Female 13 7.4 176.3 (93.8-301.4)   Female 4 9.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 3.6 nc (nc-nc)   Male 2 3.8 nc (nc-nc) 
Female 5 3.0 164.5 (53.0-383.9)   Female 3 3.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.6 nc (nc-nc)   Male 12 11.4 105.3 (54.4-184.0) 
Female 75 77.3 97.0 (76.3-121.6)   Female 6 9.7 62.0 (22.6-134.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 9.2 87.4 (37.6-172.3) 
Female 5 2.6 193.1 (62.2-450.5)   Female 2 4.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 17 22.1 77.0 (44.8-123.3)             
Female 19 22.3 85.1 (51.2-132.9)   Female 8 7.1 113.3 (48.8-223.2) 
Esophagus            Pancreas     
Male 7 5.4 129.1 (51.7-266.0)   Male 5 6.9 72.7 (23.4-169.6) 
Female 0 1.4 nc (nc-nc)   Female 8 7.2 111.0 (47.8-218.7) 
Hodgkin Lymphoma            Prostate     
Male 4 1.4 nc (nc-nc)   Male 89 72.9 122.0 (98.0-150.1) 
Female 1 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 15 10.8 139.2 (77.8-229.6)   Male 5 4.7 106.1 (34.2-247.5) 
Female 4 6.2 nc (nc-nc)   Female 3 2.8 nc (nc-nc) 
Larynx            Testis     
Male 4 3.0 nc (nc-nc)   Male 3 2.2 nc (nc-nc) 
Female 2 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 7.8 nc (nc-nc)   Male 1 4.8 nc (nc-nc) 
Female 5 5.7 88.0 (28.4-205.4)   Female 9 13.5 66.7 (30.4-126.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 6.8 88.4 (32.3-192.5)             
Female 1 2.2 nc (nc-nc)   Female 17 17.7 95.8 (55.8-153.5) 
Lung and Bronchus            All Sites / Types     
Male 28 36.5 76.6 (50.9-110.8)   Male 261 267.5 97.6 (86.1-110.2) 
Female 36 37.8 95.2 (66.7-131.9)   Female 248 264.4 93.8 (82.5-106.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
301 
Taunton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 53 55.2 96.0 (71.9-125.6)   Male 26 36.6 71.1 (46.4-104.2) 
Female 25 21.5 116.1 (75.1-171.4)   Female 29 31.3 92.5 (62.0-132.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 9 10.9 82.7 (37.7-157.0)   Male 10 10.6 94.4 (45.2-173.7) 
Female 6 9.7 62.0 (22.7-135.0)   Female 16 9.2 174.8 (99.9-283.9) 
Breast            Non-Hodgkin Lymphoma     
Male 4 1.8 nc (nc-nc)   Male 40 32.4 123.6 (88.3-168.3) 
Female 242 234.3 103.3 (90.7-117.1)   Female 41 28.9 141.7 (101.7-192.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 32 25.9 123.7 (84.6-174.6) 
Female 7 8.5 82.7 (33.1-170.5)   Female 10 12.0 83.3 (39.9-153.3) 
Colon / Rectum            Ovary     
Male 74 61.9 119.5 (93.9-150.1)             
Female 90 66.3 135.7 (109.1-166.8)   Female 19 21.4 88.6 (53.3-138.4) 
Esophagus            Pancreas     
Male 17 14.8 114.8 (66.9-183.9)   Male 28 18.9 148.5 (98.7-214.7) 
Female 3 4.1 nc (nc-nc)   Female 25 21.1 118.7 (76.8-175.2) 
Hodgkin Lymphoma            Prostate     
Male 9 4.8 188.5 (86.0-357.8)   Male 183 196.7 93.0 (80.1-107.5) 
Female 6 4.1 145.6 (53.2-316.8)             
Kidney & Renal Pelvis            Stomach     
Male 31 30.6 101.3 (68.8-143.8)   Male 17 13.0 130.5 (76.0-209.0) 
Female 26 18.7 139.4 (91.0-204.2)   Female 7 8.3 83.9 (33.6-172.9) 
Larynx            Testis     
Male 14 8.2 170.7 (93.3-286.5)   Male 11 8.3 132.1 (65.8-236.3) 
Female 3 2.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 19 22.5 84.5 (50.9-132.0)   Male 15 14.6 103.0 (57.6-169.9) 
Female 13 17.6 73.9 (39.3-126.5)   Female 75 45.5 164.9 (129.7-206.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 20 18.9 105.8 (64.6-163.5)             
Female 5 6.5 77.4 (24.9-180.7)   Female 47 52.6 89.3 (65.6-118.8) 
Lung and Bronchus            All Sites / Types     
Male 133 99.7 133.4 (111.7-158.1)   Male 807 743.2 108.6 (101.2-116.3) 
Female 122 110.7 110.2 (91.5-131.6)   Female 885 799.1 110.7 (103.6-118.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
302 
Templeton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 9.0 122.0 (60.8-218.3)   Male 5 6.0 83.0 (26.7-193.7) 
Female 3 2.9 nc (nc-nc)   Female 0 4.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 1.8 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 2 1.3 nc (nc-nc)   Female 3 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 5 5.3 94.2 (30.4-219.9) 
Female 28 32.5 86.0 (57.1-124.3)   Female 4 3.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 4.4 nc (nc-nc) 
Female 3 1.2 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 9 10.2 88.4 (40.3-167.8)             
Female 13 8.9 146.2 (77.8-250.0)   Female 6 3.0 203.2 (74.2-442.3) 
Esophagus            Pancreas     
Male 3 2.5 nc (nc-nc)   Male 4 3.1 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 2 2.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.7 nc (nc-nc)   Male 29 34.5 84.2 (56.4-120.9) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 5.2 135.0 (54.1-278.2)   Male 1 2.2 nc (nc-nc) 
Female 1 2.6 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Larynx            Testis     
Male 0 1.4 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 3.6 nc (nc-nc)   Male 2 2.4 nc (nc-nc) 
Female 3 2.4 nc (nc-nc)   Female 4 6.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 3.2 nc (nc-nc)             
Female 0 0.9 nc (nc-nc)   Female 8 7.4 108.6 (46.8-214.0) 
Lung and Bronchus            All Sites / Types     
Male 18 16.7 107.9 (63.9-170.5)   Male 115 124.6 92.3 (76.2-110.8) 
Female 24 15.1 158.8 (101.7-236.3)   Female 110 109.3 100.6 (82.7-121.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
303 
Tewksbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 44 32.3 136.1 (98.9-182.8)   Male 20 21.2 94.2 (57.5-145.4) 
Female 11 11.6 94.7 (47.2-169.5)   Female 16 16.9 94.9 (54.2-154.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 6.1 114.5 (45.9-235.9)   Male 6 6.2 96.2 (35.1-209.4) 
Female 4 5.2 nc (nc-nc)   Female 5 5.0 100.0 (32.2-233.3) 
Breast            Non-Hodgkin Lymphoma     
Male 3 1.0 nc (nc-nc)   Male 15 18.7 80.3 (44.9-132.4) 
Female 136 131.8 103.2 (86.6-122.1)   Female 18 15.8 114.2 (67.6-180.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 14 15.3 91.5 (50.0-153.6) 
Female 7 4.6 153.1 (61.4-315.5)   Female 8 6.6 120.6 (51.9-237.6) 
Colon / Rectum            Ovary     
Male 35 36.0 97.1 (67.6-135.1)             
Female 29 35.4 82.0 (54.9-117.8)   Female 15 11.9 126.0 (70.5-207.9) 
Esophagus            Pancreas     
Male 10 8.9 113.0 (54.1-207.8)   Male 15 11.1 134.9 (75.5-222.6) 
Female 4 2.2 nc (nc-nc)   Female 11 11.2 97.8 (48.8-175.1) 
Hodgkin Lymphoma            Prostate     
Male 0 2.5 nc (nc-nc)   Male 117 119.6 97.8 (80.9-117.2) 
Female 3 2.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 29 18.0 161.1 (107.8-231.3)   Male 6 7.6 78.7 (28.7-171.3) 
Female 9 10.3 87.0 (39.7-165.2)   Female 8 4.4 181.5 (78.1-357.6) 
Larynx            Testis     
Male 6 4.9 122.3 (44.7-266.2)   Male 6 4.0 148.3 (54.2-322.9) 
Female 0 1.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 22 12.8 171.7 (107.6-260.0)   Male 7 8.2 84.9 (34.0-175.0) 
Female 15 9.3 161.7 (90.4-266.6)   Female 26 24.3 106.9 (69.8-156.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 8 11.2 71.2 (30.7-140.4)             
Female 1 3.6 nc (nc-nc)   Female 35 30.2 115.8 (80.7-161.1) 
Lung and Bronchus            All Sites / Types     
Male 62 59.3 104.6 (80.2-134.1)   Male 469 438.0 107.1 (97.6-117.2) 
Female 88 61.5 143.1 (114.8-176.3)   Female 493 439.6 112.2 (102.5-122.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
304 
Tisbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 4.7 nc (nc-nc)   Male 5 3.0 164.5 (53.0-383.8) 
Female 0 1.9 nc (nc-nc)   Female 4 2.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.9 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 4 2.7 nc (nc-nc) 
Female 31 19.6 157.9 (107.3-224.1)   Female 2 2.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 2.2 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 2 1.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 5.2 nc (nc-nc)             
Female 6 5.6 107.1 (39.1-233.1)   Female 2 1.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.3 nc (nc-nc)   Male 4 1.6 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.4 nc (nc-nc)   Male 20 17.2 116.4 (71.1-179.8) 
Female 1 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 2.6 nc (nc-nc)   Male 3 1.1 nc (nc-nc) 
Female 2 1.6 nc (nc-nc)   Female 2 0.7 nc (nc-nc) 
Larynx            Testis     
Male 0 0.7 nc (nc-nc)   Male 2 0.6 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.8 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 0 1.4 nc (nc-nc)   Female 2 3.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 1.6 nc (nc-nc)             
Female 0 0.6 nc (nc-nc)   Female 5 4.6 108.6 (35.0-253.5) 
Lung and Bronchus            All Sites / Types     
Male 4 8.4 nc (nc-nc)   Male 71 62.9 113.0 (88.2-142.5) 
Female 8 9.7 82.3 (35.4-162.1)   Female 74 67.3 109.9 (86.3-138.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
305 
Tolland 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 0.7 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 2.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 0.8 nc (nc-nc)             
Female 0 0.6 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.2 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 2 3.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.3 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 1.4 nc (nc-nc)   Male 6 10.1 59.3 (21.6-129.0) 
Female 0 1.0 nc (nc-nc)   Female 2 7.2 nc (nc-nc) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
306 
Topsfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 8.0 99.7 (42.9-196.5)   Male 2 5.0 nc (nc-nc) 
Female 3 3.0 nc (nc-nc)   Female 6 3.8 158.9 (58.0-345.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.4 nc (nc-nc)   Male 0 1.5 nc (nc-nc) 
Female 2 1.2 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 7 4.4 157.6 (63.1-324.7) 
Female 33 30.0 109.9 (75.7-154.4)   Female 4 3.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 3.6 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 2 1.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 8.7 57.2 (18.4-133.4)             
Female 7 9.0 77.4 (31.0-159.4)   Female 5 2.7 182.2 (58.7-425.3) 
Esophagus            Pancreas     
Male 3 2.1 nc (nc-nc)   Male 1 2.7 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 1 2.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.5 nc (nc-nc)   Male 36 28.4 127.0 (88.9-175.8) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 4.2 nc (nc-nc)   Male 2 1.9 nc (nc-nc) 
Female 1 2.4 nc (nc-nc)   Female 3 1.2 nc (nc-nc) 
Larynx            Testis     
Male 0 1.2 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 3.1 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 3 2.3 nc (nc-nc)   Female 3 4.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 2.7 nc (nc-nc)             
Female 1 0.9 nc (nc-nc)   Female 8 6.8 118.2 (50.9-233.0) 
Lung and Bronchus            All Sites / Types     
Male 12 14.4 83.1 (42.9-145.2)   Male 103 104.5 98.6 (80.5-119.6) 
Female 15 14.6 102.4 (57.3-169.0)   Female 106 103.1 102.8 (84.2-124.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
307 
Townsend 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 7.8 140.8 (70.2-251.9)   Male 5 5.7 88.0 (28.4-205.4) 
Female 1 2.6 nc (nc-nc)   Female 7 4.5 155.3 (62.2-320.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.8 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 8 5.0 160.3 (69.0-315.9) 
Female 34 35.4 95.9 (66.4-134.0)   Female 3 3.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 4.5 nc (nc-nc) 
Female 0 1.3 nc (nc-nc)   Female 2 1.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 13 9.4 137.8 (73.3-235.7)             
Female 12 8.3 144.9 (74.8-253.1)   Female 6 3.2 190.2 (69.5-414.1) 
Esophagus            Pancreas     
Male 5 2.4 208.9 (67.3-487.4)   Male 1 2.9 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 3 2.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.8 nc (nc-nc)   Male 18 33.9 53.1 (31.5-83.9) 
Female 0 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 5.1 97.9 (31.6-228.6)   Male 2 2.0 nc (nc-nc) 
Female 5 2.6 191.8 (61.8-447.6)   Female 0 1.0 nc (nc-nc) 
Larynx            Testis     
Male 1 1.4 nc (nc-nc)   Male 2 1.3 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 3.4 nc (nc-nc)   Male 1 2.5 nc (nc-nc) 
Female 2 2.3 nc (nc-nc)   Female 8 7.3 110.0 (47.4-216.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 3.2 nc (nc-nc)             
Female 2 0.9 nc (nc-nc)   Female 5 8.2 61.3 (19.7-143.0) 
Lung and Bronchus            All Sites / Types     
Male 18 14.9 120.4 (71.3-190.3)   Male 109 118.0 92.4 (75.8-111.4) 
Female 15 14.2 105.7 (59.1-174.3)   Female 114 111.8 102.0 (84.1-122.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
308 
Truro 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 3.8 nc (nc-nc)   Male 2 2.3 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 1 1.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.6 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 2.0 nc (nc-nc) 
Female 18 12.5 144.5 (85.6-228.4)   Female 2 1.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 1.7 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 4.0 124.8 (40.2-291.3)             
Female 3 3.3 nc (nc-nc)   Female 4 1.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 1.0 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 8 14.4 55.5 (23.9-109.4) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 2.0 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 2 1.0 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Larynx            Testis     
Male 0 0.6 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.4 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 1 1.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 1.3 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 4 3.1 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 7.0 nc (nc-nc)   Male 35 49.9 70.1 (48.8-97.5) 
Female 4 6.3 nc (nc-nc)   Female 52 41.9 124.0 (92.6-162.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
309 
Tyngsborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 14 9.0 156.0 (85.2-261.8)   Male 7 6.7 105.2 (42.1-216.7) 
Female 5 3.2 157.8 (50.9-368.3)   Female 6 5.6 107.4 (39.2-233.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 2.1 nc (nc-nc)   Male 1 1.9 nc (nc-nc) 
Female 1 1.7 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 2 5.9 nc (nc-nc) 
Female 32 43.7 73.3 (50.1-103.4)   Female 3 4.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 5.3 95.2 (30.7-222.1) 
Female 0 1.7 nc (nc-nc)   Female 3 2.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 12 11.1 108.1 (55.8-188.8)             
Female 8 10.2 78.1 (33.6-154.0)   Female 4 3.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 2.7 nc (nc-nc)   Male 3 3.3 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 2 3.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 1.0 nc (nc-nc)   Male 31 37.8 82.1 (55.8-116.5) 
Female 0 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 6.0 83.9 (27.0-195.8)   Male 2 2.3 nc (nc-nc) 
Female 2 3.2 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Larynx            Testis     
Male 2 1.5 nc (nc-nc)   Male 0 1.6 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 4.0 151.9 (55.5-330.5)   Male 3 3.0 nc (nc-nc) 
Female 4 2.8 nc (nc-nc)   Female 10 9.2 108.4 (51.9-199.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 8 3.7 214.7 (92.5-423.1)             
Female 0 1.0 nc (nc-nc)   Female 8 9.7 82.2 (35.4-161.9) 
Lung and Bronchus            All Sites / Types     
Male 22 17.0 129.6 (81.2-196.2)   Male 139 135.7 102.4 (86.1-121.0) 
Female 22 17.4 126.5 (79.3-191.6)   Female 126 137.6 91.6 (76.3-109.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
310 
Tyringham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 0.7 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 3 2.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 0.7 nc (nc-nc)             
Female 0 0.6 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.2 nc (nc-nc)   Male 1 0.2 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 3 2.6 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.1 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.2 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 1.3 nc (nc-nc)   Male 8 9.0 89.4 (38.5-176.1) 
Female 0 1.2 nc (nc-nc)   Female 6 7.6 78.9 (28.8-171.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Upton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 6.5 108.4 (43.4-223.4)   Male 4 4.7 nc (nc-nc) 
Female 4 2.3 nc (nc-nc)   Female 2 3.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.5 nc (nc-nc)   Male 4 1.3 nc (nc-nc) 
Female 2 1.2 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.2 nc (nc-nc)   Male 7 4.1 170.3 (68.2-350.8) 
Female 36 30.1 119.6 (83.7-165.6)   Female 2 3.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 3.6 138.5 (44.6-323.3) 
Female 0 1.1 nc (nc-nc)   Female 2 1.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 7.8 76.8 (28.0-167.1)             
Female 3 7.3 nc (nc-nc)   Female 4 2.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 1.9 nc (nc-nc)   Male 1 2.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 4 2.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.6 nc (nc-nc)   Male 18 26.2 68.7 (40.7-108.6) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 4.1 nc (nc-nc)   Male 0 1.6 nc (nc-nc) 
Female 1 2.2 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Larynx            Testis     
Male 0 1.1 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 2.8 nc (nc-nc)   Male 1 2.0 nc (nc-nc) 
Female 2 2.0 nc (nc-nc)   Female 4 6.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 2.6 196.0 (63.1-457.3)             
Female 0 0.7 nc (nc-nc)   Female 9 6.7 134.4 (61.3-255.1) 
Lung and Bronchus            All Sites / Types     
Male 13 12.1 107.3 (57.1-183.5)   Male 86 94.9 90.6 (72.4-111.9) 
Female 12 12.4 96.6 (49.9-168.8)   Female 99 95.7 103.4 (84.0-125.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
312 
Uxbridge 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 13.4 89.2 (46.1-155.9)   Male 13 9.2 141.8 (75.4-242.5) 
Female 6 4.7 127.7 (46.6-278.0)   Female 5 7.2 69.8 (22.5-162.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 2.7 nc (nc-nc)   Male 4 2.7 nc (nc-nc) 
Female 2 2.2 nc (nc-nc)   Female 1 2.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.4 nc (nc-nc)   Male 9 8.1 111.0 (50.7-210.7) 
Female 63 55.7 113.2 (87.0-144.8)   Female 4 6.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 12 6.7 178.1 (91.9-311.0) 
Female 1 2.0 nc (nc-nc)   Female 1 2.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 17 15.5 109.6 (63.8-175.5)             
Female 16 14.6 109.8 (62.7-178.3)   Female 3 5.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 3.7 nc (nc-nc)   Male 6 4.7 128.3 (46.9-279.4) 
Female 2 0.9 nc (nc-nc)   Female 5 4.6 109.9 (35.4-256.4) 
Hodgkin Lymphoma            Prostate     
Male 0 1.2 nc (nc-nc)   Male 60 50.4 119.1 (90.9-153.4) 
Female 0 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 7.9 101.7 (43.8-200.5)   Male 4 3.2 nc (nc-nc) 
Female 6 4.3 139.3 (50.9-303.2)   Female 0 1.8 nc (nc-nc) 
Larynx            Testis     
Male 1 2.1 nc (nc-nc)   Male 4 2.0 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 5.5 108.1 (39.5-235.4)   Male 4 3.8 nc (nc-nc) 
Female 6 3.9 154.0 (56.2-335.2)   Female 9 10.8 83.3 (38.0-158.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 4.9 nc (nc-nc)             
Female 1 1.5 nc (nc-nc)   Female 16 12.5 128.2 (73.2-208.2) 
Lung and Bronchus            All Sites / Types     
Male 31 24.6 126.0 (85.6-178.8)   Male 221 186.8 118.3 (103.2-135.0) 
Female 24 25.0 96.2 (61.6-143.1)   Female 190 183.4 103.6 (89.4-119.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
313 
Wakefield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 31 27.8 111.5 (75.7-158.2)   Male 22 18.1 121.8 (76.3-184.4) 
Female 8 10.4 76.9 (33.1-151.5)   Female 27 14.8 182.5 (120.2-265.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 5.2 135.0 (54.1-278.2)   Male 4 5.3 nc (nc-nc) 
Female 5 4.5 110.4 (35.6-257.7)   Female 3 4.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.9 nc (nc-nc)   Male 11 16.0 68.9 (34.4-123.3) 
Female 124 112.9 109.8 (91.3-130.9)   Female 23 13.9 165.5 (104.9-248.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 12 12.7 94.1 (48.6-164.5) 
Female 4 4.0 nc (nc-nc)   Female 3 5.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 37 30.7 120.4 (84.7-165.9)             
Female 36 31.9 112.9 (79.0-156.3)   Female 6 10.3 58.2 (21.3-126.8) 
Esophagus            Pancreas     
Male 8 7.4 107.8 (46.4-212.5)   Male 7 9.4 74.3 (29.7-153.0) 
Female 2 2.0 nc (nc-nc)   Female 10 10.2 98.3 (47.1-180.8) 
Hodgkin Lymphoma            Prostate     
Male 3 2.2 nc (nc-nc)   Male 82 98.6 83.2 (66.2-103.2) 
Female 0 1.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 15.1 53.1 (22.9-104.7)   Male 4 6.5 nc (nc-nc) 
Female 8 9.0 89.1 (38.4-175.6)   Female 2 4.0 nc (nc-nc) 
Larynx            Testis     
Male 5 4.1 121.8 (39.2-284.2)   Male 5 3.6 137.3 (44.2-320.4) 
Female 2 1.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 11 11.0 100.0 (49.8-178.9)   Male 6 6.9 86.5 (31.6-188.2) 
Female 7 8.3 84.4 (33.8-173.9)   Female 25 21.0 118.9 (76.9-175.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 9.4 53.0 (17.1-123.8)             
Female 5 3.1 159.8 (51.5-373.0)   Female 16 25.6 62.5 (35.7-101.5) 
Lung and Bronchus            All Sites / Types     
Male 42 50.1 83.8 (60.4-113.3)   Male 335 369.4 90.7 (81.2-100.9) 
Female 53 53.6 98.9 (74.1-129.4)   Female 396 383.5 103.3 (93.3-113.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
314 
Wales 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 2.0 nc (nc-nc)   Male 0 1.4 nc (nc-nc) 
Female 2 0.6 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.4 nc (nc-nc)   Male 2 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 8 7.6 105.2 (45.3-207.2)   Female 0 0.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.0 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 2.3 nc (nc-nc)             
Female 6 1.8 333.5 (121.8-725.9)   Female 1 0.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 0.6 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 3 8.1 nc (nc-nc) 
Female 1 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 1.2 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 2 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.8 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 0 1.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 0.8 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 5 1.8 276.1 (89.0-644.4) 
Lung and Bronchus            All Sites / Types     
Male 5 3.8 132.5 (42.7-309.2)   Male 26 28.6 91.0 (59.5-133.4) 
Female 5 3.2 154.3 (49.7-360.2)   Female 32 24.4 131.3 (89.8-185.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
315 
Walpole 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 18 27.4 65.7 (38.9-103.8)   Male 27 17.7 152.8 (100.7-222.4) 
Female 11 10.0 109.6 (54.6-196.1)   Female 14 13.7 102.1 (55.8-171.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 5.1 118.0 (43.1-256.8)   Male 6 5.2 115.6 (42.2-251.5) 
Female 3 4.3 nc (nc-nc)   Female 5 4.2 118.0 (38.0-275.3) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.9 nc (nc-nc)   Male 11 15.7 70.3 (35.0-125.8) 
Female 133 106.5 124.9 (104.5-148.0)   Female 14 13.2 105.9 (57.8-177.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 12 12.4 96.4 (49.8-168.4) 
Female 4 3.6 nc (nc-nc)   Female 4 5.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 31 30.5 101.8 (69.1-144.5)             
Female 32 30.8 104.0 (71.1-146.9)   Female 9 9.7 93.0 (42.4-176.5) 
Esophagus            Pancreas     
Male 5 7.2 69.3 (22.3-161.6)   Male 13 9.3 140.3 (74.6-239.9) 
Female 2 1.9 nc (nc-nc)   Female 10 9.8 102.0 (48.8-187.6) 
Hodgkin Lymphoma            Prostate     
Male 3 2.1 nc (nc-nc)   Male 111 94.8 117.1 (96.3-141.0) 
Female 1 1.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 18 14.6 122.9 (72.8-194.3)   Male 6 6.4 93.8 (34.3-204.3) 
Female 4 8.5 nc (nc-nc)   Female 3 3.9 nc (nc-nc) 
Larynx            Testis     
Male 6 4.0 150.6 (55.0-327.9)   Male 6 3.4 179.1 (65.4-389.7) 
Female 2 1.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 10.9 64.5 (25.8-132.8)   Male 6 6.7 89.5 (32.7-194.8) 
Female 10 8.0 125.2 (60.0-230.3)   Female 20 19.0 105.1 (64.2-162.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 9.2 76.1 (30.5-156.9)             
Female 4 3.0 nc (nc-nc)   Female 26 23.9 108.9 (71.1-159.6) 
Lung and Bronchus            All Sites / Types     
Male 43 49.0 87.7 (63.5-118.2)   Male 374 360.4 103.8 (93.5-114.9) 
Female 48 51.1 93.9 (69.2-124.4)   Female 382 363.1 105.2 (94.9-116.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
316 
Waltham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 56 54.5 102.7 (77.5-133.3)   Male 32 36.6 87.5 (59.8-123.5) 
Female 20 21.0 95.0 (58.0-146.8)   Female 15 31.5 47.7 (26.7-78.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 11 11.1 99.4 (49.5-177.9)   Male 11 10.4 106.2 (52.9-190.0) 
Female 14 9.6 146.3 (79.9-245.4)   Female 4 8.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.7 nc (nc-nc)   Male 27 32.5 83.1 (54.8-121.0) 
Female 229 221.0 103.6 (90.6-117.9)   Female 36 28.2 127.5 (89.3-176.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 23 25.2 91.3 (57.8-136.9) 
Female 11 8.3 132.6 (66.1-237.2)   Female 6 11.6 51.7 (18.9-112.5) 
Colon / Rectum            Ovary     
Male 57 60.5 94.3 (71.4-122.1)             
Female 62 64.3 96.4 (73.9-123.6)   Female 19 20.8 91.5 (55.1-142.9) 
Esophagus            Pancreas     
Male 14 14.5 96.7 (52.8-162.2)   Male 20 18.5 107.9 (65.9-166.7) 
Female 2 4.0 nc (nc-nc)   Female 23 20.6 111.6 (70.7-167.5) 
Hodgkin Lymphoma            Prostate     
Male 2 5.9 nc (nc-nc)   Male 162 192.5 84.2 (71.7-98.2) 
Female 6 4.9 122.1 (44.6-265.8)             
Kidney & Renal Pelvis            Stomach     
Male 35 29.9 116.9 (81.4-162.6)   Male 16 12.8 125.1 (71.5-203.1) 
Female 15 17.9 83.8 (46.9-138.2)   Female 9 8.1 110.5 (50.4-209.9) 
Larynx            Testis     
Male 8 8.0 99.8 (43.0-196.6)   Male 11 11.2 98.0 (48.8-175.3) 
Female 2 2.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 20 22.6 88.4 (54.0-136.5)   Male 15 15.2 98.8 (55.3-163.0) 
Female 16 17.3 92.6 (52.9-150.4)   Female 46 46.1 99.7 (73.0-133.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 18 18.4 97.6 (57.8-154.3)             
Female 6 6.3 95.6 (34.9-208.0)   Female 39 50.2 77.7 (55.2-106.2) 
Lung and Bronchus            All Sites / Types     
Male 102 98.2 103.9 (84.7-126.1)   Male 692 737.4 93.8 (87.0-101.1) 
Female 113 107.2 105.4 (86.8-126.7)   Female 753 773.2 97.4 (90.6-104.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Ware 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 11.2 53.7 (19.6-117.0)   Male 4 7.3 nc (nc-nc) 
Female 5 4.0 126.4 (40.7-295.0)   Female 3 5.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 2.1 nc (nc-nc)   Male 2 2.1 nc (nc-nc) 
Female 0 1.7 nc (nc-nc)   Female 4 1.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.4 nc (nc-nc)   Male 6 6.4 93.7 (34.2-203.9) 
Female 30 42.9 70.0 (47.2-99.9)   Female 6 5.3 113.2 (41.3-246.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 5.2 96.6 (31.1-225.4) 
Female 1 1.5 nc (nc-nc)   Female 2 2.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 14 12.4 112.9 (61.7-189.5)             
Female 15 12.1 124.2 (69.5-204.8)   Female 5 3.9 126.8 (40.9-295.9) 
Esophagus            Pancreas     
Male 2 3.0 nc (nc-nc)   Male 7 3.8 182.8 (73.2-376.7) 
Female 2 0.8 nc (nc-nc)   Female 6 3.9 155.3 (56.7-338.1) 
Hodgkin Lymphoma            Prostate     
Male 0 0.9 nc (nc-nc)   Male 30 40.5 74.2 (50.0-105.9) 
Female 0 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 6.1 98.6 (36.0-214.6)   Male 4 2.6 nc (nc-nc) 
Female 8 3.4 233.8 (100.7-460.7)   Female 0 1.5 nc (nc-nc) 
Larynx            Testis     
Male 4 1.7 nc (nc-nc)   Male 2 1.4 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 4.4 nc (nc-nc)   Male 1 2.8 nc (nc-nc) 
Female 1 3.2 nc (nc-nc)   Female 3 8.0 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 3.8 nc (nc-nc)             
Female 1 1.2 nc (nc-nc)   Female 7 9.9 71.0 (28.4-146.3) 
Lung and Bronchus            All Sites / Types     
Male 20 20.2 99.2 (60.6-153.2)   Male 134 149.5 89.6 (75.1-106.2) 
Female 20 20.4 97.8 (59.7-151.1)   Female 132 146.0 90.4 (75.7-107.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Wareham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 42 28.0 150.0 (108.1-202.8)   Male 16 17.7 90.3 (51.6-146.7) 
Female 11 9.9 110.6 (55.1-197.9)   Female 15 13.6 110.0 (61.5-181.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 4.9 102.0 (32.9-238.1)   Male 7 5.3 132.4 (53.0-272.8) 
Female 3 4.2 nc (nc-nc)   Female 2 4.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.9 nc (nc-nc)   Male 22 15.5 141.9 (88.9-214.8) 
Female 94 106.6 88.2 (71.3-107.9)   Female 9 13.2 68.1 (31.1-129.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 17 12.4 136.7 (79.6-218.9) 
Female 2 3.5 nc (nc-nc)   Female 6 5.5 109.0 (39.8-237.3) 
Colon / Rectum            Ovary     
Male 42 30.1 139.6 (100.6-188.7)             
Female 39 29.8 131.0 (93.1-179.1)   Female 11 9.8 112.7 (56.2-201.6) 
Esophagus            Pancreas     
Male 11 7.5 146.5 (73.0-262.1)   Male 16 9.5 168.4 (96.2-273.4) 
Female 2 1.9 nc (nc-nc)   Female 11 9.7 113.8 (56.7-203.6) 
Hodgkin Lymphoma            Prostate     
Male 0 1.9 nc (nc-nc)   Male 93 101.4 91.7 (74.0-112.3) 
Female 3 1.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 17 14.8 114.9 (66.9-184.0)   Male 7 6.5 108.4 (43.4-223.3) 
Female 11 8.6 128.6 (64.1-230.1)   Female 2 3.7 nc (nc-nc) 
Larynx            Testis     
Male 6 4.2 144.5 (52.8-314.5)   Male 2 2.9 nc (nc-nc) 
Female 4 1.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 11 10.7 102.9 (51.3-184.1)   Male 5 6.4 78.1 (25.2-182.3) 
Female 14 7.7 181.8 (99.3-305.1)   Female 16 18.6 85.9 (49.1-139.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 13 9.4 139.0 (73.9-237.7)             
Female 6 3.0 198.9 (72.6-432.9)   Female 21 24.8 84.5 (52.3-129.2) 
Lung and Bronchus            All Sites / Types     
Male 82 51.4 159.6 (126.9-198.1)   Male 446 369.0 120.9 (109.9-132.6) 
Female 83 52.4 158.5 (126.3-196.5)   Female 397 362.4 109.5 (99.0-120.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
319 
Warren 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 5.3 112.2 (41.0-244.2)   Male 1 3.6 nc (nc-nc) 
Female 2 1.7 nc (nc-nc)   Female 1 2.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.1 nc (nc-nc)   Male 2 1.0 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 1 3.1 nc (nc-nc) 
Female 19 20.1 94.7 (57.0-148.0)   Female 1 2.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 2.6 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 6.0 nc (nc-nc)             
Female 2 5.2 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.5 nc (nc-nc)   Male 7 1.8 379.3 (152.0-781.5) 
Female 0 0.3 nc (nc-nc)   Female 0 1.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.5 nc (nc-nc)   Male 13 19.8 65.6 (34.9-112.1) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 3.0 nc (nc-nc)   Male 0 1.3 nc (nc-nc) 
Female 1 1.5 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Larynx            Testis     
Male 0 0.8 nc (nc-nc)   Male 2 0.8 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 2.2 nc (nc-nc)   Male 0 1.4 nc (nc-nc) 
Female 2 1.4 nc (nc-nc)   Female 2 4.0 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 1.9 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 6 4.5 133.0 (48.6-289.4) 
Lung and Bronchus            All Sites / Types     
Male 12 9.8 122.2 (63.0-213.4)   Male 59 73.3 80.5 (61.3-103.9) 
Female 12 8.9 134.6 (69.5-235.2)   Female 54 66.1 81.7 (61.4-106.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Warwick 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 1.1 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 1 0.2 nc (nc-nc) 
Female 1 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 3 3.8 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 1.2 nc (nc-nc)             
Female 1 0.9 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 5 4.2 118.0 (38.0-275.4) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.6 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.4 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 2 0.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.4 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 2.0 nc (nc-nc)   Male 13 14.8 87.9 (46.7-150.3) 
Female 2 1.7 nc (nc-nc)   Female 11 12.2 90.2 (45.0-161.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Washington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 0.7 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.1 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 3 2.6 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 0.8 nc (nc-nc)             
Female 0 0.6 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.2 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 2 0.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 3 3.3 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.5 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.3 nc (nc-nc)             
Female 1 0.1 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 1.4 nc (nc-nc)   Male 5 10.9 46.0 (14.8-107.4) 
Female 1 1.1 nc (nc-nc)   Female 8 8.4 95.3 (41.1-187.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Watertown 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 42 33.1 126.9 (91.4-171.5)   Male 15 21.5 69.8 (39.0-115.1) 
Female 12 13.8 86.9 (44.8-151.8)   Female 19 19.8 96.2 (57.9-150.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 10 6.2 162.3 (77.7-298.5)   Male 7 6.2 113.5 (45.5-233.9) 
Female 10 5.9 170.0 (81.4-312.7)   Female 6 5.8 103.2 (37.7-224.7) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.0 nc (nc-nc)   Male 16 18.9 84.5 (48.3-137.3) 
Female 146 141.9 102.9 (86.9-121.0)   Female 20 18.2 109.7 (67.0-169.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 17 14.4 117.9 (68.6-188.7) 
Female 8 5.3 151.9 (65.4-299.3)   Female 4 7.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 41 36.0 113.7 (81.6-154.3)             
Female 38 41.8 90.9 (64.3-124.8)   Female 18 13.2 136.7 (81.0-216.1) 
Esophagus            Pancreas     
Male 9 8.5 105.7 (48.2-200.7)   Male 14 11.1 126.5 (69.1-212.2) 
Female 2 2.6 nc (nc-nc)   Female 22 13.5 163.4 (102.4-247.5) 
Hodgkin Lymphoma            Prostate     
Male 4 2.9 nc (nc-nc)   Male 96 111.0 86.5 (70.0-105.6) 
Female 2 2.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 22 17.4 126.7 (79.3-191.8)   Male 8 7.6 104.6 (45.0-206.1) 
Female 4 11.6 nc (nc-nc)   Female 9 5.3 170.7 (77.9-324.1) 
Larynx            Testis     
Male 6 4.7 127.9 (46.7-278.4)   Male 6 5.5 109.3 (39.9-237.9) 
Female 1 1.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 13.1 76.3 (36.5-140.3)   Male 12 8.3 143.7 (74.2-251.1) 
Female 11 10.9 100.7 (50.2-180.2)   Female 23 28.2 81.6 (51.7-122.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 10 10.7 93.8 (44.9-172.5)             
Female 7 4.1 171.5 (68.7-353.3)   Female 31 32.2 96.4 (65.5-136.8) 
Lung and Bronchus            All Sites / Types     
Male 60 58.9 101.9 (77.8-131.2)   Male 431 431.0 100.0 (90.8-109.9) 
Female 71 70.6 100.5 (78.5-126.8)   Female 503 496.8 101.3 (92.6-110.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Wayland 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 17.2 46.4 (20.0-91.5)   Male 14 10.7 130.8 (71.5-219.5) 
Female 6 5.7 104.8 (38.3-228.1)   Female 13 7.8 166.2 (88.4-284.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 3.0 nc (nc-nc)   Male 5 3.2 155.0 (50.0-361.7) 
Female 5 2.5 203.1 (65.4-473.9)   Female 2 2.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 11 9.5 115.9 (57.8-207.4) 
Female 75 62.7 119.5 (94.0-149.8)   Female 12 7.6 157.4 (81.3-275.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 7.5 nc (nc-nc) 
Female 1 2.1 nc (nc-nc)   Female 1 3.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 13 18.6 69.7 (37.1-119.2)             
Female 10 17.4 57.4 (27.5-105.5)   Female 4 5.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 4.5 nc (nc-nc)   Male 5 5.8 86.5 (27.9-201.9) 
Female 0 1.1 nc (nc-nc)   Female 5 5.6 89.5 (28.8-208.8) 
Hodgkin Lymphoma            Prostate     
Male 2 1.1 nc (nc-nc)   Male 63 59.6 105.7 (81.2-135.2) 
Female 0 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 9 8.9 101.5 (46.3-192.6)   Male 3 4.0 nc (nc-nc) 
Female 5 5.0 100.9 (32.5-235.5)   Female 0 2.2 nc (nc-nc) 
Larynx            Testis     
Male 2 2.5 nc (nc-nc)   Male 3 1.5 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 6.6 122.0 (52.5-240.4)   Male 7 3.8 185.6 (74.4-382.5) 
Female 3 4.5 nc (nc-nc)   Female 13 10.7 121.4 (64.6-207.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 5.7 nc (nc-nc)             
Female 3 1.7 nc (nc-nc)   Female 10 14.5 69.1 (33.1-127.0) 
Lung and Bronchus            All Sites / Types     
Male 18 30.9 58.3 (34.5-92.1)   Male 193 222.2 86.9 (75.0-100.0) 
Female 18 29.6 60.7 (36.0-96.0)   Female 194 210.5 92.2 (79.7-106.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Webster 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 32 19.2 166.8 (114.0-235.4)   Male 11 12.2 90.0 (44.9-161.0) 
Female 9 7.5 119.7 (54.6-227.3)   Female 5 10.0 50.0 (16.1-116.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 3.5 nc (nc-nc)   Male 2 3.6 nc (nc-nc) 
Female 2 3.1 nc (nc-nc)   Female 4 3.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 4 0.6 nc (nc-nc)   Male 11 10.9 101.3 (50.5-181.3) 
Female 83 74.3 111.6 (88.9-138.4)   Female 7 9.7 72.4 (29.0-149.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 8.5 nc (nc-nc) 
Female 3 2.6 nc (nc-nc)   Female 5 4.0 126.5 (40.8-295.3) 
Colon / Rectum            Ovary     
Male 27 21.1 128.2 (84.5-186.6)             
Female 27 23.1 116.8 (77.0-170.0)   Female 9 6.9 129.8 (59.2-246.4) 
Esophagus            Pancreas     
Male 5 5.0 99.8 (32.2-232.9)   Male 7 6.5 108.1 (43.3-222.7) 
Female 1 1.4 nc (nc-nc)   Female 6 7.5 80.4 (29.4-175.0) 
Hodgkin Lymphoma            Prostate     
Male 4 1.5 nc (nc-nc)   Male 61 66.2 92.1 (70.4-118.3) 
Female 0 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 9 10.1 89.3 (40.8-169.6)   Male 4 4.5 nc (nc-nc) 
Female 9 6.1 148.4 (67.7-281.8)   Female 1 3.0 nc (nc-nc) 
Larynx            Testis     
Male 5 2.7 181.9 (58.6-424.4)   Male 2 2.5 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 13 7.6 172.0 (91.5-294.1)   Male 7 4.6 152.2 (61.0-313.5) 
Female 7 5.9 118.2 (47.4-243.6)   Female 15 13.4 111.9 (62.6-184.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 8 6.3 127.4 (54.8-251.0)             
Female 7 2.2 324.5 (130.0-668.6)   Female 20 16.7 119.5 (72.9-184.5) 
Lung and Bronchus            All Sites / Types     
Male 42 34.1 123.3 (88.9-166.7)   Male 281 250.6 112.1 (99.4-126.1) 
Female 43 36.6 117.3 (84.9-158.1)   Female 288 261.3 110.2 (97.9-123.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Wellesley 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 21 28.4 74.0 (45.8-113.1)   Male 28 18.0 155.3 (103.2-224.5) 
Female 9 10.8 83.6 (38.1-158.6)   Female 27 15.1 179.3 (118.2-260.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 5.3 nc (nc-nc)   Male 3 5.4 nc (nc-nc) 
Female 3 4.9 nc (nc-nc)   Female 8 4.6 175.7 (75.6-346.2) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.9 nc (nc-nc)   Male 23 16.0 143.5 (91.0-215.4) 
Female 129 114.7 112.5 (93.9-133.7)   Female 13 14.3 90.7 (48.2-155.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 12.8 39.0 (12.6-91.0) 
Female 2 3.8 nc (nc-nc)   Female 5 5.9 84.2 (27.1-196.5) 
Colon / Rectum            Ovary     
Male 17 31.0 54.8 (31.9-87.7)             
Female 22 32.9 66.8 (41.9-101.2)   Female 7 10.6 66.1 (26.5-136.1) 
Esophagus            Pancreas     
Male 2 7.6 nc (nc-nc)   Male 8 9.6 83.0 (35.8-163.7) 
Female 2 2.1 nc (nc-nc)   Female 7 10.5 66.4 (26.6-136.9) 
Hodgkin Lymphoma            Prostate     
Male 2 2.0 nc (nc-nc)   Male 118 101.3 116.5 (96.4-139.5) 
Female 5 2.3 221.1 (71.3-516.1)             
Kidney & Renal Pelvis            Stomach     
Male 8 15.1 52.8 (22.7-104.1)   Male 5 6.6 75.8 (24.4-176.9) 
Female 9 9.2 97.9 (44.7-185.8)   Female 3 4.2 nc (nc-nc) 
Larynx            Testis     
Male 2 4.2 nc (nc-nc)   Male 2 3.0 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 11 11.3 97.6 (48.7-174.7)   Male 12 6.6 180.5 (93.2-315.3) 
Female 13 8.9 146.8 (78.1-251.1)   Female 22 21.2 104.0 (65.1-157.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 9.5 63.1 (23.0-137.4)             
Female 2 3.2 nc (nc-nc)   Female 16 25.9 61.8 (35.3-100.4) 
Lung and Bronchus            All Sites / Types     
Male 20 51.4 38.9 (23.8-60.1)   Male 328 374.8 87.5 (78.3-97.5) 
Female 33 55.2 59.8 (41.1-83.9)   Female 368 393.5 93.5 (84.2-103.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Wellfleet 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 5.1 156.2 (67.2-307.7)   Male 3 3.0 nc (nc-nc) 
Female 1 1.9 nc (nc-nc)   Female 5 2.2 222.6 (71.7-519.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.8 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 2 2.7 nc (nc-nc) 
Female 19 18.2 104.5 (62.9-163.2)   Female 2 2.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 2.1 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 11 5.3 208.0 (103.7-372.3)             
Female 6 5.4 110.9 (40.5-241.4)   Female 3 1.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.3 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 4 1.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.3 nc (nc-nc)   Male 21 18.2 115.6 (71.5-176.7) 
Female 1 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 2.5 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 0 1.5 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Larynx            Testis     
Male 1 0.7 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 1.8 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 2 1.3 nc (nc-nc)   Female 1 2.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 1.6 nc (nc-nc)             
Female 0 0.6 nc (nc-nc)   Female 2 4.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 9.3 nc (nc-nc)   Male 64 64.9 98.7 (76.0-126.0) 
Female 12 10.0 120.4 (62.1-210.3)   Female 66 63.6 103.8 (80.3-132.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Wendell 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.0 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 4.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 1.1 nc (nc-nc)             
Female 0 0.9 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 3 4.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.6 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 1 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.4 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 2 0.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.4 nc (nc-nc)             
Female 1 0.1 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 4 1.9 nc (nc-nc)   Male 11 14.8 74.5 (37.1-133.3) 
Female 4 1.6 nc (nc-nc)   Female 9 12.6 71.4 (32.6-135.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Wenham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 5.0 159.5 (68.7-314.4)   Male 7 3.1 226.8 (90.9-467.4) 
Female 2 1.8 nc (nc-nc)   Female 6 2.4 245.7 (89.7-534.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.9 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 2 2.8 nc (nc-nc) 
Female 17 18.2 93.4 (54.4-149.6)   Female 2 2.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 2.1 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 5.4 nc (nc-nc)             
Female 6 5.4 110.9 (40.5-241.4)   Female 1 1.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 1.3 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 1.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 18 16.5 109.3 (64.8-172.8) 
Female 1 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 2.5 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 4 1.5 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Larynx            Testis     
Male 0 0.7 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 2.0 nc (nc-nc)   Male 3 1.1 nc (nc-nc) 
Female 2 1.4 nc (nc-nc)   Female 4 3.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.6 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 4 4.1 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 5 8.8 56.5 (18.2-131.9)   Male 63 63.7 98.9 (76.0-126.6) 
Female 12 9.0 133.3 (68.8-232.9)   Female 72 63.5 113.4 (88.8-142.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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West Boylston 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 16 11.1 143.5 (82.0-233.1)   Male 3 7.1 nc (nc-nc) 
Female 5 3.6 139.5 (45.0-325.5)   Female 0 4.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 1.9 nc (nc-nc)   Male 1 2.1 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 1 1.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 5 6.3 79.4 (25.6-185.2) 
Female 37 34.1 108.4 (76.3-149.4)   Female 3 4.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 5.0 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 12.4 40.4 (13.0-94.3)             
Female 4 10.8 nc (nc-nc)   Female 3 3.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 2.9 nc (nc-nc)   Male 2 3.7 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 3 3.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.8 nc (nc-nc)   Male 26 37.7 69.0 (45.0-101.1) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 5.8 nc (nc-nc)   Male 1 2.6 nc (nc-nc) 
Female 3 2.8 nc (nc-nc)   Female 2 1.4 nc (nc-nc) 
Larynx            Testis     
Male 1 1.6 nc (nc-nc)   Male 2 1.4 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 4.3 nc (nc-nc)   Male 1 2.7 nc (nc-nc) 
Female 1 2.7 nc (nc-nc)   Female 9 5.5 162.5 (74.2-308.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 3.7 nc (nc-nc)             
Female 2 1.0 nc (nc-nc)   Female 7 7.8 90.2 (36.1-185.9) 
Lung and Bronchus            All Sites / Types     
Male 19 19.6 96.7 (58.2-151.1)   Male 111 144.4 76.9 (63.2-92.6) 
Female 15 17.7 84.9 (47.5-140.1)   Female 111 120.7 92.0 (75.7-110.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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West Bridgewater 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 9.4 85.5 (36.8-168.5)   Male 9 5.8 155.2 (70.8-294.7) 
Female 2 3.3 nc (nc-nc)   Female 5 4.3 117.0 (37.7-273.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.6 nc (nc-nc)   Male 0 1.7 nc (nc-nc) 
Female 2 1.3 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 6 5.1 117.4 (42.9-255.6) 
Female 23 32.9 69.9 (44.3-104.8)   Female 7 4.3 164.6 (65.9-339.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 3.9 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 2 1.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 8 10.0 80.2 (34.5-158.0)             
Female 16 10.1 159.2 (90.9-258.5)   Female 2 3.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 5 2.4 208.6 (67.2-486.7)   Male 2 3.1 nc (nc-nc) 
Female 2 0.6 nc (nc-nc)   Female 3 3.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.6 nc (nc-nc)   Male 32 31.4 102.0 (69.8-144.0) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 4.7 nc (nc-nc)   Male 1 2.1 nc (nc-nc) 
Female 2 2.7 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Larynx            Testis     
Male 2 1.3 nc (nc-nc)   Male 3 1.0 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 3.5 nc (nc-nc)   Male 3 2.0 nc (nc-nc) 
Female 4 2.5 nc (nc-nc)   Female 9 5.6 159.6 (72.8-303.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 2.9 nc (nc-nc)             
Female 0 1.0 nc (nc-nc)   Female 7 7.4 94.4 (37.8-194.5) 
Lung and Bronchus            All Sites / Types     
Male 16 16.7 95.7 (54.7-155.4)   Male 115 119.0 96.7 (79.8-116.0) 
Female 21 16.4 127.7 (79.0-195.2)   Female 118 114.8 102.8 (85.1-123.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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West Brookfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 5.2 nc (nc-nc)   Male 0 3.2 nc (nc-nc) 
Female 1 2.1 nc (nc-nc)   Female 3 2.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.9 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 3 0.8 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 0 2.8 nc (nc-nc) 
Female 15 19.6 76.6 (42.8-126.3)   Female 2 2.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 2.2 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 2 1.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 5.5 108.2 (39.5-235.4)             
Female 3 6.2 nc (nc-nc)   Female 3 1.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.4 nc (nc-nc)   Male 0 1.7 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 2.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.3 nc (nc-nc)   Male 13 18.2 71.4 (38.0-122.1) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 2.7 nc (nc-nc)   Male 2 1.2 nc (nc-nc) 
Female 1 1.6 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Larynx            Testis     
Male 0 0.8 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.9 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 1 1.5 nc (nc-nc)   Female 1 3.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.7 nc (nc-nc)             
Female 0 0.6 nc (nc-nc)   Female 5 4.5 111.2 (35.8-259.5) 
Lung and Bronchus            All Sites / Types     
Male 10 9.3 107.2 (51.3-197.2)   Male 45 66.9 67.3 (49.1-90.0) 
Female 15 10.1 148.1 (82.8-244.3)   Female 59 69.2 85.3 (64.9-110.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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West Newbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 4.5 nc (nc-nc)   Male 3 3.1 nc (nc-nc) 
Female 0 1.4 nc (nc-nc)   Female 5 2.3 216.6 (69.8-505.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 0.9 nc (nc-nc)   Male 3 0.9 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 2 2.7 nc (nc-nc) 
Female 21 18.9 111.0 (68.7-169.7)   Female 0 2.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 2.4 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 5.3 nc (nc-nc)             
Female 1 4.5 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 1.3 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 2 1.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 17 18.8 90.4 (52.6-144.8) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 2.8 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 0 1.4 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Larynx            Testis     
Male 0 0.7 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.8 nc (nc-nc)   Male 0 1.3 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 2 3.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.8 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 6 4.4 135.3 (49.4-294.5) 
Lung and Bronchus            All Sites / Types     
Male 3 8.4 nc (nc-nc)   Male 49 65.1 75.3 (55.7-99.5) 
Female 7 7.8 89.4 (35.8-184.2)   Female 53 59.8 88.6 (66.4-115.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
333 
West Springfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 36 32.1 112.2 (78.6-155.4)   Male 14 20.7 67.8 (37.0-113.7) 
Female 10 12.0 83.6 (40.0-153.8)   Female 14 16.5 85.1 (46.5-142.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 5.9 84.2 (27.1-196.5)   Male 4 6.1 nc (nc-nc) 
Female 4 5.1 nc (nc-nc)   Female 3 5.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.0 nc (nc-nc)   Male 12 18.2 65.8 (34.0-115.0) 
Female 113 123.4 91.6 (75.5-110.1)   Female 11 15.7 70.1 (35.0-125.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 22 14.5 152.2 (95.3-230.4) 
Female 12 4.2 282.9 (146.0-494.3)   Female 9 6.5 139.1 (63.5-264.1) 
Colon / Rectum            Ovary     
Male 32 35.1 91.2 (62.3-128.7)             
Female 35 36.3 96.4 (67.1-134.0)   Female 7 11.4 61.3 (24.6-126.3) 
Esophagus            Pancreas     
Male 13 8.5 152.8 (81.3-261.3)   Male 10 10.9 92.1 (44.1-169.5) 
Female 1 2.3 nc (nc-nc)   Female 8 11.7 68.4 (29.4-134.7) 
Hodgkin Lymphoma            Prostate     
Male 3 2.5 nc (nc-nc)   Male 92 113.0 81.4 (65.7-99.9) 
Female 1 2.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 12 17.1 70.2 (36.3-122.7)   Male 6 7.4 80.5 (29.4-175.3) 
Female 8 10.0 80.0 (34.4-157.6)   Female 3 4.6 nc (nc-nc) 
Larynx            Testis     
Male 4 4.7 nc (nc-nc)   Male 5 4.2 117.8 (38.0-274.8) 
Female 2 1.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 12.7 71.1 (32.4-134.9)   Male 8 7.8 102.1 (44.0-201.3) 
Female 6 9.5 63.4 (23.1-137.9)   Female 19 22.7 83.8 (50.4-130.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 12 10.8 111.3 (57.5-194.5)             
Female 0 3.5 nc (nc-nc)   Female 28 28.1 99.6 (66.2-144.0) 
Lung and Bronchus            All Sites / Types     
Male 54 58.0 93.2 (70.0-121.6)   Male 379 423.7 89.5 (80.7-98.9) 
Female 76 60.8 125.0 (98.5-156.4)   Female 403 427.9 94.2 (85.2-103.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
334 
West Stockbridge 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 2.3 nc (nc-nc)   Male 2 1.4 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 3 0.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.4 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 8 7.7 103.4 (44.5-203.8)   Female 4 0.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 1.0 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 2.4 nc (nc-nc)             
Female 1 2.0 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.6 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.1 nc (nc-nc)   Male 11 8.2 134.1 (66.9-240.0) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.1 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.8 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 2 0.5 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.8 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 2 1.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 4 4.1 nc (nc-nc)   Male 30 29.4 101.9 (68.8-145.5) 
Female 3 3.7 nc (nc-nc)   Female 26 25.7 101.3 (66.2-148.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
335 
West Tisbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 3.6 nc (nc-nc)   Male 2 2.3 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 4 1.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.6 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 3 2.0 nc (nc-nc) 
Female 17 13.4 126.6 (73.7-202.8)   Female 3 1.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.8 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 2 0.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 3.9 nc (nc-nc)             
Female 3 3.2 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 1.0 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 13 14.4 90.1 (47.9-154.1) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 2.0 nc (nc-nc)   Male 2 0.8 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Larynx            Testis     
Male 1 0.6 nc (nc-nc)   Male 3 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.4 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 1 2.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.3 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 4 3.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 6.6 nc (nc-nc)   Male 46 49.5 93.0 (68.1-124.0) 
Female 6 5.9 102.3 (37.4-222.7)   Female 50 43.3 115.6 (85.8-152.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
336 
Westborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 17 17.7 96.0 (55.9-153.7)   Male 9 11.9 75.8 (34.6-144.0) 
Female 7 6.9 101.6 (40.7-209.4)   Female 5 9.9 50.6 (16.3-118.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 3.6 nc (nc-nc)   Male 6 3.4 175.0 (63.9-380.9) 
Female 3 3.1 nc (nc-nc)   Female 3 2.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.6 nc (nc-nc)   Male 12 10.6 113.6 (58.6-198.4) 
Female 75 74.0 101.3 (79.7-127.0)   Female 7 9.2 76.4 (30.6-157.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 8.5 70.2 (25.6-152.8) 
Female 1 2.7 nc (nc-nc)   Female 1 3.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 17 20.3 83.9 (48.8-134.3)             
Female 31 21.7 143.0 (97.1-202.9)   Female 6 6.8 88.8 (32.4-193.2) 
Esophagus            Pancreas     
Male 5 4.8 104.8 (33.8-244.5)   Male 4 6.1 nc (nc-nc) 
Female 2 1.3 nc (nc-nc)   Female 5 6.8 73.3 (23.6-171.0) 
Hodgkin Lymphoma            Prostate     
Male 2 1.5 nc (nc-nc)   Male 45 63.1 71.3 (52.0-95.4) 
Female 1 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 10.0 80.1 (34.5-157.9)   Male 3 4.2 nc (nc-nc) 
Female 2 5.8 nc (nc-nc)   Female 1 2.8 nc (nc-nc) 
Larynx            Testis     
Male 1 2.6 nc (nc-nc)   Male 1 2.7 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 7.3 122.7 (56.0-232.9)   Male 9 4.8 186.9 (85.3-354.8) 
Female 6 5.7 106.0 (38.7-230.7)   Female 9 14.3 63.0 (28.8-119.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 6.2 80.6 (26.0-188.1)             
Female 1 2.0 nc (nc-nc)   Female 19 16.2 117.5 (70.7-183.5) 
Lung and Bronchus            All Sites / Types     
Male 19 31.7 59.9 (36.1-93.6)   Male 203 240.3 84.5 (73.3-96.9) 
Female 34 34.0 100.1 (69.3-139.9)   Female 236 252.5 93.5 (81.9-106.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
337 
Westfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 40 42.1 95.0 (67.8-129.3)   Male 24 27.4 87.5 (56.0-130.2) 
Female 9 15.7 57.2 (26.1-108.5)   Female 18 22.3 80.9 (47.9-127.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 8.1 nc (nc-nc)   Male 9 8.0 112.3 (51.3-213.2) 
Female 7 7.0 100.1 (40.1-206.3)   Female 3 6.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.3 nc (nc-nc)   Male 17 24.4 69.7 (40.6-111.6) 
Female 183 167.2 109.5 (94.2-126.5)   Female 17 21.0 81.1 (47.2-129.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 13 19.6 66.4 (35.3-113.6) 
Female 8 5.8 138.9 (59.8-273.6)   Female 8 8.7 91.9 (39.6-181.1) 
Colon / Rectum            Ovary     
Male 46 46.7 98.4 (72.1-131.3)             
Female 55 48.0 114.6 (86.3-149.2)   Female 17 15.5 109.8 (63.9-175.8) 
Esophagus            Pancreas     
Male 14 11.3 123.4 (67.4-207.1)   Male 7 14.4 48.6 (19.5-100.2) 
Female 3 3.0 nc (nc-nc)   Female 12 15.4 77.9 (40.2-136.0) 
Hodgkin Lymphoma            Prostate     
Male 8 3.6 219.9 (94.7-433.3)   Male 128 152.7 83.8 (69.9-99.7) 
Female 3 3.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 14 22.9 61.0 (33.3-102.4)   Male 14 9.9 141.8 (77.5-237.9) 
Female 13 13.4 97.0 (51.6-165.8)   Female 4 6.1 nc (nc-nc) 
Larynx            Testis     
Male 4 6.3 nc (nc-nc)   Male 4 6.0 nc (nc-nc) 
Female 3 2.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 16 17.0 94.1 (53.7-152.8)   Male 5 10.7 46.7 (15.1-109.0) 
Female 13 12.7 102.4 (54.5-175.2)   Female 19 31.3 60.7 (36.5-94.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 11 14.4 76.4 (38.1-136.7)             
Female 4 4.7 nc (nc-nc)   Female 34 38.3 88.8 (61.5-124.1) 
Lung and Bronchus            All Sites / Types     
Male 79 76.1 103.8 (82.2-129.4)   Male 499 566.4 88.1 (80.5-96.2) 
Female 78 80.5 96.8 (76.6-120.9)   Female 546 574.7 95.0 (87.2-103.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
338 
Westford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 18.9 58.2 (29.0-104.2)   Male 19 13.7 139.1 (83.7-217.2) 
Female 2 6.3 nc (nc-nc)   Female 10 10.8 92.8 (44.4-170.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 4.3 115.3 (37.2-269.2)   Male 7 3.9 177.3 (71.0-365.3) 
Female 5 3.4 148.2 (47.8-345.8)   Female 3 2.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 3 0.6 nc (nc-nc)   Male 12 12.1 99.6 (51.4-174.0) 
Female 89 86.9 102.4 (82.2-126.0)   Female 7 9.3 75.3 (30.2-155.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 14 10.7 130.2 (71.1-218.5) 
Female 2 3.2 nc (nc-nc)   Female 3 4.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 23 23.1 99.7 (63.2-149.6)             
Female 18 20.0 89.8 (53.2-142.0)   Female 5 7.6 66.0 (21.3-154.0) 
Esophagus            Pancreas     
Male 4 5.7 nc (nc-nc)   Male 7 6.8 102.3 (41.0-210.7) 
Female 0 1.2 nc (nc-nc)   Female 7 6.0 116.4 (46.6-239.9) 
Hodgkin Lymphoma            Prostate     
Male 0 1.8 nc (nc-nc)   Male 80 79.2 101.1 (80.1-125.8) 
Female 2 1.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 12.3 81.4 (39.0-149.7)   Male 7 4.7 147.6 (59.1-304.1) 
Female 2 6.4 nc (nc-nc)   Female 2 2.4 nc (nc-nc) 
Larynx            Testis     
Male 4 3.2 nc (nc-nc)   Male 1 2.8 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 11 8.2 134.6 (67.1-240.9)   Male 7 6.0 116.3 (46.6-239.6) 
Female 11 5.5 199.2 (99.3-356.4)   Female 19 17.5 108.5 (65.3-169.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 7.6 78.7 (28.7-171.2)             
Female 0 2.1 nc (nc-nc)   Female 32 19.4 164.7 (112.6-232.4) 
Lung and Bronchus            All Sites / Types     
Male 32 36.0 89.0 (60.9-125.7)   Male 286 281.7 101.5 (90.1-114.0) 
Female 29 34.9 83.0 (55.6-119.2)   Female 267 271.7 98.3 (86.8-110.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
339 
Westhampton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 1.8 nc (nc-nc)   Male 2 1.3 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.4 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 10 7.6 130.8 (62.6-240.6)   Female 0 0.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 1.0 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 2.2 nc (nc-nc)             
Female 0 1.8 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.5 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 10 7.5 132.9 (63.6-244.4) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 1.1 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.7 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.7 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 3.5 nc (nc-nc)   Male 25 26.3 94.9 (61.4-140.1) 
Female 0 3.3 nc (nc-nc)   Female 14 24.5 57.2 (31.2-95.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
340 
Westminster 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 7.6 105.9 (45.6-208.6)   Male 8 5.2 153.8 (66.2-303.0) 
Female 0 2.4 nc (nc-nc)   Female 8 3.9 206.1 (88.7-406.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.5 nc (nc-nc)   Male 2 1.5 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.3 nc (nc-nc)   Male 7 4.6 153.0 (61.3-315.2) 
Female 40 30.5 131.0 (93.6-178.4)   Female 2 3.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 4.0 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 3 1.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 11 8.8 125.6 (62.6-224.7)             
Female 6 7.6 78.5 (28.7-170.8)   Female 3 2.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 2.2 nc (nc-nc)   Male 3 2.7 nc (nc-nc) 
Female 3 0.5 nc (nc-nc)   Female 4 2.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.6 nc (nc-nc)   Male 26 30.7 84.7 (55.3-124.1) 
Female 1 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 4.6 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 3 2.3 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Larynx            Testis     
Male 1 1.2 nc (nc-nc)   Male 2 1.0 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 3.1 nc (nc-nc)   Male 1 2.1 nc (nc-nc) 
Female 1 2.0 nc (nc-nc)   Female 4 6.0 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 2.9 nc (nc-nc)             
Female 0 0.8 nc (nc-nc)   Female 6 7.1 84.7 (30.9-184.5) 
Lung and Bronchus            All Sites / Types     
Male 11 14.1 77.9 (38.9-139.5)   Male 108 108.3 99.7 (81.8-120.4) 
Female 14 12.9 108.5 (59.3-182.1)   Female 103 98.6 104.5 (85.3-126.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
341 
Weston 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 15 16.5 90.8 (50.8-149.8)   Male 12 9.8 122.3 (63.1-213.6) 
Female 3 5.1 nc (nc-nc)   Female 11 6.6 165.4 (82.5-296.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 2.6 227.4 (83.0-495.0)   Male 3 3.0 nc (nc-nc) 
Female 3 2.1 nc (nc-nc)   Female 4 2.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.5 nc (nc-nc)   Male 8 8.7 91.7 (39.5-180.7) 
Female 60 52.9 113.5 (86.6-146.1)   Female 4 6.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 6.6 90.4 (33.0-196.9) 
Female 1 1.7 nc (nc-nc)   Female 1 2.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 9 17.4 51.8 (23.6-98.3)             
Female 15 15.6 96.2 (53.8-158.7)   Female 3 4.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 4.1 nc (nc-nc)   Male 5 5.4 92.0 (29.7-214.8) 
Female 1 1.0 nc (nc-nc)   Female 10 5.0 199.3 (95.4-366.5) 
Hodgkin Lymphoma            Prostate     
Male 1 0.9 nc (nc-nc)   Male 59 53.6 110.2 (83.9-142.1) 
Female 1 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 7.9 nc (nc-nc)   Male 1 3.7 nc (nc-nc) 
Female 3 4.2 nc (nc-nc)   Female 3 2.0 nc (nc-nc) 
Larynx            Testis     
Male 3 2.3 nc (nc-nc)   Male 3 1.1 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 6.1 146.7 (67.0-278.5)   Male 3 3.2 nc (nc-nc) 
Female 9 4.0 225.9 (103.1-428.9)   Female 8 8.7 91.9 (39.6-181.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 5.1 nc (nc-nc)             
Female 1 1.5 nc (nc-nc)   Female 5 12.0 41.7 (13.4-97.3) 
Lung and Bronchus            All Sites / Types     
Male 23 29.2 78.9 (50.0-118.4)   Male 188 204.1 92.1 (79.4-106.3) 
Female 24 25.9 92.6 (59.3-137.8)   Female 179 181.0 98.9 (85.0-114.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
342 
Westport 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 30 22.3 134.2 (90.6-191.7)   Male 16 13.9 114.8 (65.6-186.4) 
Female 11 7.4 149.5 (74.5-267.4)   Female 14 9.9 141.3 (77.2-237.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 3.7 nc (nc-nc)   Male 6 4.2 143.2 (52.3-311.7) 
Female 0 3.1 nc (nc-nc)   Female 5 3.1 159.0 (51.3-371.2) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.7 nc (nc-nc)   Male 12 12.2 98.2 (50.7-171.5) 
Female 68 78.4 86.8 (67.4-110.0)   Female 15 9.7 153.9 (86.1-253.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 9.7 71.9 (28.8-148.2) 
Female 6 2.6 234.5 (85.6-510.4)   Female 6 4.1 148.1 (54.1-322.4) 
Colon / Rectum            Ovary     
Male 23 23.8 96.6 (61.2-145.0)             
Female 14 21.8 64.1 (35.0-107.6)   Female 3 7.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 9 6.0 151.0 (68.9-286.7)   Male 9 7.6 119.2 (54.4-226.2) 
Female 1 1.4 nc (nc-nc)   Female 6 7.2 83.8 (30.6-182.4) 
Hodgkin Lymphoma            Prostate     
Male 1 1.4 nc (nc-nc)   Male 91 80.7 112.8 (90.8-138.5) 
Female 0 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 13 11.6 111.7 (59.4-191.1)   Male 5 5.1 97.5 (31.4-227.5) 
Female 6 6.3 95.2 (34.8-207.3)   Female 3 2.7 nc (nc-nc) 
Larynx            Testis     
Male 5 3.3 152.6 (49.2-356.1)   Male 2 2.1 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 8.3 96.0 (41.3-189.1)   Male 8 4.9 162.1 (69.8-319.4) 
Female 4 5.6 nc (nc-nc)   Female 14 13.3 105.0 (57.3-176.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 7.3 68.5 (22.1-159.9)             
Female 1 2.2 nc (nc-nc)   Female 17 18.4 92.5 (53.9-148.2) 
Lung and Bronchus            All Sites / Types     
Male 30 40.7 73.7 (49.7-105.2)   Male 298 291.6 102.2 (90.9-114.5) 
Female 32 39.0 82.1 (56.2-115.9)   Female 242 266.5 90.8 (79.7-103.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
343 
Westwood 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 18 19.6 91.7 (54.3-145.0)   Male 22 11.8 186.3 (116.7-282.0) 
Female 2 7.3 nc (nc-nc)   Female 22 9.0 243.3 (152.4-368.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 3.2 nc (nc-nc)   Male 4 3.5 nc (nc-nc) 
Female 4 2.9 nc (nc-nc)   Female 5 3.0 165.6 (53.4-386.5) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.6 nc (nc-nc)   Male 8 10.5 76.1 (32.7-149.9) 
Female 95 70.6 134.6 (108.9-164.6)   Female 6 9.2 65.0 (23.7-141.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 7.9 nc (nc-nc) 
Female 1 2.2 nc (nc-nc)   Female 7 3.7 187.1 (75.0-385.5) 
Colon / Rectum            Ovary     
Male 25 20.9 119.4 (77.2-176.2)             
Female 26 22.4 116.1 (75.8-170.1)   Female 9 6.5 138.8 (63.3-263.6) 
Esophagus            Pancreas     
Male 4 4.8 nc (nc-nc)   Male 9 6.5 139.4 (63.6-264.6) 
Female 2 1.4 nc (nc-nc)   Female 3 7.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 3 1.1 nc (nc-nc)   Male 66 61.5 107.4 (83.1-136.6) 
Female 1 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 9.4 106.1 (50.8-195.1)   Male 3 4.4 nc (nc-nc) 
Female 4 5.8 nc (nc-nc)   Female 1 2.9 nc (nc-nc) 
Larynx            Testis     
Male 0 2.6 nc (nc-nc)   Male 2 1.6 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 7.5 80.5 (29.4-175.1)   Male 7 4.0 177.0 (70.9-364.7) 
Female 7 5.6 124.1 (49.7-255.8)   Female 20 11.5 173.9 (106.2-268.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 6.0 nc (nc-nc)             
Female 3 2.1 nc (nc-nc)   Female 18 15.5 115.9 (68.6-183.2) 
Lung and Bronchus            All Sites / Types     
Male 24 34.1 70.4 (45.1-104.7)   Male 249 241.5 103.1 (90.7-116.7) 
Female 38 35.8 106.2 (75.2-145.8)   Female 290 247.9 117.0 (103.9-131.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
344 
Weymouth 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 56 58.8 95.2 (71.9-123.6)   Male 42 38.2 109.9 (79.2-148.6) 
Female 42 23.1 181.5 (130.8-245.4)   Female 41 32.6 125.7 (90.2-170.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 10 10.9 91.3 (43.7-168.0)   Male 16 11.2 143.2 (81.8-232.6) 
Female 13 10.0 129.8 (69.1-222.0)   Female 8 9.9 81.2 (35.0-160.0) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.9 nc (nc-nc)   Male 45 33.7 133.6 (97.5-178.8) 
Female 266 248.5 107.0 (94.6-120.7)   Female 26 30.9 84.2 (55.0-123.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 34 26.8 126.7 (87.7-177.1) 
Female 8 8.7 92.3 (39.7-181.8)   Female 20 12.8 155.8 (95.1-240.7) 
Colon / Rectum            Ovary     
Male 76 65.0 117.0 (92.1-146.4)             
Female 82 70.5 116.4 (92.6-144.5)   Female 29 22.8 127.4 (85.3-183.0) 
Esophagus            Pancreas     
Male 17 15.7 108.6 (63.2-173.9)   Male 21 20.0 105.2 (65.1-160.8) 
Female 1 4.4 nc (nc-nc)   Female 21 22.6 93.0 (57.6-142.2) 
Hodgkin Lymphoma            Prostate     
Male 6 4.6 130.2 (47.6-283.5)   Male 191 208.0 91.8 (79.3-105.8) 
Female 1 4.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 34 31.8 107.0 (74.1-149.6)   Male 13 13.7 94.6 (50.3-161.7) 
Female 29 19.9 145.9 (97.7-209.6)   Female 5 8.8 56.6 (18.2-132.0) 
Larynx            Testis     
Male 15 8.7 173.2 (96.9-285.7)   Male 3 7.8 nc (nc-nc) 
Female 4 3.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 21 23.3 90.3 (55.9-138.0)   Male 21 14.6 143.6 (88.8-219.5) 
Female 13 18.4 70.8 (37.6-121.0)   Female 54 46.0 117.4 (88.2-153.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 19 19.8 95.8 (57.6-149.6)             
Female 7 7.0 100.3 (40.2-206.7)   Female 59 56.7 104.0 (79.1-134.1) 
Lung and Bronchus            All Sites / Types     
Male 122 106.3 114.7 (95.3-137.0)   Male 832 780.7 106.6 (99.5-114.1) 
Female 153 119.8 127.7 (108.3-149.6)   Female 954 848.2 112.5 (105.4-119.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
345 
Whately 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 2.0 nc (nc-nc)   Male 2 1.3 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.4 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 2 7.5 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 1.0 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 2.3 nc (nc-nc)             
Female 2 2.0 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.6 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 2 0.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 5 7.7 64.8 (20.9-151.3) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 1.1 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.8 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 2 1.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.7 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 3 1.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 3.7 nc (nc-nc)   Male 19 27.6 68.8 (41.4-107.5) 
Female 1 3.4 nc (nc-nc)   Female 14 24.7 56.7 (31.0-95.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
346 
Whitman 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 23 12.4 185.8 (117.7-278.7)   Male 8 8.6 92.5 (39.8-182.3) 
Female 5 4.5 111.4 (35.9-259.9)   Female 11 7.4 149.6 (74.6-267.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 2.7 nc (nc-nc)   Male 1 2.5 nc (nc-nc) 
Female 2 2.3 nc (nc-nc)   Female 1 2.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 4 7.7 nc (nc-nc) 
Female 49 56.1 87.3 (64.6-115.5)   Female 5 6.4 77.9 (25.1-181.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 6.4 93.5 (34.1-203.4) 
Female 6 2.1 283.3 (103.4-616.6)   Female 7 2.7 255.8 (102.5-527.0) 
Colon / Rectum            Ovary     
Male 16 14.4 110.9 (63.4-180.2)             
Female 20 14.0 143.3 (87.5-221.4)   Female 1 5.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 7 3.5 198.0 (79.3-408.0)   Male 4 4.3 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 2 4.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 1.2 nc (nc-nc)   Male 51 48.2 105.8 (78.8-139.1) 
Female 0 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 15 7.5 200.0 (111.8-329.9)   Male 4 3.0 nc (nc-nc) 
Female 3 4.3 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Larynx            Testis     
Male 4 2.0 nc (nc-nc)   Male 0 2.2 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 5.3 151.0 (65.0-297.5)   Male 3 3.7 nc (nc-nc) 
Female 4 3.9 nc (nc-nc)   Female 12 11.5 103.9 (53.6-181.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 4.6 131.0 (47.8-285.1)             
Female 0 1.4 nc (nc-nc)   Female 16 12.8 125.4 (71.6-203.6) 
Lung and Bronchus            All Sites / Types     
Male 31 22.9 135.4 (92.0-192.2)   Male 203 176.6 114.9 (99.7-131.9) 
Female 36 24.4 147.3 (103.2-203.9)   Female 190 183.1 103.8 (89.6-119.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
347 
Wilbraham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 15 20.0 74.9 (41.9-123.6)   Male 22 12.2 180.5 (113.1-273.2) 
Female 8 7.3 109.3 (47.1-215.3)   Female 9 9.3 97.0 (44.2-184.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 3.3 153.2 (49.4-357.6)   Male 5 3.7 136.1 (43.9-317.6) 
Female 6 2.9 208.1 (76.0-452.9)   Female 1 3.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.6 nc (nc-nc)   Male 12 10.8 111.1 (57.3-194.0) 
Female 69 73.1 94.4 (73.4-119.5)   Female 10 9.4 106.7 (51.1-196.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 8.4 59.6 (19.2-139.0) 
Female 0 2.3 nc (nc-nc)   Female 0 3.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 16 21.4 74.8 (42.7-121.5)             
Female 21 22.2 94.6 (58.5-144.6)   Female 5 6.7 74.4 (24.0-173.5) 
Esophagus            Pancreas     
Male 4 5.1 nc (nc-nc)   Male 7 6.7 105.2 (42.1-216.8) 
Female 1 1.4 nc (nc-nc)   Female 15 7.2 208.6 (116.7-344.1) 
Hodgkin Lymphoma            Prostate     
Male 0 1.2 nc (nc-nc)   Male 63 66.8 94.4 (72.5-120.7) 
Female 1 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 9.9 70.8 (28.4-145.8)   Male 4 4.6 nc (nc-nc) 
Female 6 5.9 100.9 (36.8-219.7)   Female 0 2.8 nc (nc-nc) 
Larynx            Testis     
Male 1 2.8 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 7.5 nc (nc-nc)   Male 4 4.1 nc (nc-nc) 
Female 6 5.6 108.0 (39.4-235.0)   Female 11 11.9 92.2 (46.0-165.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 6.4 94.3 (34.4-205.2)             
Female 2 2.1 nc (nc-nc)   Female 12 16.6 72.3 (37.3-126.3) 
Lung and Bronchus            All Sites / Types     
Male 22 35.5 62.1 (38.9-94.0)   Male 220 252.3 87.2 (76.0-99.5) 
Female 23 36.8 62.5 (39.6-93.8)   Female 225 253.5 88.8 (77.5-101.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
348 
Williamsburg 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 3.1 nc (nc-nc)   Male 0 2.0 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.6 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 4 1.8 nc (nc-nc) 
Female 16 13.3 120.6 (68.9-195.8)   Female 2 1.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 1.5 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 3.5 nc (nc-nc)             
Female 6 3.5 172.6 (63.0-375.7)   Female 5 1.2 415.2 (133.8-968.8) 
Esophagus            Pancreas     
Male 0 0.9 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 7 12.1 58.1 (23.3-119.7) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 1.7 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 3 1.0 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Larynx            Testis     
Male 0 0.5 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.2 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 1 2.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.1 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 4 3.1 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 5.7 nc (nc-nc)   Male 27 42.5 63.5 (41.8-92.3) 
Female 5 6.0 83.3 (26.8-194.3)   Female 53 43.6 121.5 (91.0-158.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
349 
Williamstown 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 10.9 73.2 (31.5-144.3)   Male 4 6.2 nc (nc-nc) 
Female 5 4.3 115.9 (37.4-270.6)   Female 1 5.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.6 nc (nc-nc)   Male 2 1.9 nc (nc-nc) 
Female 1 1.6 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 7 5.6 125.4 (50.2-258.3) 
Female 27 36.6 73.8 (48.6-107.4)   Female 6 5.2 114.3 (41.7-248.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 4.0 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 1 2.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 11.0 54.4 (19.9-118.4)             
Female 10 12.8 78.1 (37.4-143.6)   Female 3 3.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 2.6 nc (nc-nc)   Male 0 3.5 nc (nc-nc) 
Female 2 0.8 nc (nc-nc)   Female 4 4.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.7 nc (nc-nc)   Male 52 33.3 156.1 (116.6-204.7) 
Female 1 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 4.7 105.4 (34.0-246.0)   Male 2 2.4 nc (nc-nc) 
Female 1 3.2 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Larynx            Testis     
Male 1 1.4 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 4.0 nc (nc-nc)   Male 4 1.9 nc (nc-nc) 
Female 1 3.2 nc (nc-nc)   Female 4 5.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 3.1 nc (nc-nc)             
Female 3 1.2 nc (nc-nc)   Female 4 8.4 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 11 18.7 58.9 (29.4-105.4)   Male 118 129.7 91.0 (75.3-109.0) 
Female 18 20.6 87.4 (51.8-138.2)   Female 101 136.4 74.0 (60.3-90.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
350 
Wilmington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 29 22.7 127.9 (85.7-183.7)   Male 9 15.1 59.4 (27.1-112.9) 
Female 12 8.1 148.7 (76.7-259.7)   Female 16 12.0 133.1 (76.0-216.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 4.5 nc (nc-nc)   Male 3 4.4 nc (nc-nc) 
Female 3 3.7 nc (nc-nc)   Female 8 3.5 231.1 (99.5-455.4) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.7 nc (nc-nc)   Male 8 13.4 59.7 (25.7-117.6) 
Female 109 93.0 117.2 (96.2-141.4)   Female 16 11.0 145.2 (83.0-235.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 11 10.9 100.6 (50.1-179.9) 
Female 1 3.3 nc (nc-nc)   Female 7 4.6 151.3 (60.6-311.8) 
Colon / Rectum            Ovary     
Male 23 25.8 89.2 (56.5-133.8)             
Female 23 25.1 91.7 (58.1-137.6)   Female 7 8.3 84.0 (33.6-173.0) 
Esophagus            Pancreas     
Male 3 6.2 nc (nc-nc)   Male 6 7.8 77.0 (28.1-167.6) 
Female 0 1.5 nc (nc-nc)   Female 10 7.8 127.6 (61.1-234.7) 
Hodgkin Lymphoma            Prostate     
Male 2 1.9 nc (nc-nc)   Male 70 82.4 84.9 (66.2-107.3) 
Female 2 1.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 17 12.8 132.4 (77.1-212.0)   Male 6 5.4 111.1 (40.6-241.9) 
Female 9 7.2 124.5 (56.8-236.3)   Female 5 3.1 159.2 (51.3-371.6) 
Larynx            Testis     
Male 3 3.4 nc (nc-nc)   Male 1 3.1 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 18 9.2 194.8 (115.4-307.9)   Male 8 6.1 132.1 (56.9-260.4) 
Female 3 6.7 nc (nc-nc)   Female 13 17.9 72.6 (38.6-124.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 8.0 nc (nc-nc)             
Female 4 2.5 nc (nc-nc)   Female 24 20.6 116.4 (74.6-173.2) 
Lung and Bronchus            All Sites / Types     
Male 46 41.3 111.5 (81.6-148.7)   Male 299 308.7 96.9 (86.2-108.5) 
Female 51 42.1 121.1 (90.1-159.2)   Female 349 309.0 112.9 (101.4-125.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
351 
Winchendon 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 14 9.7 144.7 (79.0-242.7)   Male 1 6.6 nc (nc-nc) 
Female 2 3.3 nc (nc-nc)   Female 2 5.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.0 nc (nc-nc)   Male 5 1.9 260.9 (84.1-608.9) 
Female 0 1.6 nc (nc-nc)   Female 4 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 2 5.9 nc (nc-nc) 
Female 31 39.3 78.8 (53.6-111.9)   Female 4 4.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 4.9 123.5 (45.1-268.8) 
Female 4 1.4 nc (nc-nc)   Female 2 1.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 8 11.2 71.7 (30.9-141.3)             
Female 16 10.1 157.9 (90.2-256.4)   Female 4 3.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 2.7 nc (nc-nc)   Male 5 3.4 148.3 (47.8-346.1) 
Female 2 0.6 nc (nc-nc)   Female 7 3.1 222.2 (89.0-457.9) 
Hodgkin Lymphoma            Prostate     
Male 0 0.9 nc (nc-nc)   Male 33 36.5 90.5 (62.3-127.1) 
Female 0 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 5.7 nc (nc-nc)   Male 2 2.3 nc (nc-nc) 
Female 5 3.0 164.3 (52.9-383.4)   Female 1 1.3 nc (nc-nc) 
Larynx            Testis     
Male 1 1.5 nc (nc-nc)   Male 3 1.5 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 4.0 nc (nc-nc)   Male 4 2.8 nc (nc-nc) 
Female 2 2.8 nc (nc-nc)   Female 7 7.9 88.8 (35.6-182.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 3.5 nc (nc-nc)             
Female 0 1.0 nc (nc-nc)   Female 9 8.8 102.4 (46.7-194.4) 
Lung and Bronchus            All Sites / Types     
Male 15 17.8 84.1 (47.0-138.7)   Male 124 135.2 91.7 (76.3-109.3) 
Female 24 17.7 135.6 (86.9-201.8)   Female 136 129.6 104.9 (88.0-124.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
352 
Winchester 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 23 25.1 91.7 (58.1-137.6)   Male 19 15.8 120.3 (72.4-187.8) 
Female 5 9.7 51.4 (16.6-119.9)   Female 16 12.7 125.8 (71.9-204.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 4.5 nc (nc-nc)   Male 4 4.7 nc (nc-nc) 
Female 10 4.0 248.6 (119.0-457.2)   Female 6 4.1 148.0 (54.0-322.1) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.8 nc (nc-nc)   Male 16 14.0 114.3 (65.3-185.6) 
Female 99 98.9 100.1 (81.4-121.9)   Female 11 12.6 87.6 (43.7-156.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 11.0 45.5 (14.7-106.2) 
Female 2 3.3 nc (nc-nc)   Female 5 5.1 97.2 (31.3-226.8) 
Colon / Rectum            Ovary     
Male 31 27.4 113.3 (76.9-160.8)             
Female 23 29.9 76.9 (48.7-115.4)   Female 8 9.0 88.5 (38.1-174.4) 
Esophagus            Pancreas     
Male 5 6.5 76.7 (24.7-178.9)   Male 5 8.4 59.4 (19.1-138.7) 
Female 1 1.8 nc (nc-nc)   Female 8 9.6 83.1 (35.8-163.7) 
Hodgkin Lymphoma            Prostate     
Male 0 1.7 nc (nc-nc)   Male 98 85.3 114.9 (93.2-140.0) 
Female 1 1.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 13.1 53.6 (21.5-110.4)   Male 3 5.8 nc (nc-nc) 
Female 8 8.0 100.3 (43.2-197.6)   Female 5 3.8 130.9 (42.2-305.6) 
Larynx            Testis     
Male 1 3.6 nc (nc-nc)   Male 4 2.5 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 12 9.8 122.2 (63.1-213.4)   Male 1 5.7 nc (nc-nc) 
Female 6 7.7 78.0 (28.5-169.7)   Female 22 17.1 128.7 (80.6-194.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 8.2 73.4 (26.8-159.8)             
Female 2 2.8 nc (nc-nc)   Female 19 21.9 86.6 (52.1-135.2) 
Lung and Bronchus            All Sites / Types     
Male 34 44.8 75.9 (52.6-106.1)   Male 304 324.1 93.8 (83.6-105.0) 
Female 43 48.0 89.7 (64.9-120.8)   Female 330 341.3 96.7 (86.5-107.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
353 
Windsor 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.2 nc (nc-nc)   Male 2 0.8 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.0 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 2 4.2 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 1.4 367.2 (118.3-856.9)             
Female 1 1.0 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.4 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 2 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 0 5.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.7 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.5 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 2 0.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.5 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 2.2 nc (nc-nc)   Male 10 17.1 58.4 (28.0-107.4) 
Female 2 1.7 nc (nc-nc)   Female 12 13.3 90.5 (46.7-158.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
354 
Winthrop 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 23 21.6 106.4 (67.4-159.6)   Male 24 13.9 173.1 (110.9-257.6) 
Female 8 7.9 101.8 (43.8-200.6)   Female 20 11.0 182.6 (111.5-282.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 3.8 nc (nc-nc)   Male 2 4.1 nc (nc-nc) 
Female 4 3.3 nc (nc-nc)   Female 7 3.4 208.4 (83.5-429.5) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.7 nc (nc-nc)   Male 5 12.2 41.1 (13.2-95.9) 
Female 91 84.7 107.5 (86.5-132.0)   Female 10 10.5 95.5 (45.7-175.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 11 9.7 112.8 (56.3-201.9) 
Female 4 2.9 nc (nc-nc)   Female 1 4.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 27 23.6 114.2 (75.2-166.1)             
Female 22 23.8 92.6 (58.0-140.2)   Female 12 7.7 155.1 (80.1-271.0) 
Esophagus            Pancreas     
Male 6 5.8 104.1 (38.0-226.6)   Male 11 7.3 149.7 (74.6-267.9) 
Female 0 1.5 nc (nc-nc)   Female 8 7.6 104.7 (45.1-206.3) 
Hodgkin Lymphoma            Prostate     
Male 1 1.6 nc (nc-nc)   Male 70 77.3 90.5 (70.6-114.4) 
Female 0 1.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 22 11.5 190.6 (119.4-288.6)   Male 4 5.0 nc (nc-nc) 
Female 14 6.8 206.8 (113.0-347.0)   Female 2 3.0 nc (nc-nc) 
Larynx            Testis     
Male 5 3.2 157.4 (50.7-367.2)   Male 3 2.6 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 8.4 95.8 (41.2-188.7)   Male 8 5.2 154.1 (66.4-303.6) 
Female 5 6.1 81.9 (26.4-191.1)   Female 16 15.2 105.0 (60.0-170.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 8 7.2 110.8 (47.7-218.4)             
Female 3 2.4 nc (nc-nc)   Female 22 19.5 112.6 (70.5-170.4) 
Lung and Bronchus            All Sites / Types     
Male 58 39.1 148.3 (112.6-191.7)   Male 320 285.6 112.0 (100.1-125.0) 
Female 46 41.1 111.9 (81.9-149.2)   Female 322 287.8 111.9 (100.0-124.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
355 
Woburn 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 55 43.1 127.6 (96.1-166.1)   Male 33 27.6 119.6 (82.3-168.0) 
Female 22 17.1 128.3 (80.4-194.3)   Female 21 23.0 91.2 (56.5-139.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 7.8 76.6 (28.0-166.7)   Male 7 8.0 87.2 (34.9-179.7) 
Female 10 7.0 142.0 (68.0-261.1)   Female 7 7.2 97.8 (39.2-201.6) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.3 nc (nc-nc)   Male 29 24.3 119.2 (79.8-171.2) 
Female 190 171.6 110.7 (95.5-127.6)   Female 27 22.2 121.8 (80.2-177.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 21 18.7 112.5 (69.6-172.0) 
Female 7 5.9 118.2 (47.4-243.5)   Female 11 9.0 121.6 (60.6-217.5) 
Colon / Rectum            Ovary     
Male 62 46.9 132.1 (101.3-169.4)             
Female 51 52.0 98.1 (73.0-129.0)   Female 20 15.9 126.1 (77.0-194.7) 
Esophagus            Pancreas     
Male 12 11.1 108.6 (56.0-189.7)   Male 17 14.4 118.4 (68.9-189.5) 
Female 1 3.3 nc (nc-nc)   Female 20 16.8 119.3 (72.8-184.2) 
Hodgkin Lymphoma            Prostate     
Male 2 3.4 nc (nc-nc)   Male 124 143.3 86.5 (72.0-103.2) 
Female 2 2.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 26 22.4 116.2 (75.9-170.2)   Male 10 9.9 100.7 (48.2-185.2) 
Female 17 14.1 120.8 (70.3-193.4)   Female 8 6.6 121.4 (52.3-239.3) 
Larynx            Testis     
Male 1 6.1 nc (nc-nc)   Male 7 6.0 116.5 (46.7-240.0) 
Female 4 2.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 20 16.9 118.4 (72.3-182.8)   Male 11 10.4 106.0 (52.8-189.7) 
Female 17 13.4 126.9 (73.9-203.1)   Female 34 31.3 108.5 (75.1-151.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 14 13.9 100.7 (55.0-169.0)             
Female 1 5.0 nc (nc-nc)   Female 41 38.5 106.6 (76.5-144.6) 
Lung and Bronchus            All Sites / Types     
Male 97 76.8 126.2 (102.4-154.0)   Male 618 556.3 111.1 (102.5-120.2) 
Female 83 86.5 95.9 (76.4-118.9)   Female 670 601.2 111.4 (103.2-120.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
356 
Worcester 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 176 156.5 112.4 (96.4-130.3)   Male 61 104.0 58.7 (44.9-75.4) 
Female 68 61.5 110.6 (85.9-140.2)   Female 53 90.9 58.3 (43.7-76.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 28 32.3 86.8 (57.6-125.4)   Male 28 29.6 94.4 (62.7-136.5) 
Female 24 28.6 84.0 (53.8-124.9)   Female 25 25.9 96.5 (62.4-142.5) 
Breast            Non-Hodgkin Lymphoma     
Male 2 4.9 nc (nc-nc)   Male 103 93.0 110.8 (90.4-134.4) 
Female 559 647.6 86.3 (79.3-93.8)   Female 84 82.3 102.0 (81.4-126.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 73 72.3 101.0 (79.1-126.9) 
Female 34 24.1 141.3 (97.9-197.5)   Female 38 33.8 112.3 (79.5-154.1) 
Colon / Rectum            Ovary     
Male 154 175.3 87.8 (74.5-102.9)             
Female 186 190.2 97.8 (84.2-112.9)   Female 63 60.5 104.2 (80.1-133.3) 
Esophagus            Pancreas     
Male 56 41.1 136.2 (102.9-176.8)   Male 48 53.0 90.5 (66.7-120.0) 
Female 12 11.7 102.8 (53.1-179.6)   Female 64 60.4 105.9 (81.6-135.3) 
Hodgkin Lymphoma            Prostate     
Male 14 16.0 87.7 (47.9-147.2)   Male 522 540.4 96.6 (88.5-105.3) 
Female 15 14.0 107.3 (60.0-177.1)             
Kidney & Renal Pelvis            Stomach     
Male 91 85.4 106.5 (85.8-130.8)   Male 37 36.8 100.7 (70.9-138.8) 
Female 58 52.3 110.9 (84.2-143.3)   Female 32 24.1 132.5 (90.6-187.1) 
Larynx            Testis     
Male 18 22.7 79.2 (46.9-125.1)   Male 19 29.0 65.5 (39.4-102.3) 
Female 11 7.8 141.3 (70.4-252.8)             
Leukemia            Thyroid     
Male 61 66.0 92.4 (70.7-118.8)   Male 44 42.5 103.6 (75.3-139.1) 
Female 53 51.6 102.6 (76.9-134.3)   Female 111 133.2 83.3 (68.5-100.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 83 52.9 157.0 (125.0-194.6)             
Female 22 18.2 120.9 (75.7-183.0)   Female 159 144.6 110.0 (93.5-128.4) 
Lung and Bronchus            All Sites / Types     
Male 333 278.5 119.6 (107.1-133.1)   Male 2105 2098.1 100.3 (96.1-104.7) 
Female 357 309.1 115.5 (103.8-128.1)   Female 2195 2257.4 97.2 (93.2-101.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Worthington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 1.6 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 2 0.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.1 nc (nc-nc)   Male 2 0.9 nc (nc-nc) 
Female 3 6.3 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.8 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 1.9 nc (nc-nc)             
Female 2 1.6 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.5 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 2 0.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 6 6.8 87.7 (32.0-190.9) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.0 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.6 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.6 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 4 1.5 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 5 3.1 161.2 (52.0-376.3)   Male 27 23.2 116.2 (76.5-169.0) 
Female 0 2.8 nc (nc-nc)   Female 17 20.4 83.4 (48.6-133.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
358 
Wrentham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 11.1 98.7 (49.2-176.7)   Male 5 7.6 65.8 (21.2-153.6) 
Female 3 4.3 nc (nc-nc)   Female 11 6.1 179.0 (89.2-320.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 2.3 nc (nc-nc)   Male 2 2.2 nc (nc-nc) 
Female 3 1.9 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 10 6.7 148.6 (71.1-273.3) 
Female 53 48.1 110.2 (82.6-144.2)   Female 1 5.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 5.8 nc (nc-nc) 
Female 0 1.7 nc (nc-nc)   Female 6 2.4 245.7 (89.7-534.7) 
Colon / Rectum            Ovary     
Male 20 13.0 153.6 (93.8-237.2)             
Female 9 13.7 65.7 (30.0-124.7)   Female 3 4.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 6 3.2 190.2 (69.5-414.0)   Male 4 3.9 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 4 4.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.9 nc (nc-nc)   Male 56 43.0 130.3 (98.4-169.2) 
Female 1 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 6.6 nc (nc-nc)   Male 3 2.7 nc (nc-nc) 
Female 4 3.7 nc (nc-nc)   Female 2 1.7 nc (nc-nc) 
Larynx            Testis     
Male 2 1.8 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 4.6 nc (nc-nc)   Male 2 3.1 nc (nc-nc) 
Female 4 3.5 nc (nc-nc)   Female 5 8.8 57.0 (18.4-132.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 4.2 nc (nc-nc)             
Female 3 1.3 nc (nc-nc)   Female 4 10.7 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 22 20.4 107.8 (67.5-163.2)   Male 174 156.5 111.2 (95.3-129.0) 
Female 15 21.7 69.0 (38.6-113.8)   Female 145 161.1 90.0 (75.9-105.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Yarmouth 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 52 47.3 110.0 (82.2-144.3)   Male 38 26.4 143.9 (101.9-197.6) 
Female 27 17.7 152.3 (100.3-221.6)   Female 45 19.6 230.1 (167.8-307.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 6.4 nc (nc-nc)   Male 10 8.1 123.4 (59.1-227.0) 
Female 8 6.0 132.9 (57.2-261.8)   Female 8 7.2 110.6 (47.6-218.0) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.4 nc (nc-nc)   Male 28 23.3 120.0 (79.7-173.4) 
Female 172 152.6 112.7 (96.5-130.9)   Female 23 21.5 107.1 (67.9-160.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 22 16.3 135.1 (84.7-204.6) 
Female 4 4.3 nc (nc-nc)   Female 11 8.5 128.8 (64.2-230.5) 
Colon / Rectum            Ovary     
Male 43 47.0 91.5 (66.2-123.2)             
Female 45 51.5 87.4 (63.7-117.0)   Female 9 14.4 62.5 (28.5-118.6) 
Esophagus            Pancreas     
Male 19 11.0 172.1 (103.5-268.7)   Male 19 15.0 126.3 (76.0-197.2) 
Female 5 3.4 148.7 (47.9-347.0)   Female 13 17.4 74.5 (39.6-127.4) 
Hodgkin Lymphoma            Prostate     
Male 5 2.1 234.5 (75.6-547.2)   Male 166 138.6 119.8 (102.3-139.5) 
Female 3 1.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 14 20.1 69.7 (38.1-116.9)   Male 6 10.2 58.8 (21.5-128.0) 
Female 11 13.2 83.1 (41.4-148.7)   Female 5 6.6 75.7 (24.4-176.7) 
Larynx            Testis     
Male 4 5.9 nc (nc-nc)   Male 2 2.8 nc (nc-nc) 
Female 1 2.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 29 16.5 176.2 (118.0-253.0)   Male 12 7.5 159.7 (82.4-279.0) 
Female 17 12.5 135.8 (79.1-217.4)   Female 12 21.3 56.3 (29.0-98.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 14 12.8 109.3 (59.7-183.5)             
Female 8 4.9 162.4 (69.9-319.9)   Female 31 35.4 87.5 (59.5-124.3) 
Lung and Bronchus            All Sites / Types     
Male 92 81.5 112.9 (91.0-138.4)   Male 621 545.6 113.8 (105.0-123.1) 
Female 98 88.2 111.1 (90.2-135.3)   Female 611 559.3 109.2 (100.7-118.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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